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Abstract  iv 
Abstract 
 
Myrtucommulones, originally discovered in the Mediterranean shrub Myrtus communis, are a 
class of natural active compounds nowadays well known in the literature. They offer indeed 
various alternatives to the treatment of pain, inflammation and cancer. Unfortunately, the 
pharmaceutical world still remains reluctant towards its industrial application. Our incomplete 
knowledge of the isomeric composition of these compounds as well as the cost-
effectiveness, feasibility and safety of the procedure are the most probable issues. On this 
account, it is of interest to further improve the understanding of the synthesis and mode of 
action of these substances. 
 
The present work concentrates mainly on the asymmetry of myrtucommulones. This includes 
the determination of the absolute configurations of myrtucommulone A and B, the 
achievement, through metal catalysis, of the first enantiomeric excess in the synthesis of 
myrtucommulone derivatives, and the development of an organocatalysed diastereoselective 
synthesis of this class of compounds. 
 
Simultaneously, new synthetic methods emerged and gave access to a whole new range of 
possibilities for the preparation of these active compounds. The syntheses of 
myrtucommulone derivatives under mild conditions or through a One-Pot reaction are 
described here. 
 
Finally, a new derivative of myrtucommulone bound to a biotin moiety through a polyamide 
linker was also synthesised to help identify new cellular targets for compounds of this type. 
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Zusammenfassung 
 
Myrtucommulone wurden ursprünglich aus Myrte (Myrtus communis) isoliert und stellen 
heutzutage eine gut untersuchte Naturstoffklasse dar, die zahlreiche pharmakologische 
Eigenschaften besitzt. Sie erwiesen sich beispielweise als besonders wirksam für die 
Hemmung von Proteinen, die bei der Schmerzentstehung beteiligt sind oder für die 
Auslösung des Zelltodes von Krebszellen verantwortlich sind. Trotz dieser Fähigkeiten zögert 
die pharmazeutische Industrie, diese Wirkstoffe in Medikamenten zu verwenden. Die Gründe 
dafür sind wahrscheinlich zum einen, das unvollständige Wissen über die 
Isomerenzusammensetzung der Myrtucommulon-Derivate, und zum anderen, die 
Schwierigkeiten, diese Substanzen in größerem Maßstab herzustellen. 
 
Um das allgemeine Wissen über die Myrtucommulone zu erweitern, hat sich diese Arbeit 
hauptsächlich mit der Asymmetrie dieser Verbindungen beschäftigt. Zuerst wurden die 
Absolutkonfigurationen von Myrtucommulon A und B bestimmt. Mittels Metallkatalyse, 
konnten verschiedene Derivate enantioselektiv hergestellt werden. Anschließend wurden 
durch Organokatalyse einige Myrtucommulone mit interessanten Diastereomeren-
überschüssen synthetisiert. 
 
Gleichzeitig wurden neue Methoden entwickelt, um Myrtucommulon-Derivate bei milden 
Reaktionsbedingungen oder durch eine Eintopfsynthese herzustellen. 
 
Schließlich wurde das Myrtucommulon-Grundgerüst über einen Polyamid-Linker an Biotin 
gebunden, um neue therapeutische Targets in Zellen identifizieren zu können. 
 
 
Résumé  vi 
Résumé 
 
Les myrtucommulones, d’abord découvertes dans le myrte commun (Myrtus communis), un 
arbuste persistant de la région méditerranéenne, sont aujourd’hui une famille de molécules 
bien étudiée dans la littérature. Ce type de composé actif offre de nombreuses alternatives 
en ce qui concerne le traitement de la douleur ou de certains cancers. Pourtant, l’industrie 
pharmaceutique rechigne à y voir là de possibles médicaments. Cela peut s’expliquer entre 
autre par notre connaissance incomplète de la composition isomérique de ces molécules 
ainsi que par les coûts et le manque de garanties lors de leur fabrication. 
 
Afin de peaufiner nos connaissances dans ce domaine, une grande partie du travail présenté 
se consacre à l’étude de l’asymétrie de ces composés. Dans un premier temps, ont été 
déterminées les configurations absolues des myrtucommulones A et B. Ensuite, des dérivés 
de myrtucommulone possédant un excès énantiomérique ont été synthétisés par catalyse 
asymétrique grâce à l’utilisation de complexes métalliques. Puis, une première synthèse 
diastéréosélective a pu être réalisée par organocatalyse. 
 
Parallèlement, de nouvelles méthodes ont été développées, permettant la préparation des 
myrtucommulones dans des conditions douces ainsi que par une synthèse monotope. 
 
Pour finir, un nouveau dérivé, liant la structure de la myrtucommulone A à la biotine par une 
chaine polyamide, a pu être formé afin d’identifier de nouvelles cibles protéiques pour ces 
composés. 
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1. Introduction 
1.1. Discovery of myrtucommulones 
1.1.1. Walking around the Mediterranean sea 
 
Whoever already wandered through the hills of the Mediterranean region, in the south of 
France, in Corsica, or in North Africa, may have passed by a large amount of green bushes 
looking alike and with very fine fragrances. One of these evergreen shrubs can reach up to 
three meters in height and live more than three centuries. It possesses shiny acuminate 
coriaceous leaves, and the late spring till late summer walker will enjoy its exquisite star-like 
white flowers bearing numerous white stamens (Fig. 1). From January till March the ovoid 
blue-black berries are harvested in Corsica to be used in various preparations. This plant is 
known as common (or true) myrtle (Myrtus communis) and belongs to the Myrtaceae family.1 
 
a)                                                                                         b) 
 
 
 
 
 
 
 
 
 
Fig. 1 Myrtle with a) flowers and b) berries.
2
 
 
Those who do not fancy hiking may be interested to know that this plant has a lot of culinary 
applications. As a matter of fact, one makes very fine liqueur or schnapps from myrtle (Fig. 
2). Myrtle jelly, myrtle-flavoured honey (Fig. 2) or terrine also have a place in a traditional 
Corsican grocery store.3 It is possible as well to directly season one meal with dry myrtle 
leaves and give a very specific taste. 
 
a)                                                                                         b) 
 
 
 
 
 
 
 
 
Fig. 2 a) Liqueur and b) jelly made from Myrtle.
3
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1.1.2. A well known plant 
 
Myrtus communis is a widespread bush in the whole Mediterranean area. ALIPOUR et al. 
reported it in Southern Europe, North Africa and Western Asia mostly.4 It has been known for 
millenaries, since HIPPOCRATES himself referred to it in his work as a possible remedy.5 
ELFELLAH et al. spoke about it as a known hypoglycaemic agent in the Libyan folk medicine,6 
BONJAR mentioned its antiseptic use in the Iranian traditional medicine,7 and AKIN et al. 
related about the use of common myrtle decoctions as folk remedies in Italy.8  
 
In these works it is always referred to “myrtle extracts” as the active substance. Many other 
research group focus on the various medicinal use of “myrtle extracts” but since it is not the 
main topic of this work we will only cite as reference the good and extensive work from 
ALIPOUR et al.4 This review embraces most, if not all, known properties of myrtle extracts. 
The anti-inflammatory and anti-oxidative effects are there well described, as well as the 
hypoglycaemic or anti-bacterial potency. Other very different uses such as treatment of 
impotence, or hair loss or also depicted in this work. 
 
The composition of myrtle extracts has been the subject of many studies, which mostly 
concentrated on the water distilled extracts of the leaves. It was possible to determinate 
major constituents of the myrtle oils such as α-pinene (1) and 1,8-cineol (2) (Fig. 3).9 
However, the various studies highlighted the fact that the composition is extremely 
dependent on the geographic region, the period of harvest and the length of distillation (Tab. 
1).4  
 
 
 
 
 
 
                           1                          2                          3                                    4 
 
Fig. 3 Structures of α-pinene (1), 1,8-cineol (2), linalool (3), myrtenyl acetate (4). In the articles cited 
hereafter,
8-10
 no comments were made on the enantiomeric composition of the following compounds. 
 
As an example OZEK et al.10a reported 1,8-cineol (2), linalool (3) and myrtenyl acetate (4) as 
major constituents of Turkish myrtle oil whereas BRADESI et al.10b registered α-pinene (1) and 
1,8-cineole (2) as major constituents of Corsican Myrtus communis (Fig. 3).9 In the common 
myrtle growing in Northern Cyprus, AKIN et al.8 found no α-pinene (1) but more than 50 % of 
1,8-cineole (2) and linalool (3) as major compounds of the essential oil.  
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Tab. 1 Percentage composition (main constituents) of Myrtus communis oil from three different 
geographic regions. 
Components Turkey (leaves)
10a
 
Corsica (aerial 
parts)
10b
 
Northern Cyprus 
(leaves)
8
 
α-pinene (1) 6.4 51.2 x 
1,8-cineole (2) 18.2 23.6 50.1 
linalool (3) 16.3 2.4 12.7 
myrtenyl acetate (4) 14.5 - - 
limonene 3.4 5.9 4.3 
α-terpineol 6.5 3.8 7.6 
geranyl acetate 5.5 1.9 - 
neryl acetate 1.1 - 3.9 
- : not mentioned, x : not found. 
 
1.1.3. Myrtucommulones and structure-related products 
1.1.3.1 About myrtucommulones 
 
Aware of the antibacterial potency of myrtle extracts, KASHMAN et al. isolated for the first time 
in 1974 two new nonprenylated acyl phloroglucinol compounds that they named 
myrtucommulone A (MCA) (5) and B (MCB) (6) (Fig. 4).11 
 
 
 
 
 
 
 
 
                                          5                                                                           6 
 
 
 
 
 
 
 
                                                                           7 
 
Fig. 4 Structure of MCA (5), MCB (6) and PMCA (7). 
 
After a conscientious analysis by means of NMR and mass spectrometry,11a they tested the 
effects of the newly discovered species on several bacterial strains and found that MCA (5) 
affected the growth of gram-positive bacteria to the same extent as penicillin or 
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streptomycin.11b They could also highlight the importance of the phenolic nature of MCA (5) 
since its pentacyclic derivative PMCA (7) (Fig. 4), where several phenolic hydroxyl groups 
were removed, as well as MCB (6) showed much less anti-bacterial activity. 
 
A few years later, LOUNASMAA et al. isolated myrtucommulone A (5) from Callistemon 
lanceolatus, a shrub from the Myrtaceae family endemic to Australia but grown in India.12  
 
In 1998, a French patent described a myrtle extract based preparation in which some 
myrtucommulones were identified and in particular a hydrated version of MCB (6) that was 
called myrtucommulone B’ (MCB’) (8) (Fig. 5).13 In 2006, APPENDINO’s group, wrote about 
myrtucommulones again and isolated a new compound very similar to MCB’ (8) that they 
named semimyrtucommulone (SMC) (9) (Fig. 5).14 Although the only difference between the 
compounds 8 and 9 is a methyl group in the meta-position of the isobutyryl group, they were 
not named consequently and the succeeding literature rather took over the term from 
APPENDINO. Therefore we will, for more clarity, name the compound 8 
norsemimyrtucommulone (NSMC) in accordance with 9. 
 
 
 
 
 
 
 
 
                                8                                                                                 9 
 
Fig. 5 Structures of norsemimyrtucommulone (NSMC) (8) and semimyrtucommulone (SMC) (9). 
 
That same year, SHAHEEN et al. isolated from Pakistani Myrtus communis three new 
myrtucommulones: MCC (10) (Fig. 6), MCD (11) and MCE (12) (for the structures of the 
latter two, see § 1.1.3.3: “Pharmacological studies”).15 Two years later, QUINN et al. 
discovered MCA (5) and D (11) along with four new myrtucommulones (myrtucommulone F 
(MCF) (13) (Fig. 6), and MCG to MCI) in the Australian eucalyptus tree Corymbia scabrida.16  
 
 
 
 
 
 
 
 
                                   10                                                                      13 
 
Fig. 6 Structures of MCC (10) and MCF (13). 
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More recently COTTIGLIA and co-workers17 reported myrtucommulones J (MCJ) (14) to L and 
again SHAHEEN et al. extracted myrtucommulone M and myrtucommuacetalone (15) from 
Myrtus communis (for the structures of compounds 14 and 15, see § 1.1.3.3).18 
 
Finally in 2014, NICOLETTI et al. brought myrtucommulones to a new dimension since they 
could spot MCA (5) and MCD (11) in a fungus, endophytic in myrtle, called Neofusicoccum 
australe.19 The availability of a fungal strain to be cultured in vitro could indeed provide 
access to larger amounts of these derivatives, making them even more inviting for the 
pharmacological industry. 
 
1.1.3.2 About other structure-related compounds 
 
Because they were not isolated from myrtle, a lot of natural compounds where given other 
names. Nevertheless their structures are clearly related to myrtucommulones. For this 
reason, is given here a non exhaustive insight of these other products. 
 
One of the closest examples is the one of the molecules extracted from Kunzea ericoides 
from New Zealand. BLOOR discovered in 1992,20 two new non-prenylated phloroglucinol 
derivatives 16 and 17 that he did not name but which have structures very similar to NSMC 
(8) (Fig. 7).  
 
 
 
 
 
 
                                                                                 18 
 
 
 
 
      16:                                                                                                                 20 
      17: 
 
 
                                                                                 19 
 
Fig. 7 Structures of phloroglucinol derivatives 16, 17, rhodomyrtone (18), rhodomyrtosone B (19) and 
rhodomyrtosone C (20). 
 
Other very closely related compounds were isolated from Rhodomyrtus tomentosa from 
Southeast Asia. Rhodomyrtone (18) and rhodomyrtosone B (19) and C (20)  present 
Introduction  - 6 - 
structures very close to the one of myrtucommulone B (6) and myrtucommulone E (12) (Fig. 
7).21 It is noteworthy that both plants belong to the same family as common myrtle 
(Myrtaceae). 
 
Gallomyrtucommulones isolated by APPENDINO et al.22 are also worth being cited since they 
include a syncarpic acid moiety and were extracted from Myrtus communis. Despite their 
related name, these compounds are constitutionally a little more distant from MCs since they 
possess a galloylglucose moiety. Among them, gallomyrtucommulone B (21) showed 
interesting anti-bacterial activity (Fig. 8).  
 
Finally, QUINN et al.23 isolated corymbones A and B (22) from Corymbia peltata which again 
are non-prenylated phloroglucinols having very strong similarities with myrtucommulones and 
were shown to be possible candidates for the treatment of pain (Fig. 8). 
 
 
 
 
 
 
 
 
 
 
                                           21                                                                    22 
 
Fig. 8  Structures of gallomyrtucommulone B (21) and corymbone B (22) 
 
1.1.3.3 Pharmacological studies 
 
As written above, the isolation of new molecules from Myrtus communis was motivated by 
the search for new natural products with biological activity.11 The arising of this new class of 
nonprenylated acyl phloroglucinol derivatives led to numerous pharmacological studies. 
Anti-bacterial effect 
 
The first results of KASHMAN and co-workers11 in which MCA (5) showed a growth inhibiting 
effect on gram-positive bacteria such as Staphylococcus aureus, Bacillus subtilis or 
Streptococcus faecalis were confirmed almost thirty years later by APPENDINO et al.14 who 
studied the effect of MCA (5) and SMC (9) on various Staphylococcus aureus strains. Later 
SHAHEEN et al.15 pointed out the efficacy of myrtucommulone D (11) and E (12) on the same 
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type of bacteria (Fig. 9) and COTTIGLIA et al.17 underlined the specificity of myrtucommulone J 
(14) against it. 
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Fig. 9 Structures of myrtucommulone D (11) and myrtucommulone E (12). 
 
Recently, the French company PIERRE FABRE DERMO-COSMÉTIQUE developed a dermatologic 
preparation from myrtle extracts destined to prevent the growth of Propionibacterium acnes, 
a slow growing bacterium linked to acne. They identified MCA (5), MCB (6), MCD (11), 
NSMC (8), and SMC (9) as major constituents of their extract.24 
 
Anti-inflammatory and analgesic effect 
 
Cyclooxygenases (COXs) and 5-lipooxygenase (5-LO) are key enzymes for the biosynthesis 
of prostaglandins and leukotrienes respectively. These hormones are believed to be directly 
involved in the inflammatory response leading to pain and fever. In 2005, WERZ and co-
workers25 published their work showing that MCA (5) and to a lesser extent SMC (9) directly 
inhibit cyclooxygenase-1 (COX-1) and 5-lipooxygenase (5-LO). 
The inhibition of COX enzymes leads to the non-formation of all products of the 
cyclooxygenase pathway, but it is known that some prostaglandins possess important 
physiological functions.26 A few years later, WERZ et al.26a identified microsomal 
prostaglandin E2 synthase-1 (mPGES-1) as a new target for MCA (5).26 They discovered that 
mPGES-1 was indeed inhibited in a concentration dependent manner without significant 
inhibition of COX enzymes. This provides a real advantage in the treatment of inflammatory 
diseases since it directly suppresses the formation of PGE2, a prostaglandin responsible for 
inflammation, pain and fever without preventing the formation of the other important 
prostaglandins.26 
 
According to QUINN et al.16 MCA (5), MCD (11), MCF (13) and MCG-I showed specific 
binding activity to THR receptor-2, a brain hormone receptor that has been proposed as a 
therapeutic target to treat pain. 
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Anti-oxidative activity 
 
ROSA et al.27 concentrated on the anti-oxidative properties of these compounds and showed 
that SMC (9) is more powerful than MCA (5) in scavenging hydroxyl and peroxyl radicals 
(Reactive Oxygen Species, ROS) responsible for damaging cells and tissues. This property 
seems to be directly related to the hydrogen-donating activity of its phenolic hydroxyl group. 
Similarly, myrtucommuacetalone (15) was found to possess an inhibitory effect on ROS 
generation (Fig. 10).18 
 
 
 
 
 
 
 
 
                                                                          15 
 
Fig. 10 Structure of myrtucommuacetalone (15). 
 
Hypoglycaemic activity 
 
α-Glucosidase inhibitors are used in the management on non-insulin dependent diabetes 
mellitus (Type 2, most common form of diabetes) to inhibit certain enzymes catalysing the 
transformation of starch and sucrose in absorbable monosaccharides therefore delaying the 
postprandial blood glucose peak. Myrtucommulone B (6), D (11), E (12) and especially C 
(10) were found to be all more potent inhibitors than widely prescribed acarbose and 
standard inhibitor deoxynojirimycin.15 
 
Cytotoxic activity 
 
The most inspiring property of myrtucommulones is probably the selective induction of 
apoptosis in cancer cell lines.17,28 Apoptosis is the process of programmed cell death. 
Deregulation of apoptosis may disrupt the delicate balance between cell proliferation and cell 
death leading to the formation of tumours. Two major pathways can be distinguished for 
apoptosis, the extrinsic pathway, triggered through so called death receptors and the intrinsic 
pathway, involving mitochondria.28 WERZ et al. studied the influence of MCA (5) and SMC (9) 
on various cancer cell lines. They found out that MCA (5) causes loss of the mitochondrial 
membrane potential, releasing cytochrome c from mitochondria. Cytosolic cytochrome c 
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interacts with the adaptor protein Apaf-1 recruiting caspase-9 which then activates caspase-3 
leading to cell death.28  
In cooperation with the present work, a recent study from IZGI et al.29 demonstrated that MCA 
(5) induces both extrinsic and intrinsic apoptosis pathways in 4T1 cancer cells. 
COTTIGLIA et al.17 also proved that MCJ (14) exhibits an even better activity than MCA (5) 
against MT-4 tumour cell lines (Fig. 11). 
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Fig. 11 Structure of myrtucommulone J (14). 
 
1.1.3.4 Affinity-based target identification 
 
As described above, the possibilities of pharmaceutical use of MCs are numerous. To 
discover new cellular targets of bioactive molecules, affinity-based purification (also known 
as target fishing) is one of the most commonly used methods. It relies on the direct 
interaction/binding between the active compound and the protein.30 Typically, the drug is 
attached to a suitable affinity moiety (such as biotin) or directly immobilized on a resin such 
as agarose beads through a linker. The affinity probe is then incubated with cell extracts and 
thoroughly washed to remove non-specifically bound proteins. The bound proteins are then 
eluted and separated with SDS-PAGE and identified by mass spectrometry or peptide 
sequencing (Scheme 1).30c,31 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 1 Outline of affinity chromatography using mobile affinity matrices.
31
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The affinity probe consists principally of three parts: the ligand (or drug), the linker (with or 
without a functional tag) and the sorting part (matrix). Sugar-based matrices such as agarose 
(e.g. Affigel-10) or sepharose (e.g. EAH Sepharose 4B™) have been frequently used as 
solid support in the literature.32 In 2012, HANDA et al.31 successfully developed high-
performance affinity beads composed of multiple ferrite particles coated with a special 
polymer. These so called “FG-beads” have the main advantage that they can be recovered 
magnetically. 
 
The linker may affect non specific protein binding as well as the accession of the target to the 
drug. Differing length of polymethylene and polyethylene glycol are commonly used. The 
linker may be tagged with fluorescent molecules for visual observation of the target 
compound. Biotin (23), also known as vitamin B7, B8 or H, is a widely used functional tag due 
to its very strong interaction with avidin or streptavidin (avidin is a protein found in the white 
of the eggs of birds or reptiles, streptavidin has a similar structure and is produced by 
Streptomyces avidinii).30c,33 As described in Fig. 12, biotin is bound through a linker to the 
active compound and after incubation, bound proteins can be precipitated with streptavidin-
beads. 
 
 
 
 
 
 
 
 
 
                     23 
 
 
 
Fig. 12 Representation of biotin (23) and its use as functional tag. 
 
During his PhD-Thesis,34 H. MÜLLER bound a “sebacoyl myrtucommulone” (24) to EAH 
Sepharose 4B™, which possesses a primary amine, to form an amide bond and immobilise 
the myrtucommulone moiety on agarose beads (Scheme 2). The identification of new targets 
for MC-derivatives by the research group of Prof. WERZ in Jena is still in progress. 
 
To pursue similar investigations but in different conditions, we came to the idea of making a 
different compound, namely a biotin-bound myrtucommulone. We therefore dedicated a part 
of the present work to the search for a suitable linker to bind a myrtucommulone moiety and 
biotin together (Scheme 2).  
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Scheme 2 Formation of Sepharose-bound myrtucommulone and structure of biotin-bound 
myrtucommulone. a) EAH Sepharose 4B™, EDCI, dioxane/H2O, r.t., 96 h.  
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1.2. Total synthesis of myrtucommulones 
1.2.1. First total syntheses of some myrtucommulone derivatives 
 
As an answer to the rising interest for myrtucommulones, JAUCH et al.35 proposed in 2010 the 
first total synthesis of myrtucommulone A (5), B (6), C (10), F (13) and some derivatives. 
Myrtucommulone A (5) was retrosynthetically divided in three main exchangeable units: 
isobutyryl phloroglucinol (IBPG) (25), isobutyraldehyde (IBA) (26), and syncarpic acid (SA) 
(27) (Scheme 3).  
 
 
 
 
 
 
                                                                          5 
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Scheme 3 Retrosynthetical approach of MCA (5) 
 
SA (27) is a naturally occurring compound that can be easily synthesised in the laboratory 
from phloroglucinol (PG) (28). The starting material 28 was acylated on the one hand to form 
the central unit 25, and on the other hand to form acetyl phloroglucinol (APG) (29) for the 
synthesis of the unit 27 (Scheme 4).  
 
 
 
 
 
 
 
                             28                                        29                                              30 
 
 
 
 
 
 
                                                      25                                        27 
 
Scheme 4 Synthesis of syncarpic acid (27) and isobutyryl phloroglucinol (25). 
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APG (29) was then methylated four times with methyl iodide to 30, and the acetyl group was 
removed through boiling in hydrochloric acid (5M) to give syncarpic acid (27) (Scheme 4). 
 
Isobutylidene syncarpic acid (IBSA) (31) was formed through a Knoevenagel condensation of 
SA (27) and IBA (26) shortly before use to avoid its isomerisation in the dienol-isomer, which 
is unreactive in the present reaction (Scheme 5).35a Isobutyryl phloroglucinol (IBPG) (25) was 
then deprotonated with sodium hydride and 6 equivalents of 31 (for a better yield) were 
needed to form MCA (5) in two successive Michael additions (Scheme 5). In order to 
synthesise NSMC (8), only 1.5 equivalents of the Michael acceptor 31 were added. NSMC 
(8) can also be seen as an intermediate to MCA (5). It can be isolated and used again in 
another reaction to reach MCA (5) (Scheme 5). This could also be used to synthesise non-
symmetric MCs like MCC (10) (from MCB (6)) or artificial derivatives as shown in the JAUCH 
publication35a or in the PhD-thesis of MÜLLER.34 
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Scheme 5 Synthesis of myrtucommulone A (5) and isobutylidene syncarpic acid (31) 
 
The NMR analysis of such compounds is made difficult by the presence of stereoisomers 
and the number of possible tautomers and rotamers stabilised through hydrogen bonds.35a 
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In order to be analysed fully, MCA (5) as well as NSMC (8) were cyclised to PMCA (7) and 
MCB (6) respectively, by stirring in refluxing toluene in the presence of p-TsOH (Scheme 5). 
Pharmacologically, the newly synthesised MCA (5) showed very similar potency to inhibit the 
above cited mPGES-1 or induce apoptosis, which justified the usefulness of this synthetic 
path.35 
 
1.2.2. Synthesis of other pharmacologically active derivatives 
 
After the success of the first synthesis of MCA (5) and a few naturally occurring derivatives, 
JAUCH and co-workers focused on synthetic derivatives. They could successfully identify 
unique compounds showing an improved anti-inflammatory activity or a better apoptosis-
inducing potency.34-36 Listed below are the various building blocks that were combined for the 
synthesis of derivatives (Fig. 13).  
 
Phloroglucinols 
 
 
 
 
 
 
 
 
                  25                                 32                                     33                             34 
Aldehydes 
 
 
 
                                     26                                     35                              36 
1,3-Diketones 
 
 
 
 
 
                                    27                                      37                                 38 
 
Fig. 13 Various building blocks used for the synthesis of derivatives 
 
In Fig. 14 are depicted the derivatives with the most efficacy. Interestingly, the IC50 value for 
the inhibition of mPGES-1 (one enzyme included in the pain process, see § 1.1.3.3, Anti-
inflammatory and analgesic effects), decreases when a longer chain replaces the isobutyryl 
group, when isovaleraldehyde (IVA) (35) is used and with the use of 1,3-indandione (38) as a 
Michael acceptor. The combination of hexanoyl phloroglucinol (HPG) (33) and 1,3-
indandione (38) to form the myrtucommulone derivative 39 led to an extremely efficient 
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compound showing an IC50 value of only 0.08 µmol/L (almost 10 times lower than for MCA 
(5)). Regrettably, no compound of this kind also including IVA (35) could be synthesised to 
this day. According to the existing results, we could hope to achieve an even better IC50 for 
the myrtucommulone-derivative 41 with the structure depicted in Fig. 14. 
 
 
 
 
 
 
 
 
                             MCA (5)                                                                 MCF (13) 
IC50(mPGES-1) =    0.70 μmol/L 
IC50(5-LO cell based assay) =  3.20 μmol/L 
IC50(mPGES-1) =    0.60 μmol/L 
IC50(5-LO cell based assay) =  3.10 μmol/L 
 
 
 
 
 
 
 
                                   39                                                                        40 
IC50(mPGES-1) =    0,08 μmol/L 
IC50(5-LO cell based assay) =  1.46 μmol/L 
IC50(mPGES-1) =    0.24 μmol/L 
IC50(5-LO cell based assay) =  0.46 μmol/L 
 
 
 
 
 
 
 
                                                                            41 
 
Fig. 14 Structure and IC50 of the most potent mPGES-1 and 5-LO inhibitors 
 
It is noteworthy as well that the compounds which show a good anti-inflammatory potency 
are relatively different from the one who happened to be good cytotoxic agents. In the Fig. 15 
we depicted the molecules with the best EC50 values for the induction of apoptosis. Half-
cyclised compounds like MCC (10) and 44 are around 3 times more efficient than MCA (5) 
and molecules where the syncarpic acid moiety has been replaced by a dimedone unit (37) 
showed similar potency. Moreover, it is pleasant to see that even MCB (6) which is “only” a 
half-bodied myrtucommulone is of interest in this case. 
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                              MCA (5)                                                                     42 
EC50 = 8.10 μmol/L EC50 = 4.88 μmol/L 
 
 
 
 
 
 
 
                          MCC (10)                                                                       43 
EC50 = 3.06 μmol/L EC50 = 3.29 μmol/L 
 
 
 
 
 
 
 
                               44                                                                        MCB (6) 
EC50 = 2.46 μmol/L EC50 = 7.69 μmol/L 
 
Fig. 15 Structure and EC50 of the most potent apoptosis inductors. 
 
1.2.3. Limits of the synthesis 
 
Although this synthesis is extremely efficient and led to the identification of several new 
artificial derivatives with excellent pharmaceutical properties,34,36 it has the inconvenience 
that it uses hydrides and needs therefore dry conditions. This makes the realisation of this 
reaction in a larger scale costly and dangerous. Despite the obvious interest of MCs for the 
pharmaceutical industry, this could be a major drawback to their mass production. Likewise, 
it is disadvantageous that the instable acceptor (31) needs to be prepared shortly before use 
and cannot be stored. This would lead again to complications in an industrial environment. 
 
In this regard, it was interesting to develop an alternative synthesis for myrtucommulones. 
The first concern was to identify a new class of catalysts for more security and flexibility. The 
second was to find a more comfortable method to synthesise the myrtucommulones with less 
effort. 
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1.3. Asymmetric synthesis 
1.3.1. Asymmetry of myrtucommulone A 
 
Since myrtucommulone A (5) possesses two constitutionally identical stereocenters, two 
enantiomers (R,R and S,S) and a so called meso form are expected (Fig. 16). However, due 
to the extreme complexity and variability of its structure (stabilisation of the different 
tautomers and rotamers through hydrogen bonding),35a it was not possible to isolate and 
identify them. 
 
 
 
 
 
 
 
 
                                 (R,R)-5                                                             (S,S)-5 
 
 
 
 
 
 
 
                                                                    meso-5 
 
Fig. 16 Structure of the three stereoisomers of myrtucommulone A (5) 
 
In his work from 2008,16 QUINN et al. claimed that their MCA from Corymbia scabrida should 
have the configuration R* and provided an optical rotation value of [α]𝐷
17.6 = + 42.1 (c = 0.066, 
MeOH). In the same paper, another myrtucommulone, myrtucommulone D (MCD) (11) was 
isolated from the same plant and provided a small rotatory power: [α]𝐷
17.6  = + 13.9 (c = 0.13, 
MeOH). In their publication from 2006 SHAHEEN et al.15 found in Myrtus Communis a MCD 
(11) with an optical rotation of [α]𝐷
30  = + 375 (c = 0.8, CHCl3). On this, QUINN et al. 
commented that, whereas their low value is rather in favour of a chemically controlled 
production, the high value of SHAHEEN et al. rather speaks for an enzymatic control. One 
should notice though, that the two values were not measured in the same solvent and should 
not be compared directly. 
 
In their work on the total synthesis from 2010, JAUCH et al. cyclised MCA (5) to PMCA (7) 
and separated chromatographically the meso-form (meso-7a) from the racemic mixture of 
the (R,R) and (S,S) enantiomers (rac-7b) (Scheme 6).35 Later in this work, if the ratio of the 
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(R,R) and (S,S) enantiomers is not 1:1 or just not known, we will refer to the mixture as 7b, 
or 5b if we speak about uncyclised 5 (the same nomenclature applies for other derivatives). 
They found that the ratio between rac-7b and meso-7a was 54:46 giving another hint 
concerning diastereomeric composition of synthetic and natural MCA (5). But a doubt still 
remained since it was conceivable that racemisation takes place during the cyclisation 
process. 
 
 
 
 
 
 
 
                                                                                                        meso-7a 
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                                                                                                          rac-7b
 
Scheme 6 Chromatographic resolution of PMCA (7) 
 
To extend and clarify the knowledge on the stereoisomers of myrtucommulone derivatives 
and possibly draw conclusions about the biosynthesis of this class of compounds, the JAUCH 
group concentrated on the asymmetric synthesis of such compounds. 
 
First of all it should allow to collect some data concerning the enantiomers of MCs and 
confirm or not that the isolated compounds are pure or mixtures of stereoisomers. This would 
also state if racemisation takes place during cyclisation. Then it should help discovering if the 
efficacy of myrtucommulone is due to its chirality or not. Finally this should allow better 
understanding of the formation process of myrtucommulones in the plant or the fungus. 
 
1.3.2. Strategies to the asymmetric synthesis 
 
There are numerous strategies for the preparation of enantiopure compounds. As suggested 
by SINGH et al.,37 it is possible to divide them into two categories: chiral resolution, and 
asymmetric synthesis (Fig. 17). The first means the isolation of one specific enantiomer from 
a racemic mixture. The second signifies to selectively synthesise an enantiomerically pure 
compound. Three approaches to asymmetric synthesis can be distinguished: use of the 
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chiral pool, use of chiral auxiliaries, or use of chiral catalysts. The latter has an edge over the 
other due to its cost effectiveness and environmental friendliness. Theoretically, a single 
molecule of a chiral catalyst can lead to the production of millions of target molecules.37 
 
At the beginning of this thesis no chromatographic resolution could be achieved for the 
uncyclised products, which meant that the different enantiomers of MCA (5) were not 
accessible through this method. Our first move towards asymmetric synthesis was made 
through the chiral auxiliary method in my own Diploma-thesis and will be discussed briefly in 
the next paragraph.38 As these attempts were not especially successful, we then decided to 
concentrate on metal-catalysis with which we achieved a good enantiomeric excess (ee) and 
later on organocatalysis which led to a good diastereomeric excess (de). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 17 Strategies for the preparation of enantiopure compounds. 
 
1.3.3. Work toward the asymmetric synthesis of 
myrtucommulone A using a chiral auxiliary 
 
The first attempts of asymmetric synthesis were performed in my Diploma-thesis.38 The chiral 
auxiliary method was chosen and the Ender’s auxiliary called SAMP ((S)-1-amino-2-
methoxymethylpyrrolidine) (45) was preferred. It was intended to synthesise the SAMP-
hydrazone (46) of isobutyryl phloroglucinol (25) (Scheme 7). Due to the high electron density 
on the carbonyl group, it came out that we could not synthesise the hydrazone, but the para-
substituted IBPG (para-SAMP-IBPG) 47. Nevertheless, para-SAMP-NSMC (48) could be 
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synthesised and cyclised to 49. It was possible to read the diastereomeric excess (de) 
directly on the NMR but only 13% were observed (Scheme 7). 
 
In another attempt, the SAMP-hydrazone of syncarpic acid (50) could be formed and the 
chiral auxiliary could be removed under mild conditions (Scheme 7). We then tried this new 
product in our synthesis but no myrtucommulone-derivative could be detected. 
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Scheme 7 Work towards the asymmetric synthesis of myrtucommulones using SAMP (45). 
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1.4. Objectives of this work 
 
The possibility to use myrtucommulones (MCs) as drugs is obvious. To better understand the 
mode of activity of myrtucommulones and discover new targets, one objective of this work 
was the binding of biotin to the MC main structure for the needs of affinity-based 
chromatography. From the industrial point of view, the costs of the starting materials and the 
feasibility of the procedure are often limiting factors. Therefore, one goal of this work was to 
further study and improve the synthesis of this class of compounds. 
 
The enantiomeric composition of MCs is unclear; the previous work on this theme was so far 
unsuccessful38 and research groups do not agree on the purity of the isolated compounds. 
There is no data on perfectly identified enantiomers and the biosynthetic pathway in the plant 
or in the fungus is ambiguous. Besides it is still unknown if the activity of MCs is due to its 
chirality or if this has no influence on its efficacy. For all these reasons, this work mainly 
focuses on the asymmetric synthesis of MCs (especially NSMC (8) and MCA (5)). 
 
For a start, we determined the absolute configuration of the enantiomers of MCB (6) (and 
later NSMC (8)) and the diastereomers of PMCA (7) (and later MCA (5)). As MCA (5) 
possesses two stereocenters, we focused first on the enantioselective formation of NSMC (8) 
which only has one. After some promising results, the reactions were also performed on 
MCA (5). To proceed with the asymmetric synthesis, we first came back to our previous work 
using chiral auxiliaries.38 Then we concentrated on the metal-ligand catalysis achieving good 
enantioselectivities. Afterwards, the reaction was modified for the use of organocatalysts to 
synthesise directly myrtucommulones derivatives in a One-Pot synthesis or in similar mild 
conditions affording very good diastereomeric excess. At the end, the synthesis of a 
myrtucommulone derivative bound to biotin was achieved. 
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2. Results and Discussion 
2.1. Absolute configuration of myrtucommulone B and 
pentacyclic myrtucommulone A 
2.1.1. Preliminary chromatographic work 
 
Before starting the investigation of the asymmetry of myrtucommulones, we had to define a 
reliable method to identify any ee. After unsuccessful attempts to separate the enantiomers 
of NSMC (8) or MCA (5), we could achieve the first separation of the enantiomers of MCB (6) 
using the CHIRALCEL OD-H chiral chromatography column (Fig. 18a).  
 
 
a)                                                                           b) 
 
                                   (-)-6                                                                                 (+)-6 
                                                    (+)-6                                                                            (-)-6 
 
 
 
 
 
 
 
 
Fig. 18 Chromatographic separation of MCB enantiomers a) on CHIRALCEL OD-H, iPrOH/n-hexane 
20:80, 0.5 mL/min, 15°C, (-)-6 (tR = 7.44 min), (+)-6 (tR = 9.29 min) and b) on Reprosil 100 Chiral-NR, 
iPrOH/n-hexane 5:95, 1.0 mL/min, 24°C, (+)-6 (tR = 12,37 min), (-)-6 (tR = 16.18 min). 
 
Thanks to the parallel work of M. HANS on the Reprosil 100 Chiral-NR chiral chromatography 
column, the MCB (6) enantiomers could be as well separated and isolated after processing 
the compound on the preparative version of the same column (Fig. 18b).39 It is noteworthy 
that the enantiomers come in a different order depending on the column used. 
 
Likewise the pentacyclic derivatives rac-7 and meso-7 were separated through preparative 
HPLC according to the method described above and the rac-PMCA enantiomers (+)-7 and  
(-)-7 could be likewise identified (Fig. 19). 
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                                                                                       meso-7 
 
 
                                                                              (+)-7                   (-)-7 
 
 
 
 
 
 
Fig. 19 Chromatographic separation of PMCA stereoisomers on Reprosil 100 Chiral-NR, iPrOH/n-
hexane 5:95, 1.0 mL/min, 24°C, (+)-7 (tR = 12,51 min), meso-7 (tR = 14.82 min), (-)-7 (tR = 20.37 min). 
 
2.1.2. Derivatisation of cyclic myrtucommulones 
 
Thanks to the work of M. HANS from the JAUCH group, a consequent amount of each 
enantiomer could be soon isolated to further characterise these compounds. It was then 
possible to determinate the absolute configuration of each peak by derivatising them with 
different methods, growing crystals from each and analysing it by means of X-ray 
diffraction.40 
 
2.1.2.1 Bromination of (+)-myrtucommulone B 
 
The first isolated peak from MCB (6) (on Reprosil 100 Chiral-NR) was identified to be (+)-
MCB ((+)-6) ([α]𝐷
24 = +213 (c = 1.0, CHCl3). It appeared to us that determination of the 
absolute configuration thanks to the resonant scattering effects in X-Ray Diffraction (XRD) 
was the most appropriate method.41 This effect can be achieved by introducing a heavy atom 
(e. g. Br) in the molecule and submitting it to XRD of a single crystal. When X-Rays are 
incident on an atom, they are scattered in different directions with the same wave length. 
BRAGG et al.42 figured out that certain specific wave length and incident angles produced 
peaks of reflexion of strong intensity. They considered the crystal as a set of parallel planes 
and suggested that these peaks would appear if the reflected peaks interfere constructively. 
A set of planes of the same direction is described with the Miller indices (hkl).  
According to Friedel's43 law the intensities of one reflexion hkl (e.g. (1 0 0)) and its opposite, 
noted hkl  (e.g. ( 1  0 0)) are the same. Using a wavelength that only excites one atom (e. g. 
Br) creates a phase lag in the scattering of this atom, which leads to the loss of equivalence 
of these intensities. This can be measured and subsequent calculations allow to determine 
the relative positions of the atoms hence revealing the absolute configuration. 
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Bromine was hence added to a sample of (+)-MCB ((+)-6) to form a dibrominated product, 
which eventually showed the same optical rotation sign than its precursor, we called (+)-
dibromomyrtucommulone B ((+)-DiBrMCB) ((+)-51, [α]D
24 = + 39.5 (c = 1.0, CHCl3) (Scheme 
8).44 After conscientious crystallisation from dichloromethane, white needles were obtained 
and submitted to anomalous X-ray scattering (Fig. 20).40 
 
 
 
 
 
 
 
 
 
                                  (+)-(R)-6                                                      (+)-(R)-51 
 
Scheme 8 Synthesis of (+)-dibromomyrtucommulone B (51) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 20 X-ray structure of (+)-(R)-dibromomyrtucommulone B (51); ellipsoids at the 50 % probability 
level. 
 
The configuration of the only stereocenter of (+)-DiBrMCB (51) was found to be R implying 
that the configuration of (+)-MCB ((+)-6) is also R. Consequently, the other enantiomer of 
myrtucommulone B (6) is (-)-(S)-MCB ((-)-(S)-6). 
 
2.1.2.2 Formation of the Mosher ester of pentacyclic myrtucommulone A 
 
Given that PMCA (7) possesses a single phenolic alcohol, the formation of an ester of the 
Mosher acid (52) was preferred.41a As described above, the enantiomers of rac-PMCA (rac-
7) were separated, and to each one was added a mixture of (S)-Mosher acid ((S)-52), DCC 
and DMAP to yield after a several days the desired esters 53 and 54 (Scheme 9).45  
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                                                                                                                (-)-(S,S,S)-54 
 
Scheme 9 Synthesis of the Mosher derivatives (+)-53 and (-)-54 
 
The pentacyclic myrtucommulone (+)-7 led to (+)-PMCA-(S)-Mosher ester ((+)-53) which 
showed an optical rotation of [α]D
24 = + 40.2 (c = 1.0, CHCl3) and (-)-7 led to (-)-PMCA-(S)-
Mosher ester ((-)-54) which provided an optical rotation of [α]D
24 = -15.5 (c = 1.0, CHCl3). 
After several attempts, only the (+)-53 derivative gave needle-shaped white crystals, which 
revealed the absolute configuration of (+)-7 to be R,R (Fig. 21).40 As a consequence, the 
non-crystallised diastereomer is (-)-(S,S,S)-PMCA-Mosher ester ((-)-54), which means that 
the configuration of the (-)-7 enantiomer is S,S. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 21 X-ray structure of (+)-(R,R)-PMCA-(S)-Mosher ester ((+)-(R,R,S)-53); ellipsoids at the 50 % 
probability level.  
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2.2. Investigation of various synthetic pathways 
 
Additionally to the two main methods used for our asymmetric synthesis (metal catalysis and 
organocatalysis), other synthetic pathways were also considered. We first came back to the 
chiral auxiliary method and intended the synthesis of a norsemimyrtucommulone derivative 
bound to an auxiliary through three different strategies. Another alternative synthesis 
including an asymmetric alkylation was also investigated. 
 
2.2.1. The chiral auxiliary method 
 
The previously synthesised SAMP derivative of syncarpic acid 50 was used again to try to 
form the isobutylidene derivative 55 by mixing it with IBA (26) but no transformation or any 
consumption of the starting material could be observed.38 Varying the solvent and the 
temperature or using some additives like piperidine to enhance the Mannich reaction did not 
have any influence (Scheme 10). 
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Scheme 10 Attempt to synthesise the Michael acceptor 55 from the SAMP derivative 50. 
 
As it was so far the first success in the asymmetric synthesis of NSMC (8) (13% de in the 
diastereomeric mixture of para-SAMP-MCB (49)),38 another try was given to the para-
substituted version of IBPG. The para-SAMP-IBPG (47) possessed two rotational axes along 
the C-N and the N-N axes. The idea was to suppress one rotational axis for the auxiliary and 
hence allow less degree of freedom. We aimed for 56, a derivative of SMP (S-
methoxymethylpyrrolidine) (57) and IBPG (25) (Scheme 11). Not to waste an expensive 
auxiliary, pyrrolidine was used first to form para-pyrrolidinyl-IBPG (58). Although it was no 
problem to synthesise 58 by stirring the starting materials in boiling methanol,46 no reaction 
took place when it was deprotonated and IBSA (31) was added to synthesise the NSMC 
derivative 59. Various attempts were run in different solvents and with different temperatures 
but the starting material was never consumed. 
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Scheme 11 Synthesis of para-pyrrolidinyl-IBPG (58) and attempt to synthesise the derivative 59. 
 
In previous attempts to use a chiral auxiliary, it was tried to add a hydrazine, for example 
N,N-dimethylhydrazine, as the hydrazonyl chloride 60 to phloroglucinol (28) through a 
Friedel-Crafts reaction.47 Then, we would replace N,N-dimethylhydrazine by SAMP (45) for 
instance to induce stereoselectivity. First N',N'-dimethylisobutyrohydrazide (61) was 
synthesised from isobutyryl chloride and N,N-dimethylhydrazine (Scheme 12).47c We used 
thionyl chloride in refluxing benzene to get to the intermediate 60 and used it without 
purification in a Friedel-Crafts type reaction with PG (28).47a,b All isolated products included 
the phloroglucinol structure and some of them the isopropyl group from 60 but they had lost 
the methyl groups and no product 62 could be identified. It is most probable that the 
hydrazone was hydrolysed. This path was not further investigated. 
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                                               61 
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Scheme 12 Attempts to synthesise the hydrazone 62.  
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2.2.2. Formation of an intermediate for an asymmetric alkylation 
 
As an alternative to the known synthesis of myrtucommulone derivatives (§ 1.2), it was 
thought to add a formyl group to IBPG (25) to form 63 in order to perform a Knoevenagel 
type reaction with syncarpic acid (27). The idea was to afterwards alkylate stereoselectively 
the newly formed α,β-unsaturated ketone. For this, we based on the idea of WALKER et al.48 
who condensed Meldrum’s acid (MA) (64) (Scheme 13), whose structure is close to SA (27), 
with a formyl-arene to then perform a Zn-mediated asymmetric alkynylation. We planned to 
use diisopropyl zinc and copper-ligand additives to reproduce the conditions found in the 
literature to insert an isopropyl group.49 
 
Formyl-IBPG (63) was synthesised with a poor yield through a Vilsmeier-Haack type reaction 
(Scheme 13).50 On the other hand, no reaction could be observed between the derivative 63 
and syncarpic acid (27), neither in the presence of an acid (camphersulfonic acid) nor a base 
(DMAP, piperidine), nor using a dehydrating agent (molecular sieves) and heat. 
The reaction did not run either in other solvents or with higher temperatures. It is however 
surprising that absolutely no consumption of the starting material was observed, not even to 
form the aldol product of the aldehyde 63 and the enolised ketone 27. This confirmed once 
again the results obtained formerly,38 that is to say that the electrophilicity of any carbonyl 
group attached to the phloroglucinol ring is weakened by the delocalised aromatic electrons, 
which means that the formyl group is unreactive in this conditions. 
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                                                                                   64 
 
Scheme 13 Synthesis of Formyl-IBPG (63) and structure of MA (64) for comparison. Attempt to 
synthesise compound (65). 
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2.3. Metal catalysed asymmetric synthesis 
 
After the unsuccessful tries with alternative pathways to synthesise MCs, we decided to 
come back to the simple principle of the known synthesis.35a We hence looked for methods to 
perform stereoselectively a Friedel-Crafts reaction (from the point of view of the central unit) 
or a Michael reaction (from the point of view of the isobutylidene unit). Mechanistically 
regarded, once the hydride deprotonated the central unit (25), the sodium cation stays bound 
to the alcoholate as an ion pair (Scheme 14). Therefore, we decided to simply modify the 
base to achieve a stereoselective synthesis. 
 
 
 
 
 
 
 
 
            25                                                             31                                            8 
 
Scheme 14 Mechanistic view of the Michael reaction to the formation of NSMC (8) 
 
2.3.1. Setting the reaction conditions 
 
We set up standard reaction conditions to synthesise NSMC (8) that we then varied to induce 
and improve stereoselectivity. Unless otherwise specified the catalyst (66a-r, see § 2.3.2) 
had to be prepared shortly before use under nitrogen atmosphere. It was then added to IBPG 
(25), and stirred one hour before IBSA (31) was added to the mixture at 0°C. The NSMC (8) 
formed was then cyclised to MCB (6) to allow the determination of its isomeric composition 
(ee) (Scheme 15). 
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Scheme 15 Standard reaction conditions for the asymmetric synthesis of NSMC (8) and MCB (6) 
a.1) Catalyst (66a-r), THF, r.t., 1h a.2) IBSA (31), THF, 0°C, 1-1,5 h. b) pTsOH, Toluene, 95°C, 1-2h. 
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Several experiments were performed to find out the best concentration of acceptor 31 and 
the right temperature. First we figured out that a small excess of the reagent 31 (1.2-1.6 eq.) 
was needed because of its instability.35a  
 
Then, we found out that the reaction of the formation of NSCM (8) or MCA (5) does not need 
to be catalysed to happen. After 3 days of reaction at room temperature and without any 
catalyst, NSCM (8) could be synthesised with almost 70 % yield. In the case of MCA (5), 10 
days were needed.  
 
At 0°C the addition of 1 eq. of the Michael acceptor 31 to the Michael donor 25 to form the 
intermediate 8 without catalyst takes place very slowly and the succeeding one, which would 
lead to MCA (5), almost does not happen. A lower temperature than 0°C made the reaction 
of the formation of 8 last over more than a week, making the synthesis of the final product 5 
very improbable. That is why the reaction was cooled down to 0°C to favour the formation of 
NSMC (8) over MCA (5) on the one hand, and to favour the catalysed reaction of 8 over the 
non-catalysed reaction on the other hand.  
 
2.3.2. Heterobimetallic complexes 
 
Heterobimetallic complexes have proved to be catalysts of choice for the aldol51 and 
nitroaldol52 reactions but more importantly for the Michael53 and Friedel-Crafts reactions.54 In 
most cases, the complexes we used have the general formula (Ligand)nM
1M2, ligands being 
generally BINOL (67) or derivatives, M1 a metal or a lanthanide and M2 an alkali metal.55 
These catalysts function simultaneously as a base (“BINOLate”) and a Lewis acid (M1). As a 
consequence, each unit of the catalyst as well as the solvent play an important role in its 
efficiency. Likewise, experimentation demonstrated that the temperature, the size of the 
BINOL-derivatives and their number on the catalyst can have a great influence on the yield 
and stereoselectivity of the reaction.55 
 
2.3.2.1 First ee and absolute configuration of norsemimyrtucommulone 
 
BinAl-H (66a) (Fig. 22) was developed by the Nobel prize winner NOYORI as a powerful agent 
for the asymmetric hydrogenation of ketones.56 This bimetallic complex is made of an 
aluminium core, a BINOL (67) ligand, an ethoxy group and a hydride. In the presence of 
labile hydrogen atoms, it can also work as a base. Its use in the synthesis of NSMC (8) 
brought a first ee for this compound (Tab. 2).57 
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            (S)-67                  (S)-66a                            (R,R)-68                 (R,R)-66b 
 
Fig. 22 Structure of BINOL (67), TADDOL (68) and their respective Al-complexes 66a and 66b 
 
At first only one equivalent of BinAl-H was used, which provided a very small ee of only 5%. 
The increase of the number of equivalents up to 3 eq. more than quadrupled the ee up to 25 
% (Tab. 2, entry 1 to 5). Overloading the reaction mixture with 6 eq. of catalyst improved only 
slightly the ee delivering a highest ee to this point of 34 %.57 
 
Tab. 2 Results of the tries using the catalysts 66a-d in various concentrations.
a 
Entry Catalyst 
Number 
of eq. 
T(°C) Solvent Yield (%) 
[α] 𝐷
24 of 
NSMC (8)
b 
[α] 𝐷
24 of 
MCB (6)
c 
ee
d
 (%) 
1 (S)-66a 1.0 0 THF 47 x + 15 [2.8] 5 
2 (S)-66a 2.0 0 THF 70 -3 [3.3] + 30 [1.9] 11 
3 (S)-66a 3.0 0 THF 77 - 5 [3.8] + 48 [2.9] 25 
4 (R)-66a 3.0 0 THF 64 + 4 [3.8] - 44 [2.7] 28 
5 (S)-66a 6.0 0 THF 64 - 5 [4.5] + 54 [2.7] 34 
6 (S)-66a 3.0 0 Toluene 41 x x 2 
7 (S)-66a 3.0 r. t.
 
THF 52 - 4 [4.5] + 50 [2.5] 27 
8 (S)-66a 3.0 -30
e 
THF 64 0 [4.1] x 3 
9 (R,R)-66b 1.0 0 THF 60 0 [5.2] 0 [3.1] 0 
10 (R,R)-66b 3.0 0 THF 72 0 [5.1] 0 [3.1] 0 
11 (R)-66c 0.5 0 THF 70 0 [6.0] 0 [3.3] 2 
12 (R)-66c 1.0 0 THF 77 + 1 [4.8] -10 [3.1] 15 
13 (R)-66c 2.0 0 THF 58 x x 16 
14 (S)-66d 3.0 0 THF 60 x x 2 
a) Reaction time : 1h starting when IBSA (31) was added, b) in MeOH, [c], c) in CHCl3, [c], d) determined on MCB (6) through 
HPLC on CHIRALCEL OD-H, iPrOH/n-hexane 20:80, 0.5-0.6 mL/min, 15°C. e) reaction time: 2h. 
 
A change of solvent resulted in a very poor yield, given that none of the starting materials 
could dissolve well in toluene (Tab. 2, entry 6). This was in this case a very limiting factor, 
because the solvent had to be polar enough to dissolve everything, a problem rarely 
observed in the literature. 
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Interestingly, a lower temperature than 0°C did not improve the ee. The reaction at room 
temperature resulted in a slightly higher ee but a lower yield due to the increased formation 
of undesired MCA (5) (Tab. 2, entry 4, 7-8). Depending on the asymmetry of the ligand 67, 
the ee could be shifted to one or the other direction. The use of (S)-BINOL ((S)-67) led to the 
formation of (-)-NSMC ((-)-8) which then cyclised to (+)-6. The use of (R)-BINOL ((R)-67) led 
to the formation of (+)-8 which then cyclised to (-)-MCB ((-)-6 (Tab. 2, entry 3 and 4).  
 
These first results in the asymmetric synthesis helped defining the sign and absolute 
configuration of NSMC (8). (-)-NSMC ((-)-8) was then known to have the R configuration and 
(+)-NSMC ((+)-8) the S configuration (Scheme 16). Besides, since we could obtain different 
ee with different concentrations of the catalyst, we could assert that racemisation does not 
take place during the cyclisation and assume that the ee value of 6 is the ee value of 8. 
 
 
 
 
                                                    a                                                                        a 
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                   (-)-(R)-8                                                            (+)-(S)-8 
 
Scheme 16 Absolute configuration of (-)-8 and (+)-8. a) pTsOH·H2O, Toluene, 95°C, 1h. 
 
Since TADDOL (68) can be used similarly to BINOL (67),58 TaddAlH ((R,R)-66b) (Fig. 22) 
was tried as a catalyst but provided no ee independently of the amount of equivalents used 
(Tab. 2, entry 9-10). 
 
In addition, the catalyst 66c (Fig. 23), mentioned by NOYORI in his paper from 1984,56c where 
only one molecule of the diol 67 is added to lithium aluminium hydride (LAH), was chosen 
and provided a small ee of 15% with one equivalent, but no more with 0.5 eq. or 2.0 eq (Tab. 
2, entry 11-13).  
 
 
 
 
 
 
                                           (R)-66c                                      (S)-66d 
 
Fig. 23 Structure of catalysts (R)-66c and (S)-66d 
 
Finally, the catalyst 66d,59 made of trimethylaluminium and (S)-67, was used but no ee could 
be observed (Fig. 23) (Tab. 2, entry 14). 
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2.3.2.2 ALB and maximum ee for norsemimyrtucommulone 
 
The heterobimetallic complex that brought the best results is without doubt, the aluminium-
lithium-BINOL catalyst (ALB) (66e) developed by SHIBASAKI and easily obtained from LAH 
and two equivalents of BINOL (67) (Scheme 17).53b,d 
 
 
 
 
 
 
 
 
                          (S)-67                                                                 (S,S)-66e 
 
Scheme 17 Synthesis of the ALB catalyst (S,S)-66e. 
 
0.6 or 1.0 eq. of the catalyst 66e, used in the standard conditions described above (§ 2.3.1), 
provided almost no stereoselectivity (Tab. 3, entry 1-2).53d On the other hand, a dramatic 
increase of the enantioselectivity was observed with 2 and 3 eq. (Tab. 3, entry 3-5) affording 
the MCB (6) with 62% ee (Fig. 24).57  
 
 
a)                                                                           b) 
                                                    (+)-6 
 
 
                                       (-)-6 
 
 
 
 
 
 
Fig. 24 a) HPLC chromatogram of (+)-6 with 62% ee (ChiralCelOD-H, iPrOH/n-hexane, 30:70, 0.5 
mL/min, 15°C), b) corresponding circular dichroism spectrum (0.1 mg/mL, MeOH, 20°C). 
 
4 eq. of the catalyst did not improve the asymmetric induction (Tab. 3, entry 6). As seen 
before, the use of BINOLs (67) with opposite optical rotations to form the catalyst, led to an 
opposite sign of the optical activity of the products. The use of a lower temperature (-20°C) 
led to a significant loss of yield (despite longer reaction time) but did not influence the 
stereoselectivity (Tab. 3, entry 3-4). 
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Tab. 3 Use of the ALB catalyst (66e).
a
  
Entry Catalyst 
Number 
of eq. 
T(°C) Solvent Yield (%) 
[α] 𝐷
24 of 
NSMC (8)
b
 
[α] 𝐷
24 of 
MCB (6)
c
 
ee
d
 (%) 
1 (S,S)-66e
e 
 0.6
 
0 THF 57 x x 0 
2 (S,S)-66e  1.0 0 THF 69 x x 4 
3 (S,S)-66e  2.0 -20
 f
 THF 57  -8 [4.7]  + 70 [3.0] 41 
4 (S,S)-66e  3.0 -20
 f
 THF 55  -13 [4.6]  + 107 [3.4] 62 
5 (R,R)-66e  3.0 0 THF 65  + 11 [4.8]  - 105 [3.0] 62 
6
 
(R,R)-66e  4.0 0 THF 74  +11 [5.0]  -96 [3.2] 56 
7
 
(S,S)-66e  3.5 0 DCM 62 x x 63 
8
 
(S,S)-66e  3.2 0 DT101
g 
88 x x 62 
9
g 
(R,R)-66e  3.2 0 DT101
g
 81  + 16 [3.0]  - 117 [2.9] 72 
10
h 
(R,R)-66e  3.4 0 DT101
g
 83 x x 65 
a) Reaction time : 1.5-2h starting when IBSA (31) was added, b) in MeOH, [c], c) in CHCl3, [c], d) determined on MCB (6) 
through HPLC on CHIRALCEL OD-H, iPrOH/n-hexane 20:80, 0.5-0.6 mL/min, 15°C, e) tBuOK (0.9 eq.) was added according to 
literature,
53d
 f) the reaction was run overnight g) DT101 :mixture of DCM:THF, 10:1, v:v, g) a fresh bottle of 1.0 M LiAlH4 was 
used, h) the same solution of 1.0 M LiAlH4 was used, three months later. 
 
A reaction in pure dichloromethane led to the same yield and ee as in THF, nevertheless the 
use of a mixture of DCM:THF, 10:1, v:v (DT101) clearly improved the yield of the reaction 
(Tab. 3, entry 7-8). Thus, using a fresh solution of 1.0 M LiAlH4, and taking particularly care 
that the reaction took place under very dry conditions, 72 % ee could be obtained for MCB 
(6) (Tab. 3, entry 9, Fig. 25). The use of the same solution kept under argon for three months 
resulted in a slight loss of enantioselectivity (Tab. 3, entry 10). 
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                                                                                       (+)-6 
 
 
 
 
Fig. 25 HPLC chromatogram of (-)-6 with 72% ee (ChiralCelOD-H, iPrOH/n-hexane, 20:80, 0.6 
mL/min, 15°C) 
 
These results, along with the ones of the section 2.3.2, provided the first and best results 
concerning the asymmetry of norsemimyrtucommulone (8) and myrtucommulone B (6).57 
They proved as well that no racemisation of the molecule takes place during the cyclisation 
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process, validating its utility. This also means that the observed asymmetry is also the one of 
its precursor NSMC (8), which is in what we were interested in the first place. 
 
2.3.2.3 Other heterobimetallic complexes 
 
Given that ALB (66e) gave good results towards the enantioselective synthesis of NSMC (8), 
we modified different aspects of its structure to improve its efficiency (Tab. 4). 
 
Tab. 4 Variations of the ALB catalyst
a 
a) Reaction time : 1.5 h starting when IBSA (31) was added, at 0°C, b) determined on MCB (6) through HPLC on CHIRALCEL 
OD-H, iPrOH/n-hexane 20:80, 0.5-0.6 mL/min, 15°C. 
 
Taking into account the work of SHIBASAKI et al.,53a it was first intended to form a catalyst with 
a new ratio of 2:3 for LAH:BINOL to obtain the dimeric structure of 66f (Fig. 26).60 It was not 
possible with our data to confirm the exact structure of the catalyst, but as it showed no 
asymmetric induction, it was not further investigated (Tab. 4, entry 1). 
 
In their publication from 1997, FERINGA et al.61 found out that 2.45 eq. of BINOL (67) in 
regard to LAH, was the best ratio to form the most efficient “ALB-catalyst” (66g) for their 
Michael addition of α-nitroesters to α,β-unsaturated ketones. In our case no improvement of 
the enantioselectivity could be observed (Tab. 4, entry 2). 
 
Entry Catalyst Description 
Number 
of eq. 
Solvent Yield (%) ee
b
 (%) 
1 (R)-66f Al2Li2(BINOL)3 1.0 DT101 71 4 
2 (S)-66g AlLi(BINOL)2.45 3.2 DT101 81 50 
3 (S)-66h 
AlLi3(BINOL)3/Al2(Bu)2
(BINOL)2 
3.3 THF 67 0 
4 (R,R)-66i AlNa(BINOL)2 3.2 THF 72 2 
5 (S)-66j LaLi3(BINOL)3 3.2 THF 60 6 
6 (S,S)-66k La(linked-BINOL) 3.3 THF 66 47 
7 (R,R)-66l Ti(BINOL)2 4.0 Toluene 79 1 
8 (R)-66m Ti(OiPr)2(BINOL) 4.0 DCM 68 4 
9 (S,S)-66n AlLi(linked-BINOL) 3.2 DT101 62 0 
10 (R,R)-66o AlLi(TADDOL)2 3.4 DT101 37 4 
11 (R,R)-66p AlLi(6,6’-Br2BINOL)2 3.3 DT101 88 41 
12 (R,R)-66q AlLi(3,3’-Br2BINOL)2 3.3 DT101 72 5 
13 (R,R)-66r AlLi(6-BrBINOL)2 3.3 DT101 69 61 
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One year Later, SHIBASAKI et al.62 investigated another catalyst of the aluminium-lithium-
BINOL type. They added a strong base (n-BuLi, NaO-t-Bu) to their ALB (66e) to afford a 
mixture of a hexacoordinated and a tetracoordinated aluminium complex which led to an 
excellent selectivity for the reaction between Horner-Wadsworth-Emmons reagents and 
cyclic enones. Given the similarity between ALB (66e) and AlLi3(BINOL)3/Al2(Bu)2(BINOL)2 
66h (Fig. 26) we used it in our asymmetric synthesis but it had no asymmetric influence on 
the synthesis of NSMC (8) (Tab. 4, entry 3). 
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Fig. 26 Structures of 66f, 66h and 66o. 
 
The next attempt concerned the lithium ion included in the catalyst. The result from 
SHIBASAKI53b with ALB (66e) showed that the exchange of lithium through sodium in the 
catalyst had no influence on the enantioselectivity of the Michael reaction between 
cyclohexenone and dibenzylmalonate. Surprisingly, the reaction between IBPG (25) and 
IBSA (31) catalysed through the aluminium-sodium-BINOL-catalyst (ASB) (66i) showed no 
stereoselectivity (Fig. 27) (Tab. 4, entry 4). This underlines the prime importance of lithium 
for this reaction. 
 
A lot of studies concerning heterobimetallic complexes consider lanthanides as the central 
metal. Lanthanum is the most commonly used 51-53,55,63 but other rare-earth metals such as 
praseodymium (Pr), neodymium (Nd) or europium (Eu) have been investigated.52,55,63 We 
focused on La and first prepared the so called LLB (Lanthanum-Lithium-BINOL) catalyst (66j) 
where three lithium ions and three BINOL-ligands surround the lanthanum atom (Fig. 27).51  
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We then prepared a catalyst closely related to ALB (66e) but less air sensitive for using 
lanthanum as a central metal (66k) (Fig. 27).53c It has the particularity that it is lithium free 
and the two BINOLs surrounding the lanthanum are linked through an ether bridge (linked-
BINOL) (69). To make this ligand, we had to protect (S)-BINOL ((S)-67) with MOM to form 
70,64 then formylate through an ortho-lithiation followed by addition of DMF in presence of 
TMEDA65 to yield 71 and reduce the aldehyde with NaBH4 to the methyl alcohol 72.
66 After 
that, a part of methanol-BINOL (72) was transformed into a good leaving group with mesyl 
chloride and LiBr was added to the reaction to synthesise bromomethyl-BINOL (73). Both 
ligand 72 and 73 were then bound together through a simple nucleophilic substitution and the 
“linked-ligand” 74 was deprotected in boiling methanol in presence of a few millilitres of 
concentrated hydrochloric acid to yield the desired linked-BINOL (69) (Scheme 18).66 
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Scheme 18 Synthesis of the linked-BINOL ligand (69). 
 
The use of lanthanum led to almost no enantioselectivity in the case of LLB (66j) but the La-
linked-BINOL catalyst (S,S)-66k provided an interesting ee of 47% for MCB (6) (Tab. 4, entry 
5 and 6). Based on the promising results of the linked-BINOL ligand 69, we prepared the 
Results and Discussion  - 38 - 
catalyst (S,S)-66n, using this ligand and LAH (Fig. 27). In this case the catalyst did not show 
the expected influence on the stereoselectivity (Tab. 4, entry 9). 
 
After using La as a central metal, a try was given to a transition metal. Titanium showed 
excellent enantioselectivities for the aldol67 or Friedel-Craft reaction.68 Two different catalysts 
were tried: 66l was a mixture of titanium isopropoxide and 2 eq. of BINOL (67) and 66m was 
a mixture of the same compounds but in a 1:1 ratio (Fig. 27). None of them showed any 
interesting potency (Tab. 4, entry 7 and 8).68-69 
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Fig. 27 Structure of some catalysts used for the asymmetric synthesis of NSMC (8). 
 
Based on the same principle, we further varied the shape of the ligand. We tried again 
without success to use TADDOL (68) as a ligand (Catalyst 66o (Fig. 26), Tab. 4, entry 10). 
 
A first bromine derivative 75 was synthesised with bromine in the 6,6’-positions of BINOL 
(67) by simply mixing it with bromine in DCM at -78°C (Scheme 19).70 
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Scheme 19 Formation of 6,6’-dibromo-BINOL (75) 
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Thanks to the work of K. HUWIG two additional ligands (76 and 77) could be synthesised and 
tested for the asymmetric synthesis.71 Ligand 76 possesses two bromines in the 3,3’-
positions of BINOL. This was achieved by ortho-lithiation of MOM-protected BINOL (70) 
followed by addition of bromine to form 78 and subsequent deprotection in acidic medium 
(Scheme 20).  
 
For ligand 77, one of the OH-groups of BINOL (67) was protected with pivaloyl chloride to 
give 79 and subsequent bromination led exclusively to the mono-brominated product 80 
which was deprotected under basic conditions (Scheme 20). The pivaloyl protecting group 
(Piv) plays here a double role since its bulkiness prevents esterification of both naphtol 
moieties during the protection process and its electron withdrawing character deactivates the 
6’-position to only afford the formation of 6-bromo-BINOL (77).72  
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Scheme 20 Synthesis of 3,3’-dibromo-BINOL (76) and 6-bromo-BINOL (77). a.1) NaH (3 eq.), THFabs, 
0°C, 1h, a.2) MOMBr (2.3 eq.), THFabs, 0°C, 30 min, 79 %, b.1) n-BuLi (2,4 eq.), -78°C→0°C, b.2) Br2 
(3.0 eq.), hexane, -78°C→r.t., 14h, 60 %, c) conc. HCl (2.0 eq.), 1,4-dioxane, 50°C, 14h, d) PivCl (1.0 
eq.), NEt3 (3.0 eq.), CH3CN, 0°C→r.t., 3h, 89 %, e) Br2 (2.0 eq.), CH3CN, 0°C, 3h, 90%, f) KOH (3.0 
eq.), H2O/THF, r.t., 23h, 78 %. 
 
The use of the catalyst 66p bearing the ligand 75 resulted in a small diminution of the ee 
compared to 66e (Tab. 4, entry 11). The slightly different dihedral angle between the two 
naphtaline rings due to the steric effects but also the electronic influence of bromine have, in 
our case, a negative influence on the enantioselectivity.67 The use of the catalyst 66q (ligand 
76) where bromine atoms are in the 3,3’-positions led to almost no enantioselectivity (Tab. 4, 
entry 12). As observed in the literature for titanium complexes,67 the bromination of the 3,3’-
position are very disadvantageous for our aluminium catalyst. The asymmetry of the reaction 
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was only slightly influenced by the use of the catalyst 66r (ligand 77), where only one 
bromine is at the 6-position, providing MCB (6) with an ee of 61 % (Tab. 4, entry 13).64a,71-73 
In conclusion, neither the electronic effects nor the increased steric hindrance of the bromine 
derivatives of BINOL led to an improvement of the enantioselectivity. 
 
Eventually, no variation of our catalyst 66e led to an improvement of the ee for the 
Michael/Friedel-Crafts reaction. The best way we found to synthesise enantiomerically 
enriched NSMC (8) and the closely related MCB (6) was to use 3 eq. of ALB (66e) providing 
72 % ee for the target molecule.  
 
2.3.2.4 Mechanistic investigations 
Synthetic investigations 
 
In order to understand the mechanism of the reaction and the reason why 3 eq. were needed 
we realised some complementary experiments. SHIBASAKI53b proposed a mechanistic path for 
his Michael reaction catalysed by ALB (66e) where a lithium enolate is formed with the 
Michael donor while the Michael acceptor is pre-coordinated to the catalyst through an 
aluminium-oxygen connection. The Michael reaction should then take place and lead to an 
intermediary aluminium enolate. They could prove it by adding an electrophilic aldehyde to 
their reaction 53b that caught the enolate (Scheme 21).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scheme 21 Mechanism for a Michael-Aldol reaction catalysed by ALB proposed by SHIBASAKI.
53b
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In the case of the reaction between a phloroglucinol derivative and isobutylidene syncarpic 
acid (31), three equivalents of the catalyst 66e were needed to achieve good 
enantioselectivities. SHIBASAKI53b only used 10 mol% or less. This can be explained by the 
fact that isobutyryl phloroglucinol (25) includes three highly acidic phenolic protons in a 
conjugated system.  
 
Indeed, if the catalyst coordinates once to IBPG (25), it catalyses the reaction on any of the 
two nucleophilic positions of the phloroglucinol ring. This makes the site free from catalyst 
(red path) as well more reactive and the reaction can happen “far away” from the catalyst 
(Scheme 22). As a solution, 3 equivalents were used in the reaction to occupy all the 
phenolic oxygen atoms and enhance the asymmetric induction.  
 
 
 
 
 
                               (66e) 
 
                             31 
 
             25                                                                                                              8 
                                                                                                                          Low ee 
 
Scheme 22 Possible reaction pathways for the Michael acceptor (31), either with the activated side of 
IBPG or the other because of the conjugation in IBPG. 
 
Based on the principle that the Michael donor would bind to the catalyst through the lithium 
ion after having been deprotonated, we supposed we would obtain an intermediate like 81 
where lithium is coordinated to one of the phenolic oxygen atoms and to the keto group. The 
two other equivalents of ALB (66e) probably deprotonate and bind over lithium with the two 
other phenolic oxygen atoms (Scheme 23). This way, the space surrounding the IBPG is 
overloaded with chiral catalysts, forcing the asymmetric induction. 
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                                                                                               81 
 
Scheme 23 Possible complexation of the three aluminium-complexes with IBPG (25) 
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To corroborate this hypotheses a few other experiments were realised. As we already know, 
lithium plays a crucial role for the efficiency of the catalyst, since its exchange through 
sodium led to no enantioselectivity (§ 2.3.2.3, Tab. 4, entry 4).  
The reaction was then carried out in the reverse order (Tab. 5, entry 2) and provided an ee of 
only little more than half of the maximum ee of 72 % (Tab. 5, entry 1). This result underlines 
the fact that the efficiency of the catalyst relies on the primary coordination of the aluminium 
complex on the Michael donor. 
 
Tab. 5 Experiments to better understand the mechanism of the asymmetric catalysis.
a
 
Entry 
Michael 
donor 
Michael 
acceptor Catalyst 
Number 
of eq. 
Product 
(Yield, %) 
ee
c 
(%) 
1 25 31 (R,R)-66e 3.2 8 (81) 72 
 2
d 
25 31 (R,R)-66e 3.5 8 (65) 38 
3 33 31 (S,S)-66e 3.2 82 (60) 55 
4 28 31 (S,S)-66e 0.5 84 (59) 6 
5 28 31 (S,S)-66e 3.5 84 (75) 28 
6 25 86 (S,S)-66e 3.2 87 (35) 6
e
 
a) Reaction time : 1.5-2h starting when IBSA (31)/ IBIND (86) was added at 0°C c) determined on the cyclised derivative of the 
product through HPLC on CHIRALCEL OD-H, iPrOH/n-hexane 20:80, 0.5-0.6 mL/min, 15°C, d) the starting materials were 
given in the reverse order, e) determined on the cyclised derivative of the product through HPLC on Reprosil NR, iPrOH/n-
hexane 10:90, 1.0 mL/min, 24°C 
 
To verify the importance of the coordination to the keto group we first carried out the reaction 
using hexanoyl phloroglucinol (HPG) (33), to synthesise norsemimyrtucommulone F (82) 
which was cyclised to 83 (Scheme 24). The only difference here is the long linear pentyl 
chain of 33 instead of the isopropyl group of IBPG (25). Both reactions were performed under 
the optimised conditions and it is noteworthy that the ee dropped to 17 % with the use of 
HPG (33) showing that the form of the acyl chain of the phloroglucinol moiety influences the 
enantioselectivity (Tab. 5, entry 3). 
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Scheme 24 Synthesis of the NSMC (82 and 84) and MCB derivatives (83 and 85) to observe the 
influence of the keto group on the enantioselectivity. a)1) 66e, DT101, r.t., 1h 2) IBSA (31), DT101, 
0°C, 1,5 h. b) pTsOH·H2O, Toluene, 95°C, 1h. 
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We went further and removed the keto group, using phloroglucinol (28) as a starting material 
to form 84 (cyclised to 85, Scheme 24). The reaction with only 0.5 eq. of catalyst showed, as 
observed before, no selectivity. And the reaction under the standard conditions revealed that 
the ee dropped to 28% (Tab. 5, entry 4-5). This last experiment highlights the essential 
character of the ketone for the stability of the ALB-Michael donor intermediate. 
 
A final attempt was made where we simply used isobutylidene 1,3-indandione (IBIND) (86) 
instead of SA (31) as a Michael acceptor to yield the indandione derivative 87 which was 
then cyclised to 88 (Scheme 25). A dramatic loss of enantioselectivity was observed since 
only 6% ee were measured (Tab. 5, entry 6). This implies first that the bulky character of 
IBSA (31) participates in the chiral induction and second that our conditions are very specific 
to NSMC synthesis. 
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Scheme 25 a.1) 66e, DT101, r.t., 1h, a.2) IBIND (86), DT101, 0°C, 1,5 h. b) pTsOH·H2O, toluene, 
95°C, 1h. 
 
Crystallisation attempts 
 
Thus, it is now known that the keto group and the lithium ion participate in an essential 
manner to the enantioselective process. However this is not enough in order to know how the 
3 eq. of ALB (66e) are positioned in space when the reaction takes place. To get a better 
picture of it we made several crystallisation experiments of the intermediate state when the 
aluminium is still coordinated.  
 
Basically IBPG (25) and 3 eq. of the catalyst (S,S)-66e were mixed in THF or DT101 under 
the usual conditions and the mixture was then incubated either at room temperature or at 
4°C and then -20°C (Tab. 6, entry 1-2, 5). Other attempts were made mixing both Michael 
donor (25) and acceptor (31) with (S,S)-ALB ((S,S)-66e) in different solvent mixtures (Tab. 6, 
entry 3-4). The catalyst (S,S)-66e was also directly mixed with the product of the reaction 
NSMC (8) but unfortunately no crystal of any coordinated state could be obtained (Tab. 6, 
entry 6).  
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Tab. 6 Conditions of the different crystallisation attempts. 
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                                        8 
 
Entry 
Starting 
materials 
Solvent Temperature time 
1 25 THF r.t. 7 days 
2 25 DT101 r.t. 7 days 
3 25 + 31 THF r.t. 3 days then concentrated 
4 25 + 31 DT101 r.t. 3 days then concentrated 
5 25 DT101 1) 4°C   2) -20°C  1) 7 days   2) 30 days 
6 8 DT101 1) 4°C   2) -20°C 1) 7 days   2) 30 days 
 
In these studies we could highlight the essential character of the lithium ion, the keto group 
and the 1,3-diketone concerning the efficiency of the asymmetric induction. We could also 
prove that the order used to add the starting materials is of importance and suggest a 
possible intermediate state for our synthesis. However, we could not verify the exact position 
of the catalyst in the molecule. 
 
2.3.2.5 Synthesis of myrtucommulone A and limitation of the method 
 
Having extensively investigated the asymmetric synthesis of NSMC (8) achieving a 
maximum ee of 72%, we then concentrated on the synthesis of our target molecule based on 
the optimised conditions (Tab. 7). The aim was to improve the already achieved enantiomeric 
enrichment and create diastereomeric excess (de) in MCA which bears two stereocenters. 
Since we were not able to separate the enantiomerically enriched MCA 5b (consisting of 
(S,S)-5 and (R,R)-5 in an unknown ratio) from its meso form (meso-5a), we carried out, 
similarly to NSMC (8), the cyclisation reaction to give the pentacyclic derivatives 7b and 
meso-7a (Scheme 26). Since we know from above (§ 2.3.2) that racemisation does not take 
place, we can consider the ee of 7 as the one of 5. 
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Scheme 26 Asymmetric synthesis of MCA (5) a) Catalyst, DT101, r.t., 1h b) IBSA (31) (1,5 eq.), 
DT101, 0°C, 1,5 h. c) IBSA (31) (2 eq.), DT101, 0°C, 44 h, d) pTsOH, toluene, 95°C, 1h. e) IBSA (31) 
(3 eq.), DT101, r.t., 16 h. 
 
Given that MCA (5) needs longer reaction time, we first chose to perform the reaction at 
room temperature. We used once IBPG (25) as a starting material to which we added 3 eq. 
of the Michael acceptor (31) to get directly the myrtucommulone A (5) (Scheme 26). IBSA 
(31) was added at 0°C and the reaction was left at room temperature overnight. Both NSMC 
(8) and MCA (5) were isolated. NSMC (8) showed an ee of 65 % in accordance with the 
previous results. MCA (5) showed a slight loss of ee which signified that the ALB (66e) had 
no or not much influence on the induction of enantioselectivity in the target molecule 5 (Tab. 
7, entry 1). Moreover no de was observed which confirmed that the influence of the catalyst 
66e is limited once NSMC (8) has been formed. 
 
In order to check if the ee from the enantiomerically enriched (+)-(S)-8 (62% ee) could be 
sufficient to induce stereoselectivity in MCA (5), we made an experiment with only sodium 
hydride as a base catalyst (Tab. 7, entry 2). The reaction ran very fast but neither a 
significant improvement of the ee nor an induction of any de could be observed . 
 
  
Results and Discussion  - 46 - 
Tab. 7 Asymmetric synthesis of myrtucommulone A (5) 
Entry 
Starting 
material (ee) 
Catalyst (eq.) T(°C) 
Time 
(h) 
Product 
(Yield, %) 
ee
 a
 (%) de
b
 (%) 
1 25 (S,S)-66e (3.3 eq.)
 
0 /r.t 16 
8 (40 %) 65 - 
5 (46 %) 60 0  
2 (+)-(S)-8 (62%) NaH (2 eq.) r.t 1.5 5 (67 %) 64 4 
3 (-)-(R)-8 (62%) (S,S)-66e (3.3 eq.) 0 /r.t 16 5 (62 %) 55 2 
4 (-)-(R)-8 (62%) (R,R)-66e (3.3 eq.) 0 /r.t 16 5 (77 %) 70 2 
5 (+)-(S)-8 (62%) (S,S)-66e (2.2 eq.) r.t 16 5 (61 %) 65 2 
6 (+)-(S)-8 (62%) (S,S)-66e (3.3 eq.) r.t 16 5 (57 %) 70 4 
7 (-)-(R)-8 (64%) (R,R)-66e (3.3 eq.) 0 44 5 (45 %) 81 3 
a) determined on 7b: HPLC on CHIRALCEL OD-H, iPrOH/n-hexane 20:80, 0.6 mL/min, 15°C, b) read on NMR 
 
Two parallel experiments were run where the same sample of (-)-(R)-8 (62% ee) was used 
on the one hand with (S,S)-ALB ((S,S)-66e) and on the other hand with (R,R)-ALB ((R,R)-
66e) (Tab. 7, entry 3-4).57 In the first case (entry 3) we obtained 55 % ee for 5b (mismatched) 
and only 2 % de. In the second case (entry 4), 5b showed an ee of 70% (matched) with 3 % 
de, which meant again that no diastereoselectivity was reached (Fig. 28). 
Both of the reactions of (-)-(R)-8 with either (S,S)-66e or (R,R)-66e are typical for double-
diastereodifferentiation as explained in Scheme 27.57 
 
 
 
a)                                       (+)-(R,R)-7b               b) 
 
 
 
 
 
                                            (-)-(S,S)-7b 
 
 
 
 
 
Fig. 28 a) HPLC chromatogram of (+)-(R,R)-7b with 70% ee (ChiralCelOD-H, iPrOH/n-hexane, 30:70, 
0.5 mL/min, 15°C), b) corresponding circular dichroism spectrum (0.1 mg/mL, MeOH, 20°C). 
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a)                                                                        b) 
 
 
 
 
 
 
 
 
 
Scheme 27 Results of the matched (a) and the mismatched (b) double-diastereodifferentiating second 
Michael addition from (-)-8 to (+)-5b. 
 
Given our results on NSMC (8) where the number of equivalents used in the synthesis had a 
crucial influence on the stereoselectivity, we also run parallel experiments with 2.2 and 3.2 
eq. of the catalyst (S,S)-66e (Tab. 7, entry 5-6). In this case it seemed to have only little 
influence since we only observed a 5% difference in the ee. 
 
At last we repeated the reaction under optimal conditions at 0°C which seemed more 
appropriate for a good enantioselectivity since we could reach 81 % ee (Tab. 7, entry 7). On 
the other hand, even after 44h, the yield stayed low (45%) and still no diastereoselectivity 
could be achieved. At this point, thanks to the arduous work of M. Hans39 a new method had 
been developed and it was possible to read directly the ee on the chromatogram of the 
uncyclised product (Fig. 29). 
 
 
 
                                                                                                                   meso-5 
 
 
                                                                       (S,S)-5 
                                                                                                                   (R,R)-5 
 
 
 
 
 
Fig. 29 HPLC chromatogram of 5 with 81% ee (Reprosil 100 Chiral-NR, ACN: Buffer (35:65), Buffer: 
30mM NH4OAc, pH9 DEA), 1.0 mL/min, 24°C) 
 
This ee of 81 % may look moderate at first sight but it is relatively good compared to 
published results concerning significantly sterically hindered substrates like 31. In systems 
where the Michael acceptor has a similar steric hindrance, either the ee value is comparable 
to ours and the chemical yield is rather low74 or the chemical yield is moderate and the ee 
value is zero.57,75  
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2.3.2.6 NMR-particularity 
 
NMR-spectrum splitting due to “self induced non-equivalence” or “solute-solute 
diastereomeric interactions” is a known but seldom reported phenomenon.76 WILLIAMS et al.77 
were the first to report in 1969 two sets of peaks for the same proton in the NMR-spectrum of 
dihydroquinine. More extensive research from the same authors and other groups revealed 
that this phenomenon is due to the dimeric association in solution of the different 
enantiomers of the compounds.78 Basically, in presence of two enantiomers (+) and (-), three 
equilibria are expected : 
 
                                                                                            Homochiral dimer 
                                                                                            Heterochiral dimer 
                                                                                            Homochiral dimer 
 
The homochiral dimers (+)(+) and (-)(-) are enantiomers and are diastereomeric to the 
heterochiral dimer (+)(-)/(-)(+). If there is an excess of one of the enantiomers, the chiral 
average environment experienced by the (+) isomer is then different than the one 
experienced by the (-) isomer and two signals are then reported. In the case of a racemic 
mixture only one signal in then observed.76  
One signal corresponds to the weighted average of the population of the (+), (+)(+) and (+)(-) 
species and the other to the weighted average of (-), (-)(-) and (-)(+). Both weighted averages 
are related to the total concentration of each isomer. As a consequence, it is possible to 
directly read the enantiomeric excess of a compound by measuring the integration (I1 and I2) 
of each peak on the NMR spectrum.76,78a,b 
 
 
 
 
Luckily, this phenomenon happened in the case of the cyclised derivatives 6 and 7 of NSMC 
and MCA respectively. We observed “self-induced non equivalence” even with the slightest 
ee. As an example are depicted in Fig. 30, the NMR signals (in CDCl3) for protons H5 and 
H1’ of (-)-(S)-MCB (6) in the case of a racemic mixture (a), a 34% ee (b), and with 72 % ee 
(c). All these ee were confirmed on HPLC, with the usual methods (Fig. 30, d, e). 
 
One can notice here that the bigger the ee, the larger the distance between the peaks. In the 
spectrum of the 34 % ee mixture, the peaks still overlap making it impossible to determine 
the enantioselectivity of the reaction without HPLC. It is noteworthy as well that the NMR shift 
(δ) of the splitted peaks is also directly influenced by the ee, although the concentration of 
the solute is also involved.76,78a 
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Fig. 30 Comparison of the splitting of the NMR-signals (in CDCl3) of H5 and H1’ in the spectrum of 
MCB (6) for with ee of a) 0 %, b) 34 % and c) 72 %. HPLC chromatogram of (-)-(S)-MCB (6) with d) 34 
% ee and e) 70 % ee (ChiralCelOD-H, iPrOH/n-hexane, 30:70, 0.5 mL/min, 15°C) 
 
As suggested by WILLIAMS et al.76 for cannabinoid derivatives or by FENG et al.78c for urea 
and amide derivatives, the dimers possibly form over hydrogen bonding in the solution. 
BERGMAN et al.78a reported NMR-splittings due to π-stacking interactions of polycyclic 
aromatic ligands. In the case of myrtucommulone B (6) both are possible, that’s why we 
proposed two different ways of forming the dimer in Fig. 31. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 31 Possible homochiral dimers of (-)-(S)-(6). 
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We could also observe this phenomenon on the NMR spectrum of cyclised MCA (7) on a 
mixture of the diastereomers meso-7a and 7b, making it possible to not only read the ee but 
also the de of the mixture in the signal of one single proton (Fig. 32).  
 
 
 
 
 
 
                                                                   b) 
 
 
                         meso-7a 
 
                                                                   a) 
 
 
 
 
 
 
 
                         (R,R)-7b 
 
Fig. 32 Comparison of the NMR signals (in CDCl3) of proton H1’ and H1’’’ in a) a 1:1 mixture of meso-
7 and rac-7, b) 1:1 mixture of meso-7a and 7b (with 70 % ee). 
 
As expected, in a 1:1 mixture of meso-7a and rac-7b, the hydrogen atoms H1’ and H1’’’ are 
equivalent and appear as one doublet for each diastereomer. In an enantiomerically enriched 
mixture though, they happen to give a similar splitting to the one observed for MCB (6) for 
the 7b compound (with 70% ee). In addition to that, the signal for the meso-form (meso-7a) 
is also splitted giving a sum of four doublets with integrations corresponding to the actual 
ratio of the products. This means that the meso-form probably participate to the formation of 
chiral dimers or “polymer” leading to the observed splitting. 
  
Results and Discussion  - 51 - 
2.3.3. Conclusion on the metal catalysis 
 
In conclusion on the metal catalysis, we developed an enantioselective synthesis capable of 
providing norsemimyrtucommulone (8) and myrtucommulone B (6) with 72 % ee and 
myrtucommulone A (5) with 81 % ee. We started from the achiral isobutyryl phloroglucinol 
(25) and isobutylidene syncarpic acid (31) and used ALB (66) as a chiral catalyst. This 
synthesis offers a reliable alternative for the enantioselective Michael/Friedel-Craft reactions, 
in the case of strongly sterically hindered Michael acceptors. 
 
We also demonstrated that no racemisation takes place during the cyclisation process, thus 
confirming the prior results from JAUCH et al.35a We can even now conclude that since no 
racemisation occurs, the 1:1:2 ratio that was obtained for: (R,R)-PMCA (7b):(S,S)-PMCA 
(7b):meso-PMCA (7a) is also valid for MCA (5). This shows that natural as well as synthetic 
MCA from Myrtus Communis have a 1:1 ratio between a meso form and a racemate. 
 
Moreover we showed the extreme specificity of this system, since it accepts only minor 
modifications. This specificity is especially due to the steric importance of its substrates and 
also to the rapidity of the background reaction making any asymmetric catalysis effort 
laborious.  
 
To find out if enantiomerically enriched MCA is more potent than the racemic one, these 
compounds were sent to be tested for pharmacological activity but the results are not known 
yet. 
 
At the end the enantioselectivities obtained are good but no diastereoselectivity could be 
observed. That is why we turned to the trendy organocatalysis. 
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2.4. Organocatalysed syntheses of myrtucommulone 
derivatives 
 
Already in 1912, BREDIG reported a weakly enantioselective synthesis of a cyanohydrin 
catalysed through an alkaloid.79 But the development in the early 1970’s of the Hajos-Parrish-
Eder-Sauer-Wiechert reaction marked a watershed in asymmetric organocatalysis. Two 
different industrial groups reported the first enantioselective proline-catalysed intramolecular 
aldol reactions.79-80 Because of their cost effectiveness and availability, proline and Cinchona 
alkaloids have been for many years the favourite organocatalysts. Nowadays a very broad 
spectrum of reactions has been described with a wide choice of catalysts. Aldol, Michael, 
and Mannich reactions are the most widely investigated, but Diels-Alder, Baylis-Hillman, 
Friedel-Crafts, and aza-Henry reactions have also been reported. Typical catalysts are, in 
addition to the ones mentioned above, phosphoric acid-binaphtyl derivatives, chiral thioureas 
as dual hydrogen bond donors or synthetic peptides.37,79-81 
 
The work on organocatalysed reactions was divided in two parts. First we designed a new 
One-Pot synthesis of myrtucommulones derivatives using mostly proline as a catalyst. Then 
we focused on the development of the reaction conditions to synthesise myrtucommulones 
asymmetrically. In the first part some stereoselectivity is observed but remains relatively low. 
In the second, are depicted the various catalysts, including Cinchona alkaloids, that were 
used and the asymmetry is discussed more in details. 
 
2.4.1. One-Pot synthesis of myrtucommulones 
2.4.1.1 The tandem Knoevenagel-Michael reaction. 
 
The first challenge was to determine if the reaction of formation of myrtucommulone 
derivatives can be efficiently enhanced with organocatalysts. In his dissertation, H. MÜLLER34 
already considered the One-Pot synthesis of myrtucommulone derivatives but it remained 
unsuccessful. 
 
In the synthesis from 2010, JAUCH et al.35 form the Mannich base 89 from syncarpic acid (27) 
in the presence of isobutyraldehyde (26) and piperidine (Scheme 28). After a quick work-up 
using a 1M HCl solution saturated with ammonium chloride, the Michael acceptor 31 could 
be obtained. This method is straight forward but has a few drawbacks: first it includes two 
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practical steps and second, once the product 31 is formed, it isomerises slowly but 
ineluctably to iso-31 which is unreactive.35 
 
 
 
 
 
 
 
                              26 
 
 
 
        27                                               89                                           31                    iso-31 
 
Scheme 28 Previous synthesis of isobutylidene syncarpic acid (31). 
 
A broad variety of organic reactions such as Mannich and aldol reactions but also Michael 
additions are known to be catalysed by (S)-proline (90) and other amino acids.80,81i,j,82 
Knoevenagel condensations as well are described in the literature.83 1,3-Diketones are 
known to be pretty easily enolised and are used for multicomponent syntheses to form 
heterocycles or to perform a Knoevenagel reaction in combination with a Michael addition.84 
 
The Knoevenagel-Michael tandem reactions are described for dimedone (37)85 or Meldrum’s 
acid (MA) (64)86 but nothing had been found concerning SA (27). The literature cited here for 
the condensation of aldehydes on MA (64) precisely uses proline (90) as a catalyst.86  
 
In a publication from 1987, NAIR reported the pyridine-catalysed condensation of Meldrum’s 
acid (64), benzaldehyde (36) and PG (28) to form the dihydrocoumarin 91 (Scheme 29).87 
After MA (64) condensed with the aldehyde 36, PG (28) reacts though a Michael addition on 
the intermediate to give after transesterification, acetal cleavage and decarboxylation of the 
MA (64), the expected product. One clearly sees here the parallel with the formation of 
myrtucommulones. 
 
 
 
 
 
 
 
 
                      64                36                     28                                        91 
 
Scheme 29 Synthesis of dihydrocoumarin (91) according to NAIR.
87
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Based on this, we found out that (S)-proline catalyses the Knoevenagel-condensation of 
syncarpic acid (27) with isobutyraldehyde (26) as well (Scheme 30). Isobutylidene syncarpic 
acid (31) could be synthesised in quantitative yields in a few minutes at 60°C or overnight at 
room temperature (Tab. 8). Very interestingly, the isomerisation of 31 seemed to be much 
more equilibrated in MeOH, since we obtained at first almost only the desired isomer. Later, 
we could figure out with reactions lasting up to a week that 31 finally isomerises to iso-31 but 
extremely slowly. 
 
Tab. 8 Formation of the Michael Acceptor (31) 
Catalyst Temperature Time Yield 
(S)-Proline (90) 60°C 30 min 97 % 
(S)-Proline (90) r.t. 14 h 99 % 
 
When IBPG (25) was added to the mixture directly after the formation of the acceptor 31, it 
reacted immediately to NSMC (8) and gave MCA (5) after several hours in 72 % yield 
(Method A) (Tab. 9, entry 2, Scheme 30). By mixing IBPG (25), IBA (26), SA (27), and 
proline (90) in one single vial, we could achieve the first one-pot-synthesis of 
myrtucommulone A (Method B) in 24h with 67 % yield (Tab. 9, entry 4, Scheme 30). 
 
Method A 
 
 
                                              90                                     25 
 
                          26 
 
        27                                                      31                                                      8 
 
 
  Method B 
 
 
 
 
                                                                       90 
 
 
 
            25                   27              26                                                          5 
 
Scheme 30 One-pot synthesis of myrtucommulone A (5). Number of equivalents of the starting 
materials: IBPG (25) (1): SA (27) (6): IBA (26) (8): proline (90) (0.5). 
 
If the Michael donor 25 is in the reaction mixture from the beginning (Method B), there is the 
possibility that it is consumed by the aldehyde; this would explain the slightly lower yield for 
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the One-Pot method. When only 0.5 eq. of the catalyst were used, the reaction needed twice 
as much time (Tab. 9, entry 1,3). 
 
We further investigated the new One-Pot method by choosing other amino acids as 
catalysts. We chose phenylalanine (Phe) for its neutral side chain, glutamic acid (Glu) for its 
acidic part and histidine (His) for its basic section. None of them could replace proline to 
catalyse our one-pot reaction (Tab. 9, entry 5-7). We could indeed isolate some product in 
the reaction with Phe but only small amounts. It was observed on TLC that Glu did not 
catalyse the formation of IBSA (31), and His enhanced the formation of the Michael acceptor 
31 but also the reaction between IBPG (25) and IBA (26) which consumed the starting 
material did not lead to any product. This highlights the importance of the secondary amine 
character of proline. As described in the literature,80,81d,f,j,82 the formation of the Michael 
acceptor 31 probably proceeds over an iminium/enamine intermediate. 
 
Tab. 9 Formation of myrtucommulone A (5) under different conditions. 
Entry Method Catalyst (eq.) Solvent T(°C) Time 
Product 
(yield, %) 
de
b
 (%) 
1  A
a 
90 (0.5 eq.) MeOH r.t. 48 h 5 (67) 5 
2  A
a 
90 (1 eq.) EtOH r.t. 31 h 5 (72) 24 
3
 
B
 
90 (0.5 eq.) MeOH r.t. 48 h 5 (66) 12 
4
 
B
 
90 (1 eq.) EtOH r.t. 24 h 5 (66) 12 
5 B
 Phe (1 eq.) EtOH r.t. 24 h 5 (12) 8 
6 B
 Glu (1 eq.) EtOH r.t. 48 h x - 
7 B
 
His (1 eq.) EtOH r.t. 48 h x - 
a) time was taken when IBPG (25) was added, b) determined on the NMR spectrum of the cyclised derivative. 
 
The last column of the Tab. 9 lists the diastereomeric excess that could be observed on the 
NMR of each sample of PMCA (7). With the Method B and one equivalent of proline (90), an 
encouraging de of 24 % was observed and let expect more with other bulkier catalysts. 
However, every optical rotation measured for these samples was found to be 0. This means 
that no ee was achieved. 
 
Attention was given to the products formed from IBA (26) and IBPG (25). Different conditions 
were tried to isolate the isobutylidene derivatives 92 and 93 of IBPG but the only products 
that could be identified were the two derivatives 94 and 95 (Scheme 31). 
 
These derivatives confirmed that a Knoevenagel condensation takes place between IBPG 
and IBA, but the isobutylidene derivatives formed were captured by the solvent (EtOH) to 
form unreactive derivatives. Hereby, we could demonstrate how IBPG is consumed in the 
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reaction mixture by isobutyraldehyde. Since we could not isolate the desired derivatives in 
other solvents either, the isobutylidene IBPGs were not further investigated. 
 
 
 
 
 
 
 
                                                       90                        92                                            94 
 
 
 
              25             26 
 
 
 
                                                                                  93                                             95 
 
Scheme 31 Synthesis of the IBPG derivatives 94 and 95. 
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2.4.1.2 One-Pot Synthesis of myrtucommulone-derivatives 
 
Several myrtucommulone derivatives were synthesised with the one-pot method (Method B) 
to show the scope of the One-Pot reaction conditions (Tab. 10). Among the derivatives, MCF 
(13) could be synthesised with a fair yield (Tab. 10, entry 1) and a very interesting de of 38 
%. The dimedone derivatives 42 and 43 which exhibit cytostatic potency (§ 1.2.2) gave the 
best yields (up to 95 % for 42 (Tab. 10, entry 2-3) but showed only insignificant de of 5 and 7 
% respectively. The derivatives 13, 42 and 43 were cyclised to their dehydrated pentacyclic 
derivatives respectively 96, 97, and 98 for analysis. 
 
Tab. 10 One-pot synthesis of myrtucommulone derivatives. 
 
 
 
 
                                                                         90 
 
 
 
 
13 : X = 33, Y = 26, Z = 27 
25 : R1 = CH(CH3)2 26 : R
2 = CH(CH3)2   42 : X = 25, Y = 26, Z = 37 
33 : R1 = (CH2)4(CH3) 35 : R
2 = CH2CH(CH3)2  43 : X = 33, Y = 26, Z = 37 
 
 
 
 
 
 
 
 
 
                              27              37              64 
         96 : X = 33, Y = 26, Z = 27 
         97 : X = 25, Y = 26, Z = 37 
         98 : X = 33, Y = 26, Z = 37 
 
Entry X Y Z Time Product Yield de
a
 (%) 
1 33
 
26 27 48 h 13 60 % 38 
2 25
 
26 37 24 h 42 95 % 5 
3
 
33
 
26 37 16 h 43 79 % 7 
4
 
25
 
35 27 40 h 99 10 % - 
5 33 35
 
27 40 h 100 14 % - 
6 25
 
26
 
64 16 h 101 - - 
a) determined on the NMR spectrum of the cyclised derivative 
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Unfortunately, the use of isovaleraldehyde (35) did not lead to the expected derivatives. Only 
traces of product could be isolated. In the case of entry 4, the product 99 was found to have 
the molecular weight of 678.8 g/mol which corresponds to one half-cyclised derivative of the 
expected product (Fig. 33). As for entry 5, we could only isolate the product 100 with the 
molecular mass corresponding to a product where the Michael addition took place only once 
between hexanoyl phloroglucinol and isopentylidene syncarpic acid, and again with a poor 
yield (33). 
 
 
 
 
 
 
 
 
 
                                                    99                                                             100 
 
33 Structures of the isolated products 99 and 100. 
 
We also tried our reaction with Meldrum’s acid (64) and first thought we had the expected 
product since we obtained in 16 h a clear spot on the TLC plate and the starting materials 
had disappeared. However, after mass analysis, we were forced to reconsider our results 
since we could only observe masses of 256.4 and 292.1 g/mol in the mass spectra, which is 
way below the expected mass. Eventually we could get crystals of our main product and 
submit it to XRD (the structure was determined with a high R-factor but is still reliable). We 
obtained product 101, confirmed by NMR, which is the result of a condensation of the MA 
(64) and IBA (26), on which acetone added (Fig. 34). We could then identify the second 
mass to be probably the typical dihydrocoumarin product 102 already observed by NAIR,87 
when mixing a phloroglucinol, and MA (64) in the presence of an aldehyde. We could not 
isolate the desired product because of the extreme instability of the Meldrum’s acid. 
 
a)                                                                                 b) 
 
 
 
 
 
 
 
 
 
                 101                              102 
 
Fig. 34 a) Structure of the products obtained with Meldrum’s acid (64), b) crystal structure of 101. 
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Even if the study is non exhaustive, we could say that the one-pot synthesis is worth being 
used in the case of the dimedone and syncarpic acid derivatives. The shape of the central 
phloroglucinol does not seem to have much influence on the synthesis. However, the use of 
the Meldrum’s acid and isovaleraldehyde did not lead to any satisfying results.  
 
2.4.2. Development of the organocatalysed synthesis. 
2.4.2.1 Classic synthesis of myrtucommulones in mild conditions 
 
To further investigate the possibilities of these mild reaction conditions, we made some 
experiments where the formation of MCA (5) is independent of the formation of the Michael 
acceptor (31). Therefore, we synthesised IBSA (31) either with the published method,35 or 
with the method described in Scheme 30, isolated it and added it to a new reaction mixture 
containing IBPG (25) and a catalyst (Scheme 32). 
 
Method C 
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                25                         31  
 
 
 
                                                                                                                   8 
 
Scheme 32 Classic synthesis of MCA (5) catalysed by proline (90). Number of equivalents of the 
starting materials : IBPG (25) (1): SA (27) (6): proline (90) (0.5). 
 
Thanks to the work of J. SCHMITT,88 we could selectively synthesise NSMC (8) with proline 
(90) by adding only 1.2 eq. of the acceptor 31. Besides, the use of the achiral piperidine in 
DCM also led to a good yield offering another cheap alternative for the synthesis of the 
intermediate 8 (Tab. 11, entry 1-2). Similarly to the results of Method A, MCA (5) was 
obtained with 72 % yield with proline (90) and 70 % yield with the achiral pyrrolidine with the 
Method C (Tab. 11, entry 3-4). 
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Tab. 11 Formation of MCA (5) and NSMC (8) with the Method C in different conditions. 
Entry Method Catalyst (eq.) T(°C) Time 
Product 
(yield, %) 
ee
c
 
(%) 
de
d
 
(%) 
1  C
a 
Proline (90) (0.5 eq.) r.t. 48 h 8 (87) 3  
2     C
a, b
 Piperidine (0,5 eq.) r.t. 48 h 8 (79)  - - 
3 C
 
Proline (90) (0.5 eq.) r.t. 72 h 5 (72)  5 
4 C Pyrrolidine (0,5 eq.) r.t. 72 h 5 (70) - - 
5 C
 
- r.t. 72 h 5 (18) + 8 (69) - - 
6 C
 
- r.t. 10 days 5 (68) - - 
7  A
b 
Piperidine (0.5 eq.) 65°C 72 h 5 (56) - - 
8 C Proline (90) (0.5 eq.) -20°C 7 days 5 (35 ) + 8 (60) 0 8 
a) only 1.2 eq. of IBSA (31) was added, b) the reaction was run in DCM c) time was taken when IBPG (25) was added, c) 
determined on MCB (6) through HPLC on CHIRALCEL OD-H, iPrOH/n-hexane 20:80, 0.5-0.6 mL/min, 15 °C, d) determined on 
the NMR spectrum of PMCA (7) 
 
We then tested these new reaction conditions without catalyst to evaluate its influence on the 
product formation (Tab. 11, entry 5-6). As mentioned before, NSMC (8) was synthesised 
without the effort of a catalyst in three days with good yields. Moreover, MCA (5) could be 
isolated after 10 days even if no catalyst was present.  
 
If the reaction was heated, we observed a fast formation of MCA (5) in the presence of 
piperidine. However the heat also favoured the formation of iso-31 which is unreactive and 
limited the reaction to lower yields (Tab. 11, entry 7). Looking for conditions to favour the 
asymmetric reaction, we also run the reaction at -20°C and observed a very slow formation 
of the products but no significant asymmetric induction at this point. Only 8 % de could be 
read on the NMR spectrum of PMCA (7) and both optical rotations of NSMC (8) and MCA (5) 
were found to be zero (Tab. 11, entry 8). 
 
2.4.2.2 Synthesis of indandione-derivatives 
 
We next concentrated on the synthesis of some indandione-derivatives to extend the scope 
of the reaction (Tab. 12). Isobutylidene 1,3-indadione (IBIND) (86), already used in the patent 
of JAUCH,36 and a new isopentylidene indandione 103 were used to afford two derivatives 
described in the same publication (39 and 104) and a new one 41 made of the Michael 
acceptor 103 and hexanoyl phloroglucinol (33). 
 
We could form the indandione derivatives in moderate to fair yields. However, the reaction 
mixture always included the semi-derivatives, where the Michael reaction took place only 
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once, independently of the time of reaction and in a hardly extricable mixture. As for the 
synthesis of MCF (13), the use of proline (90) induced a non negligible diastereomeric 
excess of 35 and 34 % for the isobutylidene indandione derivative 39 and 104 respectively, 
where the meso form is preponderant (39a and 104a). Interestingly, in the case of the 
isopentylidene indandione derivative 41, the excess is smaller but in the other direction 
making the chiral part of the molecule the major product (41b) (see § 4.6.5). 
 
Tab. 12 Formation of indandione-derivatives with Method C. 
 
 
 
 
                   105         33          86 
           90 (1 eq.)             106         32          86 
                   107         33         103 
 
 
 
32                                   86 
33                                 103 
 
                                                                                                      39          33          86 
                                                                                                    104          32          86 
                                                                                                      41          33         103 
Entry X Y Time Product de
a
 (%) 
1 33
 
86 18 39 (72 %) + 105 (22 %)  35 
2 32
 
86 48 104 (71 %) + 106 (23 %)  34 
3
 
33
 
103 18 41 (49 %) + 107 (39 %) 22b 
a) the de was calculated on the amount of each diastereomer isolated, b) in this case 41b is the major product. 
 
The complete products 39, 104, and 41 were cyclised for analysis to their dehydrated forms, 
108, 109, and 110 respectively (Scheme 33). We could then grow crystals from our 
derivative 110 which helped us confirm its structure (Fig. 35). 
 
 
 
 
 
 
 
 
 
   39                                                                            108 
 104                                                                            109 
   41                                                                            110 
 
Scheme 33 Cyclisation of the indandione-derivatives 39, 104, and 41 
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Fig. 35 X-ray structure of the indandione-derivative syn-110a; ellipsoids at the 50 % probability level. 
 
2.4.2.3 Alternative catalysts 
Miscellaneous 
 
Looking to improve the efficiency and the stereoselectivity of the reaction, we varied the 
polarity, size and structure of the catalysts with the Method C (Tab. 13). 
 
Tab. 13 Variation of the catalyst in the Method C of formation of MCA (5) and NSMC (8).
a
 
Entry Catalyst (eq.) Solvent Time Product (yield, %) ee (%) de (%) 
1
 
(S)-Phe (0,5 eq.) MeOH 72 h 5 (70) - 8
b
 
2 (S)-Glu (0,5 eq.) MeOH 72 h 5 (69) + 8 (10) - 1
b
 
3 (S)-His (0,5 eq.) MeOH 72 h 5 (42) + 8 (11) - - 
4 (S)-Tyr (0,5 eq.) MeOH 144 h 5 (55) + 8 (37) - - 
5 (S)-Trp (0.5 eq.) MeOH 144 h 5 (70) + 8 (12) - - 
6
c
 Sparteine (111) (1 eq.) DCM 19 h 8 (96) 1
d
 - 
7 CN (112a) (0,5 eq.) MeOH 72 h 5 (77) 13
e
 36
 e
 
8 CN (112a) (1 eq.) MeOH 24 h 5 (92) 7
e
 2
e
 
9 (-)-Ephedrine (113) (0,5 eq.) MeOH 96 h 5 (80) 0
e
 2
e
 
10 Brucine (114) (0.5 eq.)
 
DCM 114h 5 (49) 0
e
 12
e
 
11 HODPP (115) MeOH 118 h 5 (10
f
) 0
e
 13
e
 
a) all reactions were performed at room temperature, b) determined on the NMR spectrum of PMCA (7), c) only 1.2 eq. of IBSA 
(31) was added, d) determined on MCB (6) through HPLC on CHIRALCEL OD-H, iPrOH/n-hexane 20:80, 0.5-0.6 mL/min, 15°C, 
e) determined on MCA (5) by HPLC on Reprosil 100 Chiral-NR, ACN: Buffer (35:65), Buffer: 30mM NH4OAc, pH9 DEA, 1.0 
mL/min, 24°C, f) the poor yield here is only due to a massive loss of product during the work-up. 
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To the list of the three previously tested amino acids (for Method B) were added tryptophan 
(Trp) and tyrosine (Tyr) (Tab. 13, entry 1-5). Although histidine and tyrosine afforded 
moderate yields, phenylalanine, glutamic acid and tryptophan catalysed the Michael addition 
to myrtucommulone A with yields of 69-70 %, however with longer reaction times. Since the 
yields or the reaction times were not satisfactory, the stereoselectivity was not considered. 
 
We then got interested in other natural products such as, sparteine (111), (+)-cinchonine 
(CN) (112a), (-)-ephedrine (113) and brucine (114) as catalysts (Fig. 36) (Tab. 13, entry 6-
10). The use of sparteine (111) (J. SCHMITT88) in DCM in combination with a stœchiometric 
amount of the IBSA (31) led to an excellent yield of 96 % of NSMC (8) (Tab. 13, entry 1). As 
for proline, the use of 1 eq. of CN (112a) afforded the product in excellent yield (92 %) in only 
24 h (Tab. 13, entry 8). Ephedrine (113) provided a very good yield as well but not brucine 
(114). Among them, only cinchonine (112a) showed a non negligible stereoselective 
induction affording MCA (5) with 13 % ee and 36 % de. It was so far the best 
diastereoselective achievement for MCA (5). We hence decided to concentrate more closely 
on Cinchona alkaloids in the next section (§ 2.4.2.4). 
 
 
              111                                112a                           113                            114 
 
Fig. 36 Structures of sparteine (111), (+)-cinchonine (112a), (-)-ephedrine (113), and brucine (114). 
 
Since CN (112a) provided encouraging results, we aimed for a catalyst also containing the β-
hydroxy-amine motif. 5-(hydroxydiphenylmethyl)pyrrolidin-2-one (HODPP) (115), was made 
in two simple steps. Pyroglutamic acid (116) was transformed into its methyl ester 117 and 
two phenyl groups were added through a Grignard reagent to afford 115 (Scheme 34).89 With 
this reagent, we wanted to have the hydrogen bonding hydroxyl group surrounded by big 
bulky groups. Unfortunately this reagent was also ineffective for our Michael reaction (Tab. 
14, entry 11). 
 
 
 
 
                116                                                117                                            115 
Scheme 34 Synthesis of the catalyst 115. 
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The fact that the Michael addition can be catalysed indifferently by tertiary, secondary, and 
primary amines, brought us to the conclusion that the Michael addition is not enhanced by 
the iminium/enamine catalysis but rather by the Brønsted character of the bases used. This 
probably also explains the lack of stereoselectivity observed with small “bases” like the 
amino acids. 
 
Synthetic peptides 
 
As mentioned above, amino acids and synthetic peptides have been used to perform 
asymmetrically a wide range of asymmetric reaction in the literature. The aldol condensation, 
Michael addition, Mannich reaction are the most common.81g,i The Julia-Colonna epoxidation 
of a chalcone also proceeds with Poly-L-Leucine (PLL) in presence of hydrogen peroxide 
and sodium hydroxide in a triphasic mixture with toluene.81g,90 
 
In our mild reaction conditions developed in § 2.4.2.1, the PLL was used as a catalyst but 
only 16 % MCA (5) and 39 % NSMC (8) could be isolated after 72 h and none of them 
showed any asymmetric enrichment. We then performed two experiments where the Michael 
donor 25 was primarily adsorbed on PLL, by mixing it in THF and evaporating the solvent 
until we obtained a powder. In the first case we adsorbed IBPG (25) directly on PLL and in 
the second IBPG (25) was first deprotonated prior to adsorption to form an “isobutyryl 
phloroglucinolate” (IBPGlate) adsorbed on PLL (Scheme 35).  
 
 
 
                                                                                31 
 
 
 
                                                                                                            8 (1 % ee) 
 
 
 
                  25                                                           31 
 
 
 
                                                                                                            8 (0 % ee) 
 
Scheme 35 Synthesis of NSMC with help of Poly-L-Leucine. 
 
In both cases the formation of NSMC (8) was then achieved in DCM which is a solvent that 
should not dissolve the adsorbed molecule, to force it to stay close or stuck on the PLL. In 
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these conditions the intermediate 8 could be synthesised quickly and with good yields but 
PLL did not induced enantiomeric excess in the product. 
 
2.4.2.4 Cinchona alkaloids derivatives 
 
Cinchona trees have been extensively investigated since centuries to look for treatment of 
malaria.91 The first unambiguous isolation of the well-known quinine (Q) (112c) was realised 
by PELLETIER and CAVENTOU in 1820.92 Around 30 different Cinchona alkaloids (112) were 
isolated from the Cinchona trees, the best known being cinchonine (CN) (112a), its pseudo-
enantiomer cinchonidine (CD) (112b), quinine (Q) (112c) and its pseudo-enantiomer 
quinidine (QD) (112d) (Fig. 37).93 It is noteworthy that, for historical reasons, cinchonidine 
(112b) and quinine (112c) have the same absolute configuration, whereas the logic would 
have wanted the names cinchonidine (112b) and quinidine (112d), terms in “–idine”, to be 
chemically related. 
 
 
 
 
 
 
 
 
 
                 112a                                                               112b 
                 112d                                                               112c 
 
Fig. 37 Structure of the four Cinchona alkaloids CN (112a), CD (112b), Q (112c), QD (112d). 
 
Cinchona alkaloids and their derivatives have been used as catalysts to perform a wide 
range of organic reactions.94 Among them, it is easy to find reports about the Michael 
reaction.95 As an example, CHEN et al. reported the addition of 1,3-dicarbonyl compounds 
(comparable with our phloroglucinol moiety) to α,β-unsaturated ketones (comparable with our 
Michael acceptor 31) with enantioselectivity between 89 and 99 %.96 
 
In most examples using this class of molecules, the alkaloids were used as bases.94b In other 
cases however, the bifunctional character of the β-hydroxy-amine motif was exploited.94d,97 
The quinuclidine nitrogen acts as a base while the vicinal free hydroxyl group can coordinate 
to other parts of the substrate through hydrogen bonding. The stereoselectivity observed is 
then depending on the conformational isomerism of the alkaloid. In Fig. 38 are depicted the 
hypothetical two most favoured conformers of quinidine (112d) in polar solvents.98 
 
Results and Discussion  - 66 - 
 
 
 
 
 
 
 
                                  anti-closed 112d                                   syn-closed 112d 
 
Fig. 38 Two different conformers of QD (112d) favoured in polar solvents.
98
 
 
Now, by converting the methoxy group on the 6’ position into a free hydroxyl group, a new 
class of catalysts saw the light, including a new possibility of hydrogen-bonding. They are 
derived from quinine (112c) and quinidine (112d) and referred as cupreine (CPN) (118) and 
cupreidine (CPD) (119) respectively.94d,95e Most interestingly, SHI et al.95e found out that in the 
case of the Michael reaction of anthrone to nitroalkenes catalysed by CPN (118) or benzoyl 
cupreine (Bz-CPN) (120), the enantioselectivity obtained is the opposite of the one observed 
with quinine (112c). Cupreine (118) was easily formed by deprotecting the phenolic hydroxyl 
group of Q (112c) by means of sodium thioethanolate. Bz-CPN (120) was obtained by 
benzoylating the C-9 hydroxyl group of Q (112c) to benzoyl-quinine (Bz-Q) (121) and then 
removing the phenolic methoxy group with boron tribromide (Scheme 36). 
 
 
 
 
                                 a                                     b                                     c 
 
 
 
 
 
 
       CPN (118)                      Q (112c)                          Bz-Q (121)                  Bz-CPN (120) 
 
Scheme 36 Synthesis of CPN (118), Bz-Q (121), Bz-CPN (120). a) NaSEt, DMF, 110°C, 6h, 86 %, b) 
PhCOCl, 30 % w/w NaOH solution in water, DCM, r.t., 4h, 99 %, c) BBr3, DCM, -78°C→r.t., 14h, 56 %. 
 
Improvement of the diastereomeric excess 
 
As mentioned before (§ 2.4.2.3), (S)-proline and various amino acids were already used as 
catalysts to synthesise myrtucommulone A (5) from IBPG (25) and IBSA (31). (S)-Proline 
provided only a poor diastereomeric excess (de) of 12 % (Tab. 14, entry 1). Likewise 
cinchonine (112a) was utilised and a de of 36 % (diastereomeric ratio (d.r.) of approximately 
2:1) could be determined thanks to the HPLC method developed by M. HANS,39 where meso-
5 was the major product and 5b had an ee of 13 % (Tab. 14, entry 2) (Fig. 39a). 
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Tab. 14 Screening of different Cinchona alkaloids for the diastereoselective synthesis of MCA (5). 
 
 
 
 
 
 
 
 
             25                          31                                                                 5 
 
Entry 
Catalyst  
(0.5 eq.) 
Description Time Yield ee
a 
de
a 
1
b 
90 (S)-proline 72 h 72 1 12 
2
 
112a CN 72 h 77 13 36 
3 112b CD 96 h 46 28 82 
4 112b + (S)-67 
CD+ (S)-
BINOL 
72 h 64 22 45 
5 112c Q 69 h 60 22 45 
6 118 CPN 72 h 67 14 44 
7 120 Bz-Q 72 h 60 14 36 
8 121 Bz-CPN 72 h 68 23 39 
a) determined by HPLC on Reprosil 100 Chiral-NR, ACN: Buffer (35:65), Buffer: 30mM NH4OAc, pH9 DEA, 1.0 mL/min, 24°C, 
b) One-Pot method. 
 
We then started screening different Cinchona alkaloids looking to improve our 
diastereoselectivity. We used CD (112b), the pseudo-enantiomer of CN (112a), and 
achieved an astonishing leap up to a diastereomeric ratio (d.r.) of 91:9 (5a:5b) (82 % de) and 
an enantiomeric excess of 28 % (Tab. 14, entry 3). The HPLC spectrum given below in Fig. 
39 confirmed the first efficient diastereoselective synthesis of MCA (5). 
 
                                                                                                                            9  :  91 
 
a)                                                                        b) 
 
                                 meso-5                                                              meso-5 
 
 
 
                       (S,S)-5                                                                        (S,S)-5 
                                                              (R,R)-5                                                              (R,R)-5 
 
 
 
 
Fig. 39 HPLC chromatogram of 5 a) with 36% de, b) with 82 % de (Reprosil 100 Chiral-NR, ACN: 
Buffer (35:65), Buffer: 30mM NH4OAc, pH9 DEA), 1.0 mL/min, 24°C) 
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On the other hand quinine (112c), which has the same absolute configuration as 
cinchonidine (112b) (see Fig. 37), gave only a slightly better de that cinchonine (112a) (Tab. 
14, entry 5). Based on the work of ZHOU et al.99 who added BINOL (67) to their proline-
catalysed aldol reaction to enhance the enantioselectivity (71 % ee with (S)-proline, 94 % ee 
with (S)-proline + (S)-BINOL), we as well added the diol (S)- 67 to our reaction mixture. 
However, we got with 45 % de a much worse result than the one obtained with the use of 
only CD (112b) (Tab. 14, entry 4). 
 
After having synthesised the different quinine derivatives as described above, we tried to 
either improve our diastereoselectivity or reverse it by using them. But although CPN (118) 
and Bz-CPN (120) offer different hydrogen bonding possibilities than CD (112b), they could 
only provide diastereoselectivity less than half as good and the main product was still the 
meso-form of MCA (5). Likewise Bz-Q (121) which does not have any hydrogen to donate in 
a hydrogen bonding, only showed a slightly lower diastereoselectivity than Q (112c) (Tab. 
14, entry 5-8) 
 
Investigation of the reaction catalysed by cinchonidine 
 
Having obtained our best results with CD (112b), we intended to improve the 
diastereoselectivity and the yield of our reaction by modifying our reaction conditions (Tab. 
15). First was varied the number of equivalents (y) of the catalyst. We figured out that 0.5 eq. 
was the best amount for our catalysis with 82 % de Tab. 15, entry 1-4). 0.25 eq. of catalyst 
led to an interesting 65 % de, but 0.33 eq. only provided 38 % de, and 1.5 eq. a negligible 3 
%. Another attempt (not listed here) was also run with only 0.1 eq. of CN (112a) to catalyse 
the same reaction and disregarding the much longer reaction time, we obtained exactly the 
same de of 36% as with 0.5 eq. (Tab. 14, entry 2). 
 
The variation of the solvent did not improve the de either but showed a dramatic influence on 
the stereoselectivity. The use of THF led to only weak inductions since, 26 % ee and 25 % 
de were obtained. On the other hand the use of DCM and toluene led to 41 % and 49 % ee 
respectively. These values were the first example of direct enantioselective organocatalytic 
synthesis of MCA (5) (Tab. 15, entry 5-7). 
Motivated by these results, we repeated the synthesis in MeOH and toluene but at 0°C and 
with a limited amount of the Michael acceptor 31 to enhance the formation of the 
semimyrtucommulone derivative 8. As already observed, the organocatalysis at low 
temperature needed much longer but did not provide any significant ee for NSMC (8) (Tab. 
15, entry 8, 10). As for the formation of myrtucommulone A, the lower temperature seems to 
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completely inhibit the asymmetric catalysis in MeOH since only 2 % de could be observed. In 
the case of toluene, 40 % ee were reached, which is again less than at room temperature. 
 
Tab. 15 Investigation of the reaction catalysed by cinchonidine. 
 
 
 
 
 
                                                               CD (112b) 
                                                                  (y eq.) 
                                                                                                                   8 
 
 
            (1 eq.)                    (x eq.) 
               25                          31 
 
 
 
                                                                                                                  5 
 
Entry x y Solvent T°C Time 
Product 
(Yield) 
ee
a 
de
a 
1
 
4.4 0.5 MeOH r.t. 96 h 5 (46) 28 82 
2
 
4.4 0.25 MeOH r.t. 94 h 5 (40) 14 65 
3 4.4 0.33 MeOH r.t. 96 h 5 (69) 16 38 
4 4.4 1.5 MeOH r.t. 90 h 5 (73) 9 3 
5 4.4 0.5 THF r.t. 6 days 5 (36) 26 25 
6 4.4 0.5 DCM r.t. 27 h 5 (94) 41 2 
 7 4.4 0.5 Toluene r.t. 72 h 5 (86) 49 8 
8 1.4 0.5 MeOH 0°C 10 days 8 (48) 2
b
 - 
9 4.4 0.5 MeOH 0°C 10 days 5 (44) 2 2 
10 1.4 0.5 Toluene 0°C 96 h 8
 
(56) 13
b
 - 
11 4.4 0.5 Toluene 0°C 96 h 5 (64) 40 5 
a) determined by HPLC on Reprosil 100 Chiral-NR, ACN: Buffer (35:65), Buffer: 30mM NH4OAc, pH9 DEA, 1.0 mL/min, 24°C, 
b) determined on MCB (6) by HPLC on ChiralCelOD-H, iPrOH/n-hexane, 20:80, 0.5 mL/min, 15°C 
 
An attempt was made with HPG (33) as a starting material (Scheme 37). As expected, we 
could observe a diastereoselectivity similar to the one obtained with IBPG (25). Despite a 
poor yield, 84 % de and 18 % ee were measured for MCF (13), confirming our reaction to be 
an excellent possibility to synthesise the meso-form with a very good de. 
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                                                            CD (112b)                              meso-13a 
 
 
 
            33                         31 
 
 
 
                                                                                                               13b 
 
Scheme 37 Synthesis of meso-MCF (meso-13a) with 84 % de. 
 
Phase transfer catalysis 
 
Because they possess an easily quaternisable tertiary amine, Cinchona alkaloids have been 
extensively exploited in the development of phase transfer catalysts (PTC). They are known 
to catalyse various types of epoxidations of enones, using different oxidising agents such as 
hydrogen peroxide or hypochlorite.81f  
The Weitz-Scheffer epoxidation of isoflavones by hydroperoxide in the presence of a simple 
Cinchona alkaloid-based PTC was reported by ADAM et al.100 and provided an epoxide with 
ee values up to 98 %. DIEZ-IBARRA et al.101 published a short study on the Michael addition of 
different enolisable ketones on α,β-unsaturated ketones under phase transfer conditions and 
reported ee up to 70 %. Likewise COLONNA et al.102 reported Michael additions of thioalkanes 
or nitroalkanes on enones with PTC and KF as a co-catalyst but with restricted efficiency. In 
their work on asymmetric alkylation, DOLLING et al. could observe an excellent 
enantioselectivity (92 % ee) on the methylation of 2-phenyl-1-indanone catalysed by a 
Cinchona based-PTC and NaOH in toluene. 
 
Based on this reports, we applied the principle of phase transfer catalysis to our Michael 
reaction in different conditions. Two PTCs were synthesised: N-benzylcinchoninium bromide 
(BnCNBr) (122a) derived from cinchonine (112a) and N-benzylcinchonidinium bromide 
(BnCDBr) (122b) derived from cinchonidine (112b). In both cases, the Cinchona alkaloid and 
benzyl bromide were dissolved in chloroform and stirred overnight at room temperature after 
a short period at reflux (Scheme 38).103 
  
d.r. 92 : 8 
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                                     112b                                                               122b 
 
 
Scheme 38 Synthesis of the phase transfer catalysts BnCNBr (122a) and BnCDBr (122b) 
 
Our Michael addition was first performed with only 1.4 eq. of the Michael acceptor 31 to 
synthesise the semimyrtucommulone intermediate 8. As a reference the reaction was run 
with the catalyst 122a at 0°C without any added base in a homogeneous phase (i.e. without 
phase transfer) and yielded in less than 2 hours 89 % of product (Tab. 16, entry 1). This 
proved that the PTC is an excellent catalyst for the reaction. As a comparison, the same 
reaction in toluene with CD (112b) as a catalyst yielded 56 % of 8 after 96 h (Tab. 15, entry 
10). 
 
Following the procedures of ADAM et al.100 (1 M KOH) and COLONNA et al. (KF), we then used 
alkaline co-catalysts in a water/toluene mixture but despite their obvious efficiency for 
catalysing the Michael reaction, they did not induce any asymmetry (Tab. 16, entry 2-3).  
 
Next, we repeated the reactions with more equivalents of the isobutylidene syncarpic acid 
(31) to obtain MCA (5) as a product (Tab. 16, entry 4-5). In that case the reaction times were 
in accordance with the one observed with CD (112b) as a catalyst. The reaction without any 
base provided only low ee and de. Interestingly, when enhanced with 1 M KOH, the yield, 
reaction time, and stereoselectivities were improved, the last remaining though pretty low 
compared to the reaction with the natural Cinchona alkaloids (Tab. 15, entry 10). 
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Tab. 16 Synthesis of MCA (5) and NSMC (8) with Cinchona-based PTCs (122). 
 
 
 
 
 
                                                          122 (0.5 eq.) 
 
                                                                                                                8 
 
 
 
              25                     31 (x eq.) 
 
 
 
                                                                                                               5 
 
Entry 
Catalyst 
(0.5 eq.) 
Co-catalyst (eq.) x T°C Time 
Product 
(Yield) 
ee
 
de
 
1
 
122a - 1.4 0°C 1.75 h 8 (89) 1
a 
- 
2
 
122a 1 M KOH (2 eq.) 1.4 0°C 1.75 h 8 (84) 0
a 
- 
3 122a KF (1.1 eq.) 1.4 0°C 1 h 8 (86) 1
a 
- 
4 122b - 4.8 r.t. 120 h 5 (58) 18
b 
13
b
 
5 122b 1 M KOH (2 eq.) 4.8 r.t. 67 h 5 (93) 28
b
 11
b
 
a) determined by HPLC on Reprosil 100 Chiral-NR, ACN: Buffer (35:65), Buffer: 30mM NH4OAc, pH9 DEA, 1.0 mL/min, 24°C, 
b) determined on the cyclised product by HPLC on ChiralCelOD-H, iPrOH/n-hexane, 20:80, 0.5 mL/min, 15°C 
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2.4.3. Conclusion on the organocatalysis 
 
Changing the conditions of the previously published synthesis of myrtucommulones,35a we 
could develop three new methods to obtain these products. Method A and B consist of a 
three component one-pot reactions catalysed by proline where a Knoevenagel reaction and 
two successive Michael additions take place. This is to our knowledge the first report of such 
tandem reaction with syncarpic acid. We could prove that the duality of proline which can act 
as a nucleophile but also as a base was essential for this synthesis. Moreover we could use 
this one-pot reaction condition to synthesise some dimedone derivatives (42 and 43) which 
have shown interesting cytotoxic activity.34 
 
In addition, the fact that we could observe the formation of myrtucommulones by simply 
mixing the starting materials together with an amino acid as a catalyst (or without catalyst), 
gave us a hint on the biosynthesis of myrtucommulones. As a matter of fact, even if the 
formation of the isobutylidene derivative in the plant or the fungus (if it happens so) would 
need the intervention of proline (definitely present), the rest of the reaction can be catalysed 
by any weak base present around. This, along with the fact that we only isolated mixtures of 
stereoisomers, pleads in favour of a non specific pathway for the biosynthesis of MCs. 
However, it is interesting to note that instances in which an enzyme produces both 
enantiomers are known.104 
 
Method C led to more knowledge about the chemical formation of MCs. We could synthesise 
norsemimyrtucommulone (8) and myrtucommulone A (5) in good to excellent yields and 
some indandione-derivatives (39, 41 and 104), including a new potentially important active 
compound, in fair yields. Moreover, the One-Pot conditions as well as the Method C 
conditions offer a new cheap, secure and environmentally friendly alternative to synthesise 
the myrtucommulone derivatives, making them even more attractive for the pharmaceutical 
industry. 
 
Thanks to Cinchona alkaloids, we could directly synthesise myrtucommulone A (5) with good 
diastereomeric excesses in methanol (up to 82 %) and interesting ee (up to 49 %) in 
dichloromethane or toluene. This was principally realised through the use of cinchonidine 
(112b) which afforded the best diastereomeric ratio (92:8) for MCF (13). The use of synthetic 
peptides or phase transfer catalysts did not provide satisfying results. 
 
Unfortunately, the main compound obtained was always the meso-form 5a of MCA and 
despite several variations of the catalyst (e.g. cupreines, PTC), we could not synthesise 
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preferentially 5b which is the mixture of R,R and S,S enantiomers. The experimentation 
showed as well that in methanol, the reaction is weakly enantioselective for MCA (5) and not 
at all for NSMC (8). For this reason, one can conclude that the stereodifferentiation takes 
place on an almost racemic mixture of NSMC (8) and that cinchonidine (112b) favours the 
synthesis of the second stereocenter with the opposite absolute configuration of the one 
already present. In other words, both (R)-NSMC ((R)-8) and (S)-NSMC ((S)-8) are formed in 
the reaction mixture in more or less equal amounts. From (R)-8, the cinchonidine (112b) 
catalyses preferentially the formation of (R,S)-MCA ((R,S)-5a) and from (S)-8, CD (112b) 
favours the formation of (S,R)-MCA ((S,R)-5a), both being one and the same molecule 
because of the symmetry of the compound, namely meso-5a (Scheme 39). 
 
 
 
 
 
 
 
 
                                                              25                     31 
                                                                             CD (112b) 
 
 
 
 
 
 
                           (R)-8                                                                                (S)-8 
                                 31 + CD (112b)                                      CD (112b) + 31 
  
 
 
 
 
 
 
 
                                                    (R,S)-5a or (S,R)-5a = meso-5a 
 
Scheme 39 Diastereoselectivity in the formation of MCA (5) catalysed by CD (112b). 
 
As a matter of fact, if we found a method to form the racemate preferentially, we could think 
about combining our metal-catalysed reaction with good ee with an organocatalytic method 
to reach almost enantiopure compounds (see § 3 Conclusion and Perspectives). 
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2.5. Synthesis of a biotin-linked myrtucommulone 
 
As described in the introduction (§ 1.1.3.4), in order to perform affinity based 
chromatography (also known as target fishing) experiments, we busied ourselves with the 
formation of a biotin-linked myrtucommulone. Two strategies were considered principally: the 
first concerned the introduction of an alkyl linker and the other the use of a diamine spacer to 
bind biotin and myrtucommulone through peptide bonds. 
 
2.5.1. Attempts with an alkyl linker 
 
To form a biotin-bound myrtucommulone we first aimed for a synthesis where the linker is as 
simple as possible and where we could use as little as possible of the expensive biotin (23) 
As depicted in Fig. 40 the first goal was to introduce a decyl chain (green) between the 
myrtucommulone moiety (in this section (§ 2.5) the part in blue on Fig. 40 will be referred as 
myrtucommulone) and an amide bound biotin (red) (10-biotinamido-1-myrtucommulone-
decane (123)). 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                            123 
 
Fig. 40 Structure of the aimed 10-biotinamido-1-myrtucommulone-decane (123) 
 
Our first attempt consisted in synthesising 11-amino-undecanoyl-phloroglucinol (AUPG) 
(124) to then directly form an amide bond with biotin (23). It based on a German patent from 
1963 which used a warm solution of polyphosphoric acid (PPA), obtained by stirring 
phosphoric acid (85% wt. in water) together with phosphorus pentoxide at 200°C for 2h,105 to 
bind 11-aminoundecanoic acid (AUA) (125) and phenol.106 AUA (125) and phloroglucinol (28) 
were then mixed in PPA to form the desired amino-undecanoyl-phloroglucinol (124) (Scheme 
40). Unfortunately, our efforts to form AUPG (124) led to a hardly manageable product 
(hypothetic-124), insoluble in most solvents making it unidentifiable with the common 
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methods. Since no formation of myrtucommulone-derivative (MC-derivative) was observed in 
presence of the Michael acceptor 31 under different conditions, we did not further investigate 
this unidentified product and changed our synthetic strategy. 
 
 
 
                                                                                                                            hypothetic-124 
 
                                                                        125 
                               28                                                                                                         31 
 
                                                                                                                                     MC- 
                                                                                                                               derivative 
 
                   23                                                    124 
 
 
Scheme 40 Attempts using the PPA method and structure of expected AUPG (124) for an amide 
bonding with biotin (23). 
 
Our next attempt was directed to 11-bromo-undecanoyl-phloroglucinol (BrUP) (126) that 
would then be bound to biotinamide (BtA) (127) through a nucleophilic substitution of the 
bromine to form 11-biotinamido-undecanoyl-phloroglucinol (128). To begin with, 11-
bromoundecanoic acid (129) was transformed into its acyl chloride with oxalyl chloride and 
added to PG (28) in presence of aluminium trichloride for an aromatic electrophilic 
substitution on the aromatic ring to obtain BrUP (126) (Scheme 41).107 
 
 
 
 
                                                                28 
                                           129  
                                                                                                               126 
 
 
 
 
 
 
                                   23                                                                   127 
  
 
 
 
 
                                                                                            130 
 
Scheme 41 Preparation of the starting material for the alkylation attempts of biotinamide (127). 
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Next, biotin was dissolved in thionyl chloride and an ammonium chloride solution was added 
after removing the excess of thionyl chloride to afford biotinamide (127) with poor yield due to 
the work up procedure.108 Not to waste the expensive biotinamide, isobutyramide (130) was 
also synthesised from isobutyryl chloride with a similar procedure but a better yield (Scheme 
41).109 
 
Then, following the procedure of LELE et al.110 for the preparation of acrylamides, we mixed 
BtA (127) and BrUP (126) in presence of aluminium trichloride in acetone but only one of the 
isolated products showed some of the characteristic biotin peaks in the NMR-spectrum but in 
improbable proportion to the rest of the hydrogen atoms (Tab. 17, entry 1). We repeated the 
reaction with isobutyramide (130) and different amounts of aluminium trichloride but only got 
similar products (Tab. 17, entry 2). Raising the reaction temperature to 80°C and changing 
the solvent to DMF did not lead to any product formation (Tab. 17, entry 3).111 Finally with 
added KOH to a mixture of the starting materials in DME but even though we could see the 
consumption of the starting material, no main product could be identified (Tab. 17, entry 4).112 
 
Tab. 17 Attempts to bind an amide to 11-bromo-undecanoyl-phloroglucinol (126). 
 
 
 
 
 
                                                 127: R = “Biotin” 
                              126             130: R = iPr                                  128: R = “Biotin” 
 
Entry RCONH2 Reagent Solvent T°C 
1
 
127 AlCl3 (4 eq.) Acetoneabs 50°C 
2
 
130 AlCl3 (2 eq.) Acetoneabs 50°C 
3 130 - DMF 80°C 
4 130 KOH (2.5 eq.) DME 75°C 
 
Since we did not isolate the desired product we changed our plans and decided to first add 
biotin (23) on the alkyl moiety and then bind it to the phloroglucinol unit. For this new route, 
we synthesised in three steps 11-biotinamido-undecanoic acid (131). We first had to esterify 
AUA (125) by using thionyl chloride in methanol to synthesise 11-amino-undecanoic acid 
methyl ester (AUMe) (132),113 then bind biotin (23) through an amide bond to the amino-ester 
to form 133 using diisopropylcarbodiimide (DIC) and hydroxybenzotriazole (HOBT)114 and 
finally deprotect the acid function in basic aqueous medium (Scheme 42).113 Unfortunately, 
our efforts to synthesise the desired biotin-phloroglucinol derivative 128 through a Friedel-
Crafts type reaction remained unsuccessful.  
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Scheme 42 Formation of 11-biotinamido-undecanoic acid (131) and attempt to synthesise 128. 
 
Several starting materials were synthesised but attempts to bind biotin (23) to the 
phloroglucinol moiety led to undefined products. Attempts to bind biotin (23) to an alkyl chain 
over a peptide bond worked pretty well, however no derivative like 124  could be obtained. 
Therefore we decided to change our target molecule and focused on the reliability of the 
peptide bond formation. 
  
Results and Discussion  - 79 - 
2.5.2. Introduction of a polyamide linker 
 
We knew from the prior work of H. MÜLLER that it is possible to bind “sebacoyl-
myrtucommulone” (24) through a peptide bond to agarose-beads with free amines. Besides, 
it is not unusual to find biotin bound to different diamino-alkanes such as 1,4-diaminobutane 
or 1,6-diaminohexane in the literature.115 In consequence, we aimed for a new compound 
called N-(4-(biotinamido)butyl)-5-myrtucommulone-pentanamide (biotin-linked-MC) (134). In 
this molecule, the myrtucommulone-oxopentane moiety (blue) is bound to a small spacer 
(green) through an amide bond on the one hand, and biotin (red) is bound likewise to the 
other side of the spacer on the other hand (Fig. 41). 
 
 
 
 
 
 
 
 
 
 
 
                                                                        134 
 
Fig. 41 Structure of biotin-linked-MC (134) 
 
We focused on the myrtucommulone moiety first und synthesised over 4 steps 5-
myrtucommulone-pentanoic acid (MCPA) (135) that was derivatised for better analysis to its 
pentacyclic derivative 136 (PMCPA). 
Starting from adipic acid (137) that we transformed to its diacyl chloride,116 the monoester of 
adipoyl chloride was formed (138), through slow addition of an ethanol/triethylamine 
mixture.117 Despite special attention, a mixture of the monoester and the diester was 
obtained, which explains the low yield. Phloroglucinol (28) was then acylated under Friedel-
Crafts conditions to form 6-oxo-6-phloroglucinol-hexanoic acid ethyl ester (139) (Scheme 
43).107b 
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Scheme 43 Synthesis of 6-phloroglucinol-hexanoic acid ethyl ester (139) 
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The ester was subsequently saponified in presence of sodium hydroxide to 140.118 After that, 
two equivalents of isobutylidene syncarpic acid (31) were added to 140 which had been 
deprotonated with sodium hydride to form MCPA (135) with a yield of 67 % (Scheme 44).35a 
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                                        140                                                                  135 
 
Scheme 44 Synthesis of MCPA (135) 
 
Like other MCs, the NMR-analysis was only made possible on the cyclic derivative. As 
usually done for myrtucommulone derivatives, the product 135 was cyclised using pTsOH in 
hot toluene to yield its pentacyclic derivative 136 (Scheme 45). 
 
 
 
 
 
 
  
                                135                                                                                  136 
 
Scheme 45 Cyclisation of MCPA (135) to PMCPA (136). 
 
We then concentrated on the other side of the product, namely the biotin-bound-spacer 
(Scheme 46). As depicted above in green, 1,4-diaminobutane (DAB) (141), one of the 
molecules responsible for the bad smell of decayed flesh, was chosen as a spacer. It was 
first protected on one side with Boc anhydride to form the carbamate (Boc-DAB) (142).115a 
Using the conditions described by POOLE et al.115a biotin (23) was then bound to the amino-
carbamate 142 in presence of HOBT and DCC to synthesise tert-butyl-4-biotinamido-
butylcarbamate (143) with 72 % yield. The amine was then deprotected to afford 4-
biotinamido-butylamine (BtABA) in form of its trifluoroacetate salt (144).115d 
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Scheme 46 Synthesis of the Biotin-spacer moiety (144). 
 
Once both parts were ready, BtABA (144) and MCPA (135) were put together following the 
previously used procedure from SOURAL et al.114 for peptide bond formation. After 14 h 
stirring and appropriate purifying, biotin-linked-MC (134) could be isolated with 47 % total 
yield based on biotin (Scheme 47). 
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Scheme 47 Synthesis of biotin-linked-MC (134)  
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Because of the myrtucommulone moiety, whose analysis is complicated, but also because of 
the general the size of the molecule, NMR-analysis was challenging for this compound. 
However, high resolution mass spectrometry confirmed the mass of each molecule. As a 
comparison, the cyclised derivative 136 was used in presence of BtABA (144) in the same 
conditions as 135 to afford biotin-linked-PMC with a very good yield (145) (Scheme 48). 
 
 
 
 
 
 
 
 
 
                                     144                                                         136 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                         145 
 
 
Scheme 48 Synthesis of biotin-linked-PMC (145). 
 
After some unsuccessful attempts to bind biotin and myrtucommulone through a simple alkyl 
ligand by different means, the longer but more efficient approach where biotin is bound over 
a diaminobutyl spacer afforded the expected product. The compound was then sent to the 
research group of Prof. WERZ for the so called affinity based chromatography experiments. 
Unfortunately, until the compilation of this work the results of these experiments were not 
available. 
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3. Conclusion and perspectives 
 
The objectives of this work were to further investigate the different methods for the synthesis 
of myrtucommulone-derivatives, search for an asymmetric synthesis of such compounds 
(together with the determination of the absolute configuration). One part is dedicated to the 
synthesis of a new biotin-linked myrtucommulone for pharmacological experiments. 
 
The development of new mild reaction conditions using amino acids as catalysts for the 
synthesis of MC-derivatives in ethanol brought additional knowledge about this class of 
compounds. We could observe the slow formation of NSMC (8) and MCA (5) without the 
need of any catalyst, which gave us a hint concerning the biosynthesis of this type of 
molecules. It is indeed thinkable that isobutyryl phloroglucinol (25), syncarpic acid (27) and 
isobutyraldehyde (26) are synthesised in the plant and react together thanks to the 
intervention of free amino acids, especially proline, without the interference of an enzyme. At 
this time, further investigations are in progress to know whether myrtle itself or the newly 
found endophytic fungus19 (or both together) are responsible for the synthesis of MCs. 
 
Furthermore, the development of One-Pot reaction conditions, which are so far the first 
known example of a tandem Knoevenagel-Michael reaction using syncarpic acid as a 1,3-
diketone, allowed the direct formation of some MC-derivatives avoiding tedious isolation 
steps. 
 
The use of environmentally-friendly solvents such as ethanol and non-hazardous catalysts 
such as amino acids or cheap natural products is a real advantage for the possible industrial 
synthesis of myrtucommulones. Moreover, the possibility to use continuous flow 
processes,119 rather unusual in the laboratory, could largely improve the yields. As an 
example, if the Michael acceptor 31 is continuously synthesised in a reactor containing the 
immobilised catalyst (e.g. proline) and dropped to another reactor with the Michael donor 25, 
the consumption of the phloroglucinol 25 by the aldehyde 26 is avoided. Besides, one could 
imagine that IBSA (31) can be added at such a rate that it is consumed without having much 
time to isomerise (Scheme 49). 
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Scheme 49 Possible industrial conception of MCA (5). 
 
Two new important derivatives were synthesised: the indandione derivative 41 (§ 2.4.2.2), 
from which great therapeutic potency is expected due to compounds with similar structure, 
and the biotin-linked myrtucommulone 134 (§ 2.5.2) for the research for new cellular targets 
for MCs. Unfortunately, the results concerning the usefulness of these compounds are not 
known yet. 
 
Finally, the main focus of this work was the investigation of the stereoselective synthesis of 
MCs and especially NSMC (8) and MCA (5). The first achievement was to determine the 
absolute configuration of MCB (6) and PMCA (7) which, after the first success of the 
asymmetric catalysis, also gave access to the absolute configuration of NSMC (8) and MCA 
(5) respectively.  
 
After arduous work, NSCM (8) and likewise MCB (6) were synthesised with 72 % ee using 
the heterobimetallic complex ALB (66e). Numerous variations of the catalyst, including 
variations of the central metal, the counterion, the size and shape of ligands led to the 
conclusion that 3 eq. of ALB (in regard to the Michael donor) in a DCM/THF mixture at 0°C 
were the optimal conditions for this reaction. However, other variations, such as the zinc-
BINOL complex 146 (Scheme 50)120 used for the Michael addition of unmodified ketones on 
enones or the zirconium-BINOL complexes (147),54,121 very efficient for the Friedel-Crafts 
reaction between indoles and α,β-unsaturated ketones can still be considered (Scheme 50). 
Likewise salen ligands like 148 or 149 made of BINOL and/or aluminium, have shown a great 
asymmetric influence on the Michael reaction (Scheme 50).122 
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Scheme 50 Structures of the possible catalysts 146, 147, 148 and 149 for the enantioselective 
Michael reaction. (M
1
 = transition metal M
2
 = alkali or earth alkali metal). 
 
Generally speaking, this enantioselective Michael addition offers an interesting possibility to 
couple a sterically hindered acceptor with a donor with more than one reaction site. However 
the mechanistic investigations showed the limits of the reaction since the keto-group of the 
acyl-phloroglucinol derivative seemed to directly participate in the asymmetric catalysis. 
Likewise the syncarpic acid moiety showed to be essential for good enantioselectivity. 
 
Nevertheless this is the only example of enantioselective synthesis of a myrtucommulone- 
derivative to this day.57 For this reason, the same conditions were used to form MCA (5) and 
likewise PMCA (7) with 81 % ee. Unfortunately, we do not know yet if the enantiomerically 
enriched MCA (5) shows a better efficacy than racemic MCA (5) from the pharmacological 
point of view. 
 
The metal-catalysis was only enantioselective, and all the attempts afforded only insignificant 
diastereomeric excess. For this reason we concentrated also on organocatalysis. After some 
unsuccessful experiments with synthetic peptides and various natural products, the Cinchona 
alkaloids happened to be remarkably efficient to synthesise MCA (5) enantio- and 
diastereoselectively. As a matter of fact MCA (5) and MCF (13) could be obtained with d.r. of 
91:9 (5a: 5b) and 92:8 (13a:13b) respectively by adding cinchonidine (112b) to the mixture of 
the starting materials in methanol. Additionally, the use of cinchonidine (112b) in toluene led 
to an ee of 49 % in the direct synthesis of MCA (5). Unfortunately only meso-5a was made 
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accessible under these conditions, and the diastereomeric ratio could not be inverted 
towards a major formation of 5b, independently of the variations of the catalysts (cupreines, 
PTC). 
 
Hence, two different reaction conditions were developed to synthesise MCA (5): on the one 
hand enantioselectively and on the other hand diastereoselectively. Regrettably, it was not 
possible to combine both to form only one enantiomer of MCA. Indeed the organocatalysed 
reaction only led to meso-5 as summarised in Scheme 51a and never 5b. Otherwise, it would 
have been conceivable that the use of the enantiomerically enriched NSMC (8), made 
through metal-catalysis, with a diastereoselective organocatalyst would lead to the formation 
of one enantiomer of myrtucommulone preferentially. If we had an organocatalyst which has 
the reverse diastereomeric effect than cinchonidine (112b), that we would call anti-
cinchonidine (anti-CD), we would be able to produce the racemic mixture preferentially 
(Scheme 51b). Now if we applied it on (S)-NSMC ((S)-8) with 72 % ee (ratio 86:14), we can 
imagine in the case of a matched stereodifferentiation that we would obtain (S,S)-5b with a 
good de and an ee superior to 72 % (Scheme 51c). 
 
a) b) c) 
IBPG (25)      +      IBSA (31) 
 
                          CD (112b) 
 
      (R)-(8)      +        (S)-(8) 
           1          :           1 
               CD (112b)  
           31                 31 
 
  (R,S)-(5a)          (S,R)-(5a) 
 
           meso-MCA (5a) 
 
IBPG (25)      +      IBSA (31) 
 
                          anti-CD 
 
      (R)-(8)      +       (S)-(8) 
           1          :           1 
 
    31         anti-CD          31 
 
   (R,R)-(5b)          (S,S)-(5b) 
                       = 
               MCA (5b) 
                   0% ee 
IBPG (25)       +      IBSA (31) 
 
     (R,R)-ALB     (66e) 
 
      (R)-(8)      +       (S)-(8) 
          14          :         86 
 
    31         anti-CD          31 
 
   (R,R)-(5b)          (S,S)-(5b) 
                       = 
                MCA (5b) 
               ee > 72 % ? 
   
Scheme 51 Possible selective synthesis of the 5b a) with CD (112b) b) and c) with a hypothetic anti-
CD. 
 
A good way to start looking for “anti-CD” would be the use of thiourea derivatives widely used 
in the literature for Michael reactions especially the ones including a nitro compound,37,81h,123 
but not necessarily.124 Various papers report Cinchona alkaloids-derived thioureas as 
organocatalysts of choice due to the hydrogen bonding ability of thiourea combined with the 
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basicity and rigidity of the Cinchona alkaloids structure (see compounds 150 and 151 Fig. 
42).37,123,125 
 
 
 
 
 
 
 
 
 
 
 
 
                                           150                                                        151 
 
Fig. 42 Structures of the possible thiourea catalysts 150 and 151 for the Michael addition. 
 
A final suggestion would be another combination of both methods used in this work. This 
would imply the synthesis of an aluminium catalyst with Cinchona alkaloids ligand such as 
the one used in the work of FENG et al.126 for the Michael addition of malonitrile to chalcone. 
Similarly the use a mixture of both BINOL and Cinchona alkaloid as bifunctional 
metal/organo-catalyst has been already described in the literature.127 
 
To conclude with, this work treated most of the set objectives with the success and troubles 
that go along with such projects. Some room remains for further investigations on the theme 
of myrtucommulones and their derivatives, for instance by improving the asymmetric 
synthesis or refining the direct formation of MC-derivatives under mild conditions. 
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4. Experimental 
4.1. General 
 
1H and 13C NMR spectra were recorded on a AV II BRUKER FT-NMR spectrometer (400 MHz 
and 101 MHz respectively) The spectra were processed with the MestRec 4.9.9.6 software of 
the MESTRELAB RESEARCH S.L. company. Chemical shifts (δ) are reported in ppm, relative to 
the following internal standards: chloroform-d (CDCl3, 
1H: δ = 7.26 ppm, 13C: δ = 77.00 ppm), 
acetone-d6 (CO(CD3)2,
1H: δ = 2.05 ppm, 13C: δ = 30.83 ppm), methanol-d4 (CD3OD, 
1H: δ = 
3.31 ppm, 13C: δ = 49.05 ppm), and dimethylsulfoxide-d6 (DMSO-D6, 
1H: δ = 2.50 ppm, 13C : 
39.43 ppm). The coupling constants are given in Hertz (Hz) and the multiplicities of the 
signals as follow: s, singlet; d, doublet; t, triplet; q, quartet; quint, quintet; sext, sextet; sept, 
septet; m, multiplet. 
 
High Pressure Liquid Chromatography (HPLC) analysis was performed on :  
 A SYKAM equipment consisting of a S7121 Reagent Organizer, a S1122 Solvent 
Delivery System, a S8111 Low Press Gradient Mixer, a S3210 UV/Vis Detector, and 
a Rheodyne 7725i Injector Valve. The processing of the data was realised with the 
Chromstar 6.3 Software from SCPA GMBH. 
 A BECKMANN System Gold® HPLC equipment consisting of a 127 NM Solvent 
Module, a 166 NM Detector and a Rheodyne 7125 Injector Valve. The data was 
treated with the Clarity Lite 2.6.4.402 Software from DATA APEX. 
For reversed phase (RP) non chiral chromatography, the columns NUCLEODUR® 100-5 C18 
ec (250 x 4 mm, MACHEREY-NAGEL) and Chromolith® Performance 100-4.6 (MERCK) were 
used. The Reprosil 100 Chiral-NR (250 x 4.6 mm, DR. MAISCH GMBH) column was used for 
chiral chromatography on RP and normal phase (NP). For chiral chromatography on normal 
phase, the CHIRALCEL® OD-H (250 x 4.6 mm, DAICEL CHEMICAL INDUSTRIES) column was 
used as well. UV detection was performed at 210 nm, 254 nm and 292 nm. 
 
High Resolution Mass Spectra (HRMS) were recorded by TOBIAS DIER on a SolariX FTMS 
7.0 T (BRUKER) equipment and analysed with Data Analysis 4.2 (BRUKER) in cooperation with 
the bio analytics group of Prof. VOLMER, Universität des Saarlandes. 
Liquid Chromatography-Low Resolution Mass Spectrometry was performed on a LC-MS 
equipment from SHIMADZU composed of an Auto-Injector SIL-6B coupled to a System 
Controller SCL-6B, a Liquid Chromatography system using a LC-AT10 vp pump coupled to a 
SCL-10 A vp System Controller and a Diode Array Detector SPD M10A vp. The masses 
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were recorded on the mass spectrometer LC/MS-2020 and the spectra were interpreted with 
LabSolutions 5.65 from SHIMADZU. EC 250x4 NUCLEODUR® 100-5 C18 ec (MACHEREY-
NAGEL). and Chromolith® Performance 100-4.6 (MERCK) were used as chromatographic 
columns. 
 
Thin Layer Chromatography (TLC) was performed on silicagel Si 60 F254 glass plates 
(MERCK). The solvents used are abbreviated as follow: acetone (A), petroleum ether (PE), 
ethyl acetate (EA), dichloromethane (DCM), methanol (MeOH) and the mixtures are given in 
volume ratios. The compounds were detected with UV-light or the following stains: 
 Phosphomolybdic acid 
 Eckert’s Reagent (anisaldehyde, acetic acid, sulphuric acid, methanol, 0.5:10:5:85, 
v:v:v:v) 
 Ehrlich’s Reagent (p-dimethylaminobenzaldehyde, methanol, HCl, 1:25:75, m:v:v) 
 Dragendorff’s Reagent (solution (1): Bi(NO3)3 (0.11 g), tartaric acid (1.25 g), water (5 
mL); solution (2): KI (2.0 g), water (5 mL); reagent : (1) (5 mL) + (2) (5 mL) + tartaric 
acid (20 g) + water (100 mL)) 
 
Flash Column Chromatography was carried out on Silicagel 60 (40-63 μm) from MERCK 
Company. Solvents were distilled before use and are abbreviated as detailed above. 
 
Crystallographic Data was obtained through single crystal X-Ray Diffraction on a CCD-
Detector-X8 Apex II from BRUKER AXS. The data was calculated with a Micro Vax II-
computer form the DIGITAL EQUIPMENT CORPORATION. The following software was used : 
 Space group determination :  XPREP 
 Structure identification:   SHELXS-97 
 Structure refinement:   SHELXL-97 
The graphical projections were realised with the MOLECULAR GRAPHICS and DIAMOND 2.1 
software. 
 
Optical Rotations were measured on a 241 MC Polarimeter (PERKIN-ELMER) equipped with 
a sodium-vapour lamp (D-line, λ = 589.3 nm) in 0.1, 0.2 or 1.0 dm cells. Concentrations (c) 
are given in g/100 mL. 
 
Melting points were measured with a capillary melting point apparatus BÜCHI 150 and are 
uncorrected. 
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Solvents and chemicals were purchased at the ZENTRALES CHEMIKALIENLAGER DER 
UNIVERSITÄT DES SAARLANDES (ZCHL), from SIGMA-ALDRICH, ACROS ORGANICS or ABCR 
GMBH and used without purification unless otherwise specified. Anhydrous solvents were 
prepared according to the general methods under nitrogen atmosphere. Tetrahydrofurane, 
diethyl ether and toluene were distilled over sodium with benzophenone as an indicator. 
Methanol was dried over magnesium, and dichloromethane over calcium hydride. Anhydrous 
dimethylformamide was purchased from SIGMA-ALDRICH and stored on molecular sieves. 
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4.2. General Procedures 
4.2.1. Preparation of standard starting materials 
 
The frequently used acyl phloroglucinols such as acetyl phloroglucinol (APG) (29), isobutyryl 
phloroglucinol (25), isovaleryl phloroglucinol (32) and hexanoyl phloroglucinol (HPG) (33) 
were synthesised routinely with the general procedure GP 1. The obtained analytical data 
was in agreement with the literature. 
 
GP 1: Preparation of acyl phloroglucinols107b 
 
In a flame dried equipment, were suspended phloroglucinol (28) (1.0 eq.) and aluminium 
trichloride (2.0 eq.) in anhydrous dichloromethane (1mL/mmol PG (28)). Nitromethane (0.3 
mL/mmol PG (28)) was added dropwise under nitrogen atmosphere to dissolve the 
aluminium trichloride and the mixture was heated to 50°C. The acyl chloride (1.0 eq.) was 
dissolved in anhydrous dichloromethane (0.4 mL/mmol acyl chloride) and added dropwise to 
the warm solution. The completion of the reaction was confirmed by TLC. The reaction 
mixture was poured on an ice/1M HCl mixture (1/1, v/v, ≈ 30 mL/mmol PG (28)) and 
evaporated for 1h under reduced pressure (50°C/15 mbar) to remove the solvents. The 
aqueous phase was then extracted with ethyl acetate (1 x 30 mL, 2 x 15 mL for 1 mmol PG 
(28)) and the organic layer was dried over magnesium sulfate. After filtration, the solvents 
were removed under vacuum and the product was purified by flash chromatography on silica 
gel to yield the desired acyl phloroglucinol. In the case of acetyl phloroglucinol (29), it could 
be easily purified by recrystallization from water. 
 
GP 2: Preparation of syncarpic acid107b 
 
In a flame-dried equipment, sodium hydride (11.9 g, 297 mmol, 5.0 eq.) was washed twice 
with anhydrous THF (2 x 50 mL). APG (29) (10.0 g, 59 mmol, 1.0 eq.), prepared according to 
the general procedure GP 1, was dissolved in anhydrous THF (30 mL) and added dropwise 
to the mixture under nitrogen atmosphere. After stirring for 1h at room temperature, methyl 
iodide (37 mL, 594 mmol, 10.0 eq.) was added dropwise and the mixture was stirred 
overnight at room temperature. A 1 M HCl solution, saturated with NH4Cl, was added to the 
mixture and the aqueous phase was extracted with Et2O (3 x 300 mL). The combined organic 
extracts were washed with a saturated solution of sodium thiosulfate, a saturated solution of 
sodium chloride and then dried over MgSO4. The solvents were evaporated under reduced 
pressure and the crude product was fully loaded on a broad silica gel column (diameter: 7.5 
Experimental  - 92 - 
cm, length: 15 cm) washed with 500 mL petroleum ether and eluted with a Et2O/PE (1/9) 
mixture to give acetyl syncarpic acid (30) (10.2 g, 45 mmol, 77 % yield) as a yellowish white 
sticky solid. 
 
Acetyl syncarpic acid (30) (10.2 g, 45 mmol) was suspended in 2 M HCl and heated to 140°C 
(oil temperature) overnight (if needed, HCl was added and the reaction was run for a few 
more hours). The reaction was then cooled down to room temperature and placed at 4°C 
overnight. The yellowish white crystals were filtered off and dried in vacuo overnight to give 
syncarpic acid (27) (7.0 g, 0.38 mmol) with 85 % yield. The analytical data was in agreement 
with the literature. 
 
GP 3a: Preparation of isobutylidene syncarpic acid in DCM (classic method)35a 
 
Syncarpic acid (27) (1.0 eq.) was suspended in DCM (3 mL/mmol) and piperidine (2.0 eq.) 
and isobutyraldehyde (26) (1.5 eq.) were added. After stirring for 10 min at room 
temperature, a solution of 1M HCl, saturated with ammonium chloride, was added and the 
biphasic mixture was vigorously stirred for 15 min. The layers were separated and the 
aqueous phase was extracted once with DCM. The organic layers were combined, filtrated 
through a 5 cm thick pad of silica gel (PE/A, 2:1) and the eluent was removed by evaporation 
under reduced pressure. Isobutylidene syncarpic acid (IBSA) (31) was obtained with 95-99 % 
yield as a clear yellow oil and was used without further purification. 
 
GP 3b: Preparation of isobutylidene syncarpic acid in MeOH (new method) 
 
Syncarpic acid (27) (1.0 eq.) was dissolved in MeOH (1.5 mL/mmol) and proline (90) (0.3 
eq.) and isobutyraldehyde (26) (1.5 eq.) were added. After stirring for 30-40 min at 60°C 
(TLC monitoring), a solution of 1M HCl, saturated with ammonium chloride, was added and 
the aqueous phase was extracted twice with DCM. The organic layers were combined and 
filtered through a 5 cm thick pad of silica gel (PE/A, 2:1). The eluent was removed by 
evaporation under reduced pressure to afford isobutylidene syncarpic acid (IBSA) (31) with 
95-99 % yield as a clear yellow oil which was used without further purification. 
 
GP 4: Preparation of the alkylidene indandiones34,128 
 
In a round bottom flask fitted with an inverse Dean-Stark apparatus, 1,3-indandione (38) (1.0 
eq.) and ammonium acetate (0.2 eq.) were dissolved in chloroform (2 mL/mmol of 38) before 
glacial acetic acid (0.5 eq.) and the aldehyde (1.5 eq.) were added. The mixture was refluxed 
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until no more water separated. The dark mixture was washed with water containing a few 
drops of sodium bicarbonate until neutrality was reached, then washed with water. The 
organic phase was dried over sodium sulfate and the solvent was removed under reduced 
pressure to afford the crude alkylidene indandione which was used without further 
purification in the next step. 
 
4.2.2. Preparation of myrtucommulone derivatives 
 
GP 5: One-Pot preparation of myrtucommulone derivatives (Method B) 
 
The 1,3-diketone (4.0-6.0 eq.), proline (90) (0.5 eq.) and the acyl phloroglucinol (1.0 eq.) 
were dissolved in EtOH (8 mL/mmol of acyl phloroglucinol). After the addition of the aldehyde 
(8.0 eq.), the mixture was stirred at room temperature until completion of the reaction was 
observed by TLC. Diethyl ether (40 mL/mmol of acyl phloroglucinol) and a saturated solution 
of ammonium chloride (same volume) were added. The layers were separated and the 
aqueous phase was extracted twice with the same volume of Et2O. The combined organic 
layers were dried over magnesium sulfate, filtrated and the solvents were removed under 
reduced pressure. The crude product was purified on silica gel column chromatography. 
 
GP 6: Preparation of myrtucommulone derivatives using different catalysts (Method C) 
 
The acyl phloroglucinol (1.0 eq.) and the catalyst (0.5 eq., variable) were dissolved in the 
solvent (4 mL/mmol acyl phloroglucinol) and brought to the desired temperature. The 
alkylidene 1,3-diketone (1.5-6.0 eq.), prepared according to the general procedures GP 3a or 
GP 3b, was dissolved in the solvent (0.5 mL/mmol alkylidene) and added to the mixture. The 
reaction was stirred at room temperature until completion of the reaction was observed on 
TLC. After the reaction was hydrolysed with a saturated solution of ammonium chloride, the 
crude product was extracted with diethyl ether (3 x 20 mL). The product was then dried with 
magnesium sulfate and the solvent was evaporated under reduced pressure. The product 
was purified by column chromatography on silica gel. 
 
GP 7: Preparation of myrtucommulone derivatives using phase transfer catalysts 
(PTC)100,102,129 
 
The acyl phloroglucinol (1.0 eq.) and the PTC (122) (0.5 eq.) were suspended in toluene (4 
mL/mmol acyl phloroglucinol) and a base (1M KOH or KF) was added. After stirring for 15 
min, the solution was brought to the desired temperature and the isobutylidene syncarpic 
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acid (31) (1.5-4.8 eq.), which had been prepared according to the general procedures GP 3a 
or GP 3b, was dissolved in toluene (0.25 mL/mmol 31) and added to the mixture. The 
reaction was stirred at room temperature until completion of the reaction was observed by 
TLC. After the reaction was hydrolysed with a saturated solution of ammonium chloride, the 
crude product was extracted with diethyl ether (3 x 20 mL). The product was then dried with 
magnesium sulfate and the solvent was evaporated under reduced pressure. The product 
was purified by column chromatography on silica gel. 
 
GP 8: Preparation of myrtucommulone derivatives using metal catalysis 
 
The phloroglucinol derivative (1 eq.) was dissolved in the solvent (2 mL/mmol) under N2 and 
slowly added to the freshly prepared solution of the catalyst (66) (0.15-0.25 M solution) by 
syringe. The resulting suspension was stirred at room temperature for an additional hour. 
Then the alkylidene 1,3-diketone (0.60-0.75 M solution), freshly prepared according to the 
general procedures GP 3a, GP 3b or GP 4, was added dropwise at the desired temperature 
(usually 0°C). Stirring was continued for several hours (monitored by TLC, A/PE, 1/1) and 
then the reaction mixture was quenched with 1M HCl (aqueous solution saturated with 
NH4Cl). The mixture was extracted with diethyl ether (3 x 50 mL), and the combined organic 
extracts were dried with MgSO4. Filtration and evaporation of the solvent gave the crude 
product, which was purified by flash chromatography (PE/A) to give the desired 
myrtucommulone derivative. 
 
GP 9: Cyclisation of myrtucommulone derivatives. 
 
The myrtucommulone derivative (1.0 eq.) was suspended in toluene (1 mL/10 mg) and a few 
drops of acetone were added to dissolve it completely. pTsOH·H2O (3.0 eq. for derivatives 
with only one condensation site, 6.0-7.0 eq. otherwise) was added and the mixture was 
stirred at 95°C (bath temperature) until completion of the reaction (monitored by TLC, usually 
1h). The solvents were removed under reduced pressure and the residue was directly 
transferred on a silica gel chromatography column for purification. 
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4.3. Elucidation of the absolute configuration of the 
enantiomers of myrtucommulone B and pentacyclic 
myrtucommulone A 
 
(+)-(R)-Dibromo-MCB (51)44 
 
(+) MCB ((+)-6) (121 mg, 0.29 mmol, 1.0 eq.) was dissolved in acetic acid (3 mL) and 0.4 mL 
of a 1.7 M solution of Br2 (0.69 mmol, 2.4 eq.) in acetic acid was slowly added to the mixture. 
After 30 minutes of vigorous stirring, the reaction mixture was poured on a saturated sodium 
thiosulfate solution and stirred for 5 more minutes. Sodium bicarbonate was then added until 
the gas formation had ceased and the product was extracted with diethyl ether, dried using 
magnesium sulfate and concentrated. The residue was purified by flash chromatography on 
silica gel (A/PE, 1:5, Rf = 0.16) to yield 152 mg (0.27 mmol, 92% yield) of (+)-(R)-Dibromo-
MCB (51) as a white foam which was crystallised from dichloromethane to afford thin white 
needles (mp = 179-181°C). [𝛼]𝐷
24 = + 40.2 (CHCl3, c = 1.0) 
 
1H-NMR (400 MHz, CDCl3): δ = 5.91 (s, 1 H, C6-OH), 5.77 (s, 
1H, C4-OH), 4.36 (d, 3JH1’,H8’ = 3.5 Hz, 1H, H1’), 2.064, 2.059 (2 x 
s, 6 H, H3’’’, H4’’’), 1.98 (dsept, 3JH8’,H9’-10’= 6.8 Hz and 
3JH8’,H1’ = 
3.5 Hz, 1H, H8’), 1.55 (s, 3H, H12’), 1.41 (s, 3H, H14’), 1.36 (s, 
3H, H11’), 1.35 (s, 3H, H13’), 0.84 (d, 3JH8’,H9’ = 7.0 Hz, 3H, H9’), 
0.79 (d, 3JH8’,H10’ = 7.0 Hz, 3 H, H10’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.9 (C5’), 198.9 (C1’’’), 197.7 (C7’), 168.4 (C3’), 151.0 
(C4), 149.0 (C6), 147.3 (C2), 111.3 (C2’), 108.5 (C1), 105.6 (C3), 95.5 (C5), 65.2 (C2’’’), 56.1 
(C6’), 47.5 (C4’), 34.8 (C8’), 33.1 (C1’), 30.54, 30.51 (C3’’’, C4’’’), 25.2 (C12’), 24.7 (C14’), 
24.5,  24.3 (C11’, C13’), 19.0 (C10’), 18.9 (C9’) ppm. 
 
HRMS (ESI+) calcd. for C24H29Br2O6
+ [M+H]+: 571.0331, found: 571.0312 
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Crystal Structure Data : (for the complete data see Appendix 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exp. Data Tab. 1 Crystal data and structure refinement for 51 (sh3343). 
Identification code sh3343  
Empirical formula C24 H28 Br2 O6 * 0.5 C H2 Cl2  
Formula weight 612.73  
Temperature 123(2) K  
Wavelength 0.71073 Å  
Crystal system Orthorhombic  
Space group P2(1)2(1)2(1)  
Unit cell dimensions a = 9.7566(2) Å α= 90°. 
 b = 19.1985(4) Å β= 90°. 
 c = 27.6028(5) Å γ = 90°. 
Volume 5170.34(18) Å3  
Z 8  
Density (calculated) 1.574 Mg/m3  
Absorption coefficient 3.276 mm-1  
F(000) 2472  
Crystal size 0.43 x 0.26 x 0.18 mm3  
Theta range for data collection 1.29 to 26.37°.  
Index ranges 
-11<=h<=12, -23<=k<=23, -
34<=l<=28 
 
Reflections collected 38038  
Independent reflections 10541 [R(int) = 0.0316]  
Completeness to theta = 26.37° 99.8 %  
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.5932 and 0.3345  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 10541 / 220 / 650  
Goodness-of-fit on F2 1.097  
Final R indices [I>2sigma(I)] R1 = 0.0436, wR2 = 0.1275  
R indices (all data) R1 = 0.0487, wR2 = 0.1305  
Absolute structure parameter 0.004(8)  
Largest diff. peak and hole 0.793 and -1.437 e.Å-3  
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(+)-(S,R,R)-PMCA-Mosher ester (53)45 
 
To (+)-PMCA ((+)-7) (50 mg, 0.08 mmol, 1.00 eq.) in a 4 mL-vial were added 1.1 mL of a 
0.09 M solution of (S)-Mosher acid (52) (23.5 mg, 0.1 mmol, 1.25 eq.) in dichloromethane, 
1.5 mL of a 0.07 M solution of DCC (21 mg, 0.1 mmol, 1.25 eq.) in dichloromethane, and 
several crystals of DMAP. After 24 h, additional (S)-Mosher acid (52) (13 mg, 0.06 mmol, 
0.75 eq.) and DCC (12 mg, 0.06 mmol, 0.75 eq.) were added. After 4 days, the reaction was 
judged complete by TLC. A saturated solution of ammonium chloride was added, the mixture 
was extracted with diethyl ether, dried over magnesium sulfate and concentrated. The 
residue was purified by flash chromatography on silica gel (A/PE, 1/9, Rf = 0.16) to yield 46 
mg (0.05 mmol, 68% yield) of (+)-(S,R,R)-PMCA-Mosher ester (53) as a white foam which 
was crystallised from dichloromethane to afford thin white needles (mp = 224-230°C). [𝛼]𝐷
24 = 
+ 39.5 (CHCl3, c = 1.0) 
Two different conformers are observed in the NMR-spectrum: 
 
1H-NMR (400 MHz, CDCl3) : δ = 7.82 (d, 
3JH12,H13 = 7.8 
Hz, 1.67H, H12), 7.73 (d, 3JH12,H13  = 7.8 Hz, 0.37H, 
H12), 7.66-7.60 (m, 2H, H13), 7.56-7.50 (m, 1H, H14), 
4.19 (brs, 1.35H, H1’, H1’’), 4.07 (d, 3JH1’,H8’ = 4.5 Hz, 
0.22 H, H1’), 4.04 (d, 3JH1’’,H8’’ = 4.3 Hz, 0.22H, H1’’), 
3.86 (s, 2.47H, H10), 3.67 (s, 0.52H, H10), 3.12 (sept, 
3JH2’’’,H3’’’-H4’’’ = 7.0 Hz, 1H, H2’’’), 1.85-1.76 (m, 0.40H, 
H8’, H8’’), 1.73-1.65 (m, 1.70H, H8’, H8’’), 1.53 (s, 
4.80H, H12’, H11’’), 1.51 (s, 1.20H, H12’, H11’’), 1.43-
1.33 (m, 18H, H11’, H12’’, H13’, H13’’, H14’, H14’’), 1.27 (d, 3JH3’’’,H2’’’ = 7.0 Hz, 3H, H3’’’), 
1.26 (d, 3JH4’’’,H2’’’ = 7.3 Hz, 3H, H4’’’), 0.70-0.49 (m, 12H, H9’, H9’’, H10’, H10’’) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 211.71, 211.67 (C5’, C5’’), 203.6 (C1’’’), 197.2, 197.0 (C7’, 
C7’’), 167.9, 167.82, 167.78, 167.76 (C3’, C3’’), 165.1 (C7), 147.33, 147.26 (C2, C6), 144.8 
(C4), 130.1 (C14), 129.21, 129.15 (C11; C13), 127.9, 127.8 (C12), 124.5, 121.6 (C9), 116.8, 
116.6 (C3, C5), 116.4, 115.9, 115.5 (C1), 110.5, 110.2, 110.0, 109.6 (C2’, C2’’), 85.1, 84.9 
(C8), 56.1, 56.0 (C6’, C6’’), 55.9 (C10), 47.5, 47.43, 47.42 (C4’, C4’’), 43.1, 42.7 (C2’’’), 35.4, 
35.3 (C8’, C8’’), 33.31, 33.25, 32.7 (C1’, C1’’), 25.7, 25.3, 25.0, 24.94, 24.90, 24.85, 24.7, 
24.6, 24.1, 24.0, 23.8, 23.7 (C12’, C11’’, C13’, C14’’, C11’, C12’’, C14’, C13’’), 20.8, 19.9, 
19.8, 19.3, 19.1, 16.6 (C9’, C9’’, C10’, C10’’), 17.9, 17.8, 17.50, 17.45 (C3’’’, C4’’’) ppm. 
 
HRMS (ESI+) calcd. for C48H56F3O10
+ [M+H]+: 849.3825, found: 849,3830  
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Crystal Structure Data: (for the complete data see Appendix 2) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exp. Data Tab. 2 Crystal data and structure refinement for 53 (sh3365). 
Identification code  sh3365  
Empirical formula  C48 H55 F3 O10  
Formula weight  848.92  
Temperature  122(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P 21  
Unit cell dimensions a = 6.4479(10) Å α= 90°. 
 b = 40.961(5) Å β= 91.687(8)°. 
 c = 17.888(3) Å γ = 90°. 
Volume 4722.3(11) Å3  
Z 4  
Density (calculated) 1.194 Mg/m3  
Absorption coefficient 0.090 mm-1  
F(000) 1800  
Crystal size 0.806 x 0.120 x 0.064 mm3  
Theta range for data collection 0.994 to 26.357°.  
Index ranges 
-8<=h<=7, -47<=k<=50, -
21<=l<=21 
 
Reflections collected 27828  
Independent reflections 15089 [R(int) = 0.0825]  
Completeness to theta = 25.242° 93.4 %   
Absorption correction Semi-empirical from equivalents  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 15089 / 399 / 1149  
Goodness-of-fit on F2 1.230  
Final R indices [I>2sigma(I)] R1 = 0.0915, wR2 = 0.1989  
R indices (all data) R1 = 0.1333, wR2 = 0.2133  
Absolute structure parameter 0.2(8)  
Extinction coefficient 0.0050(7)  
Largest diff. peak and hole 0.609 and -0.362 e.Å-3  
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(-)-(S,S,S)-PMCA-Mosher ester (54)45 
 
54 was synthesised according to the same procedure as for (+)-(S,R,R)-PMCA-Mosher ester 
(53) starting from (-)-PMCA ((-)-7) (50 mg, 0.08 mmol, 1.00 eq.) and (S)-Mosher acid (52). 
The crude product was purified by flash chromatography (A/PE, 1/9, Rf = 0.13) to give (-)-
(S,S,S)-PMCA-Mosher ester (54) (52 mg, 0.06 mmol) with 77 % yield as a shiny white solid 
(mp = 226-229°C). [𝛼]𝐷
24 = - 15.5 (CHCl3, c = 1.0) 
 
1H-NMR (400 MHz, CDCl3) : δ = 7.79 (d, 
3JH12,H13 = 7.8 
Hz, 2H, H12), 7.64-7.58 (m, 2H, H13), 7.54-7.48 (m, 
1H, H14), 4.10 (brs, 2H, H1’, H1’’), 3.54 (s, 3H, H10), 
3.12 (sept, 3JH2’’’,H3’’’-H4’’’ = 7.0 Hz, 1H, H2’’’), 1.66-1.57 
(m, 2H, H8’, H8’’), 1.52 (s, 6H, H12’, H11’’), 1.40 (s, 
12H, H13’, H13’’, H14’, H14’’), 1.37 (s, 6H, H11’, H12’’) 
1.26 (d, 3JH3’’’,H2’’’ = 7.0 Hz, 3H, H3’’’), 1.25 (d, 
3JH4’’’,H2’’’ = 
7.3 Hz, 3H, H4’’’), 0.56 (d, 3JH9’,H8’ = 
3JH9’’,H8’’ = 7.0 Hz, H, 
H9’, H9’’), 0.50 (d, 3JH10’,H8’ = 
3JH10’’,H8’’ = 7.0 Hz, H, H10’, 
H10’’) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 211.7 (C5’, C5’’), 203.7 (C1’’’), 197.1 (C7’, C7’’), 167.8, 
(C3’, C3’’), 164.8 (C7), 147.3 (C2, C6), 144.9 (C4), 130.3 (C14), 129.7 (C11) 129.3 (C13), 
128.1 (C12), 124.8, 121.9 (C9), 116.6 (C3, C5), 116.3 (C1), 109.7 (C2’, C2’’), 85.1, 84.8 
(C8), 55.9 (C6’, C6’’), 55.1 (C10), 47.5 (C4’, C4’’), 42.7 (C2’’’), 35.2 (C8’, C8’’), 32.6 (C1’, 
C1’’), 25.5, 25.3, 24.7, 23.9, 23.8 (C12’, C11’’, C13’, C14’’, C11’, C12’’, C14’, C13’’), 19.8, 
16.6 (C9’, C9’’, C10’, C10’’), 17.9, 17.5 (C3’’’, C4’’’) ppm. 
 
HRMS (ESI+) calcd. for C48H56F3O10
+ [M+H]+: 849.3825, found: 849,3815 
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4.4. Synthesis of various intermediates 
 
Syncarpic acid SAMP-hydrazone (50)38 
 
Syncarpic acid (27) (650 mg, 3.6 mmol, 1.0 eq.) was dissolved in hot THFabs and molecular 
sieves were added under nitrogen atmosphere. SAMP (45) (489 mg, 0.50mL, 3.6 mmol, 1.0 
eq.) was added and the mixture was stirred overnight at 70°C (bath temperature). The 
molecular sieves were filtered off and the filtrate was concentrated in vacuo. The residue was 
dissolved in DCM and water was added. The layers were separated and the aqueous layer 
was extracted 4 more times with DCM. The combined organic extracts were washed with 
brine and dried with magnesium sulfate. The crude product was purified by column 
chromatography on silica gel (A/PE, 1/5, Rf = 0.17) to afford syncarpic acid SAMP-hydrazone 
(50) (780 mg, 2.7 mmol, 75 % yield) as shiny white needles (mp = 154-155°C). [𝛼]𝐷
24 = + 58.5 
(MeOH, c = 1.1) 
 
MS (ESI+) for C16H27N2O3
+ [M+H]+: 295.3 (100). 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 7.11 (s, 1H, NH), 5.75 (s, 1H, 
H2), 3.42 (dd, 2JH11a,H11b = 9.5H, 
3JH11a,H10 = 4.8 Hz, 1H, H11a), 
3.28 (dd, 2JH11b,H11a = 9.5H, 
3JH11b,H10 = 6.5 Hz, 1H, H11b), 3.25 (s, 
3H, H12), 3.24-3.20 (m, 1H, H7a), 3.11-3.03 (m, 1H, H10), 2.70 
(q, J = 8.5 Hz, 1H, H7b), 2.01-1.93 (m, 1H, H9a), 1.85-1.77 (m, 2H, H8), 1.69-1.59 (m, 1H, 
H9b), 1.46 (s, 3H, H13), 1.44 (s, 3H, H14), 1.24 (s, 3H, H15), 1.23 (s, 3H, H16) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 215.7 (C5), 196.7 (C3), 167.2 (C1), 95.0 (C2), 76.6 
(C11), 66.5 (C10), 60.1 (C12), 56.2 (C7), 55.6 (C4), 47.3 (C6), 28.3 (C9), 27.2, 27.0 (C13, 
C14), 26.2, 25.9 (C15, C16) ppm. 
 
N',N'-dimethylisobutyrohydrazide (61)47c 
 
N,N-dimethyl-hydrazine (0.55 mL, 7.1 mmol, 1.0 eq.) and triethylamine (1.10 mL, 7.2 mmol, 
1.0 eq.) were mixed in anhydrous diethyl ether (35 mL) under nitrogen atmosphere. The 
mixture was cooled to 0°C and isobutyryl chloride (0.77 mL, 7.1 mmol, 1.0 eq.) was added 
dropwise. The resultant suspension was then stirred overnight at room temperature. The 
precipitate was filtered off to afford a colourless solution which was concentrated under 
vacuum to give the hydrazide 61 (863 mg, 6.6 mmol, 93 % yield) as shiny white needles after 
recrystallization from diethyl ether (mp = 96-98°C, Lit.47c 94-96°C). 
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 1H-NMR (400 MHz, CDCl3): δ = 6.21 (brs, 0.52H, 
NH), 5.96 (brs, 0.40H, NH), 3.14 (sept, 3JH2,H3 = 6.8 
Hz, 0.44H, H2), 2.58 (s, 3.34H, H4), 2.51 (s, 2.66H, 
H4), 2.21 (sept, 3JH2,H3 = 6.8 Hz, 0.57H, H2), 1.13 (d, 
3JH3,H2 = 6.8 Hz, 3.36H, H3), 1.11 (d, 
3JH3,H2 = 6.8 Hz, 2.65H, H3) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 180.1, 174.5 (C1), 48.9, 47.5 (C2), 34.1, 29.6 (C4), 19.4, 
19.1 (C3) ppm. 
 
para-pyrrolidinyl-IBPG (58)46 
 
IBPG (25) (787 mg, 4.0 mmol, 1.0 eq.) was suspended in methanol (3 mL) and pyrrolidine 
(0.33 mL, 4.0 mmol, 1 eq.) was added. The mixture was stirred and refluxed for 6h and the 
solvent was evaporated under reduced pressure. The residue was transferred directly onto a 
silica gel column and chromatographically purified (A/PE, 1/5, Rf = 0.24) to give 794 mg of 
para-pyrrolidinyl-IBPG (58) (3.2 mmol, 80 % yield) as a brownish yellow powder (mp = 178-
180°C). 
 
MS (ESI+) for C14H20NO3
+ [M+H]+: 250.2 (100). 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 11.69 (s, 2H, OH), 5.59 (s, 2H, H3, 
H5), 3.96 (sept, 3JH2’‘‘,H3’‘‘-H4‘‘’ = 6.8 Hz, 1H, H2‘’‘), 3.31-3.25 (m, 4H, H1‘, 
H4‘), 2.02-1.94 (m, 4H, H2‘, H3‘), 1.12 (d, 3JH3‘’‘-H4‘’‘,H2’‘‘ = 6.8 Hz, 6H, H3’‘‘, 
H4‘’‘) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 209.7 (C1’’’), 165.8 (C4), 154.8 (C2, 
C6), 102.3 (C1), 92.8 (C3, C5), 49.0 (C1’, C4’), 39.9 (C2’’’), 26.9 (C2’, 
C3’), 20.8 (C3’’’, C4’’’) ppm. 
 
Formyl-IBPG (63)50 
 
To the solution of IBPG (25) (980 mg, 5.0 mmol, 1.0 eq.) in ethyl acetate (75 mL) were added 
molecular sieves, dimethylformamide (0.39 mL, 5.0 mmol, 1.0 eq.) and phosphoryl chloride 
(0.51 mL, 5.5 mmol, 1.1 eq.) at room temperature under nitrogen atmosphere. The reaction 
mixture was further stirred for 5h at 60°C. A saturated solution of NH4Cl was added, the 
phases were separated, and the aqueous layer was extracted with ethyl acetate (4 x 100 
mL). The ethyl acetate layer was washed with brine, dried over Na2SO4 and concentrated to 
afford the crude product. Column chromatography over silica gel using (A/PE, 1/5, Rf = 0.14) 
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provided formyl-isobutyryl-phloroglucinol (63) (405 mg, 1.8 mmol, 35 % yield) as a white 
powder (mp = 114-123°C). 
 
HRMS (ESI+) calcd. for C11H13O5
+ [M+H]+: 225,0763, found: 225,0763. 
 
1H-NMR (400 MHz, CDCl3): δ = 15.49 (brs, 0.23H, OH), 15.18 (brs, 0.52H, 
OH), 14.35 (s, 0.63H, OH), 12.64 (brs, 0.20H, OH), 10.14 (s, 0.29H, H7), 
10.06 (s, 0.68H, H7), 7.89 (brs, 0.82H, OH), 5.88 (s, 0.66H, H3), 5.83 (s, 
0.30H, H3), 3.98-3.77 (m, 1H, H2’’’), 1.20 (d, 3JH3‘’‘-H4’‘‘,H2’‘‘ = 6.8 Hz, 6H, H3‘’‘, 
H4‘’‘) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.5 (C1’’’), 191.2 (C7), 174.4 (C6), 169.7 (C4), 165.2 
(C2), 104.0 (C1), 103.5 (C5), 95.6 (C3), 39.5 (C2’’’), 19.0, 18.9 (C3’’’, C4’’’) ppm. 
 
Isobutyryl phloroglucinol derivatives 94 and 95 
 
Isobutyryl phloroglucinol (IBPG) (25) (200 mg, 1.0 mmol, 1.0 eq.), histidine (170 mg, 1.1 
mmol, 1.1 eq.) and isobutyraldehyde (26) (100 µL, 1.1 mmol, 1.1 eq.) were mixed in ethanol 
(4 mL) and stirred at room temperature for 24 h. A solution of ammonium chloride was 
added, the product was extracted with ethyl acetate (3 x 20 mL) and dried using magnesium 
sulfate. The solvents were evaporated under reduced pressure and the residue was purified 
through column chromatography on silica gel (A/PE, 1/9) to afford 35 mg of the derivative 94 
and 41 mg of the derivative 95. 
 
Derivative 94 
1H-NMR (400 MHz, CDCl3): δ = 14.28 (brs, 0.48H, OH), 13.96 (brs, 
0.31H, OH), 10.19 (s, 0.34H, OH), 9.66 (brs, 0.46H, OH), 6.71 (brs, 
0.76H, OH), 5.83 (brs, 1H, H3), 4.61 (brs, 1H, H1’), 3.91 (sept, 
3JH2’‘‘,H3‘’‘-H4’‘‘ = 6.5 Hz, 1H, H2’’’), 3.59-3.58 (m, 1H, H5a’), 3.56-3.46 
(m, 1H, H5b’), 2.06-1.95 (m, 1H, H2’), 1.23 (t, 3JH6‘,H5‘ = 6.8 Hz, 3H, 
H6‘), 1.18 (d, 3JH3’’‘-H4’’,H2’’‘ = 6.8 Hz, 3H, H6‘), 1.00 (d, 
3JH3‘,H2‘ = 6.5 
Hz, 3H, H3‘), 0.92 (d, 3JH4‘,H2‘ = 6.8 Hz, 3H, H4‘) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 210.9, 210.8, 208.9 (C1’’’), 172.1 (C2), 164.7, 163.1, 163.0, 
162.9, 159.1, 159.0 (C4, C2), 110.0 (C5), 104.8, 104.7 (C1), 95.4 (C3), 82.5 (C1’), 66.0 (C5’), 
39.2 (C2’’’), 33.4 (C2’), 19.3, 19.2, 19.0, 18.1, 17.9 (C3’, C4’, C3’’’, C4’’’), 14.9 (C6’) ppm. 
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Derivative 95 
 
1H-NMR (400 MHz, CDCl3): δ = 14.29-14.17 (m, 1H, OH), 
13.96 (brs, 0.31H, OH), 10.08 (s, 1H, OH), 9.77, 9.76 (2 x s, 
1H, OH), 4.71-4.63 (m, 1H, H1’, H1’’), 4.62-4.54 (m, 1H, H1’, 
H1’’), 3.93 (sept, 3JH2’‘‘,H3‘’‘-H4’‘‘ = 6.5 Hz, 1H, H2’’’), 3.71-3.59 
(m, 1.66H, H5’, H5’’), 3.59-3.43 (m, 2.59H, H5’, H5’’), 2.11-
1.91 (m, 2H, H2’, H2’’), 1.28-1.14 (m, 12H, H3’’’, H4’’’, H6’, 
H6’‘), 1.06-0.84 (m, 12H, H3‘, H3’’, H4’, H4’’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.1 (C1’’’), 163.4, 163.2 (C2, C6), 161.2, 161.1 (C4), 
159.9, 159.7 (C2, C6), 103.63, 103.59 (C1), 103.02, 102.98, 102.5 (C3, C5), 82.6, 82.4 (C1’, 
C1’’), 66.1, 65.8 (C5’, C5’’), 39.3 (C2’’’), 33.5, 33.4 (C2’, C2’’), 19.5, 19.4, 19.3, 19.1, 19.0, 
18.9, 18.8, 18.7, 18.0, 17.7 (C3’, C4’, C3’’, C4’’, C3’’’, C4’’’), 15.0, 14.8 (C6’) ppm. 
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4.5. Synthesis of the catalysts 
4.5.1. Synthesis of the catalysts for the organocatalysis 
 
Cupreine (CPN) (118)94b 
 
In a flame dried equipment under nitrogen atmosphere, quinine (112c) (649 mg, 2.00 mmol, 
1.0 eq.) and NaSEt (670 mg, 90 % technical grade, 8 mmol, 4.0 eq.) were suspended in dry 
DMF (12.5 mL) and stirred at 110°C until a TLC analysis showed that the starting material 
was completely consumed (5.5h). The reaction mixture was cooled down to room 
temperature and mixed with a saturated NH4Cl solution (12.5 mL) and H2O (10 mL). The pH 
value of the solution was determined to be around 8. The resulting mixture was extracted 
with ethyl acetate (2 x 50 mL). The organic phase was washed with brine, dried over Na2SO4 
overnight and concentrated in vacuo. The residue was subjected to flash chromatography 
(EA/MeOH/TEA, 100/2/3, Rf = 0.19) on silica gel to afford CPN (118) (533 mg, 1.72 mmol) as 
a yellowish white solid (mp = 192°C (decomposition)) with 86 % yield. 
[𝛼]𝐷
24 = - 159.6 (EtOH, c = 1.0), Lit.94b [𝛼]𝐷
25 = - 162.8 (EtOH, c = 0.93) 
 
1H-NMR (400 MHz, CD3OD): δ = 8.59 (d, 
3JH1,H2 = 4.5 Hz, 1H, H1), 
7.90 (d, 3JH8,H7 = 9.3 Hz, 1H, H8), 7.63 (d, 
3JH2,H1 = 4.5 Hz, 1H, H2), 
7.36-7.29 (m, 2H, H5, H7), 5.74 (ddd, 3JH18,H19Z = 17.6 Hz, 
3JH18,H19E = 
10.5 Hz, 3JH18,H17 = 7.5 Hz, 1H, H18), 5.56 (d, 
3JH10,H11 = 3.0 Hz, 1H, 
H10), 4.98 (dt, 3JH19Z,H18 = 17.3 Hz, 
2J H19Z,H19E = 1.3 Hz, 1H, H19Z), 
4.91 (dt, 3JH19E,H18 = 10.3 Hz, 
2J H19E,H19Z = 1.3 Hz, 1H, H19E), 3.76 
(dddd, 2J H15a,H15b = 13.3 Hz, 
3J H15a,H14a = 10.5 Hz, 
3J H15a,H14b = 5.0 Hz, 
4J H15a,H13 = 2.5 Hz, 1H, 
H15a), 3.20-3.11 (m, 2H, H11, H16a), 2.83-2.69 (m, 2H, H15b, H16b), 2.44-2.35 (m, 1H, 
H17), 1.95-1.84 (m, 1H, H12a, H14a), 1.84-1.79 (m, 1H, H13), 1.67-1.57 (m, 1H, H14b), 
1.49-1.40 (m, 1H, H12b) ppm. 
 
13C-NMR (101 MHz, CD3OD): δ = 157.9 (C6), 149.5 (C3), 147.5(C1), 144.0 (C9), 142.3 
(C18), 131.5 (C8), 128.4 (C4), 123.3 (C7), 119.9 (C2), 115.2 (C19), 105.2 (C5), 71.9 (C10), 
61.1 (C11), 57.4 (C16), 44.4 (C15), 40.7 (C17), 29.2 (C13), 27.9 (C14), 21.6 (C12) ppm. 
 
LC-MS (ESI-) for C19H21N2O2
- [M-H]-: 309.20. 
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O-benzoyl-quinine (Bz-Q) (121)95e 
 
To a stirred solution of quinine (112c) (1.298 g, 4.00 mmol, 1.0 eq.) in anhydrous DCM (40 
mL), were sequentially added benzoyl chloride (2.3 mL, 20 mmol, 5.0 eq.) and a 30% w/w 
NaOH solution (5.6 mL) at room temperature. After 4 hours of vigorous stirring, H2O and 
DCM were added. The two layers were separated and the aqueous layer extracted with 
DCM. The combined organic extracts were dried over Na2SO4, filtered and evaporated under 
reduced pressure. The residue was purified by flash chromatography. (EA/TEA = 50/1, Rf = 
0.27) to give Bz-Q (121) (1.624 g, 3.95 mmol, 99% yield) as a white solid (mp = 122-123°C). 
 
1H-NMR (400 MHz, CDCl3): δ = 8.72 (d, 
3JH1,H2 = 4.5 Hz, 1H, H1), 
8.13-8.07 (m, 2H, H22), 8.02 (d, 3JH8,H7 = 9.3 Hz, 1H, H8), 7.63-7.57 
(m, 1H, H24), 7.52 (d, 4JH5,H7 = 2.8 Hz, 1H, H5), 7.50-7.47 (m, 2H, 
H23), 7.43 (d, 3JH2,H1 = 4.5 Hz, 1H, H2), 7.38 (dd, 
3JH7,H8 = 9.3 Hz, 
4JH7,H5 = 2.8 Hz, 1H, H7), 6.74 (d, 
3JH10,H11 = 6.8 Hz, 1H, H10), 5.84 
(ddd, 3JH18,H19Z = 17.3 Hz, 
3JH18,H19E = 10.3 Hz, 
3JH18,H17 = 7.3 Hz, 1H, 
H18), 5.02 (dt, 3JH19Z,H18 = 17.3 Hz, 
2J H19Z,H19E = 1.3 Hz, 1H, H19Z), 
5.00 (dt, 3JH19E,H18 = 10.3 Hz, 
2J H19E,H19Z = 1.3 Hz, 1H, H19E), 3.98 (s, 
3H, H25), 3.54-3.45 (m, 1H, H11), 3.21 (dddd, 2J H15a,H15b = 13.5 Hz, 
3J H15a,H14a = 10.3 Hz, 
3J 
H15a,H14b = 5.5 Hz, 
4J H15a,H13 = 2.5 Hz, 1H, H15a), 3.09 (dd, 
2J H16a,H16b = 13.9 Hz, 
3J H16a,H17 = 
10.3 Hz, 1H, H16a), 2.75-2.62 (m, 2H, H15b, H16b), 2.34-2.26 (m, 1H, H17), 1.98-1.87 (m, 
2H, H13, H12a), 1.83-1.67 (m, 2H, H12b, H14a), 1.63-1.52 (m, 1H, H14b) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 165.5 (C20), 158.0 (C6), 147.5 (C1), 144.7 (C3), 143.7 
(C9), 141.7 (C18), 133.4 (C24), 131.8 (C8), 129.7 (C21), 129.6 (C22), 128.6 (C23), 126.9 
(C4), 121.9 (C7), 118.7 (C2), 114.5 (C19), 101.4 (C5), 74.6 (C10), 59.4 (C11), 56.7 (C16), 
55.6 (C25), 42.6 (C15), 39.7 (C17), 27.9 (C14), 27.6 (C13), 24.2 (C12) ppm. 
 
O-benzoyl-cupreine (120)95e 
 
O-benzoyl-quinine (121) (428 mg, 1.00 mmol, 1.0 eq.) was dissolved in 20 mL of anhydrous 
DCM under nitrogen atmosphere and cooled to -75oC in an acetone/dry ice bath. A solution 
of BBr3 (0.38 mL, 4.00 mmol, 4.0 eq.) in anhydrous DCM (3 mL), prepared under nitrogen 
atmosphere, was slowly added to the cooled solution. While stirring, the reaction mixture was 
allowed to slowly warm to room temperature (3h) and subsequently refluxed at 40oC for 1.5 h 
and then cooled to 0oC. While maintaining the temperature of the mixture below 5oC, a 
solution of 40% NH4OH (10 mL) was slowly added (after 1 mL, temperature evolution 
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ceased). After 30 minutes of vigorous stirring, H2O and DCM were added. The two layers 
were separated and the aqueous layer extracted with 1-butanol, the combined organic 
extracts were dried over MgSO4, filtered and evaporated under reduced pressure (10 
mbar/50°C). The residue was purified by flash chromatography. (EA/MeOH/TEA = 50/2/1, Rf 
= 0.20) to give Bz-CPN (120) (232 mg, 0.56 mmol, 56% yield) as a white solid (mp = 132°C 
(decomposition)). [𝛼]𝐷
24 = + 114.0 (CH2Cl2, c = 1.0), Lit.
95e[𝛼]𝐷
20 = + 115.8 (CH2Cl2, c = 0.63) 
 
1H-NMR (400 MHz, DMSO-D6): δ = 10.14 (s, 1H, OH), 8.62 (d, 
3JH1,H2 
= 4.5 Hz, 1H, H1), 8.09-8.04 (m, 2H, H22), 7.89 (d, 3JH8,H7 = 9.0 Hz, 
1H, H8), 7.72-7.66 (m, 1H, H24), 7.60-7.53 (m, 3H, H5, H23), 7.51 (d, 
3JH2,H1 = 4.5 Hz, 1H, H2), 7.32 (dd, 
3JH7,H8 = 9.0 Hz, 
4JH7,H5 = 2.5 Hz, 
1H, H7), 6.44 (d, 3JH10,H11 = 7.5 Hz, 1H, H10), 5.94 (ddd, 
3JH18,H19Z = 
17.6 Hz, 3JH18,H19E = 10.5 Hz, 
3JH18,H17 = 7.8 Hz, 1H, H18), 5.06-4.96 
(m, 2H, H19Z, H19E), 3.54-3.42 (m, 1H, H11), 3.14-3.01 (m, 1H, 
H15a), 3.09 (dd, 2J H16a,H16b = 13.5 Hz, 
3J H16a,H17 = 10.3 Hz, 1H, H16a), 
2.59-2.40 (m, 2H, H15b, H16b), 2.28-2.19 (m, 1H, H17), 1.98-1.90 (m, 1H, H12a), 1.81-1.77 
(m, 1H, H13), 1.73-1.63 (m, 1H, H14a), 1.61-1.43 (m, 2H, H12b, H14b) ppm. 
 
13C-NMR (101 MHz, DMSO-D6): δ = 165.5 (C20), 155.7 (C6), 146.6 (C1), 143.30 (C3), 
143.25 (C9), 142.3 (C18), 133.7 (C24), 131.4 (C8), 129.3 (C22), 129.2 (C21), 128.9 (C23), 
126.9 (C4), 121.9 (C7), 119.0 (C2), 114.4 (C19), 104.5 (C5), 74.7 (C10), 59.3 (C11), 56.0 
(C16), 41.7 (C15), 39.2 (C17), 27.3 (C14), 27.2 (C13), 24.7 (C12) ppm. 
 
LC-MS (ESI-) for C52H51N4O6
- [2M-H]-: 827.45. 
 
Pyroglutamic acid methyl ester (117)89a 
 
To a stirred solution of (S)-pyroglutamic acid (116) (5.0 g, 39 mmol, 1.0 eq.) in anhydrous 
methanol (125 mL) at -15°C was added thionyl chloride (3.4 mL, 5.6 g, 46 mmol, 1.2 eq.) 
dropwise. The mixture was stirred 30 min at -15°C, slowly warmed to r.t. and stirred 
overnight. The mixture was concentrated in vacuo and the remaining yellow oil was purified 
by column chromatography on silica gel (A/PE, 1/1, Rf = 0.21) yielding the product 117 as a 
colourless oil (2.5 g, 17 mmol, 44 % yield). 
 
1H-NMR (400 MHz, CDCl3): δ = 6.18 (brs, 1H, NH), 4.26 (dd, 
3JH4,H3a = 5.0 
Hz, 3JH4,H3b = 8.5 Hz, 1H, H4), 3.77 (s, 3H, H6), 2.55-2.44 (m, 1H, H3a), 
2.44-2.32 (m, 2H, H2), 2.31-2.19 (m, 1H, H3b) ppm. 
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(S)-5-(hydroxydiphenylmethyl)pyrrolidin-2-one (HODPP) (115)89 
 
In a flame dried round bottom flask, magnesium turnings (1.67 g, 69.6 mmol, 4.0 eq.) were 
suspended in anhydrous THF (24 mL) under nitrogen atmosphere. A first portion of 
bromobenzene (2.3 mL, 3.44 g, 21.9 mmol, 1.3 eq.) was then added dropwise and the 
reaction was heated with a heat gun until it started. The second portion of bromobenzene 
(5.0 mL, 7.48 g, 47.6 mmol, 2.8 eq.), dissolved in 4 mL anhydrous THF, was then added over 
15 min and the mixture was stirred for 2h at reflux. The reaction was then cooled to 0°C and 
the ester 117 (2.46 g, 17.2 mmol, 1.0 eq.), dissolved in anhydrous THF (10 mL), was added 
over 15-20 min. The mixture was then allowed to warm to room temperature and stirred 
overnight. The reaction was hydrolysed with a saturated solution of ammonium chloride and 
extracted with ethyl acetate (6 x 30 mL). The combined organic extracts were dried using 
magnesium sulfate and the solvents were evaporated under reduced pressure. After 
recrystallisation from hot ethanol, HODPP (115) (3.51 g, 13.1 mmol, 76 % yield) was 
obtained as a white solid (mp = 185-186°C, decomposition, Lit.89a 190°C, decomposition). 
 
1H-NMR (400 MHz, CDCl3): δ = 7.50-7.42 (m, 4H, H7), 7.35-7.26 (m, 
4H, H8), 7.26-7.17 (m, 2H, H9), 5.45 (brs, 1H, NH), 4.70 (dd, 3JH4,H3a = 
4.8 Hz, 3JH4,H3b = 8.3 Hz, 1H, H4), 3.87 (s, 1H, OH), 2.34 (ddd, 
2JH2a,H2b 
= 17.1 Hz, 3JH2a,H3a = 10.3 Hz, 
3JH2a,H3b = 6.3 Hz, 2H, H2), 2.23 (ddd, 
2JH2b,H2a = 17.1 Hz, 
3JH2b,H3a = 10.3 Hz, 
3JH2b,H3b = 6.3 Hz, 2H, H2), 2.15-2.03 (m, 1H, H3a), 
1.98-1.87 (m, 1H, H3b) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 179.3 (C1), 145.2, 143.2 (C6), 128.8, 128.3 (C8), 127.5, 
127.0 (C9), 125.8, 125.6 (C7), 78.7 (C5), 60.6 (C4), 30.2 (C2), 21.6 (C3) ppm.  
 
Benzylcinchoninium bromide (122a)103 
 
Cinchonine (112a) (588 mg, 2.0 mmol, 1.0 eq.) was suspended in dry chloroform (12 mL) in 
a flame dried round-bottom flask containing molecular sieves (3Å). Benzyl bromide (250 µL, 
360 mg, 2.1 mmol, 1.1 eq.) was added and the mixture was heated to reflux for 1 hour 
resulting in a dark red solution which was stirred at r.t. overnight. Molecular sieves were 
filtered off and the solvent was removed under reduced pressure. The residue was stirred 
with acetone/MeOH (10/1) for 5 min and filtered off. The solid was then stirred again in 
acetone for 15 min, filtered off and dried in vacuo to afford 598 mg of the PTC 122a (1.3 
mmol, 64 % yield) as a pale yellow solid (mp = 230°C, decomposition). 
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1H-NMR (400 MHz, CDCl3): δ = 8.81 (d, 
3JH1,H2 = 4.5 Hz, 1H, 
H1), 8.30-8.24 (m, 1H, H8), 7.85 (d, 3JH2,H1 = 4.5 Hz, 1H, H2), 
7.58 (d, 3JH22,H23 = 7.0 Hz, 1H, H22), 7.54-7.49 (m, 1H, H6), 
7.19-7.12 (m, 1H, H24), 7.11-7.05 (m, 2H, H23), 7.04-6.94 (m, 
2H, H5, H7), 6.59 (d, 3JH10,H11 = 5.5 Hz, OH), 6.50-6.43 (m, 1H, 
H10), 6.14 (d, 2JH20a,H20b = 11.5 Hz, 1H, H20a), 5.81 (ddd, 
3JH18,H19Z = 17.3 Hz, 
3JH18,H19E = 10.3 Hz, 
3JH18,H17 = 7.0 Hz, 1H, H18), 5.34 (d, 
2JH20b,H20a = 11.8 
Hz, 1H, H20b), 5.20 (d, 3JH19E,H18 = 10.3 Hz, 1H, H19E), 5.15 (d, 
3JH19Z,H18 = 17.3 Hz, 1H, 
H19Z), 4.48-4.38 (m, 1H, H16a), 4.24-4.07 (m, 2H, H11, H15a), 3.26 (t, 3JH16b,H16a = 11.5 Hz, 
1H, H16b), 2.78-2.65 (m, 1H, H15b), 2.25 (q, 3J = 8.8 Hz, 1H, H17), 2.11-2.01 (m, 1H, H14a), 
1.77-1.63 (m, 3H, H12a, H12b, H13), 0.74-0.63 (m, 1H, H14b) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 149.4 (C1), 147.0 (C9), 144.3 (C3), 135.2 (C18), 134.0 
(C22), 129.9 (C24), 129.4 (C6), 128.6 (C23), 128.2 (C7), 127.1 (C5), 126.9 (C21), 123.4 
(C4), 123.2 (C8), 119.7 (C2), 118.0 (C19), 66.6 (C11), 65.6 (C10), 61.3 (C20), 56.2 (C16), 
53.5 (C15), 38.0 (C17), 27.2 (C13), 23.7 (C14), 21.8 (C12) ppm. 
 
HRMS (ESI+) calcd. for C26H29N2O
+ [M]+: 385,2280; found 385,2261. 
 
Benzylcinchonidinium bromide (122b)103 
 
Cinchonidine (112b) (588 mg, 2.0 mmol, 1.0 eq.) was suspended in dry chloroform (12 mL) 
in a flame dried round-bottom flask containing molecular sieves. Benzyl bromide (250 µL, 
360 mg, 2.1 mmol, 1.1 eq.) was added and the mixture was heated to reflux for 1 hour 
resulting in a dark red solution which was stirred at r.t. overnight. Molecular sieves were 
filtered off and the solvent was removed under reduced pressure. The residue was stirred 
with Et2O/MeOH (2/1) overnight and filtered off. The solid was then stirred again in the same 
mixture (1h), filtered off and dried in vacuo to afford 559 mg of the PTC 122b (1.2 mmol, 60 
% yield) as a pale yellow solid (mp = 168-170°C). 
 
1H-NMR (400 MHz, CDCl3): δ = 8.80 (d, 
3JH1,H2 = 4.5 Hz, 1H, H1), 
8.16 (d, 3JH8,H7 = 7.8 Hz, 1H, H8), 7.80 (d, 
3JH2,H1 = 4.5 Hz, 1H, H2), 
7.68 (d, 3JH22,H23 = 7.0 Hz, 1H, H22), 7.64 (d, 
3J = 7.8 Hz, 1H, H6), 
7.24-7.11 (m, 5H, H5, H7, H23, H24), 6.57-6.48 (m, 2H, H10, OH), 
5.90 (d, 2JH20a,H20b = 12.0 Hz, 1H, H20a), 5.55 (d, 
2JH20b,H20a = 12.0 
Hz, 1H, H20b), 5.41 (ddd, 3JH18,H19Z = 17.3 Hz, 
3JH18,H19E = 10.3 Hz, 
3JH18,H17 = 5.8 Hz, 1H, H18), 5.26 (d, 
3JH19Z,H18 = 17.3 Hz, 1H, 
H19Z), 4.91 (d, 3JH19E,H18 = 10.3 Hz, 1H, H19E), 4.67-4.56 (m, 1H, H15a), 4.12 (t, 
3J = 9.0 Hz, 
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1H, H11), 3.88 (d, 3JH16a,H15b = 12.8 Hz, 1H, H16a), 3.17-3.04 (m, 2H, H15b, H16b), 2.50-2.40 
(m, 1H, H17), 2.14-2.00 (m, 1H, H14a), 1.93-1.83 (m, 2H, H12a, H13), 1.63-1.52 (m, 1H, 
H14b), 1.10-0.98 (m, 1H, H12b) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 149.5 (C1), 147.1 (C9), 144.5 (C3), 136.0 (C18), 134.0 
(C22), 130.0 (C24), 129.6 (C6), 128.7 (C23), 128.5 (C7), 127.3 (C5), 126.9 (C21), 123.6 
(C4), 122.9 (C8), 119.9 (C2), 117.8 (C19), 67.1 (C11), 65.0 (C10), 62.2 (C20), 60.1 (C16), 
50.3 (C15), 37.8 (C17), 26.5 (C13), 25.1 (C14), 22.3 (C12) ppm. 
 
HRMS (ESI+) calcd. for C26H29N2O
+ [M]+: 385,2280; found 385,2290. 
 
4.5.2. Synthesis of the catalysts for the metal catalysis 
4.5.2.1 Synthesis of the ligands 
 
6,6’-dibromo-BINOL (75)70 
 
In a flame-dried round-bottom flask was dissolved (R)-BINOL ((R)-67) (2.30 g, 8.0 mmol, 1 
eq.) in 40 mL dry dichloromethane under nitrogen. The system was cooled to -78°C in an 
acetone/dry ice bath and bromine (1.1 mL, 3.41 g, 21.4 mmol, 2.7 eq.) dissolved in 4 mL 
DCMabs was added dropwise over 20-25 min. The mixture was stirred for 2.5 h while warming 
up to room temperature and stirred for another half an hour at r.t. before the excess of Br2 
was destroyed with a saturated solution of sodium thiosulfate. The layers were separated 
and the organic phase was washed with brine and dried using magnesium sulfate. The 
solvents were removed under reduced pressure to afford 3.14 g of 6,6’-dibromo-BINOL (75) 
(7.1 mmol, 89 % yield) as a white brownish powder (mp = 95-100°C, Lit.64a 93-95°C). 
Rf = 0.25 (PE/A, 5/1), [𝛼]𝐷
24 = - 132 (CHCl3, c = 0.8)
70 
 
1H-NMR (400 MHz, CDCl3): δ = 8.04 (d, 
3JH5,H7 = 
3JH5’,H7’ = 2.0 Hz, 2H, 
H5, H5’), 7.87 (d, 3JH3,H2 = 
3JH3’,H2’ = 9.0 Hz, 2H, H3, H3’), 7.37 (d, 
3JH2,H3 = 
3JH2’,H3’  = 9.0 Hz, 2H, H2, H2’), 7.36 (dd, 
3JH7,H8 = 
3JH7’,H8’ = 9.0 
Hz, 4JH7,H5 = 
4JH7’,H5’ = 2.0 Hz, 2H, H7, H7’), 6.96 (d, 
3JH8,H7 = 
3JH8’,H7’ = 
9.0 Hz, 2H, H8, H8’), 5.10 (brs, 2H, OH) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 152.9 (C1, C1’), 131.9 (C4, C4’), 130.9 (C7, C7’), 130.6 
(C3, C3’), 130.5 (C9, C9’), 130.4 (C5, C5’), 125.9 (C8, C8’), 119.0 (C2, C2’), 118.0 (C6, C6’) 
110.7 (C10, C10’) ppm. 
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HRMS (ESI+) calcd. for C20H12Br2NaO2
+ [M+Na]+: 464.9101; found 464.9089. 
 
(S)-MOM-BINOL (70)64b 
 
In a flame dried reaction flask, NaH (3.77 g, 60% dispersion in mineral oil, 94.3 mmol, 3.0 
eq.) was washed with THFabs (2 x 50 mL) under nitrogen and stirred in 100 mL THFabs. (S)-
BINOL ((S)-67) (9.00 g, 31.4 mmol), dissolved in 50 mL THFabs was added dropwise at 0°C 
to the stirred suspension of NaH in THFabs. 30 min after the hydrogen evolution had ceased 
(approx. 1h), bromomethyl methyl ether (9.00 g, 72.0 mmol, 2.3 eq.) was added dropwise 
and the reaction was further stirred for 1 h at room temperature. It was then diluted with ether 
(200 mL), washed with a saturated solution of ammonium chloride, brine and then dried over 
magnesium sulfate. After the mixture was filtered and the solvents removed under vacuum 
the crude product was purified through flash chromatography on silica gel (A/PE, 1:15, Rf = 
0.16) to yield 79 % of (S)-MOM-BINOL (70) (9.30 g, 24.8 mmol) as a white powder (mp = 99-
102°C, Lit.64a 103-104°C). [𝛼]𝐷
24 = - 84.0 (CHCl3, c = 1.0)
64b 
 
1H-NMR (400 MHz, CDCl3): δ = 7.97 (d, 
3JH3,H2 = 
3JH3’,H2’ = 9.0 Hz, 
2H, H3, H3’), 7.89 (d, 3JH5,H6 = 
3JH5’,H6’ = 8.3 Hz, 2H, H5, H5’), 7.60 
(d, 3JH2,H3 = 
3JH2’,H3’  = 9.0 Hz, 2H, H2, H2’), 7.36 (ddd, 
3JH7,H8 = 
3JH7’,H8’ = 8.0 Hz, 
3JH7,H6 = 
3JH7’,H6’ = 6.5 Hz, 
4JH7,H5 = 
4JH7’,H5’ = 1.3 Hz, 
2H, H7, H7’), 7.27-7.22 (m, 2H, H6, H6’), 7.20-7.16 (m, 2H, H8, 
H8’), 5.11 (d, 2JH11a,H11b = 
2JH11’a,H11’b = 6.8 Hz, 2H, H11a, H11a’), 5.00 (d, 
2JH11b,H11a = 
2JH11’b,H11’a = 6.8 Hz, 2H, H11b, H11b’), 3.16 (s, 6H, H12, H12’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 152.6 (C1, C1’), 134.0 (C4, C4’), 129.8 (C9, C9’), 129.4 
(C3, C3’), 127.8 (C5, C5’), 126.3 (C6, C6’), 125.5 (C8, C8’), 124.0 (C7, C7’), 121.3 (C10, 
C10’), 117.2 (C2, C2’), 95.1 (C11, C11’), 55.8 (C12, C12’) ppm. 
 
LC-MS (ESI+) for C24H22NaO4
+ [M+Na]+: 397.10. 
 
(S)-3-Formyl-MOM-BINOL (71)65 
 
In a thoroughly dried, 1 L single-necked, round-bottomed flask equipped with a magnetic 
stirring bar, fitted with a three way nitrogen inlet, was dissolved (S)-MOM-BINOL (70) (8.35 g, 
22.3 mol, 1.0 eq.) in 350 mL anhydrous diethyl ether and the mixture was cooled to 0°C with 
an ice-water bath. Tetramethylethylenediamine (TMEDA) (3.3 mL, 2.55 g, 22.0 mmol, 1.0 
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eq.) was added and n-BuLi (2.5 M in hexane, 9.8 mL, 24.5 mmol, 1.1 eq.) was added 
dropwise by syringe to the stirring mixture over 10-15 min at 0°C. After stirring for 10 min at 
0°C, the mixture was allowed to warm to room temperature and stirred for 2 h, which 
produced a grey slurry mixture. The mixture was cooled to 0°C again and dry N,N-
dimethylformamide (DMF) (2.1 mL, 26.8 mmol, 1.2 eq.) was added dropwise. The reaction 
mixture was allowed to warm to room temperature and stirred for 2 h under nitrogen 
atmosphere. A 1M HCl (200 mL) solution was slowly added to the flask at 0°C and the 
aqueous layer was extracted with ethyl acetate (100 mL × 3). The combined organic extracts 
were washed with brine (100 mL), dried over anhydrous magnesium sulfate, filtered and 
concentrated by rotary evaporation. The residue was fully loaded onto a silica gel column 
and was eluted with PE/DCM/EA (20/3/1, Rf = 0.18) to give 68 % of (S)-3-Formyl-MOM-
BINOL (71) (6.14 g, 15.2 mmol) as a yellow solid (mp = 121-122°C, Lit.130 110-112°C). 
[𝛼]𝐷
24 = - 70.5 (CHCl3, c = 1.1) (Lit.
130 - 83.5 (CHCl3, c = 0.4)) 
 
1H-NMR (400 MHz, CDCl3): δ = 10.59 (brs, 1H, H13), 8.57 (s, 1H, 
H3), 8.04 (d, 3JH5,H6 = 8.3 Hz, 1H, H5), 8.00 (d, 
3JH3’,H2’ = 9.0 Hz, 1H, 
H3’), 7.89 (d, 3JH5’,H6’ = 8.0 Hz, 1H, H5’), 7.61 (d, JH2’,H3’ = 9.3 Hz, 
1H, H2’), 7.47 (ddd, 3JH6,H5 = 8.0 Hz, 
3JH6,H7 = 6.8 Hz, 
4JH6,H8 = 1.0 
Hz, 1H, H6), 7.38 (ddd, 3JH7’,H8’ = 8.3 Hz, 
3JH7’,H6’ = 6.8 Hz, 
4JH7’,H5’ = 
1.3 Hz, 1H, H7’), 7.36 (ddd, 3JH7,H8 = 8.5 Hz, 
3JH7,H6 = 6.8 Hz, 
4JH7,H5 
= 1.3 Hz, 1H, H7), 7.28 (ddd, 3JH6’,H5’ = 8.0 Hz, 
3JH6’,H7’ = 6.8 Hz, 
4JH6’,H8’ = 1.3 Hz, 1H, H6’), 7.23 (d, 
3JH8,H7 = 8.5 Hz, 1H, H8), 7.15 (d, 
3JH8’,H7’ = 8.3 Hz, 1H, 
H8’), 5.15 (d, 2JH11’a,H11’b = 7.0 Hz, 1H, H11a’), 5.04 (d, 
2JH11’b,H11’a = 7.0 Hz, 1H, H11b’), 4.75 
(d, 2JH11a,H11b = 5.8 Hz, 1H, H11a), 4.63 (d, 
2JH11b,H11a = 5.8 Hz, 1H, H11b), 3.16 (s, 3H, H12’), 
3.00 (s, 3H, H12) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 191.2 (C13), 153.8 (C1), 152.9 (C1’), 145.4 (C2), 137.0 
(C9), 133.7 (C9’), 131.0 (C3), 130.3 (C3’), 130.17 (C5), 130.16 (C10), 129.6 (C4’), 129.0 
(C7), 128.0 (C5’), 126.9 (C6’), 126.8 (C4), 126.0 (C8), 125.9 (C6), 125.2 (C8’), 124.3 (C7’), 
119.5 (C10’), 116.4 (C2’), 100.2 (C11), 94.9 (C11’), 57.1 (C12), 56.0 (C12’) ppm. 
 
LC-MS (ESI+) for C25H22NaO5
+ [M+Na]+: 425.15. 
 
(S)-3-hydroxymethyl-MOM-BINOL (72)66 
 
In a flame-dried round-bottom flask, was suspended (S)-3-Formyl-MOM-BINOL (71) (3.62 g, 
9.0 mmol, 1.0 eq.) in anhydrous methanol (30 mL) under nitrogen atmosphere. The mixture 
was cooled down to 0°C and NaBH4 (1.14 g, 30.2 mmol, 3.2 eq.) was added in small 
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portions. After stirring for 2 h, water (10 mL) was added to quench the reaction and the 
product was extracted with ethyl acetate (3 x 30 mL) and dried over MgSO4. After filtration, 
the organic solvent was removed under reduced pressure to afford (S)-3-hydroxymethyl-
MOM-BINOL (72) (3.30 g, 8.1 mmol) with 91 % yield as a white sticky solid. 
 
Rf = 0.32 (PE/EE, 4/1), [𝛼]𝐷
24 = - 56.8 (CHCl3, c = 1.1) (Lit.
66 + 63.5 (CHCl3, c = 1.0 for the 
(R)-3-hydroxymethyl-MOM-BINOL) 
 
1H-NMR (400 MHz, CDCl3): δ = 8.00-7.97 (m, 2H, H3, H3’), 7.90, 
7.89 (2 x d, 3JH5,H6 = 
3JH5’,H6’ = 8.0 Hz, 2H, H5, H5’), 7.60 (d, JH2’,H3’ = 
9.0 Hz, 1H, H2’), 7.40, 7.37 (2 x ddd, 3JH7,H8 = 
3JH7’,H8’ = 8.3 Hz, 
3JH7,H6 = 
3JH7’,H6’ = 6.8 Hz, 
4JH7,H5 = 
4JH7’,H5’ = 1.3 Hz, 2H, H7, H7’), 
7.30-7.20 (m, 2H, H6, H6’), 7.19-7.13 (m, 2H, H8, H8’), 5.12 (d, 
2JH11’a,H11’b = 7.0 Hz, 1H, H11a’), 5.04 (d, 
2JH11’b,H11’a = 7.0 Hz, 1H, H11b’), 4.98-4.86 (m, 2H, 
H13), 4.68 (d, 2JH11a,H11b = 6.0 Hz, 1H, H11a), 4.48 (d, 
2JH11b,H11a = 6.0 Hz, 1H, H11b), 3.55-
3.42 (m, 1H, OH), 3.25 (s, 3H, H12), 3.16 (s, 3H, H12’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 153.2 (C1), 152.7 (C1’), 134.3 (C9), 133.74 (C9’), 133.72 
(C10), 131.0 (C2), 130.0, 129.1 (C3, C3’), 129.7 (C4’), 128.0, 127.9 (C5, C5’), 126.8, 126.2 
(C6, C6’), 125.6, 125.3 (C8, C8’), 125.2, 124.2 (C7, C7’), 125.5 (C4), 120.4 (C10’), 116.5 
(C2’), 99.3 (C11), 94.7 (C11’), 62.1 (C13), 57.0 (C12), 56.0 (C12’) ppm. 
 
LC-MS (ESI+) for C25H24NaO5
+ [M+Na]+: 427.20. 
 
(S)-3-bromomethyl-MOM-BINOL (73)66 
 
To a solution of (S)-3-hydroxymethyl-MOM-BINOL (72) (1.82 g, 4.5 mmol, 1.0 eq.), dissolved 
in toluene (30 mL) and ethyl acetate (30 mL), was added triethylamine (1.4 mL, 9.4 mmol, 
2.0 eq.) at 0°C. Mesyl chloride (0.45 mL, 6.0 mmol, 1.3 eq.) was slowly added and the 
mixture was stirred for 2 h before being filtrated. The filtrate was concentrated under reduced 
pressure and the residue was dissolved in DMF (20 mL) before lithium bromide (4.3 g, 50 
mmol) was added triggering an exothermic reaction. DMF (10 mL) was added to dilute the 
viscous mixture and the reaction was stirred overnight at room temperature. Water was 
added (20 mL), the product was extracted with EA (3 x 50 mL), and after evaporation of the 
solvents, the residue was purified by silica gel column chromatography (EA/PE, 1/8, Rf = 
0.22) to yield 87 % of (S)-3-bromomethyl-MOM-BINOL (73) (1.84 g, 3.9 mmol) as a greyish 
white powder (mp = 79-89°C). 
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[𝛼]𝐷
24 = - 60.5 (CHCl3, c = 1.1) (Lit.
66 + 60.0 (CHCl3, c = 1.0 for the (R)-3-bromomethyl-MOM-
BINOL) 
 
1H-NMR (400 MHz, CDCl3): δ = 8.06 (s, 1H, H3), 7.99 (d, 
3JH3’,H2’ = 
9.0 Hz, 1H, H3’), 7.88 (d, 3JH5,H6 = 
3JH5’,H6’ = 8.3 Hz, 2H, H5, H5’), 
7.60 (d, JH2’,H3’ = 9.0 Hz, 1H, H2’), 7.44-7.34 (m, 2H, H7, H7’), 7.32-
7.22 (m, 2H, H6, H6’), 7.21-7.15 (m, 2H, H8, H8’), 5.13 (d, 
2JH11’a,H11’b = 7.0 Hz, 1H, H11a’), 5.07 (d, 
2JH11’b,H11’a = 7.0 Hz, 1H, 
H11b’), 4.90 (d, 2JH13a,H13b = 11.5 Hz, 1H, H13a), 4.88 (d, 
2JH13b,H13a = 11.5 Hz, 1H, H13b), 
4.71 (d, 2JH11a,H11b = 5.5 Hz, 1H, H11a), 4.48 (d, 
2JH11b,H11a = 5.5 Hz, 1H, H11b), 3.20 (s, 3H, 
H12’), 3.04 (s, 3H, H12) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 152.8 (C1), 152.0 (C1’), 134.1 (C9), 133.8 (C9’), 131.0 (C2), 
130.8 (C3), 130.7 (C10), 130.0 (C3’), 129.6 (C4’), 128.0, 127.9 (C5, C5’), 126.9, 126.8 (C6, 
C6’), 125.9 (C4), 125.8, 125.4 (C8, C8’), 125.3, 124.2 (C7, C7’), 120.2 (C10’), 116.4 (C2’), 
99.2 (C11), 94.8 (C11’), 62.1 (C13), 56.8 (C12), 56.0 (C12’) ppm. 
 
LC-MS (ESI+) for C25H23BrNaO4
+ [M+Na]+: 489.25. 
 
(S,S)-linked-BINOL (69)66 
 
In a flame-dried round-bottom flask, was suspended NaH (0.28 g, 7.0 mmol, 2.0 eq.) in 
THFabs (30 mL) and (S)-3-hydroxymethyl-MOM-BINOL (72) (1.42 g, 3.5 mmol, 1.0 eq.) 
dissolved in THFabs (50 + 10 mL) was added slowly under nitrogen atmosphere. After stirring 
for 1 h at room temperature, (S)-3-bromomethyl-MOM-BINOL (73) (1.64 g, 3.5 mmol, 1.0 
eq.), dissolved in THFabs (40 + 10 mL), was added and the mixture was refluxed for 22 h. The 
reaction was quenched with water (30 mL) and after extraction with ethyl acetate (3 x 100 
mL) and evaporation of the solvents, 2.56 g (3.2 mmol) of the crude (S,S)-linked-MOM-
BINOL (74) were obtained as a white solid (91 % yield). 
 
The solid was dissolved in methanol (170 mL) and 1mL of HCl (12 M) was added before the 
mixture was refluxed for one hour. Since no difference was seen on the TLC plate, 15 mL 
HCl were added in portions and the solution was stirred overnight at room temperature. 
Water was added and the aqueous phase was saturated with ammonium chloride and 
separated. The organic solvents were removed under reduced pressure and the residue was 
dissolved in DCM. The organic phase was washed with water (3 x 100 mL) until neutrality 
was reached, then washed with brine and dried over magnesium sulfate. The residue was 
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purified by silica gel column chromatography (EA/PE, 1/4, Rf = 0.14) to afford 1.08 g (1.7 
mmol, 56 % yield) of (S,S)-linked-BINOL (69) as a brownish white solid (mp = 148°C, 
decomposition) 
 
[𝛼]𝐷
24 = - 56.5 (CHCl3, c = 1.0) (Lit.
66 + 60.6 (CHCl3, c = 1.0 for the (R,R)-linked-BINOL) 
 
1H-NMR (400 MHz, CDCl3): δ = 7.93 (s, 2H, H3), 7.87 (d, 
3JH3’,H2’ = 8.8 Hz, 1H, H3’), 7.82 (t, 
3JH5,H6 = 
3JH5’,H6’ = 7.5 
Hz, 4H, H5, H5’), 7.35-7.30 (m, H2, H6), 7.30-7.21 (m, 
6H, H7, H7’, H2’), 7.21-7.15 (m, 2H, H6), 7.10, 7.07 (2 x 
d, JH8,H7 = JH8’,H7’ = 8.5 Hz, 4H, H8, H8’), 6.33 (brs, 2H, 
OH), 5.04 (brs, 2H, OH), 5.00 (s, 4H, H11) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 152.2 (C1), 151.8 (C1’), 133.6, 133.4 (C4, C4’), 130.8, 
130.0 (C3, C3’), 129.3, 128.9 (C9, C9’), 128.3, 128.2 (C5, C5’), 127.4, 127.1 (C6, C6’), 125.5 
(C2), 124.4 (C8, C8’), 124.2, 123.7 (C7, C7’), 117.7 (C2’), 112.5, 112.1 (C10, C10’), 70.3 
(C11) ppm. 
 
LC-MS (ESI+) for C42H30NaO5
+ [M+Na]+: 637.50. 
 
4.5.2.2 Formation of the catalysts 
 
GP 10: Preparation of BinAlH type catalysts according to the known procedure from 
NOYORI56c 
 
In a flame dried round bottom flask, LiAlH4 (308 mg, 8.1 mmol, 1.0 eq.) was suspended in 
anhydrous THF (5 mL, 1.62 M solution) under nitrogen atmosphere. Absolute EtOH (0.47 
mL, 8.1 mmol, 1.0 eq.) was added dropwise and the mixture was stirred for 5 min at room 
temperature. (S)-BINOL ((S)-67) (2.29 g, 8.0 mmol, 1.0 eq.) was dried under vacuum for 3h 
at 70°C prior use. It was then dissolved in dry THF (13 mL, 0.6 M solution) and added 
dropwise to the LAH/EtOH mixture leading to a cloudy 0.38 M solution of (S)-BinAlH ((S)-
66a). 
 
(R)-BinAlH ((R)-66a) and TaddAlH (R,R)-66b were prepared according to the same 
procedure 
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GP 11: Preparation of LiAlH4 based catalysts: 
 
The ligand (1.1 or 2.2 eq.) was dried overnight under vacuum at 50-60°C. It was dissolved in 
the appropriate solvent (2.2 mL/mmol of ligand) under nitrogen atmosphere and added 
dropwise to a 1.0 M solution of LiAlH4 (1.0 eq.) at room temperature. After stirring for 1h at 
room temperature, the catalyst was cooled to 0°C. The 0.15-0.25 M solution of the catalyst 
was then directly used for metal catalysed synthesis. 
 
Preparation of (R,R)-ALB ((R,R)-66e) and related catalysts53d 
 
Following the general procedure GP 11, (R)-BINOL (67) (3.850 mg, 13.44 mmol, 2.1 eq.) 
dissolved in DT101 (30 mL) was mixed with a 1.0 M solution of LAH (6.4 mL, 6.4 mmol, 1.0 
eq.) to give a 0.21 M solution of the catalyst (R,R)-ALB ((R,R)-66e) as cloudy suspension 
ready to be used for metal catalysis. 
 
The same procedure was repeated with TADDOL (68), 6,6’-dibromo-BINOL (75), 3,3’-
dibromo-BINOL (76), 6-bromo-BINOL(77) as ligands to form the catalysts 66o, 66p, 66q, 66r 
respectively. 
 
Likewise, when NaAlH4, Ti(OiPr4), Al(Me)3 were used instead of LAH, the catalysts 66d 66i, 
66l, 66m could be obtained. By varying the ratio of BINOL and LAH, the catalysts 66c, 66f 
and 66g were prepared. 
 
Preparation of the Al-Li-linked-BINOL catalyst 
 
Following the general procedure GP 11, (S,S)-linked-BINOL (69) (959 mg, 1.56 mmol, 1.1 
eq.) dissolved in DT101 (12 mL) was mixed with a 1.0 M solution of LAH (1.4 mL, 1.4 mmol, 
1.0 eq.) to give a 0.1 M solution of the catalyst 66n as cloudy suspension ready to be used 
for metal catalysis. 
 
Preparation of the La-linked-BINOL catalyst (66k)53c 
 
(S,S)-linked-BINOL (69) (890 mg, 1.45 mmol, 1.0 eq.) was dried for 3h under vacuum, 
dissolved in anhydrous THF (10 mL) and cooled down to -78°C under nitrogen atmosphere. 
Lanthanum isopropoxide (458 mg, 1.45 mmol, 1.0 eq.) was suspended in anhydrous THF 
(8.5 mL) and added to the ligand. The cooling bath was removed and the mixture was stirred 
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at room temperature for 5h. The solvent was evaporated to afford the catalyst 66k in 
quantitative yield. 
 
Preparation of the LLB catalyst (66h)51 
 
(S)-BINOL ((S)-67) (1.376 g, 4.8 mmol, 3.0 eq.) was dried under vacuum for 3h at 70°C, 
dissolved in dry THF (20 mL) and cooled to 0°C and n-BuLi (1.92 mL of a 2.5 M solution in 
hexane, 4.8 mmol, 3.0 eq.) was slowly added under nitrogen atmosphere to give a milky 
suspension. After stirring for 1h at 0°C, La(OiPr)3 was suspended in dry THF (4 mL) and 
added to the mixture which became clearer. It was stirred overnight at room temperature and 
used directly for metal-catalysed synthesis 
 
Preparation of Al3Li3BINOL3 (66h)
62 
 
(R)-BINOL ((R)-67) (1.840 g, 6.4 mmol, 2.0 eq.) was dried under vacuum for 3h at 70°C. 
After the flask had cooled down to room temperature, it was dissolved in THFabs (12 mL) and 
slowly added under nitrogen atmosphere to a solution of LiAlH4 (128 mg, 3.2 mmol, 1.0 eq.) 
in THF (2 mL). After stirring for 1h at room temperature, n-BuLi (1.28 mL of a 2.5 M solution 
in hexane, 3.2 mmol, 1.0 eq.) was slowly added and the solution was stirred overnight to give 
the catalyst 66h. 
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4.6. Syntheses of myrtucommulone derivatives 
 
Due to the reasons explained in the introduction (§ 1.2, rotamer and tautomer mixture),35a the 
NMR analyses of MCA (5) and similar uncyclised derivatives are not always significant. 
Therefore, for some derivatives, only the 1H-NMR spectrum is given. In general, the NMR 
spectra of the uncyclised derivatives cannot be precisely interpreted. The complete and 
precise peak assignments are made on the cyclised derivatives. 
 
4.6.1. Syncarpic acid derivatives 
4.6.1.1 Preparation and cyclisation of the semimyrtucommulone derivative 
84 
 
Semimyrtucommulone derivative 84 
 
According to GP 8, PG (28) (60 mg, 0.48 mmol, 1.0 eq.) was dissolved in a 1/1 mixture of 
DCMabs/THFabs (2 mL) and added dropwise to the freshly prepared (S,S)-ALB ((S,S)-66e) 
(9.1 mL of a 0.18 M solution in DT101, 1.6 mmol, 3.3 eq.). IBSA (0.9 mL of a 0.83 M solution 
in DT101, 0.75 mmol, 1.6 eq.) was added dropwise to the mixture at 0°C. After 1.5h stirring 
at 0°C, the reaction was quenched and the product extracted and dried. After purification by 
column chromatography on silica gel (A/PE, 1/2 (400 mL)-1/1 (600 mL)-3/2 (600 mL), Rf = 
0.13 (A/PE, 1/1)), 130 mg of the semimyrtucommulone derivative 84 (0.36 mmol, 75 % yield) 
were obtained as a pale brownish yellow powder (mp = 171-172°C, decomposition). 
 
HRMS (ESI+) calcd. for C20H27O6
+ [M+H]+: 363.1807, found: 363.1798. 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 5.82-5.79 (m, 1H, H3, 
H5), 5.79-5.76 (m, 1H, H3, H5), 4.21, 4.16 (2 x sept, 
3JH2‘’’,H3’’‘-H4‘‘‘ = 6.9 Hz, 1H, H2’’’), 3.85 (d, 
3JH1’,H8‘ = 11.0 Hz, 
1H, H1’), 3.25 (dsept, 3JH8’,H1‘ = 11.0 Hz, 
3JH8’,H9‘-H10‘ = 6.5 
Hz, 1H, H8’), 1.30–1.19 (m, 12H, H11’, H12’, H13’, H14’), 
0.82 (d, 3JH9’,H8‘ = 6.5 Hz, 3H, H9’), 0.71 (d, 
3JH10’,H8‘ = 6.5 
Hz, 3H, H10’) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 218.1 (C5’), 198.9, 197.5 (C7’), 159.8, 159.7, 158.2 (C4, 
C6, C3’, C2), 114.2 (C3), 112.8 (C2’), 106.8, 106.2 (C1), 98.2, 97.3 (C3, C5), 53.4 (C4’, C6’), 
43.0 (C-1’), 27.6 (C8’), 27.0, 26.6, 25.9 (C11’, C12’, C13’, C14’), 23.9, 23.8 (C9’, C10’) ppm. 
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Tricyclic semimyrtucommulone derivative 85 (28 % ee) 
 
Following the GP 9 procedure, semimyrtucommulone derivative 84 (80 mg, 0.22 mmol, 1.0 
eq.) and pTsOH (126 mg, 0.66 mmol, 3.0 eq.) were heated to 95 °C in toluene (8 mL) for 1h 
to yield, after purification on column chromatography (A/PE, 1/9, Rf = 0.13), 37 mg of the 
cyclised derivative 85 (0.11 mmol, 49 % yield). It was dissolved in a DCM/PE (1/9) mixture 
and evaporated under reduced pressure to afford a white powder (mp > 245°C). 
 
 1H-NMR (400 MHz, CO(CD3)2): δ = 8.66 (brs, 1H, OH), 8.44 (brs, 
1H, OH), 6.31, (d, 4JH1,H5 = 2.3 Hz, 1H, H1), 6.21, (d, 
4JH5,H1 = 2.3 
Hz, 1H, H5), 4.26 (d, 3JH1’,H8’ = 3.8 Hz, 1H, H1’), 1.93 (dsept, 
3JH8’,H1’ 
= 3.8 Hz, 3JH8’,H9’-10’= 6.8 Hz, 1H, H8’), 1.55 (s, 3H, H12’), 1.42 (s, 
3H, H14’), 1.36 (s, 3H, H11’), 1.30 (s, 3H, H13’), 0.79 (d, 3JH9’,H8’ = 
7.0 Hz, 3H, H9’), 0.75 (d, 3JH10’,H8’ = 7.0 Hz, 3H, H10’) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 213.8 (C5’), 198.8 (C7’), 170.3 (C3’), 158.9, 157.5 (C4, 
C6), 155.5 (C2), 113.2 (C2’), 105.4 (C3), 101.2 (C1), 96.3 (C5), 57.3 (C6’), 49.0 (C4’), 36.6 
(C8’), 33.9 (C1’), 26.6 (C11’, C12’), 25.7, 25.3 (C13’, C14’), 20.7, 20.1 (C9’, C10’) ppm. 
 
Crystal Structure: (for the complete data see Appendix 3) 
 
 
 
 
 
 
 
 
 
 
 
 
Exp. Data Tab. 3 Crystal data and structure refinement for 85 (sh3169). 
Identification code  sh3169  
Empirical formula  C20 H24 O5  
Formula weight  344.39  
Temperature  153(2) K  
Wavelength  0.71073 Å  
Crystal system  Orthorhombic  
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Space group  Pna2(1)  
Unit cell dimensions a = 11.642(3) Å α= 90°. 
 b = 17.302(4) Å β= 90°. 
 c = 9.182(2) Å γ = 90°. 
Volume 1849.5(8) Å3  
Z 4  
Density (calculated) 1.237 Mg/m3  
Absorption coefficient 0.088 mm-1  
F(000) 736  
Crystal size 0.48 x 0.07 x 0.05 mm3  
Theta range for data collection 2.11 to 27.52°.  
Index ranges -14<=h<=15, -13<=k<=22, -
7<=l<=11 
 
Reflections collected 8555  
Independent reflections 3300 [R(int) = 0.1492]  
Completeness to theta = 27.52° 99.3 %   
Absorption correction None  
Max. and min. transmission 0.9953 and 0.9592  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 3300 / 1 / 233  
Goodness-of-fit on F2 0.951  
Final R indices [I>2sigma(I)] R1 = 0.0744, wR2 = 0.1092  
R indices (all data) R1 = 0.2271, wR2 = 0.1524  
Absolute structure parameter 2(3)  
Extinction coefficient 0.0081(10)  
Largest diff. peak and hole 0.337 and -0.311 e.Å-3  
 
4.6.1.2 Preparation of norsemimyrtucommulone (NSMC) (8) 
According to general procedure GP 688 
 
According to the general procedure GP 6, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.), sparteine (111) (115 µL, 0.50 mmol, 1.0 eq.), and isobutylidene syncarpic 
acid (IBSA) (31) (354 mg, 1.50 mmol, 1.5 eq.), were mixed in DCM (4 mL) and stirred at 
room temperature for 19h. The reaction was worked up and the product was purified through 
column chromatography on silica gel (A/PE, 1/2 (400 mL), 1/1 (1000 mL), Rf = 0.15 (A/P, 
1/1)) to afford 209 mg of NSMC (8) (0.48 mmol, 96 % yield) as a brownish yellow powder. 
[𝛼]𝐷
24 = 0.0 (MeOH, c = 2.0) 
 
NSMC (8) was also synthesised according to GP 6 using piperidine (Tab. 13, entry 2), poly-
L-leucine (PLL) (§ 2.4.2.3) and cinchonidine (112b) (Tab. 15, entry 8, 10) as catalysts. 
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Attempts with Poly-L-Leucine 
 
IBPG (25) (98 mg, 0.50 mmol, 1.0 eq.) was dissolved in THFabs (6 mL) and NaH (52 mg, 60 
% dispersion on mineral oil, 1.30 mmol, 2.5 eq.) was added. After stirring for 10 min at room 
temperature, PLL (324 mg, ≈ 5.6 eq.) was added and the mixture was stirred for another 15 
min. The solvent was removed under reduced pressure until a brownish powder formed. The 
residue was stirred in DCMabs (2 mL) and IBSA (31), dissolved in DCM (2 mL), was added at 
0°C to the mixture. After 1h, the completion of the reaction was observed on TLC and the 
reaction was hydrolysed with a saturated solution of ammonium chloride. The crude product 
was extracted with diethyl ether (3 x 20 mL) and then dried with magnesium sulfate. The 
solvent was evaporated under reduced pressure and the purification on silica gel column 
chromatography (A/PE, 1/2 (400 mL), 1/1 (1000 mL)) afforded 181 mg of NSMC (8) (0.42 
mmol, 82 % yield) as a yellow powder. 
 
With a phase transfer catalyst (PTC)102 
 
According to the general procedure GP 7, isobutyryl phloroglucinol (IBPG) (25) (100 mg, 
0.51 mmol, 1.0 eq.) was mixed with the PTC 122a (302 mg, 0.65 mmol, 1.3 eq.) and KF (38 
mg, 0.65 mmol, 1.3 eq.).The mixture was brought to 0°C before isobutylidene syncarpic acid 
(IBSA) (31) (183 mg, 0.77 mmol, 1.5 eq.) was added. After stirring for 1h, the reaction was 
worked up (use of CaCl2 to catch fluoride ions) and the product was purified through column 
chromatography on silica gel (A/PE, 1/2 (400 mL), 1/1 (1000 mL)) to afford 190 mg of NSMC 
(8) (0.44 mmol, 86 % yield) as a pale yellow powder. 
 
Typical metal catalysed synthesis 
 
According to GP 8, IBPG (25) (390 mg, 2.0 mmol, 1.0 eq.) was dissolved in DT101 (8 mL) 
and added dropwise to the freshly prepared (R,R)-ALB ((R,R)-66e) (36.4 mL of a 0.18 M 
solution in DT101, 6.4 mmol, 3.2 eq.). IBSA (654 mg, 2.77 mmol, 1.4 eq.) was dissolved in 
DT101 (5.5 mL, 0.68 M solution) and added dropwise to the mixture at 0°C. After 2h stirring 
at 0°C, the reaction was quenched and the product extracted and dried. After purification by 
column chromatography on silica gel (A/PE, 1/2 (400 mL), 1/1 (1000 mL), Rf = 0.15 (A/P, 
1/1)), 661 mg of NSMC (8) (1.53 mmol, 81 % yield) were obtained as a pale yellow powder. 
[𝛼]𝐷
24 = + 16.1 (MeOH, c = 2.98). 
 
HRMS (ESI+) calcd. for C24H32NaO7
+ [M+Na]+: 455.2045, found: 455.2030. 
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The same procedure was repeated for every attempted metal-catalysed reaction, changing 
the catalyst, the number of equivalents of the catalyst, the solvent, and the temperature. 
 
Characterisation 
 
Since the NMR spectra showed no difference relatively to the method used for the synthesis 
of NSMCs (8), only one NMR spectrum is displayed here. Two sets of peaks are observed in 
both 1H and 13C NMR-spectra probably related to two different rotamers.57 
 
1H-NMR (500 MHz, CO(CD3)2): δ = 14.36 (brs, 0.46H, OH), 
13.75-13.60 (brs, 1H, OH), 13.49 (brs, 0.31H, OH), 13.04 
(brs, 0.35H, OH), 5.67, 5.66 (2 x s, 1H, H5), 4.21, 4.16 (2 x 
sept, 3JH2‘’’,H3’’‘-H4‘‘‘ = 6.9 Hz, 1H, H2’’’), 3.85, 3.82 (2 x d, 
3JH1’,H8‘ = 11.0 Hz, 1H, H1’), 3.30, 3.25 (2 x dsept, 
3JH8’,H1‘ = 
11.0 Hz, 3JH8’,H9‘-H10‘ = 6.3 Hz, 1H, H8’), 1.31-1.25 (m, 6H, 
H11’, H12’, H13’, H14’), 1.22-1.17 (s, 6 H, (m, 6H, H11’, H12’, H13’, H14’), 1.14, 1.13 (2 x d, 
JH3‘’’,H2’’‘ = 6.9 Hz, 3H, H3‘‘‘), 1.09, 1.08 (2 x d, JH4‘’’,H2’’‘ = 6.9 Hz, 3H, H4‘‘‘), 0.83, 0.82 (2 x d, 
3JH9’,H8‘ = 6.3 Hz, 3H, H9’), 0.71, 0.67 (2 x d, 
3JH10’,H8‘ = 6.3 Hz, 3H, H10’) ppm.  
 
13C-NMR (125 MHz, CO(CD3)2): δ = 218.7 (C5’), 212.1, 211.8 (C1'), 195.0, 192.5 (C7’), 
167.39, 166.36 (C4), 166.64, 166.58 (C6), 164.1, 163.5 (C3’, C2), 114.2, 113.7 (C3), 113.3, 
113.1 (C2’), 106.8, 106.2 (C1), 98.4, 97.4 (C5), 56.5, 53.54, 53.4, 53.34, 53.26 (C4’, C6’), 
43.6, 43.4 (C-1’), 40.25, 40.18 (C2’’’), 27.5, 27.19 (C8’), 27.3, 27.24, 26.9, 26.8, 26.72, 26.65 
(C11’, C12’, C13’, C14’), 23.9, 23.8, 23.76, 23.74, 23.68 (C4’’’, C3’’’), 21.4, 21.2 (C9’), 20.7, 
20.3 (C10’) ppm. 
 
NSMC (8) was dissolved in DCM with a drop of acetone and precipitated with PE before 
being evaporated under vacuum to obtain a pale yellow powder (mp = 170°C, 
decomposition). 
 
HRMS (ESI+) calcd. for C24H33O7
+ [M+H]+: 433.2221, found: 433.2220. 
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4.6.1.3 Preparation of myrtucommulone B (6) 
 
Following the GP 9 procedure, NSMC (8) (70 mg, 0.16 mmol, 1.0 eq.) and pTsOH (93 mg, 
0.49 mmol, 3.0 eq.) were heated to 95°C in toluene (7 mL) for 1h to yield, after purification on 
column chromatography (A/PE, 1/9, Rf = 0.08), 43 mg of MCB (6) (0.10 mmol, 65 % yield). It 
was dissolved in a DCM/PE (1/9) mixture and evaporated under reduced pressure to afford a 
white foam. 
 
In the case of MCB (6), the experimental properties are dependent on the ee of the sample. 
For this reason two examples are given. In the 2% ee sample, two very close sets of peaks 
can be observed in 1H-NMR but also on some peaks of the 13C-NMR spectrum. Likewise, in 
the 72 % ee sample, two more distinguishable sets of peaks are visible but sometimes not in 
the 13C-NMR spectrum where the concentration of the less concentrated peak is too low. 
 
Sample with 2% ee 
 
 1H-NMR (400 MHz, CDCl3): δ = 13.39 (s, 1H, C6- OH), 7.71 (brs, 
1H, C4-OH), 6.339, 6.336 (2 x s, 1H, H5), 4.40, 4.39 (d, 3JH1’,H8’ = 
3.5 Hz, 1H, H1’), 3.90 (sept, 3JH2’’’,H3’’’-H4’’’ = 6.8 Hz, 1H, H2’’’), 1.92 
(dsept, 3JH8’,H1’ = 3.5 Hz, 
3JH8’,H9’-10’ = 6.8 Hz, 1H, H8’), 1.62 (s, 3H, 
H12’), 1.46 (s, 3H, H14’), 1.43 (s, 3H, H11’), 1.40 (s, 3H, H13’), 
1.25 (d, 3JH4’’’,H2’’’ = 6.5 Hz, 3H, H4’’’), 1.24 (d, 
3JH3’’’,H4’’’ = 7.0 Hz, 
3H, H3’’), 0.83, 0.82 (2 x d, 3JH9’,H8’ = 7.3 Hz, 3H, H9’), 0.79 (d, 
3JH10’,H8’ = 7.0 Hz, 3H, H10’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.8 (C5’), 208.9 (C1’’’), 199.2, 199.1 (C7’), 168.41, 
168.37 (C3’), 164.7 (C4), 159.9 (C6), 153.4 (C2), 112.1 (C2’), 103.9 (C3), 103.7 (C1), 100.6 
(C5), 56.1 (C6’), 47.3 (C4’), 39.6 (C2’’’), 34.8 (C8’), 31.4 (C1’), 25.2, 25.0 (C12’), 24.97 
(C14’), 24.94 (C11’), 24.2 (C13’), 20.9 (C3’’’), 18.9 (C9’), 18.6 (C10’), 17.7 (C4’’’) ppm. 
 
HRMS (ESI+) calcd. for C24H31O6
+ [M+H]+: 415.2121, found: 415.2112,  mp = 85-95°C 
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Sample with 72% ee: (-)-(S)-MCB (6) 
 
In this NMR spectrum, the “self induced non-equivalence” discussed in § 2.3.2.6 (NMR 
particularity) can be clearly observed. 
 
1H-NMR (400 MHz, CDCl3): δ = 13.40 (s, 1H, C6-OH), 7.98 (brs, 
1H, C4-OH), 6.36 (s, 0.13H, H5), 6.33 (s, 0.82H, H5), 4.42 (d, 
3JH1’,H8’ = 3.8 Hz, 0.84H, H1’), 4.39 (d, 
3JH1’,H8’ = 3.8 Hz, 0.14H, 
H1’), 3.95-3.83 (m, 1H, H2’’’), 1.92 (dsept, 3JH8’,H1’ = 3.8 Hz, 
3JH8’,H9’-
10’= 6.8 Hz, 1H, H8’), 1.62 (s, 3H, 12’), 1.46 (s, 3H, H14’), 1.44 (s, 
0.50H, H11’), 1.42 (s, 2.71H, H11’), 1.39 (s, 3H, H13’), 1.26 (d, 
3JH4’’’,H2’’’ = 6.5 Hz, 3H, H4’’’), 1.24 (d, 
3JH3’’’,H2’’’ = 7.0 Hz, 3H, H3’’’), 0.84 (d, 
3JH8’,H9’ = 6.8 Hz, 
3H, H9’), 0.80 (d, 3JH8’,H10’ = 6.8 Hz, 3H, H10’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.8 (C5’), 208.9 (C1’’’), 199.3 (C7’), 168.5, 168.3 (C3’), 
164.72, 164.69 (C4), 160.02, 159.97 (C6), 153.4, 153.3 (C2), 112.2, 112.1 (C2’), 103.9, 
103.8 (C3), 103.63, 103.58 (C1), 100.6 (C5), 56.14, 56.11 (C6’), 47.3 (C4’), 39.6 (C2’’’), 34.8, 
34.7 (C8’), 31.41, 31.37 (C1’), 25.1 (C12’), 25.03 (C14’), 24.95, 24.92 (C11’), 24.15, 24.10 
(C13’), 20.9 (C3’’’), 18.91, 18.86 (C9’), 18.6, 18.5 (C10’), 17.7 (C4’’’) ppm. 
 
HRMS (ESI+) calcd. for C24H31O6
+ [M+H]+: 415.2121, found: 415.2112 (different measure 
from the one above), mp = 168-174°C, [𝛼]𝐷
24 = - 117.1 (CHCl3, c = 2.92). 
 
4.6.1.4 Preparation of myrtucommulone A 
One-Pot Method 
 
According to the general procedure GP 5, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), syncarpic acid (27) (550 mg, 3.02 
mmol, 6.0 eq.) and isobutyraldehyde (26) (0.36 mL, 3.94 mmol, 8.0 eq.) were mixed in 
ethanol (4 mL) and stirred at room temperature for 24 h. The reaction was worked up and the 
product was purified through column chromatography on silica gel (A/PE, 1/2, Rf = 0.15) to 
afford 219 mg of MCA (5) (0.33 mmol, 66 % yield) as a pale yellow powder (mp = 160-185°C, 
Lit.35a 150-180°C). [𝛼]𝐷
24 = 0.0 (MeOH, c = 3.0) 
 
HRMS (ESI+) calcd. for C38H53O10
+ [M+H]+: 669.3638, found: 669.3666. 
  
Experimental  - 124 - 
According to the general procedure GP 6 
a) High yielding unstereoselective synthesis 
 
According to the general procedure GP 6, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.), cinchonine (112a) (147 mg, 0.5 mmol, 1.0 eq.), and isobutylidene syncarpic 
acid (IBSA) (31) (732 mg, 3.1 mmol, 6.2 eq.), were mixed in MeOH (5 mL) and stirred at 
room temperature for 27h. The reaction was worked-up and the product was purified through 
column chromatography on silica gel (A/PE, 1/2) to afford 309 mg of MCA (5) (0.46 mmol, 92 
% yield) as a pale yellow powder. [𝛼]𝐷
24 = 0.0 (MeOH, c = 2.0) This sample has an ee of 7% 
and a de of 2 %. 
b) Diastereoselective synthesis 
 
According to the general procedure GP 6, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.), cinchonidine (112b) (73.6 mg, 0.25 mmol, 0.5 eq.), and isobutylidene 
syncarpic acid (IBSA) (31) (520 mg, 2.2 mmol, 4.4 eq.), were mixed in MeOH (5 mL) and 
stirred at room temperature for 91h. The reaction was worked-up and the product was 
purified through column chromatography on silica gel (A/PE, 1/2) to afford 151 mg of MCA 
(5) (0.23 mmol, 46 % yield) as a pale yellow powder. [𝛼]𝐷
24 = + 2.0 (MeOH, c = 2.05). This 
sample showed an ee of 28 % and de of 82 %. mp = 162-185°C (Lit.35a 150-180°C) 
 
This procedure was repeated with piperidine, pyrrolidine, proline (90), Phe, His, Glu, Tyr, Trp, 
CN (112a), Q (112c), CPN (118), Bz-Q (121), Bz-CPN (120), brucine (114), ephedrine (113), 
and HODPP (115). 
 
HRMS (ESI+) calcd. for C38H53O10
+ [M+H]+: 669.3638, found: 669.3649. 
 
With a phase transfer catalyst (PTC)100,129 
 
According to the general procedure GP 7, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.) was mixed with the PTC 122b (116 mg, 0.25 mmol, 0.5 eq.) and a 1.0 M KOH 
solution (1.0 mmol, 2.0 eq.) was added. After the addition of isobutylidene syncarpic acid 
(IBSA) (31) (570 mg, 2.4 mmol, 4.8 eq.), the mixture was stirred at room temperature for 67h 
before being worked-up. The crude product was purified through column chromatography on 
silica gel (A/PE, 1/2) to afford 309 mg of MCA (5) (0.46 mmol, 92 % yield) as a pale yellow 
powder. 
Experimental  - 125 - 
Typical metal catalysed synthesis57 
 
According to GP 8, (-)-(R)-NSMC ((R)-8) (183 mg, 0.42 mmol, 1.0 eq.) was dissolved in 
DT101 (0.8 mL) and added dropwise to the freshly prepared (R,R)-ALB ((R,R)-66e) (7.6 mL 
of a 0.18 M solution in DT101, 1.38 mmol, 3.3 eq.). IBSA (1.1 mL of a 0.73 M solution, 0.80 
mmol, 2.0 eq.) was added dropwise to the mixture at 0°C and the reaction was stirred at this 
temperature for 10h then at room temperature for 6h. The reaction was quenched and the 
product extracted and dried. After purification by column chromatography on silica gel (A/PE, 
1/2), 216 mg of MCA (5) (0.32 mmol, 77 % yield) were obtained as a pale yellow powder with 
70% ee. [𝛼]𝐷
24 = + 22.1 (MeOH, c = 2.08). 
 
HRMS (ESI+) calcd. for C38H53O10
+ [M+H]+: 669.3638, found: 669.3628. 
 
Characterisation 
 
Since the NMR spectra showed no difference relatively to the method used for the synthesis 
of MCA (5), only one NMR spectrum is displayed here. 
 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 15.80 
(brs, 0.38H, OH), 15.41 (brs, 0.51H, OH), 
14.54-14.08 (m, 0.33H, OH), 13.93-13.59 (m, 
0.11H, OH), 13.14-12.77 (m, 0.85H, OH), 
4.47-4.26 (m, 0.58H), 4.22 (d, 3J =11.3 Hz, 
1.08H, H1’, H1’’), 4.16-4.03 (m, 0.96H, H2’’’), 
3.81 (dd, 3J =6.0 Hz, J = 2.0 Hz, 0.08H), 3.28-2.99 (m, 1.78H, H8’, H8’’), 1.47-1.06 (m, 30.0H, 
H3’’’ H4’’’, H11’, H12’, H13’, H14’’, H11’’, H12’’, H13’’, H14’’), 0.89-0.64 (m, 12H, H9’, H10’, 
H9’’, H10’’) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 216.1, 212.9, 200.0, 180.6, 180.5, 162.81, 162.78, 
157.5, 148.5, 147.4, 119.8, 119.7, 119.4, 118.8, 112.3, 101.9, 97.5, 92.4, 91.4, 55.4, 51.2, 
41.4, 40.4, 36.4, 28.3, 28.1, 26.9, 26.8, 26.2, 26.0, 23.6, 23.43, 23.38, 23.34, 21.1 ppm. 
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4.6.1.5 Preparation of pentacyclic myrtucommulone A (7) 
 
Following the GP 9 procedure, MCA (5) (150 mg, 0.22 mmol, 1.0 eq.) and pTsOH (270 mg, 
1.42 mmol, 6.5 eq.) were heated to 95°C in toluene (14 mL) for 1h to yield, after purification 
on column chromatography (A/PE, 1/9), 116 mg of PMCA (7) (0.18 mmol, 83 % yield). This 
white foam is obtained as a mixture of a linear cyclised MCA: l-PMCA (l-7) (104 mg, 0.16 
mmol, 75 % yield, Rf = 0.19), and an angular cyclised MCA: a-PMCA (a-7) (11 mg, 0.02 
mmol, 8 % yield, Rf = 0.36). 
l-PMCA (l-7): sample with a d.r. of 56:44 (meso:rac) 
 
1H-NMR (400 MHz, CDCl3) : δ = 8.07 (brs, 0.55 H, OH-
meso), 7.91 (brs, 0.42H, OH-rac), 4.64 (d, 3JH1’,H8’ = 
3JH1’’,H8’’ = 3.8 Hz, 1.04H, H1’, H1’’, meso), 4.61 (d, 
3JH1’,H8’ = 
3JH1’’,H8’’ = 3.5 Hz, 0.79H, H1’, H1’’, rac), 3.19, 
3.17 (2 x sept, 3JH2‘’’,H3‘’’ = 
3JH2‘’’,H4’‘’ = 7.0 Hz, 
3JH2‘’’,H3‘’’ = 
3JH2‘’’,H4’‘’ = 6.8 Hz, 1H, H2’’’), 2.03-1.90 (m, 2H, H8’, 
H8’’), 1.54 (s, 2.40H, H12’, H11’’, rac), 1.52 (s, 3.06H, H12’, H12’’, meso), 1.48-1.40 (m, 12H, 
rac: H11’, H12’‘, H13’, H14’’, H13’’, H14’, meso: H13’, H13’’), 1.38 (s, 6H, H11’, H11’’, meso), 
1.36 (s, 6H, H14’, H14’’, meso), 1.29 (d, J = 7.0 Hz, 3H, H3’’’, H4’’’, meso), 1.24 (t, J = 7.5 
Hz, 3H, H3’’’, H4’’’, rac), 0.89-0.85, 0.80-0.74 (2 x m, 3.79H, 8.25H, H9’, H9’’, H10’, H10’’) 
ppm.  
 
13C-NMR (101 MHz, CDCl3) : δ = 211.78, 211.75 (C5’, C5’’), 205.3 (C1’’’-meso), 204.3 (C1’’’-
rac), 198.9 (C7’, C7’’, rac), 198.8 (C7’, C7’’, meso), 169.2 (C3’, C3’’, meso), 168.9 (C3’, C3’’, 
rac), 152.5 (C4, meso), 152.1 (C4, rac), 147.5 (C2, C6, rac), 147.45 (C2, C6, meso), 111.3 
(C3, C5, meso), 110.9 (C3, C5, rac), 110.4 (C1, meso), 110.0 (C1, rac), 108.8 (C2’, C2’’, 
rac), 108.5 (C2’, C2’’, meso), 55.9 (C6’, C6’’, meso), 55.8 (C6’, C6’’, rac), 47.53, 47.51 (C4’, 
C4’’), 43.3 (C2’’’, meso), 42.7 (C2’’’, rac), 35.10, 35.09 (C8’, C8’’), 32.4 (C1’, C1’’, meso), 
32.2 (C1’, C1’’, rac), 25.2 (C12’, C11’’, rac), 24.88, 24.85, 24.78, 24.76 ( meso: C11’, C11’’, 
C12’, C12’’, C14’, C14’’, rac: C12’’, C11’, C13’, C14’’), 24.3 (C14’, C13’’, rac), 24.2 (C13’, 
C13’’, meso), 19.3, 19.1 (C10’, C10’’), 18.8, 18.5 (C9’, C9’’), 18.0, 17.7  (C3’’’, C4’’’) ppm. 
15 
 
HRMS (ESI+) calcd. for C38H49O8
+ [M+H]+: 633.3422, found: 633.3415. 
[𝛼]𝐷
24 = 0.0 (CHCl3, c = 0.7) 
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a-PMCA (a-7): 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.56 (s, 0.12H, OH), 13.29 
(s, 0.78 H, OH), 4.48 (d, 3JH1’,H8’ = 2.8 Hz, 0.12H, H1’), 4.43 
(d, 3JH1’’,H8’’ = 3.3 Hz, 0.17H, H1’’), 4.41 (d, 
3JH1’,H8’ = 3.3 Hz, 
0.76H, H1‘), 4.37 (d, 3JH1’’,H8’’ = 3.5 Hz, 0.79H, H1’’), 3.92 
(sept, 3JH2‘’’,H3’’‘-H4‘‘‘ = 6.8 Hz, 1H, H2’’’), 2.06 (dsept, 
3JH8’,H1‘ = 
3.3 Hz, 3JH8’,H9’-H10‘ = 7.0 Hz, 1H, H8’), 1.93. (dsept, 
3JH8‘’,H1‘‘ = 
3.5 Hz, 3JH8’‘,H9‘’-H10‘‘ = 6.8 Hz, 1H, H8‘’), 1.67-1.64 (m, 3H), 
1.62 (s, 2.40H), 1.59 (1.24), 1.51-1.48 (m, 3.05), 1.46-1.40 (m, 9H), 1.38 (s, 3.45H), 1.35 (s, 
2.49H), 1.30-1.26 (m, 5.45H) (H11’, H12’, H13’, H14’, H11‘’, H12’‘ H13’’, H14‘’), 0.94-0.90, 
0.84-0.65 (2 x m, 3.15H,9.10H, H9’, H9’’, H10’, H10’’) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 211.8, 211.5, (C5’, C5’’), 209.5 (C1’’’), 197.6, 197.4 (C7’, 
C7’’), 167.6, 167.2 (C3’, C3’’), 161.0 (C6), 153.2, 151.0 (C2, C4), 111.8, 111.7 (C3, C5), 
110.2 (C1), 106.1 (C2’), 103.0 (C2’’), 56.2, 56.1 (C6’, C6’’), 47.53, 47.51 (C4’, C4’’), 40.2 
(C2’’’), 35.3, 34.2 (C8’, C8’’), 32.1, 31.8 (C1’, C1’’), 25.4, 25.2, 25.1, 25.0, 24.9, 23.9, 23.8 
(C11’, C11’’, C12’, C12’’, C13’, C13’’, C14’, C14’’), 20.7, 19.7, 19.4, 18.5, 18.4 (C9’, C9’’, 
C10’, C10’’), 17.7 (C3’’’, C4’’’) ppm. 
 
[𝛼]𝐷
24 = +2.3 (CHCl3, c = 0.6) 
 
The preparation of PMCA (7) from (+)-MCA (5) with 70 % ee (see above) led to a similar 
mixture of isomers from which we isolated l-7a and l-7b whose NMR data is listed below. In 
the 1H-NMR spectrum of l-7b, the “self induced non-equivalence” discussed in § 2.3.2.6 
(NMR particularity) can be observed. 
 
l-PMCA (l-7b): sample with an ee 70 % 
 
1H-NMR (400 MHz, CDCl3): δ = 6.91 (brs, 1H, OH), 
4.53 (d, 3JH1’,H8’ = 
3JH1’’,H8’’ = 3.5 Hz, 0.27H, H1’, H1’’), 
4.47 (d, 3JH1’,H8’ = 
3JH1’’,H8’’ = 3.3 Hz, 1.65H, H1’, H1’’), 
3.24-3.11 (m, 1H, H2’’’), 2.02-1.89 (m, 2H, H8’, H8’’), 
1.54 (s, 6H, H12’, H11’’), 1.45 (m, 6H, H13’, H14’’), 
1.44-1.38 (m, 12H, H11’, H12’’, H14’, H13’’), 1.28-1.22 
(m, 6H, H3’’’, H4’’’), 0.88-0.74 (m, 12H, H10’, H10’’, 
H9’, H9’’) ppm. 
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13C-NMR (101 MHz, CDCl3): δ =  211.8 (C5’, C5’’), 204.30 (C1’’’), 198.4 (C7’, C7’’), 168.6 
(C3’, C3’’), 151.8 (C4), 147.6 (C2, C6), 110.9 (C3, C5), 110.0 (C1), 108.5 (C2’, C2’’), 55.9 
(C6, C6’’), 47.5 (C4’, C4’’), 42.7 (C2’’’), 35.1 (C8’, C8’’), 32.4 (C1’, C1’’), 25.2 (C12’, C11’’), 
24.81 (C13’, C14’’), 24.79 (C11’, C12’’), 24.4 (C14’, C13’’), 19.1 (C10’, C10’’), 18.7 (C9’, 
C9’’), 18.0 (C3’’’, C4’’’) ppm. 
 
l-meso-PMCA (l-7a): 
 
1H-NMR (400 MHz, CDCl3): δ = 7.81 (brs, 1H, OH), 4.59 
(d, 3JH1’,H8’ = 
3JH1’’,H8’’ = 3.8 Hz, 2H, H1’, H1’’), 3.19 (sept, 
3JH2’’,H3’’-4’’ = 7.0 Hz 1H, H2’’’), 2.06-1.90 (m, 2H, H8’, 
H8’’), 1.52 (s, 6H, H12’, H12’’), 1.44 (s, 6H, H13’, H13’’), 
1.38 (s, 6H, H11’, H11’’), 1.36 (s, 6H, H14’, H 14’’), 1.29 
(d, J = 6.8 Hz, 6H, H3’’’, H4’’’), 0.86 (d, J = 6.8 Hz, 6H, 
H9’, H9’’), 0.79 (d, J = 6.8 Hz, 6H, H10’, H10’’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ =  211.8 (C5’, C5’’), 205.30 (C1’’’),  198.6 (C7’, C7’’), 169.1 
(C3’, C3’’), 152.4 (C4), 147.5 (C2, C6), 111.2 (C3, C5), 110.4 (C1), 108.5 (C2’, C2’’), 56.0 
(C6’, C6’’), 47.5 (C4’, C4’’), 43.3 (C2’’’), 35.1 (C8’, C8’’), 32.4 (C1’, C1’’), 24.9 (C12’, C12’’), 
24.77 (C14’, C14’), 24.75 (C11’, C11’’), 24.3 (C13’, C13’’), 19.1 (C10’, C10’’), 18.8 (C9’, C9’’), 
17.7 (C3’’’, C4’’’) ppm. 
 
4.6.1.6 Preparation and cyclisation of norsemimyrtucommulone F 
 
Norsemimyrtucommulone F (NSMCF) (82) 
 
According to GP 8, HPG (33) (224 mg, 1.0 mmol, 1.0 eq.) was dissolved in DT101 (4 mL) 
and added dropwise to the freshly prepared (S,S)-ALB ((S,S)-66e) (18.2 mL of a 0.18 M 
solution in DT101, 3.2 mmol, 3.2 eq.). IBSA (31) (2.4 mL of a 0.62 M solution in DT101, 1.5 
mmol, 1.5 eq.) was added dropwise to the mixture at 0°C. After 2h stirring at 0°C, the 
reaction was quenched and the product extracted and dried. After purification by column 
chromatography on silica gel (A/PE, 1/2 (500 mL), 1/1 (1000 mL), Rf = 0.19 (A/PE, 1/1)), 322 
mg of (-)-NSMCF (82) (0.70 mmol, 70 % yield) were obtained as a pale yellow powder (mp = 
186°C, decomposition). [𝛼]𝐷
24 = - 10.7 (MeOH, c = 3.0). 
 
HRMS (ESI+) calcd. for C26H37O7
+ [M+H]+: 461.2539, found: 461.2532. 
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1H-NMR (400 MHz, CO(CD3)2): δ = 14.24 (brs, 0.53H, OH), 
13.64 (brs, 0.79H, OH), 5.69 (s, 1H, H5), 3.83 (m, 1H, H1’), 
3.34-3.20 (m, 1H, H8’), 3.15-3.00 (m, 2H, H2’’’), 1.71-1.60 
(H3’’’) 1.38-1.32 (m, 4H, H4’’’, H5’’’), 1.31-1.18 (m, 12 H, 
H11’, H12’, H13’, H14’), 0.93-0.87 (m, 3H, H6’’’), 0.83, 0.82 
(2 x d, 3JH9’,H8‘ = 6.3 Hz, 3H, H9’), 0.71, 0.68 (2 x d, 
3JH10’,H8‘ = 
6.5 Hz, 3H, H10’) ppm.  
 
13C-NMR (101 MHz, CO(CD3)2): δ = 218.0 (C5’), 209.6, 208.1, 207.7 (C1', C7’), 167.3, 166.0, 
165.1, 164.4, 154.7, 111.9, 98.3, 97.4 (C5), 53.4, 53.3 (C4’, C6’), 45.7, 45.5 (C2’’’), 43.3, 
43.2 (C1’), 33.6 (C4’’’), 27.6 (C8’), 27.2, 27.1, 26.8, 26.7, 26.6 (C11’, C12’, C13’, C14’), 24.5 
(C5’’’), 23.72, 23.69, (C9’, C10’), 15.3 (C6’’’) ppm. 
 
Tricyclic NSMCF (83) (55% ee) 
 
Following the GP 9 procedure, (-)-NSMCF (82) (85 mg, 0.18 mmol, 1.0 eq.) and pTsOH (105 
mg, 0.55 mmol, 3.0 eq.) were heated to 95°C in toluene (8.5 mL) for 1h to yield, after 
purification on column chromatography (A/PE, 1/9, Rf = 0.14), 55 mg of the cyclised product 
(+)-(R)-83 (0.12 mmol, 69 % yield) with 55 % ee. It was dissolved in a DCM/PE (1/9) mixture 
and evaporated under reduced pressure to afford a white foam (mp = 68-81°C). [𝛼]𝐷
24 = 
+90.4 (CHCl3, c = 2.92). 
 
HRMS (ESI+) calcd. for C26H35O6
+ [M+H]+: 443.2433, found: 443.2422. 
 
1H-NMR (400 MHz, CDCl3): δ = 13.49 (s, 1H, C6-OH), 7.67 (brs, 
1H, C4-OH), 6.33 (s, 0.21H, H5), 6.32 (s, 0.71H, H5), 4.40 (d, 
3JH1’,H8’ = 3.8 Hz, 0.73H, H1’), 4.38 (d, 
3JH1’,H8’ = 3.8 Hz, 0.20H, 
H1’), 3.31-3.20 (m, 1H, H2a’’’), 3.09-2.97 (m, 1H, H2b’’’), 1.91 
(dsept, 3JH8’,H1’ = 3.8 Hz, 
3JH8’,H9’-10’= 6.8 Hz, 1H, H8’), 1.83-1.69 
(m, 2H, H3’’’), 1.66 (s, 3H, 12’), 1.48-1.43 (m, 6H, H11’, H14’), 
1.40 (s, 3H, H13’), 1.39-1.33 (m, 4H, H4’’’, H5’’’), 0.94-0.88 (m, 
3H, H6’’’), 0.83 (d, 3JH8’,H9’ = 6.8 Hz, 3H, H9’), 0.79 (d, 
3JH8’,H10’ = 
7.0 Hz, 3H, H10’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.8 (C5’), 204.5, 204.4 (C1’’’), 199.3, 199.1 (C7’), 168.5, 
168.3 (C3’), 164.4 (C4), 160.0, 159.9 (C6), 153.7 (C2), 112.2 112.1 (C2’), 104.8 (C3), 103.9, 
103.8 (C1), 100.4 (C5), 56.11, 56.08 (C6’), 47.4 (C4’), 44.6 (C2’’’), 34.9, 34.8 (C8’), 31.42, 
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31.38 (C1’, C5’’’), 25.3, 25.0 (C12’, C14’, C11’), 24.14, 24.10, 24.0 (C13’, C3’’’), 22.6 (C4’’’), 
18.92, 18.89, 18.63, 18.57 (C9’, C10’), 13.9 (C6’’’) ppm. 
 
4.6.1.7 Preparation and cyclisation of myrtucommulone F 
 
Preparation of myrtucommulone F (MCF) (13) (38 % de) 
 
According to the general procedure GP 5, hexanoyl phloroglucinol (HPG) (33) (112 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), syncarpic acid (27) (550 mg, 3.02 
mmol, 6.0 eq.) and isobutyraldehyde (26) (0.36 mL, 3.94 mmol, 8.0 eq.) were mixed in 
ethanol (4 mL) and stirred at room temperature for 48 h. The reaction was worked up and the 
product was purified through column chromatography on silica gel (A/PE, 1/2, Rf = 0.19) to 
afford 202 mg of MCF (13) (0.30 mmol, 60 % yield) as a light yellow powder (mp = 147-
180°C, decomposition). 
 
LC-MC (ESI-) for C40H55O10
- [M-H]-: 696.80 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 15.86 
(brs, 0.34H, OH), 15.47 (brs, 0.64H, OH), 
14.67-14.15 (m, 0.30H, OH), 14.06-13.80 (m, 
0.08H, OH), 13.23-12.75 (m, 1.09H, OH), 
4.51-4.25 (m, 0.41H), 4.21 (d, 3J = 11.0 Hz, 
1.30H, H1’, H1’’), 4.09-3.90 (m, 0.12H), 3.82-
3.77 (m, 0.04H), 3.23-3.00 (m, 3.77H, H8’, 
H8’’, H2’’’), 1.70-1.60 (m, 2H, H3’’’), 1.45-1.10 (m, 29H, H4’’’, H5’’’, H11’, H12’, H13’, H14’’, 
H11’’, H12’, H13’’, H14’’), 0.94-0.65 (m, 15H, H6’’’, H9’, H10’, H9’’, H10’’) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 216.1, 200.1, 181.7, 167.3, 162.8, 145.0, 116.0, 115.4, 
112.3, 112.2, 111.9, 106.4, 55.5, 55.4, 51.2, 45.6 (C2’’’), 41.3 (C1’, C1’’), 33.6 (C4’’’), 28.3 
(C8’, C8’’), 28.1, 26.8 (C3’’’), 26.7, 26.4, 26.3, 26.1, 24.4, 23.6, 23.5, 23.4, 23.3, 23.1, 20.3, 
15.3 ppm. 
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Pentacyclic MCF (PMCF) (96) 
 
Following the GP 9 procedure, MCF (13) (90 mg, 0.13 mmol, 1.0 eq.) and pTsOH (176 mg, 
0.93 mmol, 6.5 eq.) were heated to 95°C in toluene (9 mL) for 1h to yield, after purification on 
column chromatography (A/PE, 1/9, Rf = 0.17), 65 mg of PMCF (7) (0.10 mmol, 76 % yield) 
as a white foam. (mp = 105-158°C) 
 
LC-MC (ESI-) for C42H51O8
- [M-H]-: 659.75 
 
→ A d.r. of 69:31 (meso:rac) can be seen in the NMR-spectrum 
 
1H-NMR (400 MHz, CDCl3) : δ = 8.00 (brs, 0.57 H, OH-
meso), 7.79 (brs, 0.42H, OH-rac), 4.62 (d, 3JH1’,H8’ = 
3JH1’’,H8’’ = 3.5 Hz, 1.20H, H1’, H1’’, meso), 4.59 (d, 
3JH1’,H8’ = 
3JH1’’,H8’’ = 3.5 Hz, 0.72H, H1’, H1’’, rac), 2.93 (t, 
3JH2’’,H3’’ = 7.3 Hz, 1.36H, H2’’’), 2.90-2.74 (m, 0.56H, 
H2’’’)  2.04-1.88 (m, 2H, H8’, H8’’), 1.84-1.69 (m, 2H, 
H3‘‘‘) 1.56 (s, 2.10H, H12’, H11’’, rac), 1.54 (s, 3.60H, 
H12’, H12’’, meso), 1.48-1.30 (m, 22H, H4‘‘‘, H5‘‘‘, H11’, H11‘‘, H12’‘, H13’, H14’’, H13’’, 
H14’), 0.92-74 (m, 15H, H6‘‘‘, H9’, H9’’,H10’,H10’’) ppm.  
 
13C-NMR (101 MHz, CDCl3) : δ = 211.76 (C5’, C5’’), 201.6, 200.6 (C1’’’), 198.8 (C7’, C7’’, 
rac), 198.7 (C7’, C7’’, meso), 169.2 (C3’, C3’’, meso), 169.0 (C3’, C3’’, rac), 152.6 (C4, 
meso), 152.1 (C4, rac), 147.6 (C2, C6, meso), 147.5 (C2, C6, meso), 111.3 (C3, C5, meso), 
111.0 (C3, C5, rac), 110.9 (C1, meso), 110.8 (C1, rac), 108.8 (C2’, C2’’, rac), 108.6 (C2’, 
C2’’, meso), 55.94 (C6’, C6’’, meso), 55.84 (C6’, C6’’, rac), 47.55 (C4’, C4’’, meso), 47.53 
(C4’, C4’’, rac), 45.8 (C2’’’, meso), 45.7 (C2’’’, rac), 35.2 (C8’, C8’’, meso), 35.1 (C8’, C8’’, 
rac), 32.4 (C1’, C1’’, meso), 32.3 (C1’, C1’’, rac), 31.6 (C5’’’, meso), 31.4 (C5’’’, rac), 25.3, 
25.0, 24.9, 24.8, 24.7, 24.3, 24.2, 24.04, 23.96 (C11’, C11’’, C12’, C12’’, C13’, C13’’, C14’, 
C14’’), 22.5 (C4’’’), 19.3, 19.1, 18.8, 18.5 (C9’, C9’’, C10’, C10’’), 13.8 (C6’’’) ppm 
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4.6.2. Dimedone myrtucommulone derivatives 
4.6.2.1 Preparation and cyclisation of the myrtucommulone derivative 42 
 
Dimedone-myrtucommulone derivative 42 
 
According to the general procedure GP 5, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), dimedone (37) (420 mg, 3.00 mmol, 
6.0 eq.) and isobutyraldehyde (26) (0.36 mL, 3.94 mmol, 8.0 eq.) were mixed in ethanol (4 
mL) and stirred at room temperature for 24 h. The reaction was worked up and the product 
was purified through column chromatography on silica gel (A/PE, 1/5, Rf = 0.25) to afford 278 
mg of the dimedone derivative 42 (0.48 mmol, 95 % yield) as a yellow powder (mp = 80-
125°C). 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 13.59-
11.32 (m, 0.60H, OH), 10.94-9.52 (m, 0.21H, 
OH), 6.57 (s, 0.77H, OH), 5.84 (brs, 0.74H, 
OH), 4.21 (d, 3J= 5.5 Hz, 0.08H), 4.17-4.05 
(m, 0.63H, H2’’’), 4.00-3.79 (m, 1.26H, H1’, 
H1’’), 3.12-2.90 (m, 1.75H, H8’, H8’’), 2.55 (d, 
2J = 15.3 Hz, 1.04H, H6a’, H6a’’), 2.49-2.33 (m, 4.37H, H4’, H4’’, H6’, H6’’), 2.21 (d, 2J = 15.3 
Hz, 0.97H, H6b’, H6b’’), 1.96 (dd, 2J = 13.8 Hz, 4J = 0.8 Hz, 0.89H, H4a’, H4a’’), 1.67 (d, 2J = 
13.8 Hz, 0.97H, H4b’, H4b’’) 1.39, 1.27 (2 x s, 6H, H11’, H11’’), 1.20-1.02 (m, 14.72H, H3’’’, 
H4’’’, H9’, H12’, H12’’), 1.00 (s, 3H, H12’, H12’’), 0.94-0.83 (m, 5.09H), 0.80 (d, 3J = 6.5 Hz, 
0.76H), 0.74 (d, 3J = 6.5 Hz, 1.25H), 0.71 (d, 3J = 6.5 Hz, 0.73H), 0.65 (d, 3J = 6.5 Hz, 
0.32H), 0.62 (d, 3J = 6.5 Hz, 0.51H) (H9’, H10’, H9’’, H10’’) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 199.2, 162.0, 147.3, 139.3, 137.2, 118.0, 117.9, 117.6, 
117.5, 117.4, 111.7, 106.7, 106.4, 98.5, 79.8, 75.9, 56.4, 55.2, 53.7, 45.9, 41.0, 40.9, 40.7, 
40.4, 33.0, 32.9, 32.8, 32.7, 32.5, 32.0, 31.5, 28.6, 28.2, 28.14, 28.06, 27.9, 27.6, 25.1, 24.4, 
23.7, 23.6, 23.5, 23.3, 23.2, 23.1, 23.0, 22.9, 21.3, 20.8, 20.7, 20.6, 20.2, 19.6 ppm. 
 
LC-MC (ESI-) for C34H47O8
- [M-H]-: 583.75 
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Pentacyclic dimedone derivative (97) 
 
Following the GP 9 procedure, the dimedone derivative 42 (110 mg, 0.19 mmol, 1.0 eq.) and 
pTsOH (250 mg, 1.32 mmol, 6.9 eq.) were heated to 95°C in toluene (11 mL) for 1h to yield, 
after purification on column chromatography (A/PE, 1/10), 59 mg of the pentacyclic derivative 
97 (0.11 mmol, 57 % yield) as a white foam. This product cyclised orthogonally as two 
isolable products: anti-97 (28 mg, 0.05 mmol, 27 %, Rf = 0.17) and syn-97 (31 mg, 0.06 
mmol, 30 %, Rf = 0.07). 
 
 Characterisation of anti-97  
 
LC-MC (ESI-) for C34H43O6
- [M-H]-: found: 547.65,    (mp = 95-135°C) 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.56 (s, 1H, OH), 4.26 (d, 
3JH1’,H8’ = 3.5 Hz, 1H, H1’), 4.19 (d, 
3JH1‘’,H8’’ = 4.0 Hz, 1H, 
H1’‘), 3.75 (sept, 3JH2‘‘’,H3‘’’-H4‘‘‘ = 6.8 Hz, 1H, H2‘‘‘), 2.64-2.50, 
2.48-2.24 (2 x m, 8H, H4‘, H4‘‘, H6‘, H6‘‘), 1.96 (dsept, 3J 
H8‘-H1 ‘ = 3.5 Hz, 
3JH8‘,H9‘-H10‘ = 7.0 Hz, 1H, H8’), 1.88 (dsept, 
3JH8‘’,H1‘‘ = 4.0 Hz, 
3JH8’‘,H9‘’-H10‘‘ = 6.8 Hz, 1H, H8‘’), 1.23 (d, 
3JH3‘’’-H4‘‘‘,H2‘‘’ = 6.8 Hz, 6H, H3‘‘‘, H4‘‘‘), 1.21, 1.174, 1.168, 
1.12 (4 x s, 4 x 3H, H11‘, H11‘‘, H12‘, H12‘‘), 0.79-0.72 (m, 
9H), 0.69 (d, 3JH9‘-H10‘-H8‘ = 6.8Hz, 3H) (H9’, H9’’, H10’, 
H10’’) ppm.  
 
13C-NMR (101 MHz, CDCl3) : δ = 210.0 (C1’’’), 196.92, 196.9 (C7’, C7’’), 165.8, 165.6 (C3’, 
C3’’), 161.4 (C6), 153.4 (C4), 151.0 (C2), 113.9, 113.3 (C2’, C2’’), 110.7 (C5), 106.2 (C1), 
103.8 (C3), 50.95, 50.87 (C6’, C6’’), 41.2, 41.1 (C4’, C4’’), 40.2 (C2’’’), 35.2 (C8’’), 34.5 (C8’), 
32.0, 31.9 (C5’, C5’’), 31.4 (C1’), 31.0 (C1’’), 30.0, 29.7 (C11’, C11’’), 27.1, 27.0 (C12’, 
C12’’), 19.33, 19.29 (C3’’’, C4’’’), 20.0, 18.7 (C9’, C9’’, C10’, C10’’) ppm. 
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Crystal Structure: (for the complete data see Appendix 4) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exp. Data Tab. 4 Crystal data and structure refinement for anti-97 (sh3587a). 
Identification code  sh3587a  
Empirical formula  C34 H44 O6 x C H2 Cl2  
Formula weight  633.62  
Temperature  152(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P21/c  
Unit cell dimensions a = 13.4239(5) Å α= 90°. 
 b = 21.6721(8) Å β= 105.9659(19)°. 
 c = 11.9123(4) Å γ = 90°. 
Volume 3331.9(2) Å3  
Z 4  
Density (calculated) 1.263 Mg/m3  
Absorption coefficient 0.238 mm-1  
F(000) 1352  
Crystal size 0.382 x 0.337 x 0.078 mm3  
Theta range for data collection 1.578 to 27.955°.  
Index ranges -17<=h<=17, -28<=k<=27, -
15<=l<=15 
 
Reflections collected 31543  
Independent reflections 7919 [R(int) = 0.0511]  
Completeness to theta = 25.242° 100.0 %   
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.7456 and 0.7100  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 7919 / 0 / 399  
Goodness-of-fit on F2 1.463  
Final R indices [I>2sigma(I)] R1 = 0.0782, wR2 = 0.1934  
R indices (all data) R1 = 0.1302, wR2 = 0.2120  
Extinction coefficient n/a  
Largest diff. peak and hole 1.243 and -1.153 e.Å-3  
 
  
Experimental  - 135 - 
 Characterisation of syn-97 
 
LC-MC (ESI-) for C34H43O6
- [M-H]-: 547.70,     (mp = 85-135°C) 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.53 (s, 1H, OH), 4.23 (d, 
3JH1’,H8’ = 3.5 Hz, 1H, H1’), 4.15 (d, 
3JH1‘’,H8’’ = 3.5 Hz, 1H, 
H1’‘), 3.75 (sept, 3JH2‘‘’,H3‘’’-H4‘‘‘ = 6.8 Hz, 1H, H2‘‘‘), 2.60-2.44, 
2.42-2.22 (2 x m, 8H, H4‘, H4‘‘, H6‘, H6‘‘), 2.02 (dsept, 3J 
H8‘-H1 ‘ = 3.8 Hz, 
3JH8‘,H9‘-H10‘ = 7.0 Hz, 1H, H8’), 1.91 (dsept, 
3JH8‘’,H1‘‘ = 3.8 Hz, 
3JH8’‘,H9‘’-H10‘‘ = 7.0 Hz, 1H, H8‘’), 1.25 (d, 
3J 
= 6.8 Hz, 3H), 1.19 (d, 3J = 6.8 Hz, 9H), 1.17-1.10 (m, 6H) 
(H3‘‘‘, H4‘‘‘, H11‘, H11‘‘, H12‘, H12‘‘), 0.84, 0.81, 0.78, 0.75 
(4 x d, 3JH9‘-H10‘,H8‘ = 
3JH9‘‘-H10‘‘,H8‘‘ = 7.0 Hz, 12H, H9’, H9’’, 
H10’, H10’’) ppm.  
 
13C-NMR (101 MHz, CDCl3) : δ = 210.0 (C1’’’), 197.0, 196.9 (C7’, C7’’), 165.7, 165.4 (C3’, 
C3’’), 161.2 (C6), 153.7 (C4), 151.7 (C2), 113.7, 113.4 (C2’, C2’’), 110.3 (C5), 106.0 (C1), 
103.8 (C3), 51.0, 50.9 (C6’, C6’’), 41.4, 41.1 (C4’, C4’’), 40.2 (C2’’’), 35.2 (C8’’), 34.3 (C8’), 
32.0, 31.8 (C5’, C5’’), 31.4 (C1’), 31.2 (C1’’), 29.9, 29.6 (C11’, C11’’), 27.1, 27.0 (C12’, 
C12’’), 20.1, 19.6, 19.5, 19.1, 18.9, 18.6 (C3’’’, C4’’’, C9’, C9’’, C10’, C10’’) ppm. 
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Crystal Structure: (for the complete data see Appendix 5) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exp. Data Tab. 5 Crystal data and structure refinement for syn-97 (sh3590). 
Identification code  sh3590  
Empirical formula  C34 H44 O6  
Formula weight  548.69  
Temperature  152(2) K  
Wavelength  0.71073 Å  
Crystal system  Triclinic  
Space group  P-1  
Unit cell dimensions a = 10.7960(5) Å α= 103.800(2)°. 
 b = 11.1104(5) Å β= 108.9765(19)°. 
 c = 13.6046(6) Å γ = 91.466(2)°. 
Volume 1489.13(12) Å3  
Z 2  
Density (calculated) 1.224 Mg/m3  
Absorption coefficient 0.082 mm-1  
F(000) 592  
Crystal size 0.667 x 0.276 x 0.196 mm3  
Theta range for data collection 1.640 to 33.178°.  
Index ranges -16<=h<=16, -17<=k<=16, -
20<=l<=20 
 
Reflections collected 41676  
Independent reflections 11328 [R(int) = 0.0323]  
Completeness to theta = 25.242° 100.0 %   
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.7465 and 0.6947  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 11328 / 0 / 537  
Goodness-of-fit on F2 1.041  
Final R indices [I>2sigma(I)] R1 = 0.0458, wR2 = 0.1164  
R indices (all data) R1 = 0.0735, wR2 = 0.1325  
Extinction coefficient n/a  
Largest diff. peak and hole 0.445 and -0.245 e.Å-3  
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4.6.2.2 Preparation and cyclisation of the myrtucommulone derivative 43 
 
Dimedone-myrtucommulone derivative 43 
 
According to the general procedure GP 5, hexanoyl phloroglucinol (HPG) (33) (112 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), dimedone (37) (550 mg, 3.02 mmol, 
6.0 eq.) and isobutyraldehyde (26) (0.36 mL, 3.94 mmol, 8.0 eq.) were mixed in ethanol (4 
mL) and stirred at room temperature for 16 h. The reaction was worked up and the product 
was purified through column chromatography on silica gel (A/PE, 1/15, Rf = 0.08) to afford 
243 mg of the dimedone derivative 43 (0.40 mmol, 79 % yield) as a yellow oil. 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 13.73-
11.40 (m, 0.92H, OH), 11.73-8.92 (m, 0.29H, 
OH), 6.57 (s, 0.46H, OH), 5.84 (brs, 0.41H, 
OH), 3.99-3.79 (m, 1.96H, H1’, H1’’), 3.27-
2.88 (m, 6.16H, H8’, H8’’, H2’’’), 2.55 (d, 2J = 
15.0 Hz, 0.95H, H6a’, H6a’’), 2.46-2.28 (m, 
7.07H, H4’, H4’’, H6’, H6’’), 2.21 (d, 2J = 15.0 
Hz, 0.80H, H6b’, H6b’’), 1.96 (dd, 2J = 13.8 Hz, 4J = 0.8 Hz, 1.02H, H4a’, H4a’’), 1.72-1.62 
(m, 2.55H, H3’’, H4b’, H4b’’), 1.42-1.32 (m, H11’, H11’’, H4’’’), 1.27 (s, 1.69, H11’, H11’’), 
1.15 (s, 2.12H, H12’, H12’’) 1.14-1.02 (m, 12.35H, H11’, H11’’, H12’, H12’’, H5’’’), 1.00 (s, 
3H, H12’, H12’’), 0.96-0.86 (m, 9.83H), 0.80 (d, 3J = 6.5 Hz, 1.10H), 0.74 (d, 3J = 6.5 Hz, 
2.11H), 0.69 (d, 3J = 6.5 Hz, 1.11H), 0.65 (d, 3J = 6.5 Hz, 0.59H), 0.62 (d, 3J = 6.5 Hz, 1.23H) 
(H9’, H10’, H9’’, H10’’) ppm. 
 
13C-NMR-APT (101 MHz, CO(CD3)2): δ = 197.6, 139.3, 53.8, 45.9, 45.8, 41.0, 40.7, 40.3, 
33.4, 33.0, 32.9, 32.8, 32.5, 31.5, 28.5, 28.2, 28.14, 27.9, 27.4, 26.3, 26.2, 25.1, 24.4, 24.3, 
23.6, 23.5, 23.3, 23.2, 23.1, 22.9, 15.3 ppm. 
 
LC-MC (ESI-) for C36H51O8
- [M-H]-: found: 611.80 
 
Pentacyclic dimedone derivative (98) 
 
Following the GP 9 procedure, the dimedone derivative 43 (100 mg, 0.16 mmol, 1.0 eq.) and 
pTsOH (217 mg, 1.14 mmol, 7.1 eq.) were heated to 95°C in toluene (10 mL) for 1h to yield, 
after purification on column chromatography (A/PE, 1/15), 43 mg of the pentacyclic derivative 
98 (0.07 mmol, 46 % yield) as a white foam. This product cyclised orthogonally as two 
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isolable products: anti-98 (23 mg, 0.04 mmol, 25 %, Rf = 0.14) and syn-98 (20 mg, 0.03 
mmol, 21 %, Rf = 0.10). 
 
 Characterisation of anti-98 
 
LC-MC (ESI-) for C36H47O6
- [M-H]-: 575.75,     (mp = 80-140°C) 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.66 (s, 1H, OH), 4.26 (d, 
3JH1’,H8’ = 3.3 Hz, 1H, H1’), 4.18 (d, 
3JH1‘’,H8’’ = 4.0 Hz, 1H, 
H1’‘), 3.10 (dt, 2JH2a‘‘’,H2b‘‘’ = 16.6 Hz, 
3JH2a‘‘’,H3‘’’ = 7.3 Hz, 1H, 
H2a‘‘‘), 3.10 (dt, 2JH2b‘‘’,H2a‘‘’ = 16.6 Hz, 
3JH2b‘‘’,H3‘’’ = 7.5 Hz, 1H, 
H2b‘‘‘), 2.66-2.51, 2.49-2.24 (2 x m, 8H, H4‘, H4‘‘, H6‘, H6‘‘), 
2.02-1.88 (m, 1H, H8’), 1.81-65 (m, 3H, H3‘‘‘, H8‘’), 1.42-1.36 
(m, 4H, H4‘‘‘, H5‘‘‘), 1.22-1.10 (m, 12H, H11‘, H11‘‘, H12‘, 
H12‘‘), 0.96-0.89 (m, 3H, H6‘‘‘), 0.88-0.72 (m, 9H), 0.70 (d, 
3JH9‘-H10‘,H8‘ = 6.8Hz, 3H) (H9’, H9’’, H10’, H10’’) ppm.  
 
13C-NMR (101 MHz, CDCl3) : δ = 205.0 (C1’’’), 196.9 (C7’, C7’’), 165.8, 165.6 (C3’, C3’’), 
161.2 (C6), 153.4 (C4), 151.4 (C2), 114.0, 113.4 (C2’, C2’’), 110.5 (C5), 106.8 (C1), 103.8 
(C3), 50.94, 50.87 (C6’, C6’’), 44.8 (C2’’’) 41.3, 41.2 (C4’, C4’’), 35.2 (C8’’), 34.5 (C8’), 31.96, 
31.94 (C5’, C5’’), 31.6 (C4’’), 31.3 (C1’), 31.0 (C1’’), 30.0, 29.7 (C11’, C11’’), 27.1 (C12’, 
C12’’), 24.4 (C3’’’), 22.6 (C5’’’), 19.9, 19.3, 18.8 (C9’, C9’’, C10’, C10’’), 14.0 (C6’’’) ppm. 
 
 Characterisation of syn-98 
 
LC-MC (ESI-) for C36H47O6
- [M-H]-: 575.75,     (mp = 75-95°C) 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.63 (s, 1H, OH), 4.26 (d, 
3JH1’,H8’ = 3.5 Hz, 1H, H1’), 4.18 (d, 
3JH1’‘,H8‘’ = 3.8 Hz, 1H, 
H1’‘), 3.08 (dt, 2JH2a‘‘’,H2b‘‘’ = 16.6 Hz, 
3JH2a‘‘’,H3‘’’ = 7.5 Hz, 1H, 
H2a‘‘‘), 3.05 (dt, 2JH2b‘‘’,H2a‘‘’ = 16.6 Hz, 
3JH2b‘‘’,H3‘’’ = 7.5 Hz, 1H, 
H2b‘‘‘), 2.60-2.44, 2.42-2.18 (2 x m, 8H, H4‘, H4‘‘, H6‘, H6‘‘), 
2.01 (dsept, 3J H8‘-H1‘ = 3.5 Hz, 
3JH8‘,H9‘-H10‘ = 6.8 Hz, 1H, H8’), 
1.90 (dsept, 3JH8‘’,H1‘‘ = 3.8 Hz, 
3JH8’‘,H9‘’-H10‘‘ = 6.8 Hz, 1H, H8‘’), 
1.76-1.67 (m, 2H, H3‘‘‘), 1.41-1.34 (m, 4H, H4‘‘‘, H5‘‘‘), 1.20, 
1.18, 1.15, 1.11 (4 x s, 12H, H11‘, H11‘‘, H12‘, H12‘‘), 0.95-
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0.90 (m, 3H, H6‘‘‘), 0.84, 0.81, 0.79, 0.75 (4 x d, 3JH9‘-H10‘,H8‘ = 
3JH9‘‘-H10‘‘,H8‘‘ = 6.8 Hz, 12H, H9’, 
H9’’, H10’, H10’’) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 205.8 (C1’’’), 197.0, 196.9 (C7’, C7’’), 165.7, 165.6 (C3’, 
C3’’), 161.0 (C6), 153.8 (C4), 151.0 (C2), 113.7, 113.4 (C2’, C2’’), 110.2 (C5), 106.8 (C1), 
103.8 (C3), 51.0, 50.9 (C6’, C6’’), 44.9 (C2’’’) 41.4, 41.3 (C4’, C4’’), 35.3 (C8’’), 34.3 (C8’), 
32.0, 31.8 (C5’, C5’’), 31.6 (C4’’’), 31.4, 31.2 (C1’, C1’’), 29.8, 29.6 (C11’, C11’’), 27.3, 27.1 
(C12’, C12’’), 24.5 (C3’’’), 22.6 (C5’’’), 20.0, 19.5, 18.9, 18.6 (C9’, C9’’, C10’, C10’’), 13.8 
(C6’’’) ppm. 
 
Crystal Structure: (for the complete data see Appendix 6) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Crystal data and structure refinement for syn-98 (sh3583). 
Identification code  sh3583  
Empirical formula  C36 H48 O6  
Formula weight  576.74  
Temperature  153(2) K  
Wavelength  0.71073 Å  
Crystal system  Triclinic  
Space group  P-1  
Unit cell dimensions a = 11.2643(8) Å α= 71.787(5)°. 
 b = 11.9208(8) Å β= 87.308(5)°. 
 c = 13.4429(10) Å γ = 66.348(4)°. 
Volume 1564.2(2) Å3  
Z 2  
Density (calculated) 1.224 Mg/m3  
Absorption coefficient 0.082 mm-1  
F(000) 624  
Crystal size 0.247 x 0.182 x 0.040 mm3  
Theta range for data collection 1.601 to 29.065°.  
Index ranges -14<=h<=15, -14<=k<=16, -
18<=l<=18 
 
Reflections collected 31788  
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Independent reflections 8286 [R(int) = 0.0870]  
Completeness to theta = 25.242° 99.6 %   
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.7458 and 0.6952  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 8286 / 94 / 417  
Goodness-of-fit on F2 0.968  
Final R indices [I>2sigma(I)] R1 = 0.0617, wR2 = 0.1212  
R indices (all data) R1 = 0.1563, wR2 = 0.1559  
Extinction coefficient n/a  
Largest diff. peak and hole 0.316 and -0.282 e.Å-3  
 
4.6.3. Derivatives made with isovaleraldehyde 
 
Isovaleryl-myrtucommulone derivative 99 
 
According to the general procedure GP 5, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), syncarpic acid (27) (550 mg, 3.02 
mmol, 6.0 eq.) and isovaleraldehyde (35) (0.43 mL, 4.01 mmol, 8.0 eq.) were mixed in 
ethanol (4 mL) and stirred at room temperature for 40 h. The reaction was worked up and the 
product was purified through column chromatography on silica gel (A/PE, 1/2, Rf = 0.10) to 
afford 35 mg of the derivative 99 (0.05 mmol, 10 % yield) as a brownish white powder (mp = 
142°C, decomposition). 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 4.86-4.72 (m, 
0.13H), 4.64-4.50 (m, 0.49H), 4.32-4.18 (m, 0.83H), 
4.16-3.95 (m, 0.42H), 3.65-3.36 (m, 0.93H), 2.55 (brs, 
0.53H), 2.38-2.23 (1.12H), 1.96-1.84 (m, 0.56H) 1.70-
1.49 (m, 3.29H) 1.48-1.18 (m, 28.10H), 1.18-1.08 (m, 
6.08H), 0.91-0.74 (m, 9.64H) ppm. 
 
LC-MC (ESI-) for C40H53O9
- [M-H]-: 677.80 
 
Isovaleryl-myrtucommulone derivative 100 
 
According to the general procedure GP 5, hexanoyl phloroglucinol (HPG) (33) (112 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), syncarpic acid (27) (550 mg, 3.02 
mmol, 6.0 eq.) and isovaleraldehyde (35) (0.43 mL, 4.01 mmol, 8.0 eq.) were mixed in 
ethanol (4 mL) and stirred at room temperature for 48 h. The reaction was worked up and the 
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product was purified through column chromatography on silica gel (A/PE, 1/2, Rf = 0.13) to 
afford 33 mg of the derivative 100 (0.07 mmol, 14 % yield) as a brownish white powder (mp = 
122-145°C). 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 4.89-4.74 (m, 0.49H), 4.55-
4.35 (m, 0.11H), 4.32-4.17 (m, 0.08H), 4.16-3.95 (m, 0.42H), 
3.23-3.07 (m, 1.17H), 2.55 (brs, 0.39H), 2.41-2.17 (1.00H), 
1.72-1.58 (m, 2.12H), 1.47-1.15 (m, 20.29H), 0.93-0.87 (m, 
2.59H), 0.86-0.73 (m, 6.00H) ppm. 
 
LC-MC (ESI-) for C27H37O7
- [M-H]-: 473.35. 
 
4.6.4. Attempt with Meldrum’s acid 
 
Meldrum’s acid-myrtucommulone derivative 101 
 
According to the general procedure GP 5, isobutyryl phloroglucinol (IBPG) (25) (98 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), Meldrum’s acid (423 mg, 2.93 
mmol, 6.0 eq.) and isobutyraldehyde (26) (0.32 mL, 3.51 mmol, 7.0 eq.) were mixed in 
ethanol (4 mL) and stirred at room temperature for 7 h. The reaction was worked up and the 
product was purified through column chromatography on silica gel (A/PE, 1/6, Rf = 0.06) to 
afford 144 mg of the Meldrum’s acid derivative 101 (0.56 mmol) as a white powder (mp = 81-
88°C). The crystal structure could not be refined because of the bad quality of the crystals 
but was confirmed by mass spectroscopy and NMR (the crystal data is not provided here). 
 
 
 
 
 
 
 
 
 
 
 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 4.02 (d, 
3JH5,H4 = 1.3 Hz, H5). 2.88-2.77 (m, 3H, H3, H4), 
2.09 (s, 3H, H1), 2.00-1.86 (m, 1H, H9), 1.80 (s, 3H, H12), 1.71 (s, 3H, H13), 0.91 (d, 3JH10,H9 
= 6.8 Hz, 3H, H10), 0.87 (d, 3JH11,H9 = 6.8 Hz, 3H, H11) ppm. 
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13C-NMR (101 MHz, CO(CD3)2): δ = 209.4 (C2), 167.4 (C6, C8), 106.4 (C7), 49.0 (C3), 45.4 
(C5), 40.9 (C1), 32.0 (C9), 31.1 (C4), 29.5, 28.0 (C12, C13), 22.2, 21.9 (C10, C11) ppm. 
 
LC-MC (ESI-) for C13H19O5
- [M-H]-: 255.40 
 
4.6.5. Indandione derivatives 
4.6.5.1 Preparation and cyclisation of the semimyrtucommulone derivative 
87 
 
Semimyrtucommulone derivative 87 
 
According to GP 8, IBPG (25) (196 mg, 1.0 mmol, 1.0 eq.) was dissolved in DT101 (4 mL) 
and added dropwise to the freshly prepared (S,S)-ALB ((S,S)-66e) (18.2 mL of a 0.18 M 
solution in DT101, 3.2 mmol, 3.2 eq.). Isobutylidene indandione (IBIND) (86) (240 mg, 1.2 
mmol, 1.2 eq.) was dissolved in DT101 (1.5 mL, 0.80 M solution) and added dropwise to the 
mixture at 0°C. The mixture was allowed to warm up to room temperature and was stirred for 
24h more. The reaction was quenched and the product extracted and dried. After purification 
by column chromatography on silica gel (A/PE, 1/2-1/1), 142 mg of the derivative 87 (0.36 
mmol, 36 % yield) were obtained as a yellow solid (mp = 114-138°C, decomposition). [𝛼]𝐷
24 = 
+ 1.7 (MeOH, c = 2.88). 
 
HRMS (ESI+) calcd. for C23H25O6
+ [M+H]+: 397.1651, found: 397.1643. 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 14.19 (brs, 0.22H, OH), 
14.04 (s, 0.39H, OH), 13.26 (s, 0.33H, OH), 9.80-9.38 (m, 
0.89H, OH), 9.26 (brs, 0.23H, OH), 8.02 (d, J = 7.8 Hz, 0.36H, 
HAr), 7.96 (d, J = 7.8 Hz, 0.46H, HAr), 7.91-7.84 (m, 0.41H, HAr), 
7.84-7.73 (m, 1.28H, HAr), 7.70-7.65 (m, 0.28H, HAr), 7.57-7.52 
(m, 1.43H, HAr), 5.98 (s, 0.32H, H5), 5.86 (s, 0.28H, H5), 5.83 
(s, 0.40H, H5), 4.27 (sept, J = 6.8 Hz, 0.41H, H2’’’), 3.94-3.81 (m, 1H), 3.58-3.48 (m, 1H), 
3.41 (d, J = 2.0 Hz , 0.34H, H2’), 3.41 (d, J = 1.5 Hz , 0.39H, H2’), 2.89-2.78 (m, 0.38H), 
2.36-2.25 (m, 0.38H), 2.25-2.16 (m, 0.44H), 1.19, 1.18 (2 x d, J = 6.8 Hz, 3H), 1.14 (d, J = 
6.8 Hz, 1.66H), 1.10 (d, J = 6.8 Hz, 1.58H), 1.07-1.03 (m, 2.11H), 1.02 (d, J = 6.5 Hz, 1.15H), 
0.99 (d, J = 6.8 Hz, 0.70H), 0.93, 0.92 (2 x d, J = 6.8 Hz, 2.27H), 0.73 (d, J = 6.8 Hz, 0.76H). 
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13C-NMR (101 MHz, CO(CD3)2): δ = 219.2, 218.4, 212.7, 211.6, 203.6, 166.8, 165.7, 164.3, 
163.3, 161.5, 160.7, 157.1, 154.7, 154.2, 153.8, 137.7, 137.6, 137.4, 137.1, 136.9, 136.1, 
125.5, 125.4, 124.2, 123.9, 123.8, 123.7, 110.1, 109.1, 108.0, 106.5, 99.1, 98.2, 96.2, 58.2, 
57.9, 56.7, 40.8, 40.5, 40.4, 40.1, 39.5, 32.7, 32.2, 28.5, 23.9, 23.6, 22.7, 22.3, 22.21, 22.16, 
22.0, 20.7, 20.53, 20.48, 19.4,  
 
Tetracyclic semimyrtucommulone derivative 88 (6% ee) 
 
Following the GP 9 procedure, the derivative 87 (70 mg, 0.18 mmol, 1.0 eq.) and pTsOH 
(100 mg, 0.53 mmol, 3.0 eq.) were heated to 95°C in toluene (7 mL) for 1h to yield, after 
purification on column chromatography (A/PE, 1/9, Rf = 0.08), 48 mg of the tetracyclic 
derivative 88 (0.13 mmol, 70 % yield) as a yellow solid (mp = 185-220°C, decomposition). 
[𝛼]𝐷
24 = - 23.0 (MeOH, c = 2.88) 
 
HRMS (ESI+) calcd. for C23H23O5
+ [M+H]+: 379.1540, found: 379.1542. 
 
1H-NMR (400 MHz, CDCl3): δ = 13.55 (s, 1H, OH), 7.50 (d, 
3JH8’,H7’ 
= 7.0 Hz, 0.52H, H8’), 7.46 (d, 3JH8‘,H7’ = 7.0 Hz, 0.56H, H8‘), 7.44-
7.37 (m, 0.71H, H6‘), 7.35 (d, 3J = 7.5 Hz, 0.89H, H6‘, H7‘), 7.33-
7.27 (m, 0.76H, H7‘), 7.21 (d, 3JH5‘,H6‘ = 7.0 Hz, 0.54H, H5‘), 7.15 
(d, 3JH5’‘,H6‘’ = 7.0 Hz, 0.54H, H5’), 6.31 (s, 0.45H, H5), 6.22 (s, 
0.48H, H5), 4.04 (d, 3JH1’,H11’ = 3.0 Hz, 1H, H1’), 3.98 (d, 
3JH1‘’,H11’’ = 
3.0 Hz, 0.46H, H1’‘), 3.93 (sept, 3JH2‘‘’,H3‘’’-H4‘‘‘ = 6.5 Hz, 1H, H2‘‘‘), 2.26-2.17 (m, 0.75H, H11’), 
2.13 (dsept, 3JH11‘’,H1‘‘ = 3.0 Hz, 
3JH11’‘,H12‘’-H13‘‘ = 6.8 Hz, 0.56H, H11‘’), 1.34 (d, 
3JH12‘,H11‘ = 6.8 
Hz, 1.63H, H12‘), 1.31 (d, 3JH12‘,H11‘ = 6.8 Hz, 1.78H, H12‘), 1.22, 1.21 (2 x d, 
3JH3‘‘‘,H2‘‘‘ = 6.8 
Hz, 3H, H3‘‘‘), 1.07-1.03 (m, 3H, H4‘‘‘), 0.72 (d, 3JH13‘,H11‘ = 6.8 Hz, 3H, H13‘), 0.66 (d, 
3JH13‘,H11‘ = 6.8 Hz, 3H, H13‘‘) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.2, 209.5 (C1’’’), 1200.8, 197.2 (C10’), 170.7 (C3’), 
164.9, 163.7, 159.9, 157.8, 156.3, 153.2 (C6, C4, C2), 136.6, 136.5 (C9’), 132.6, 132.4 (C6’), 
132.2 (C4’), 130.3, 130.1 (C7’), 122.2, 121.9 (C8’), 117.8, 117.7 (C5’), 110.5, 110.4, 110.0 
(C2’), 106.9, 106.4 (C1), 105.1 (C3), 100.9, 95.6 (C5), 40.3, 39.8 (C2’’’), 34.0, 33.3, 33.2, 
33.1 (C1’, C11’), 29.0, 28.9, 27.7, 22.6, 21.3, 21.0, 20.4, 19.6, 19.4, 19.2, 19.1, 18.7 (C12’, 
C3’’’, C4’’’), 17.5, 17.3 (C13’), 14.3, 11.4 (C3’’’, C4’’’) ppm. 
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4.6.5.2 Preparation and cyclisation of the myrtucommulone derivative 39 
 
Indandione-myrtucommulone derivative 39 
 
According to the general procedure GP 6, hexanoyl phloroglucinol (HPG) (33) (112 mg, 0.50 
mmol, 1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.) and IBIND (86) (600 mg, 3.00 mmol, 
6.0 eq., prepared according to GP 4) were mixed in ethanol (4 mL) and stirred at room 
temperature for 18h. The reaction was worked up and the product was purified through 
column chromatography on silica gel (A/PE, 1/3 to 1/1) to afford 224 mg of the derivative 39 
(0.36 mmol, 72 % yield) in two portions: 73 mg of 39b (0.12 mmol, 24 % yield, Rf = 0.32) and 
151 mg of meso-39a (0.24 mmol, 48 % yield, Rf = 0.32) were separated both as orange 
powders. Besides 48 mg of the semi-derivative 105 (0.11, 22 %, Rf = 0.41) were also 
isolated. 
 
Since the NMR-spectra of the non cyclised molecules are challenging to interpret due to their 
numerous possible conformers and tautomers, only the 1H-NMR spectrum of meso-39 is 
given. 
 
LC-MS (ESI-) for 105 (C25H27O6
-) [M-H]-:   423.25. 
LC-MS (ESI-) for 39b (C38H39O8
-) [M-H]-:   625, 35. 
HRMS (ESI+) calcd. for meso-39a (C38H41O8
+) [M+H]+: 625,2801 found: 625,2817. 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 13.77 (s, 0.67H, 
OH), 8.23 (d, J = 7.8 Hz, 0.67H, HAr), 8.01 (d, J = 
7.8 Hz, 1.05H, HAr), 7.98-7.91 (m, 0.45H, HAr), 7.89-
7.83 (m, 1H, HAr), 7.80-7.76 (m, 1H, HAr), 7.59-7.46 
(m, 4H, HAr), 7.19-7.00 (m, 68H, OH), 3.57 (dd, J = 
1.3 Hz, J = 8.8 Hz, 0.86H), 3.40-3.28 (m, 2.41H), 
3.27-3.22 (m, 0.82H), 3.08 (dt, J = 17.8 Hz, J = 7.3 
Hz, 1.27H), 1.67-1.50 (m, 3H), 1.38-1.26 (m, 4.81H), 1.02 (d, J = 6.8 Hz, 2.18H), 0.93-0.86 
(m, 4H), 0.80 (d, J = 6.8 Hz, 2H), 0.66 (d, J = 6.8 Hz, 2.17H), 0.19 (d, J = 6.8 Hz, 2.17H) 
ppm. 
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Heptacyclic indandione-myrtucommulone derivative syn-108 
 
Following the GP 9 procedure, the indandione derivative 39b (80 mg, 0.13 mmol, 1.0 eq.) 
and pTsOH (190 mg, 1.00 mmol, 7.6 eq.) were heated to 95°C in toluene (8 mL) for 1h to 
yield, after purification on column chromatography (A/PE, 1/9, Rf = 0.29), 47 mg of the 
heptacyclic derivative syn-108 (0.08 mmol, 61 % yield) as a yellow solid (mp = 205-215°C). 
 
1H-NMR (400 MHz, CDCl3): δ = 13.77 (s, 1H, OH), 7.51 (d, 
3JH8’,H7’ = 7.0 Hz, 1H, H8’), 7.47 (d, 
3JH8’‘,H7‘’ = 7.0 Hz, 1H, H8‘’), 
7.45-7.40 (m, 2H, H6‘, H6‘‘), 7.39-7.31 (m, 2H, H7‘, H7‘‘), 
7.29 (d, 3JH5’,H6’ = 7.0 Hz, 1H, H5’), 7.17 (d, 
3JH5’‘,H6‘’ = 7.0 Hz, 
1H, H5‘’), 4.18 (d, 3JH1’,H11’ = 3.0 Hz, 1H, H1’), 4.06 (d, 
3JH1‘’,H11’’ = 2.8 Hz, 1H, H1’‘), 3.35 (dt, 
2JH2a‘‘’,H2b‘‘’ = 17.6 Hz, 
3JH2a‘‘’,H3‘’’ = 7.5 Hz, 1H, H2a‘‘‘), 3.24 (dt, 
2JH2b‘‘’,H2a‘‘’ = 16.6 Hz, 
3JH2b‘‘’,H3‘’’ = 7.3 Hz, 1H, H2b‘‘‘), 2.22 (dsept, 
3J H11‘-H1‘ = 3.0 Hz, 
3JH11‘,H12‘-H13‘ = 6.8 Hz, 1H, H11’), 2.15 (dsept, 
3JH11‘’,H1‘‘ = 3.0 
Hz, 3JH11’‘,H12‘’-H13‘‘ = 7.0 Hz, 1H, H11‘’), 1.87-1.75 (m, 2H, H3‘‘‘), 1.49-1.38 (m, 4H, H4‘‘‘, H5‘‘‘), 
1.12 (d, 3JH12‘,H11‘ = 6.8 Hz, 3H, H12‘), 1.06 (d, 
3JH12‘‘,H11‘‘ = 7.0 Hz, 3H, H12‘‘), 0.95 (t, 
3JH6‘‘‘-H5‘‘‘ 
= 7.0 Hz, 3H, H6‘‘‘), 0.80 (d, 3JH13‘,H11‘ = 6.8 Hz, 3H, H13‘), 0.66 (d, 
3JH13‘‘,H11‘‘ = 6.8 Hz, 3H, 
H13‘‘) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 205.9 (C1’’’), 192.6, 192.4 (C10’, C10’’), 169.8, 169.7 (C3’, 
C3’’), 161.2 (C6), 153.8 (C4), 151.3 (C2), 136.4 (C9’, C9’’), 132.5, 132.4 (C6’, C6’’), 132.1, 
132.0 (C4’, C4’’), 130.4, 130.2 (C7’, C7’’), 122.2, 121.9 (C8’, C8’’), 117.8, 117.7 (C5’, C5‘’), 
111.5 (C5), 110.2, 109.8 (C2’, C2’’), 107.5 (C1), 105.3 (C3), 45.5 (C2’’’), 35.2 (C11’’), 33.64, 
33.55 (C1’, C1’’), 33.0 (C11’), 31.6 (C4’’’), 23.9 (C3’’’), 22.6 (C5’’’), 21.2, 20.9, (C12’, C12’’), 
17.8, 17.3 (C13’, C13’’), 14.0 (C6’’’) ppm. 
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Heptacyclic indandione-myrtucommulone derivative anti-108 
 
Following the GP 9 procedure, the indandione derivative meso-39a (80 mg, 0.13 mmol, 1.0 
eq.) and pTsOH (190 mg, 1.00 mmol, 7.6 eq.) were heated to 95°C in toluene (8 mL) for 1h 
to yield, after purification on column chromatography (A/PE, 1/9, Rf = 0.28), 38 mg of the 
heptacyclic derivative anti-108 (0.06 mmol, 49 % yield) as a yellow solid. 
 
1H-NMR (400 MHz, CDCl3): δ = 13.87 (s, 1H, OH), 7.53 (d, 
3JH8’,H7’ = 7.0 Hz, 1H, H8’), 7.49 (d, 
3JH8’‘,H7‘’ = 7.0 Hz, 1H, 
H8‘’), 7.46-7.41 (m, 2H, H6‘, H6‘‘), 7.40-7.32 (m, 2H, H7‘, 
H7‘‘), 7.25 (d, 3JH5’,H6’ = 7.0 Hz, 1H, H5’), 7.19 (d, 
3JH5’‘,H6‘’ = 
7.0 Hz, 1H, H5‘’), 4.28 (d, 3JH1’,H11’ = 3.0 Hz, 1H, H1’), 4.11 
(d, 3JH1‘’,H11’’ = 3.3 Hz, 1H, H1’‘), 3.39 (ddd, 
2JH2a‘‘’,H2b‘‘’ = 17.3 
Hz, 3JH2a‘‘’,H3a‘’’ = 8.0 Hz, 
3JH2a‘‘’,H3b‘’’ = 6.8 Hz, 1H, H2a‘‘‘), 3.26 
(ddd, 2JH2b‘‘’,H2a‘‘’ = 17.3 Hz, 
3JH2b‘‘’,H3a‘’’ = 8.0 Hz, 
3JH2b‘‘’,H3b‘’’ = 
6.8 Hz, 1H, H2b‘‘‘), 2.20 (dsept, 3J H11‘-H1‘ = 3.3 Hz, 
3JH11‘,H12‘-
H13‘ = 7.0 Hz, 1H, H11’), 2.06 (dsept, 
3JH11‘’,H1‘‘ = 3.0 Hz, 
3JH11’‘,H12‘’-H13‘‘ = 7.0 Hz, 1H, H11‘’), 
1.89-1.77 (m, 2H, H3‘‘‘), 1.50-1.39 (m, 4.89H, H4‘‘‘, H5‘‘‘), 1.14 (d, 3JH12‘,H11‘ = 6.8 Hz, 3H, 
H12‘), 1.06 (d, 3JH12‘‘,H11‘‘ = 7.0 Hz, 3H, H12‘‘), 0.96 (t, 
3JH6‘‘‘-H5‘‘‘ = 7.0 Hz, 3H, H6‘‘‘), 0.70 (d, 
3JH13‘,H11‘ = 7.0 Hz, 3H, H13‘‘), 0.64 (d, 
3JH13‘‘,H11‘‘ = 6.8 Hz, 3H, H13‘) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 205.9 (C1’’’), 192.6, 192.5 (C10’, C10’’), 170.06, 170.05 
(C3’, C3’’), 161.7 (C6), 153.7 (C4), 151.6 (C2), 136.4 (C9’, C9’’), 132.6, 132.5 (C6’, C6’’), 
132.1 (C4’, C4’’), 130.4, 130.2 (C7’, C7’’), 122.3, 122.0 (C8’, C8’’), 117.7, 117.5 (C5’, C5‘’), 
111.8 (C5), 110.2, 109.9 (C2’, C2’’), 107.7 (C1), 105.2 (C3), 45.5 (C2’’’), 34.7 (C11’’), 33.7, 
33.6 (C1’, C1’’), 33.2 (C11’), 31.6 (C4’’’), 24.0 (C3’’’), 22.6 (C5’’’), 21.3, 21.2, (C12’, C12’’), 
17.4, 17.3 (C13’, C13’’), 14.0 (C6’’’) ppm. 
 
4.6.5.3 Preparation and cyclisation of the myrtucommulone derivative 104 
 
Indandione-myrtucommulone derivative 104 
 
According to the general procedure GP 6, isovaleryl phloroglucinol (32) (105 mg, 0.50 mmol, 
1.0 eq.), proline (90) (57 mg, 0.50 mmol, 1.0 eq.), IBIND (86) (600 mg, 3.00 mmol, 6.0 eq., 
prepared according to GP 4) were mixed in ethanol (4 mL) and stirred at room temperature 
for 48h. The reaction was worked up and the product was purified through column 
chromatography on silica gel (A/PE, 1/2) to afford 216 mg of the derivative 104 (0.36 mmol, 
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71 % yield) in two portions: 71 mg of 104b (0.12 mmol, 24 % yield, Rf = 0.50 (A/PE,1/1)) and 
145 mg of meso-104a (0.24 mmol, 48 % yield, Rf = 0.34 (A/PE, 1/1)) were separated both as 
orange powders. Besides, 47 mg of the semi-derivative 106 (0.12 mmol, 23 %, Rf = 0.62, 
(A/PE,1/1)) were also isolated. 
 
Since the NMR-spectra of the non cyclised molecules are challenging to interpret due to their 
numerous possible conformers and tautomers, only the 1H-NMR spectrum of meso-104 is 
given. 
 
LC-MS (ESI-) for meso-104a (C37H37O8
-) [M-H]-: 609, 70. 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 13.77 (s, 0.97H, 
OH), 8.22 (d, J = 7.8 Hz, 0.67H, HAr), 8.01 (d, J = 
7.8 Hz, 1.11H, HAr), 7.89-7.84 (m, 1H, HAr), 7.81-
7.76 (m, 1.16H, HAr), 7.61-7.44 (m, 4.93H, HAr + 
OH), 7.17-7.01 (m, 0.90H, OH), 3.60-3.54 (m, 1H), 
3.40-3.25 (m, 2.74H), 3.24 (s, 0.68H), 2.92 (d, J = 
6.8 Hz, 0.75H), 2.87 (d, J = 6.8 Hz, 0.62H), 2.19 (sept, J = 6.8 Hz, 1.42H), 2.12-2.05 (m, 1H), 
1.64-1.51 (m, 1H), 1.19-1.07 (m, 2.45H), 1.02 (d, J = 6.8 Hz, 2.18H), 0.97 (d, J = 6.8 Hz, 
3.15H), 0.96-0.88 (m, 5.28H), 0.80 (d, J = 6.8 Hz, 2.30H), 0.67 (d, J = 6.8 Hz, 2.59H), 0.17 
(d, J = 6.8 Hz, 1.98H) ppm. 
 
Heptacyclic indandione-myrtucommulone derivative syn-109 
 
Following the GP 9 procedure, the indandione derivative 104b (60 mg, 0.10 mmol, 1.0 eq.) 
and pTsOH (114 mg, 0.60 mmol, 6.0 eq.) were heated to 95°C in toluene (6 mL) for 1h to 
yield, after purification on column chromatography (A/PE, 1/9, Rf = 0.18), 27 mg of the 
heptacyclic derivative syn-109 (0.05 mmol, 47 % yield) as a yellow solid (mp = 218-221°C). 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.81 (s, 1H, OH), 7.52 (d, 
3JH8’,H7’ = 7.0 Hz, 1H, H8’), 7.47 (d, 
3JH8’‘,H7‘’ = 7.0 Hz, 1H, H8‘’), 
7.45-7.40 (m, 2H, H6‘, H6‘‘), 7.39-7.31 (m, 2H, H7‘, H7‘‘), 
7.29 (d, 3JH5’,H6’ = 7.0 Hz, 1H, H5’), 7.19 (d, 
3JH5’‘,H6‘’ = 7.0 Hz, 
1H, H5‘’), 4.19 (d, 3JH1’,H11’ = 3.0 Hz, 1H, H1’), 4.07 (d, 
3JH1‘’,H11’’ = 3.0 Hz, 1H, H1’‘), 3.28 (dd, 
2JH2a‘‘’,H2b‘‘’ = 17.3 Hz, 
3JH2a‘‘’,H3‘’’ = 6.8 Hz, 1H, H2a‘‘‘), 3.13 (dd, 
2JH2b‘‘’,H2a‘‘’ = 17.3 Hz, 
3JH2b‘‘’,H3‘’’ = 6.8 Hz, 1H, H2b‘‘‘), 2.38 (sept, 
3JH3‘‘’,H4‘’’-H5‘‘‘= 6.8 
Hz, 1H, H3‘‘‘), 2.23 (dsept, 3JH11‘’,H1‘‘ = 3.0 Hz, 
3JH11’‘,H12‘’-H13‘‘ = 
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7.0 Hz, 1H, H11‘’), 2.16 (dsept, 3J H11‘-H1‘ = 3.0 Hz, 
3JH11‘,H12‘-H13‘ = 7.0 Hz, 1H, H11’), 1.12 (d, 
3JH12‘,H11‘ = 6.8 Hz, 3H, H12‘), 1.09 (d, 
3JH4‘‘‘,H3‘‘‘ = 6.5 Hz, 3H, H4‘‘‘), 1.06 (d, 
3JH5‘‘‘,H3‘‘‘ = 6.8 Hz 
= 3JH12‘‘,H11‘‘, 6H, H4‘‘‘, H12‘‘), 0.81 (d, 
3JH13‘,H11‘ = 6.8 Hz, 3H, H13‘), 0.67 (d, 
3JH13‘‘,H11‘‘ = 6.8 
Hz, 3H, H13‘‘) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 205.4 (C1’’’), 192.6, 192.5 (C10’, C10’’), 169.81, 169.77 
(C3’, C3’’), 161.5 (C6), 153.8 (C4), 151.2 (C2), 136.5 (C9’, C9’’), 132.54, 132.45 (C6’, C6’’), 
132.1, 132.0 (C4’, C4’’), 130.4, 130.2 (C7’, C7’’), 122.2, 122.0 (C8’, C8’’), 117.8, 117.7 (C5’, 
C5‘’), 111.6 (C5), 110.3 (C2’’), 109.9 (C2’), 107.8 (C1), 105.3 (C3), 54.3 (C2’’’), 35.3 (C11’), 
33.7, 33.6 (C1’, C1’’), 33.1 (C11’’), 24.6 (C3’’’), 22.89, 22.86 (C4’’’, C5’’’), 21.2, 21.0 (C12’, 
C12’’), 17.9, 17.4 (C13’, C13’’) ppm. 
 
Heptacyclic indandione-myrtucommulone derivative anti-109 
 
Following the GP 9 procedure, the indandione derivative meso-104 (90 mg, 0.15 mmol, 1.0 
eq.) and pTsOH (190 mg, 1.00 mmol, 6.7 eq.) were heated to 95°C in toluene (9 mL) for 1h 
to yield, after purification on column chromatography (A/PE, 1/9, Rf = 0.25), 41 mg of the 
heptacyclic derivative anti-109 (0.07 mmol, 49 % yield) as a yellow solid (mp = 195°C, 
decomposition). 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.83 (s, 1H, OH), 7.52 (d, 
3JH8’,H7’ = 6.8 Hz, 1H, H8’), 7.49 (d, 
3JH8’‘,H7‘’ = 6.8 Hz, 1H, H8‘’), 
7.46-7.40 (m, 2H, H6‘, H6‘‘), 7.39-7.31 (m, 2H, H7‘, H7‘‘), 
7.25 (d, 3JH5’,H6’ = 7.0 Hz, 1H, H5’), 7.20 (d, 
3JH5’‘,H6‘’ = 7.0 Hz, 
1H, H5‘’), 4.27 (d, 3JH1’,H11’ = 3.0 Hz, 1H, H1’), 4.11 (d, 
3JH1‘’,H11’’ = 3.0 Hz, 1H, H1’‘), 3.33 (dd, 
2JH2a‘‘’,H2b‘‘’ = 17.1 Hz, 
3JH2a‘‘’,H3‘’’ = 6.3 Hz, 1H, H2a‘‘‘), 3.11 (dd, 
2JH2b‘‘’,H2a‘‘’ = 17.1 Hz, 
3JH2b‘‘’,H3‘’’ = 7.0 Hz, 1H, H2b‘‘‘), 2.39 (sept, 
3JH3‘‘’,H4‘’’-H5‘‘‘= 6.8 
Hz, 1H, H3‘‘‘), 2.20 (dsept, 3JH11‘’,H1‘‘ = 3.0 Hz, 
3JH11’‘,H12‘’-H13‘‘ = 7.0 Hz, 1H, H11‘’), 2.06 (dsept, 
3J H11‘-H1‘ = 3.0 Hz, 
3JH11‘,H12‘-H13‘ = 7.0 Hz, 1H, H11’), 1.17-1.12 (m, 3H, H12‘), 1.09 (d, 
3JH4‘‘‘,H3‘‘‘ 
= 6.5 Hz, 3H, H4‘‘‘), 1.06 (d, 3JH5‘‘‘,H3‘‘‘ = 6.5 Hz, 3H, H4‘‘‘), 1.05 (d, 
3JH12‘‘,H11‘‘ = 7.0 Hz, 3H, 
H12‘‘), 0.71 (d, 3JH13‘,H11‘ = 6.8 Hz, 3H, H13‘), 0.64 (d, 
3JH13‘‘,H11‘‘ = 6.8 Hz, 3H, H13‘‘) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 205.4 (C1’’’), 192.51, 192.46 (C10’, C10’’), 170.04, 170.01 
(C3’, C3’’), 161.6 (C6), 153.7 (C4), 151.6 (C2), 136.4 (C9’, C9’’), 132.5 (C6’, C6’’), 132.1 
(C4’, C4’’), 130.4, 130.2 (C7’, C7’’), 122.2, 122.0 (C8’, C8’’), 117.7, 117.5 (C5’, C5‘’), 111.8 
(C5), 110.2, 109.9 (C2’, C2’’), 107.9 (C1), 105.2 (C3), 54.2 (C2’’’), 34.7 (C11’), 33.7, 33.6 
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(C1’, C1’’), 33.2 (C11’’), 24.8 (C3’’’), 23.0, 22.8 (C4’’’, C5’’’), 21.3, 21.1 (C12’, C12’’), 17.4, 
17.3 (C13’, C13’’) ppm. 
 
4.6.5.4 Preparation and cyclisation of the myrtucommulone derivative 41 
 
Indandione-myrtucommulone derivative 41128 
 
According to the general procedure GP 6, HPG (33) (224 mg, 1.00 mmol, 1.0 eq.), proline 
(90) (115 mg, 1.00 mmol, 1.0 eq.), isopentylidene indandione (103) (1.5 g, 6.93 mmol, 6.9 
eq., prepared according to GP 4) were mixed in ethanol (8 mL) and stirred at room 
temperature for 18h. The reaction was worked up and the product was purified through 
column chromatography on silica gel (A/PE, 1/3 to 1/1) to afford 320 mg of the indandione 
derivative 41 (0.49 mmol, 49 % yield) in two portions: 125 mg of meso-41a (0.19 mmol, 19 % 
yield, Rf = 0.34 (A/PE, 1/2)) and 195 mg of 41b (0.30 mmol, 30 % yield, Rf = 0.22 (A/PE, 1/2)) 
were separated both as orange powders. Besides 169 mg of the semi-derivative 107 (0.39, 
39 %, Rf = 0.36 (A/PE, 1/2)) were also isolated. 
 
LC-MS (ESI-) for 107 (C26H29O6
-) [M-H]-:    437.20. 
LC-MS (ESI-) for meso-41a (C40H43O8
-) [M-H]-:   651.30. 
HRMS (ESI+) calcd. for 41b (C40H45O8
+) [M+H]+:   653.3114 found: 653.3136 
 
Since the NMR-spectra of the non cyclised molecules are not meaningful due to their 
numerous possible conformers and tautomers, only the 1H-NMR spectrum of rac-41 is given. 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 14.28 (brs, 
0.15H, OH), 13.69 (brs, 0.15H, OH), 13.63 (brs, 
0.14H, OH), 13.42-13.36 (m, 0.07H, OH), 10.01-
9.75 (m, 0.13H, OH), 9.68 (brs, 0.14H, OH), 9.40 
(s, 0.14H, OH), 8.26 (d, J = 7.5 Hz, 0.25H, HAr), 
8.17-7.76 (m, 5.60H, HAr), 7.76-7.43 (m, 1.93H, 
HAr), 7.39 (t, J = 8.0 Hz, 0.25H, HAr), 5.04-4.94 (m, 
0.15H), 4.87-4.57 (m, 0.51H), 4.46 (brs, 0.35H), 4.20 (d, J = 5.8 Hz, 0.17H), 4.17-4.09 (m, 
0.18H), 4.08-3.93 (m, 0.47H), 3.93-3.78 (m, 0.28H), 3.78-3.64 (m, 0.16H), 3.56-3.35 (m, 
0.61H), 3.34-3.11 (m, 2.41H), 3.11-2.97 (m, 0.91H), 2.92 (dd, J = 7.8 Hz, J = 6.8 Hz, 0.32H), 
2.14-1.53 (m, 5.58H), 1.46-1.06 (m, 8.31H), 1.05-0.65 (m, 14.41), 0.64-0.50 (m, 1.37H) ppm. 
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Heptacyclic indandione-myrtucommulone derivative anti-110 
 
Following the GP 9 procedure, the indandione derivative meso-41a (80 mg, 0.12 mmol, 1.0 
eq.) and pTsOH (135 mg, 0.71 mmol, 5.9 eq.) were heated to 95°C in toluene (8 mL) for 1h 
to yield, after purification on column chromatography (A/PE, 1/6), 15 mg of the heptacyclic 
derivative anti-110 (0.02 mmol, 20 % yield, Rf = 0.44) as a yellow solid (mp = 195-200°C). 
 
HRMS (ESI+) calcd. for anti-110 (C40H40NaO6
+) [M+Na]+: 639.2717 found: 639.2718. 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.83 (s, 1H, OH), 7.54-
7.51 (m, 1H, H8’), 7.50 (d, 3JH8’‘,H7‘’ = 7.5 Hz, 1H, H8‘’), 7.47-
7.40 (m, 2H, H6‘, H6‘‘), 7.40-7.32 (m, 2H, H7‘, H7‘‘), 7.31 (d, 
3JH5’,H6’ = 7.0 Hz, 0.73H, H5’), 7.31 (d, 
3JH5’,H6’ = 7.0 Hz, 
0.32H, H5’), 7.18 (d, 3JH5’‘,H6‘’ = 6.8 Hz, 1H, H5‘’), 4.33 (d, 
3JH1’,H11’ = 3.8 Hz, 0.32H, H1’), 4.31 (d, 
3JH1’,H11’ = 3.5 Hz, 
0.34H, H1‘’), 4.28-4.23 (m, 0.27H, H1‘, H1‘‘), 4.21 (d, 3J = 
5.8 Hz, 0.21H, H1’, H1‘‘), 4.14 (d, 3J = 3.3 Hz, 0.34H, H1’, 
H1‘‘), 4.12 (d, 3J = 3.0 Hz, 0.34H, H1’, H1‘‘), 4.10 (d, 
3J = 3.3 
Hz, 0.14H, H1’, H1‘‘), 4.08 (d, 3J = 3.0 Hz, 0.14H, H1’, H1‘‘), 3.43-3.21 (m, 2H, H2‘‘‘), 1.89-
1.77 (m, 2H, H3‘‘‘), 1.73-1.52 (m, 6H, H11‘, H11‘‘, H12‘, H12‘‘), 1.50-1.39 (m, 4H, H4‘‘‘, H5‘‘‘), 
1.21-1.16 (m, 3H, H13‘, H13‘‘), 1.07-1.01 (m, 3.16H, H13‘, H13‘‘), 0.97 (t, 3JH6‘‘‘-H5‘‘‘ = 7.0 Hz, 
3H, H6‘‘‘), 0.84 (d, 3J14‘,H12‘ = 6.3 Hz, 0.91H, H14‘), 0.78 (d, 
3J14‘,H12‘ = 6.0 Hz, 0.94H, H14‘‘), 
0.77-0.71 (m, 4.08, H14‘, H14‘‘) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 205.9 (C1’’’), 192.6, 192.5 (C10’, C10’’), 168.7, 168.4 (C3’, 
C3’’), 161.8 (C6), 153.0 (C4), 151.6 (C2), 136.6 (C9’, C9’’), 132.5 (C6’, C6’’), 132.0 (C4’, 
C4’’), 130.4, 130.2 (C7’, C7’’), 122.3, 122.0 (C8’, C8’’), 117.83, 117.80 (C5’, C5‘’), 115.3 
(C5), 113.0, 112.8, 112.4 (C2’, C2’’), 107.9 (C1), 106.4 (C3), 47.4, 45.53 (C11’, C11’’), 45.49 
(C2’’’), 31.6 (C4’’’), 26.1, 26.0, 25.9 (C1’, C1’’), 25.5, 25.3 (C12’, C12’’), 24.1, 24.0, 23.9 
(C3’’’, C14’, C14’’), 22.7 (C5’’’), 22.23, 22.15 (C13’, C13’’), 14.0 (C6’’’) ppm. 
 
Heptacyclic indandione-myrtucommulone derivative syn-110 
 
Following the GP 9 procedure, the indandione derivative 41b (90 mg, 0.14 mmol, 1.0 eq.) 
and pTsOH (157 mg, 0.83 mmol, 5.9 eq.) were heated to 95°C in toluene (9 mL) for 1h to 
yield, after purification on column chromatography (A/PE, 1/6), 30 mg of the heptacyclic 
derivative syn-110 (0.05 mmol, 35 % yield, Rf = 0.34) as a yellow solid (mp = 198-202°C). 
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HRMS (ESI+) calcd. for syn-110 (C40H41O8
+) [M+H]+: 617.2897 found: 617.2908 
 
1H-NMR (400 MHz, CDCl3) : δ = 13.83 (s, 1H, OH), 7.49 (d, 
3JH8’‘,H7‘’ = 7.0 Hz, 1H, H8‘’), 7.47-7.44 (m, 1H, H8‘’), 7.43-
7.31 (m, 4H, H6‘, H6‘‘, H7‘, H7‘‘), 7.27-7.23 (m, 1H, H5’), 
7.15 (d, 3JH5’‘,H6‘’ = 7.0 Hz, 1H, H5‘’), 4.18-4.13 (m, 1H, H1‘, 
H1‘‘), 4.02 (d, 3J = 3.0 Hz, 0.45H, H1’, H1‘‘), 4.00 (d, 
3J = 3.0 
Hz, 0.46H, H1’, H1‘‘), 3.33 (dt, 2JH2a‘‘’,H2b‘‘’ = 17.6 Hz, 
3JH2a‘‘’,H3‘’’ = 7.5 Hz, 1H, H2a‘‘‘), 3.22 (dt, 
2JH2b‘‘’,H2a‘‘’ = 17.6 
Hz, 3JH2b‘‘’,H3‘’’ = 7.3 Hz, 1H, H2b‘‘‘), 1.94 (sept, 
3J = 6.8 Hz, 
0.63H, H12‘), 1.85-1.76 (m, 2H, H3‘‘‘), 1.69-1.61 (m, 4H, 
H11‘, H11‘‘), 1.77-1.70 (m, 1.22H, H12‘, H12‘‘), 1.48-1.39 (m, 4H, H4‘‘‘, H5‘‘‘), 1.15 (d, 
3J13‘,H12‘ = 6.3 Hz, 3H, H13‘), 1.03-1.00 (m, 3H, H13‘‘), 0.99-0.93 (m, 3H, H6‘‘‘), 0.80 (d, 
3J14‘,H12‘ = 6.5 Hz, 0.91H, H14‘), 0.75 (d, 
3J14‘‘,H12‘‘ = 6.0 Hz, 3H, H14‘‘) ppm. 
 
13C-NMR (101 MHz, CDCl3) : δ = 205.8 (C1’’’), 192.5, 192.4 (C10’, C10’’), 168.4, 168.1 (C3’, 
C3’’), 161.7 (C6), 153.0 (C4), 150.6 (C2), 136.54, 136.50 (C9’, C9’’), 132.6 (C6’, C6’’), 132.0, 
131.9 (C4’, C4’’), 130.4, 130.2 (C7’, C7’’), 122.1, 121.9 (C8’, C8’’), 117.9, 117.8 (C5’, C5‘’), 
113.1 (C5), 112.32, 112.28 (C2’, C2’’), 107.7 (C1), 106.4 (C3), 45.6, 45.5 (C11’, C11’’), 37.1 
(C2’’’), 31.6 (C4’’’), 26.0 (C1’, C1’’), 28.8 (C3’’’), 25.5, 25.4 (C12’, C12’’), 23.92, 23.89, 23.87 
(C14’, C14’’), 22.7, 22.5 (C5’’’), 22.3, 22.0 (C13’, C13’’), 14.0 (C6’’’) ppm. 
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Crystal Structure: (for the complete data see Appendix 7) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Exp. Data Tab. 6 Crystal data and structure refinement for syn-110 (sh3552). 
Identification code  sh3552  
Empirical formula  C40 H40 O6  
Formula weight  616.72  
Temperature  133(2) K  
Wavelength  0.71073 Å  
Crystal system  Monoclinic  
Space group  P21/c  
Unit cell dimensions a = 11.2500(8) Å α = 90°. 
 b = 19.6628(13) Å β = 96.290(2)°. 
 c = 15.0044(10) Å γ = 90°. 
Volume 3299.1(4) Å3  
Z 4  
Density (calculated) 1.242 Mg/m3  
Absorption coefficient 0.082 mm-1  
F(000) 1312  
Crystal size 0.545 x 0.379 x 0.120 mm3  
Theta range for data collection 1.714 to 30.574°.  
Index ranges -16<=h<=14, -28<=k<=18, -
21<=l<=17 
 
Reflections collected 39027  
Independent reflections 10077 [R(int) = 0.0380]  
Completeness to theta = 25.242° 100.0 %   
Absorption correction Semi-empirical from equivalents  
Max. and min. transmission 0.7461 and 0.7140  
Refinement method Full-matrix least-squares on F2  
Data / restraints / parameters 10077 / 0 / 575  
Goodness-of-fit on F2 1.017  
Final R indices [I>2sigma(I)] R1 = 0.0523, wR2 = 0.1322  
R indices (all data) R1 = 0.0790, wR2 = 0.1490  
Extinction coefficient n/a  
Largest diff. peak and hole 0.621 and -0.251 e.Å-3  
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4.7. Synthesis of the myrtucommulone-biotin derivative 
4.7.1. Syntheses for the introduction of an alkyl linker 
 
11-Bromo-undecanoyl-phloroglucinol (BrUP) (126)107 
 
11-bromo-undecanoic acid (129) (2.0 g, 7.5 mmol, 1.0 eq.) was dissolved in 4 mL DCMabs 
and oxalyl chloride (1.0 mL, 1.5 g, 11.6 mmol, 1.5 eq.) was added slowly. After stirring for 2h 
the solvent and excess oxalyl chloride were removed under reduced pressure to yield 2.0 g 
(7.0 mmol, 94 % yield) of the crude 11-bromo-undecanoyl chloride that was used without 
purification. 
 
According to the general procedure GP 1, 11-bromo-undecanoyl chloride (2.0 g, 7.0 mmol, 
1.0 eq.) was added to phloroglucinol (28) (897 mg, 7.12 mmol, 1.0 eq.) and aluminium 
trichloride (1.898 g, 14.24 mmol, 2.0 eq.) dissolved in anhydrous dichloromethane (7 mL) 
and nitromethane (2.3 mL). After purification by flash chromatography on silica gel (A/PE, 
1/3, Rf = 0.16) 11-bromo-undecanoyl-phloroglucinol (126) (2.166 g, 5.79 mmol) as a white 
solid (mp = 150-151°C) with 82 % yield.  
 
 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 11.73 (brs, 2H, C2'-OH, C6'-OH), 9.19 (brs, 1H, C4'-OH), 
5.92 (s, 2H, H3', H5'), 3.48 (t, 3JH11,H10 = 6.8 Hz, 2H, H11), 3.06 (m, 2H, H2), 1.88-1-80 (m, 
2H, H10), 1.66 (quint, 3JH3,H2 = 
3JH3,H4 = 7.0 Hz, 2H, H3), 1.48-1.40 (m, 2H, H9), 1.37-1.29 (m, 
10H, H4, H5, H6, H7, H8) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 207.5 (C1), 166.4 (C2', C6'), 166.1 (C4'), 106.1 (C1'), 
96.8 (C3', C5'), 45.4 (C2), 35.6 (C11), 34.6 (C10), 31.4, 31.2, 31.1, 30.4, 29.8, 26.5 (C3, C4, 
C5, C6, C7, C8, C9) ppm. 
 
HRMS (ESI+) calcd. for C17H26BrO4
+ [M+H]+: 373.1014; found 373.1001. 
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Biotinamide (127)108 
 
Biotin (23) (311 mg, 1.27 mmol) was dissolved in thionyl chloride (6 mL) and stirred 5 min at 
room temperature in the absence of moisture. The excess thionyl chloride was co-
evaporated twice with dichloromethane under reduced pressure. To the crude acyl chloride 
were then added 10 mL of aqueous ammonia releasing white fumes. After stirring for 30 
minutes, the precipitate was washed with cold water and cold methanol (which dissolved 
partially the product) to yield 35 % of biotinamide (127) (107 mg, 0.44 mmol). 
 
1H-NMR (400 MHz, SO(CD3)2): δ = 7.22 (s, 1H, NH2), 6.68 (s, 1H, 
NH2), 6.42 (s, 1H, NH), 6.35 (s, 1H, NH), 4.33-4.27 (m, 1H, H3), 
4.15-4.09 (m, 1H, H5), 3.14-3.06 (m, 1H, H5), 2.82 (dd, 2JH9a,H9b = 
12.3 Hz and 3JH9a,H8 = 5.0 Hz, 1H, H2a), 2.69 (d, 
2JH9b,H9a = 12.3 
Hz, 1H, H2b), 2.03 (t, 3JH2,H3 = 7.3 Hz, 2H, H9), 1.66-1.41 (m, 4H, 
H6, H8), 1.38-1.24 (m, 2H, H7) ppm. 
 
Isobutyramide (130)109 
 
Isobutyryl chloride (2.0 mL, 2.0 g, 19.0 mmol) was slowly added to 8 mL aqueous ammonia. 
The milky mixture was then stirred for 1h and evaporated to dryness under reduced 
pressure. The white residue was then boiled in 10 mL ethyl acetate filtrated quickly on a hot 
funnel. This process was repeated twice with the same amount of ethyl acetate and the 
combined organic extracts were cooled to 0°C. Crystalline isobutyramide (130) which had 
precipitated was removed by filtration. The filtrate was concentrated to a third and cooled 
down again to collect a second fraction of the product. The shiny needles of isobutyramide 
(130) were dried under vacuum to yield 1.0 g (11.5 mmol, 60 % yield) of the product. 
 
1H-NMR (400 MHz, SO(CD3)2): δ = 7.19 (s, 1H, NH2), 6.63 (s, 1H, NH2), 2.31 
(sept, 3JH2,H3 = 7.0 Hz,1H, H2), 0.98 (d, 
3JH3,H2 = 7.0 Hz,1H, H3) ppm. 
 
 
mp = 124-127°C (Lit. 109 127-129°C) 
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11-Aminium chloride-undecanoic acid methyl ester (AUMe) (132)113 
 
 
 
11-Aminoundecanoic acid (1.85 g, 9.19 mmol, 1.0 eq.) was suspended in 9 mL anhydrous 
methanol. The mixture was cooled to 0°C and thionyl chloride (2.0 mL, 27.57 mmol, 3.0 eq.) 
was added dropwise. The resulting solution was then heated to reflux overnight and the 
methanol and thionyl chloride in excess were then removed under reduced pressure. 11-
aminium chloride-undecanoic acid methyl ester (132) was obtained as a yellowish white 
powder (2.26 g, 8.98 mmol, 98 % yield). 
 
1H-NMR (400 MHz, CDCl3): δ = 8.25 (brs, 3H, NH3
+), 3.65 (s, 3H, H12), 2.97 (brs, 2H, H11), 
2.29 (t, 3JH2,H3 = 7.5 Hz, 2H, H2), 1.76 (brs, 2H, H10), 1.60 (quint, 
3JH3,H2 = 
3JH3,H4 =7.3 Hz, 
2H, H3), 1.43-1.33 (m, 2H, H9), 1.33-1.22 (m, 10H, H4, H5, H6, H7, H8) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 174.3 (C1), 51.4 (C12), 40.0 (C11), 34.1 (C2), 29.3, 29.2, 
29.1, 28.9 (C4, C5, C6, C7, C8), 27.6 (C10), 26.5 (C9), 24.9 (C3) ppm. 
 
Methyl 11-(biotinamido)undecanoate (BtAUMe) (133)113-114 
 
Biotin (23) (150 mg, 0.61 mmol, 1.0 eq.) was dissolved in DMFabs at 70°C and the solution 
was cooled to room temperature. DIC (380 µL, 2.44 mmol, 4.0 eq.) and HOBT (118 mg, 84-
89 % as a hydrate, ≥0.73 mmol, 1.2 eq.) were added to the mixture and stirred 1h at room 
temperature. AUMe (132) (184 mg, 0.73 mmol, 1.2 eq.) was suspended in DMFabs and TEA 
(140 µL, 1.0 mmol, 1.6 eq.) stirred until the ester was dissolved. The solution was then 
transferred with a syringe into the flask containing biotin (23) and stirred at room temperature 
overnight. Water (10 mL) was added to the mixture, and the crude product was extracted 
with DCM (3 x 10 mL). The organic layer was washed with a 1M HCl solution, a saturated 
solution of NaHCO3 and brine. After drying with sodium sulfate, the mixture was filtrated and 
the solvent was removed under reduced pressure. The crude product was purified with silica 
gel column chromatography (DCM/MeOH, 95/5, Rf = 0.15) to afford 192 mg of methyl 11-
(biotinamido)-undecanoate (BtAUMe) (133) (0.44 mmol, 73 % yield) as a white powder. 
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1H-NMR (400 MHz, CDCl3): δ = 6.39 (brs, 1H, C18-NH), 6.00 (t, 
3JHN,H11 = 5.8 Hz, 1H, C11-
NH), 5.55 (brs, 1H, C19-NH), 4.50 (dd, 3JH19,H18 = 7.8 Hz, 
 3JH19,H20a = 5.0 Hz, 1H, H19), 4.32-
4.28 (m, 1H, H18), 3.65 (s, 3H, H22), 3.23-3.17 (m, 2H, H11), 3.14 (dt, 3JH17,H18 = 4.8, 
3JH17,H16 
=7.3 Hz, 1H, H17) 2.90 (dd, 2JH20a,H20b = 12.8 Hz, 
3JH20a,H19 = 5.0 Hz, 1H, H20a), 2.73 (d, 
2JH20b,H20a = 12.8 Hz, 1H, H20b), 2.29 (t, 
3JH2,H3 = 7.5 Hz, 2H, H2), 2.19 (t, 
3JH13,H14 = 7.5 Hz, 
2H, H13), 1.80-1.54 (m, 6H, H3, H14, H16), 1.51-1.38 (m, 4H, H15, H10), 1.33-1.22 (m, 12H, 
H4, H5, H6, H7, H8, H9) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 174.3 (C1), 173.1 (C12), 163.9 (C21), 61.2 (C18), 60.2 
(C19), 55.6 (C17), 51.4 (C22), 40.5 (C20), 39.5 (C11), 36.1 (C13), 34.1 (C2), 29.6, 29.4, 
29.31, 29.25, 29.2, 29.1, 28.2, 28.1, 26.9, 25.7, 24.9, (C3, C4, C5, C6, C7, C8, C9, C10, 
C14, C15, C16) ppm. 
 
11-Biotinamido-undecanoic acid (BtAU) (131)113 
 
BtAUMe (133) (190 mg, 0.43 mmol, 1.0 eq.) was suspended in a mixture of MeOH (4.3 mL), 
water (2.6 mL) and THF (1.5 mL), and lithium hydroxide hydrate (36 mg, 0.85 mmol, 2.0 eq.) 
was added in one portion. The mixture was then stirred overnight at 55°C. After removal of 
the majority of the solvents under vacuum, the mixture was acidified to pH 2.0 with 1M HCl. 
The precipitation was filtered off and washed with cold water and cold ether subsequently, 
before being dried under vacuum to give 11-biotinamido-undecanoic acid (131) (154 mg, 
0.36 mmol) with 84 % yield as a hardly soluble white solid. 
 
 
 
1H-NMR (400 MHz, CD3OD): δ = 4.47 (dd, 
3JH19,H18 = 7.8 Hz, 
 3JH19,H20a = 5.0 Hz, 1H, H19), 
4.28 (dd, 3JH18,H19 = 7.8 Hz,
 3JH18,H17 = 4.3 Hz, 1H, H18), 3.21-3.17 (m, 2H, H17), 3.14 (dt, 
3JH11,H10 = 7.3, 
3JH11,H9 = 2.0 Hz, 2H, H11), 2.91 (dd, 
2JH20a,H20b = 12.8 Hz, 
3JH20a,H19 = 5.0 Hz, 
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1H, H20a), 2.69 (d, 2JH20b,H20a = 12.8 Hz, 1H, H20b), 2.17 (q, 
3J = 7.0 Hz, 4H, H2, H13), 1.78-
1.52 (m, 6H, H3, H14, H16), 1.52-1.36 (m, 4H, H15, H10), 1.34-1.26 (m, 12H, H4, H5, H6, 
H7, H8, H9) ppm. 
 
13C-NMR (101 MHz, CD3OD): δ = 176.0 (C12), (C1 not seen), 166.2 (C21), 63.4 (C18), 61.7  
(C19), 57.1 (C17), 41.1 (C20), 40.5 (C11), 36.7 (C13), 30.8, 30.7, 30.6, 30.5, 29.8, 29.6, 
28.1, 27.5, 27.0 (C2, C3, C4, C5, C6, C7, C8, C9, C10, C14, C15, C16) ppm. 
 
4.7.2. Syntheses for the introduction of a polyamide linker 
 
tert-Butyl-4-aminobutylcarbamate (Boc-DAB) (142)115a 
 
1,4-Diamino-butane (DAB) (141) (11.2 g, 127 mmol, 10 eq.) was melted at 50°C (mp = 25-
28°C) on the hot plate, transferred to a flame dried flask with dropping funnel a under 
nitrogen atmosphere and dissolved in 170 mL anhydrous DCM. Boc anhydride (2.8 g, 13 
mmol, 1.0 eq.) was dissolved in DCM under nitrogen atmosphere and added to the dropping 
funnel. The DAB (141) solution was cooled down to 0°C and the anhydride wad added over 
1h, stirred 2h more at 0°C after completion of the addition, and overnight at room 
temperature. The reaction was quenched with water, washed with brine, the organic layer 
was separated washed with sodium sulfate and the solvents were evaporated. The N-Boc-
diaminobutane (Boc-DAB) (142) (1.9 g, 10 mmol) was obtained with 76 % yield as a viscous 
white oil. 
 
1H-NMR (400 MHz, CDCl3): δ =4.65 (brs, 1H, NH) 3.18-3.04 (m, 
2H, H4), 2.70 (t, 3JH4,H3 = 6.8 Hz, 2H, H1), 1.56-1.45 (m, 4H, H2, 
H3), 1.44 (s, 9H, H7), 1.21 (brs, 1H, NH2) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 156.0 (C5), 78.9 (C6), 41.7 (C3), 40.4 (C4), 30.8 (C2), 28.3 
(C7), 27.4 (C3) ppm. 
 
tert-Butyl-4-biotinamidobutylcarbamate (Boc-DAB-Bt) (143)115a 
 
In a flame dried equipment, biotin (23) (200 mg, 0.82 mmol, 1.0 eq.) was dissolved in 
anhydrous DMF (6.6 mL) at 70°C. After the reaction was cooled down to room temperature, 
molecular sieves (3Å), and hydroxybenzotriazole (26 mg, 84-89 % as hydrate, 0.16 mmol, 
0.2 eq.) were added and the mixture was stirred 5 minutes before DCC (0.9 mL of a 1.0 M 
solution in DCM, 0.90 mmol, 1.1 eq.) was slowly added. After stirring for 3h, Boc-DAB (142) 
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and a few crystals of DMAP were dissolved in 2 mL DCMabs/DMFabs (1/1) and added to the 
biotin (23) mixture. The reaction mixture was then stirred 4h at 60°C and overnight at room 
temperature. Molecular sieves were separated by filtration and washed with a DCM/MeOH, 
1/1 solution before the solvents were removed under reduced pressure (10 mbar/50°C). The 
residue was then submitted to flash chromatography on silica gel (DCM/MeOH, 90/10 to 
85/15, Rf = 0.19 (DCM/MeOH, 9/1)) to give the biotinamidobutyl-carbamate (Boc-DAB-Bt) 
143 (244 mg, 0.59 mmol) with 72 % yield as a white solid (mp = 176-181°C, Lit.115a 178-
180°C). [𝛼]𝐷
24 = 0.0 (MeOH, c = 1.0) 
 
 
1H-NMR (400 MHz, CD3OD): δ = 4.49 (dd, 
3JH3,H4 = 7.8 Hz, 
 3JH3,H2a = 5.0 Hz, 1H, H3), 4.31 
(dd, 3JH4,H3 = 7.8 Hz, 
 3JH4,H5 = 4.5 Hz, 1H, H4), 3.24-3.15 (m, 3H, H5, H11), 3.07-3.02 (m, 2H, 
H14), 2.93 (dd, 2JH2a,H2b = 12.8 Hz, 
3JH2a,H3 = 5.0 Hz, 1H, H2a), 2.71 (d, 
2JH2b,H2a = 12.8 Hz, 
1H, H2b), 2.22 (t, 3JH9,H8 = 7.4 Hz, 2H, H9), 1.79-1.55 (m, 4H, H6, H8), 1.54-1.47 (m, 4H, 
H12, H13), 1.46-1.39 (m, 11H, H7, H17) ppm. 
 
13C-NMR (101 MHz, CD3OD): δ = 176.0 (C10), 166.1 (C1), 158.6 (C15), 79.9 (C16) 63.4 
(C4), 61.7 (C3), 57.0 (C5), 41.1 (C14), 41.0 (C2), 40.1 (C11), 36.9 (C9), 29.8 (C7), 29.5 (C6), 
28.8 (C17), 28.4, 27.8 (C12, C13), 26.9 (C8) ppm. 
 
HRMS (ESI+) calcd. for C19H35N4O4S
+ [M+H]+: 415.2379; found 415.2379 
 
4-Biotinamido-butan-1-aminium trifluoroacetate (BtABA) (144)115d 
 
Boc-DAB-Bt (143) (465 mg, 1.12 mmol) was suspended in DCM, 2 mL TFA were added and 
the mixture was stirred at room temperature for 2h before the solvent were removed under 
vacuum. The product was dried in an exsiccator filled with KOH pellets to remove the excess 
trifluoroacetic acid. BtABA (144) (489 mg, 96 % purity based on 19F-NMR, 1.09 mmol) was 
obtained as its trifluoroacetate salt (white solid) in slightly over-quantitative yield, because 
TFA could not be removed completely, but it did not matter for the following reaction.  
Rf = 0.21 (DCM/MeOH, 4/1), mp = 83-102°C, [𝛼]𝐷
24 = + 4.0 (MeOH, c = 1.0) 
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1H-NMR (400 MHz, CD3OD): δ = 4.50 (dd, 
3JH3,H4 = 8.0 Hz, 
 3JH3,H2a = 5.0 Hz, 1H, H3), 4.31 
(dd, 3JH4,H3 = 8.0 Hz, 
 3JH4,H5 = 4.5 Hz, 1H, H4), 3.24-3.18 (m, 3H, H5, H11), 2.98-2.92 (m, 2H, 
H14), 2.93 (dd, 2JH2a,H2b = 12.8 Hz, 
3JH2a,H3 = 5.0 Hz, 1H, H2a), 2.71 (d, 
2JH2b,H2a = 12.8 Hz, 
1H, H2b), 2.21 (t, 3JH9,H8 = 7.4 Hz, 2H, H9), 1.79-1.54 (m, 8H, H6, H8, H12, H13), 1.46-1.39 
(m, 2H, H7) ppm. 
 
13C-NMR (101 MHz, CD3OD): δ = 176.3 (C10), 166.2 (C1), 162.1 (CF3C(O)O
-), 63.5 (C4), 
61.7 (C3), 57.1 (C5), 41.1 (C14), 40.4 (C2), 39.5 (C11), 36.8 (C9), 29.8 (C7), 29.5 (C6), 27.5, 
26.9 (C12, C13), 25.9 (C8) ppm. 
 
19F-NMR (377 MHz, CD3OD): δ = -76.83 (s, 1.00F, trifluoroacetic acid), -77.20 (s, 28.34F, 
trifluoroacetate) ppm. 
 
HRMS (ESI+) calcd. for C14H27N4O2S
+ [M+H]+: 315.1854; found 315.1845. 
 
Adipoyl chloride monoethylester (138)116-117 
 
Adipic acid (137) (5.0 g, 34.2 mmol) was suspended in thionyl chloride (7.0 mL, 96.5 mmol) 
in absence of moisture and was heated at 90°C overnight under nitrogen atmosphere. The 
excess thionyl chloride was removed under vacuum to afford 6.23 g of crude adipoyl chloride 
that was used without further purification. 
 
In a flame-dried round-bottom flask containing molecular sieves (3Å) and fitted with a 
dropping funnel, was dissolved the acyl chloride (6.23 g, ≈ 34.2 mmol) in anhydrous THF (60 
mL). 59 mL of an equimolar 0.58M solution of ethanol (2.00 mL, 34.2 mmol) and 
triethylamine (4.80 mL, 34.2 mmol) were then added dropwise over 2h and the mixture was 
stirred 1.5h more after the end of the addition. The ammonium chloride salt that had formed 
during the reaction was filtrated through a hot funnel and the solvents were evaporated under 
reduced pressure. 6.3 g of crude product was obtained containing 2.9 g of the monoester 
(138) (15.0 mmol, determined on NMR) representing 44 % yield. The rest of the mixture 
includes unreacted dichloride, the diester and diethyl sulfite. 
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1H-NMR (400 MHz, CDCl3): δ = 4.19 (q, 
3J = 7.3 Hz, 0.5 H, 
CH2CH3, SO(OEt)2), 4.13, 4.12 (2 x q, 
3J = 7.0 Hz, 2H, H7, mono- 
and diester), 2.97-2.98 (m, 2H, H2, monoester and dichloride), 
2.35-2.26 (m, 2.8 H, H5, monoester, diester, dichloride), 1.80-1.63 
(m, 4H, H3, H4, monoester, diester, dichloride), 1.28 (t, 3J = 7.0 Hz, CH2CH3, SO(OEt)2), 
1.254, 1.248 (2 x t, 3J = 7.0 Hz, 3H, H8, mono- and diester) ppm. 
 
13C-NMR (101 MHz, CD3OD): δ = 173.5, 173.4, 173.3, 172.9 (C1, C6, monoester, diester, 
dichloride), 61.4, 60.5, 60.3 (C7, monoester, diester, diethylsulfite), 46.7, 46.4 (C2, 
monoester, dichloride), 33.9, 33.6 (C5, monoester, diester), 24.5, 24.4 (C3, C4, mono- and 
diester), 23.8, 23.7 (C3, C4, monoester, dichloride), 14.20, 14.15 (C8, monoester, diester, 
diethylsulfite) ppm. 
 
Phloroglucinol adipic acid ethyl ester (139)107b 
 
According to the general procedure GP 1, to phloroglucinol (28) (2.9 g, 23 mmol, 1.5 eq.) and 
aluminium trichloride (8.4 g, 63 mmol, 2.7 eq.) dissolved in anhydrous dichloromethane (21 
mL) and nitromethane (7 mL), was added the acyl chloride 138 (2.9 g, 15 mmol, 1.0 eq.). 
After purification by flash chromatography on silica gel (A/PE, 1/2, Rf = 0.25) phloroglucinol 
adipic acid ethyl ester (139) (2.65 g, 9.4 mmol) was obtained with 63 % yield as a light yellow 
solid (mp = 136-139°C). 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 11.63 (brs, 2H, C6-
OH, C2-OH), 9.51 (brs, 1H, C4-OH), 5.92 (s, 2H, H3, 
H5), 4.07 (q, 3JH13,H14 = 7.0 Hz, 2H, H13), 3.11-3.05 (m, 
2H, H8), 2.35-2.29 (m, 2H, H11), 1.74-1.63 (m, 4H, H9, 
H10), 1.20 (t, 3JH14,H13 = 7.0 Hz, 3H, H14) ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 207.1 (C7), 174.5 (C12), 166.4 (C2, C6), 166.2 (C4), 
106.1 (C1), 96.8 (C3, C5), 61.4 (C13), 45.0 (C8), 35.6 (C11), 26.5, 25.9 (C9, C10), 15.5 
(C14) ppm. 
 
HRMS (ESI+) calcd. for C14H19O6
+ [M+H]+: 283.1182; found 283.1169. 
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6-oxo-6-phloroglucinol-hexanoic acid (140)118 
 
The ethyl ester 139 (2.6 g, 9.2 mmol) was dissolved in a MeOH (14 mL)/THF (14 mL) mixture 
and 21 mL of NaOH 2M were added. The yellow solution turned dark green. After stirring for 
2h at room temperature, the volatile components were evaporated under vacuum. The 
aqueous phase was acidified with 2 M HCl and the crude product was extracted with ethyl 
acetate (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtrated 
and evaporated. The residue was purified on silica gel column chromatography (A/PE, 1/1, + 
1% AcOH, Rf = 0.45) to afford 2.1 g of the free acid (140) (8.2 mmol, 89 % yield) as a pale 
yellow powder (mp = 188-194°C). 
 
1H-NMR (400 MHz, CO(CD3)2): δ = 10.73 (brs, 4H, C6-OH, 
C2-OH, C4-OH, C(O)OH), 5.93 (s, 2H, H3, H5), 3.13-3.07 (m, 
2H, H8), 2.36-2.32 (m, 2H, H11), 1.75-1.64 (m, 4H, H9, H10), 
ppm. 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 207.1 (C7), 175.9, 175.8 (C12), 166.4 (C2, C6), 166.1 
(C4), 106.1 (C1), 96.8 (C3, C5), 61.4 (C13), 45.0 (C8), 35.1, 34.9 (C11), 26.5, 26.1, 26.0 
(C9, C10), 15.5 (C14) ppm. 
 
HRMS (ESI+) calcd. for C12H15O6
+ [M+H]+: 255.0869; found 255.0862. 
 
5-myrtucommulone-pentanoic acid (MCPA) (135)35a 
 
In a flame-dried round-bottom flask, the phloroglucinol 140 (254 mg, 1.00 mmol, 1.0 eq.) was 
dissolved in anhydrous THF (5 mL) under nitrogen atmosphere. Sodium hydride (132 mg, 60 
% dispersion in mineral oil, 3.30 mmol, 3.3 eq.) was added in one portion and the mixture 
was stirred for 10 min before IBSA (31) (1.31 g, 5.5 mmol), prepared according to the 
general method GP 3 and dissolved in 5 mL anhydrous THF, was added as well. After 
stirring for 1h at room temperature, almost no reaction was observed. 132 mg of NaH (3.3 
mmol, 3.3 eq.) were added and the completion of the reaction could be confirmed by TLC 
after 1h. A 1M HCl solution, saturated with ammonium chloride, was then added and the 
crude product was extracted with ethyl acetate (3 x 50 mL). After drying the combined 
organic layers with Na2SO4, the mixture was filtrated and evaporated under vacuum. The 
residue was purified by silica gel column chromatography (A/PE, 1/1, Rf = 0.40) to afford 489 
mg of 5-myrtucommulone-pentanoic acid (135) (0.67 mmol, 67 % yield) as a pale yellow 
powder (mp = 146°C, decomposition). 
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1H-NMR (400 MHz, CO(CD3)2): δ = 15.85 (s, 0.5H), 
15.47 (s, 0,5H), 12.95 (brs, 1H), 4.40 (brs, 0.4H), 4.25-
4.14 (m, 1.32H, H1', H1''), 4.02 (brs, 0.23H), 3.25-2.97 
(m, 4H, H8, H8', H8''), 2.38-2.28 (m, 2H, H11), 1.75-
1.65 (m, 4H, H9, H10), 1.40-1.17 (m, 24H, H11', H12', 
H13', H14', H11'', H12'', H13'', H14''), 0.89-0.55 (m, 12 
H, H9', H10', H9'', H10'') ppm. 
 
 
13C-NMR (101 MHz, CO(CD3)2): δ = 216.1, 216.0 (C5', C5''), 200.4, 200.1 (C7', C7''), 195.2 
(C7), 181.6, 181.5 (C3', C3''), 175.9, 175.8 (C12), 162.8 (C2, C6), 160.5 (C4), 115.9, 115.4 
(C1), 112.33, 112.25 (C3, C5), 106.4, 104.0 (C2', C2''), 55.5, 55.4 (C6', C6''), 51.21, 51.18 
(C4', C4''), 45.2 (C8), 41.32, 41.30 (C1', C1''), 35.4 (C11), 28.3, 28.1 (C8', C8''), 26.9, 26.8, 
26.7, 26.4, 26.3, 26.1, 26.0 (C9, C10, C11', C12', C13', C14', C11'', C12'', C13'', C14''), 23.9, 
23.6, 23.3, 23.1 (C9', C10', C9'', C10'') ppm 
 
HRMS (ESI+) calcd. for C40H51O10
+ [M+H]+: 727.3694, found: 727.3695. 
 
N-(4-biotinamidobutyl)-5-myrtucommulone-pentanamide (biotin-linked-MC) (134)113-114 
 
MCPA (135) (155 mg, 0.21 mmol, 1.0 eq.) was dissolved in DMFabs (1.5 mL). Molecular 
sieves (3Å), and hydroxybenzotriazole (41 mg, 84-89 % as a hydrate, ≥0.26 mmol, 1.2 eq.) 
were added and the mixture was stirred 5 minutes before DIC (160 µL, 1.02 mmol, 4.9 eq.) 
was added and the reaction mixture was stirred for another hour at room temperature. In 
another round-bottom flask, BtABA (144) (110 mg, 0.25 mmol, 1.2 eq.) was suspended in 
DMFabs/DCMabs (1/2, 3.0 mL) and TEA (53 µL, 0.39 mmol, 1.9 eq.) was added and the 
mixture stirred for 10 min. The solution containing MCPA (135) was then transferred with a 
syringe into the flask containing BtABA (144) and stirred at room temperature overnight. 
Water (10 mL) was added to the mixture, and the crude product was extracted with DCM (10 
mL) and ethyl acetate (2 x 10 mL). The combined organic layers were treated with a 1M HCl 
solution, saturated with NH4Cl, and brine. After drying with sodium sulfate, the mixture was 
filtrated and the solvents were removed under reduced pressure. The crude product was 
purified with silica gel column chromatography (DCM/MeOH, 90/10 to 80/20, Rf = 0.20 
(DCM/MeOH, 85/15)) to afford 141 mg of biotin-linked-MC (134) (0.14 mmol, 65 % yield) as 
a pale yellow powder (mp = 110°C, decomposition). [𝛼]𝐷
24 = + 20.0 (MeOH, c = 1.1). 
 
Experimental  - 163 - 
 
 
1H-NMR (400 MHz, CD3OD): δ = 4.50 (dd, 
3JH24,H23 = 8.0 Hz and 
 3JH24,H25a = 5.0 Hz, 1H, 
H24), 4.31 (dd, 3JH23,H24 = 8.0 Hz and 
 3JH23,H22 = 4.5 Hz, 1H, H23), 4.26-4.00 (m, 1.7H, H1', 
H1''), 3.24-3.11 (m, 6H, H8, H13, H16, H22), 3.11-2.96 (m, 2H, H8', H8''), 2.92 (dd, 2JH25a,H25b 
= 12.8 Hz and 3JH25a,H23 = 4.8 Hz, 1H, H25a), 2.70 (d, 
2JH25b,H25a = 12.8 Hz, 1H, H25b), 2.31-
2.16 (m, 2H, H11), 2.21 (t, 3JH18,H19 = 7.4 Hz, 2H, H18), 1.80-1.58 (m, 8H, H14, H15, H19, 
H21),1.57-1.48 (H9, H10), 1.46-1.40 (m, 2H, H20), 1.40-1.11 (m, 24H, H11', H12', H13', 
H14', H11'', H12'', H13'', H14''), 0.96-0.62 (m, 12H, H9', H10', H9'', H10'') ppm. 
 
13C-NMR (101 MHz, CD3OD): δ =219.1, 216.1, 215.7, 214.8, 214. 5, 202.9 (C5', C5'', C7), 
199.9, 199.5 (C7', C7''), 188.3 (C3', C3''), 176.2, 176.0, 171.3, 171.1 (C12, C17), 169,4 (C3', 
C3''), 166.0 (C26), 160.5 (C2, C6), 157.3 (C4), 112.8, 112.7 (C3, C5), 102.4 (C2', C2''), 63.4 
(C23), 61.7 (C24), 57.1, 57.0 (C22), 55.0 (C6', C6''), 53.2, 53.0 (C4', C4''), 44.9 (C8), 41.1 
(C25), 41.0, 40.9 (C1', C1''), 39.9 (C13, C16), 37.2, 36.9 (C11, C18), 32.7, 32.4 (C1', C1''),  
29.8, 29.5 (C19, C20, C21), 27.93, 27.90, 27.8 (C9, C10, C8', C8''), 27.0, 26.9, 26.7, 26.4, 
25.9, 25.8, 25.7, 24.9, 24.5, 23.7 (C11', C12', C13', C14', C11'', C12'', C13'', C14''), 22.7, 
22.5, 22.3 (C9', C10', C9'', C10'') ppm. 
 
HRMS (ESI+) calcd. for C54H79N4O13S
+ [M+H]+: 1023.5364, found: 1023.5351. 
 
5-pentacyclic-myrtucommulone-pentanoic acid (PMCPA) (136)35a 
 
The pentacyclic derivative 136 was synthesised according to the general procedure GP 9 
starting from 5-myrtucommulone-pentanoic acid (135) (146 mg, 0.20 mmol, 1.0 eq.) and 
using pTsOH (267 mg, 1.41 mmol, 7.0 eq.) as a reagent. After purification over column 
chromatography on silica gel (Ac/PE, 1/2, Rf = 0.14), 107 mg of PMCPA (136) (0.16 mmol, 78 
% yield) were synthesised as a white solid (mp = 140°C, decomposition). 
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1H-NMR (400 MHz, CDCl3): δ = 7.84 (s, 1 H), 4.61, (d, 
3JH1’,H8’ = 
3JH1’’,H8’’ = 3.8 Hz, 1H, H1’, H1’’, meso), 4.57 (d, 
3JH1’,H8’ = 
3JH1’’,H8’’ = 3.8 Hz, 1H, H1’, H1’’, rac), 3.03-2.79 
(m, 2H, H8), 2.42 (q, 3JH11,H10 = 6.8 Hz, 2H, H11),  2.02-
1.89 (m, 2H, H8’, H8’’), 1.87-1.71 (m, 4H, H9, H10), 1.56 
(s, 3H, H12’, H11’’, rac), 1.53 (s, 3H, H12’, H12’’, meso), 
1.46 (s, 3H, H13’, H14’’, rac), 1.44 (s, 3H, H13’, H13’’, 
meso), 1.43-1.38 (s, 9H, meso: H11’, H11’’, rac: H11', 
H12'', H13'', H14'), 1.36 (s, 3H, H14’, H 14’’, meso), 
0.87-0.84 (m, 3H,) and  0.81-0.75 (m, 9H) (H9’, H9’’, 
H10’, H10’’) ppm. 
 
13C-NMR (101 MHz, CDCl3): δ = 211.7 (C5', C5''), 200.7, 199.8 (C7), 198.8 (C7', C7''), 
178.51, 178.49 (C12), 169.2, 168.9 (C3', C3''), 152.7, 152.3 (C4), 147.7, 147.6 (C2, C6), 
111.4, 111.0 (C3, C5), 110.7, 110.6 (C1), 108.9, 108.7 (C2', C2''), 55.93, 55.91 (C6', C6''), 
47.54, 47.49 (C4', C4''), 45.3, 45.2 (C8), 35.1, 35.0 (C8', C8'') 33.7 (C11), 32.4, 32.3 (C1', 
C1''), 25.3 (C12’, C11’’, rac), 25.0 (C13’, C14’’, rac), 24.9 (C12’, C12’’, meso), 24.8, 24.70, 
24.67, 24.4, 24.1 (meso: C11', C11'', C13', C13'', C14', C14'', rac: C11', C12'', C13'', C14'), 
24.36, 24.2, 23.6, 23.5 (C9, C10), 19.3, 19.1, 18.9, 18.5 (C9', C10', C9'', C10'') ppm. 
 
HRMS (ESI+) calcd. for C40H55O12
+ [M+H]+: 691.3482, found: 691,3487. 
 
N-(4-biotinamidobutyl)-5-myrtucommulone-pentanamide (biotin-linked-PMC) (145) 
 
Following the same procedure as the one used for the synthesis of biotin-linked-MC (134), 
70 mg of PMCPA (136) (0.101 mmol, 1.0 eq.) was mixed with molecular sieves, HOBT (20 
mg, 0.12 mmol, 1.2 eq.) and DIC (65 µL, 0.40 mmol, 4.0 eq.), and then added to BtABA 
(144) (80 mg, 0.18 mmol, 1.8 eq.) and TEA (50 µL, 0.39 mmol, 4.0 eq.) in a DCMabs/DMFabs 
mixture. The reaction was stirred overnight at room temperature. Subsequent purification 
through column chromatography on silica gel (DCM/MeOH, 9/1, Rf = 0.24) provided the 
biotin-linked-PMC (145) (86 mg, 0.087 mmol) as a yellowish white powder (mp = 153-160°C, 
decomposition) with 86 % yield. [𝛼]𝐷
24 = +15.0 (MeOH, c = 1.0) 
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1H-NMR (400 MHz, CD3OD): δ = 4.49 (dd, 
3JH24,H23 = 7.8 Hz and 
 3JH24,H25a = 5.0 Hz, 1H, 
H24), 4.44, (d, 3JH1’,H8’ = 
3JH1’’,H8’’ = 4.0 Hz, 1H, H1’, H1’’, meso), 4.40 (d, 
3JH1’,H8’ = 
3JH1’’,H8’’ = 
3.8 Hz, 1H, H1’, H1’’, rac), 4.30 (dd, 3JH23,H24 = 7.5 Hz and 
 3JH23,H22 = 4.5 Hz, 1H, H23), 3.24-
3.14 (m, 5H, H13, H16, H22), 3.00-2.88 (m, 2H, H8), 2.92 (dd, 2JH25a,H25b = 12.5 Hz and 
3JH25a,H24 = 5.0 Hz, 1H, H25a), 2.70 (d, 
2JH25b,H25a = 12.5 Hz, 1H, H25b), 2.26-2.17 (m, 4H, 
H11, H18), 1.98-1.87 (m, 2H, H8’, H8’’), 1.80-1.58 (m, 8H, H9, H10, H19, H21), 1.56-1.49 (s, 
10H, H14, H15, rac: H12’, H11’’, meso: H12’, H12’’), 1.47-1.41 (m, 2H, H20), 1.41-1.37 (m, 
12H, meso: H11’, H11’’, H13’, H13'' rac: H11’, H12'', H13', H14’’), 1.34 (s, 3H, rac: H13'', 
H14’), 1.32 (s, 3H meso: H14’, H 14’’), 0.88-0.73 (m, 12H) (H9’, H9’’, H10’, H10’’) ppm. 
 
13C-NMR (101 MHz, CD3OD): δ = 213.1, 210.1 (C5', C5''), 203.0, 202.6 (C7), 199.40, 199.36 
(C7', C7''), 176.0, 175.58, 175.56 (C12, C17), 169.8 (C3', C3''), 166.1 (C26), 154.7, 154.4 
(C4), 149.03, 148.98 (C2, C6), 112.6, 112.3 (C3, C5), 111.72, 111.65 (C1), 111.1, 110.6 
(C2', C2''), 63.4 (C23), 61.7 (C24), 57.14, 57.09 (C6', C6''), 57.0 (C22), 48,7 (C4', C4''), 46.6, 
46.5 (C8), 41.1 (C25), 40.04, 40.02 (C13, C16), 37.00, 36.95, 36.7 (C11, C18), 36.3, 36.2 
(C8', C8''), 33.7, 33.6 (C1', C1''), 29.8 (C20), 29.5 (C19, C21), 27.8 (C14, C15), 26.93, 26.90, 
26.8 (C9, C10), 25.8, 25.64, 25.58, 25.2 (rac: C11', C12'', C11'', C12', C13', C14'', meso: 
C11’, C11’’, C12’, C12’’, C13’, C13''), 25.0, 24.9 (C9, C10), 24.6 (rac: C13'', C14’, meso: 
C14’, C14’’), 20.0, 19.7, 19.3, 18.8 (C9', C10', C9'', C10'') ppm. 
 
HRMS (ESI-) calcd. for C54H73N4O11S
- [M-H]-: 985.4997, found: 985.4959. 
 
 
References  - 166 - 
5. References 
[1] F. Figari-Pompa, P. P. Grimaldi, Fiori è fiure, plantes sauvages de Corse, Colonna 
Edition, 2011. 
[2] Pepinières de Kerzarc'h, http://www.pepinieresdekerzarch.fr/e-
catalogue/Myrtacees./MYRTUS-communis/Myrte-commune-herbe-du-Lagui-Nerte-
Nerto-en-proven%C3%A7al/ref392700, 25/02/15, 17:12 
[3] a), Panier Corse, http://www.paniercorse.com/produit/liqueur-de-myrte-rouge-24---
mavela-986, 29/01/2015, 13:04; b) Panier Corse, 
http://www.paniercorse.com/produit/gelee-de-myrte-1402, 29/01/2015, 13:09 
[4] G. Alipour, S. Dashti, H. Hosseinzadeh, Phytother. Res. PTR 2014, 28, 1125-1136. 
[5] E. Littré, Oeuvres complètes d'Hippocrate II: traduction nouvelle avec le texte grec en 
regard, Vol. 2, 1840. 
[6] M. S. Elfellah, M. H. Akhter, M. T. Khan, J. Ethnopharmacol. 1984, 11, 275-281. 
[7] G. H. Bonjar, Fitoterapia 2004, 75, 231-235. 
[8] M. Akin, A. Aktumsek, A. Nostro, Afr. J. Biotechnol. 2010, 9, 531-535. 
[9] N. Venturini, PhD thesis, Université de Corse-Pascal Paoli 2012. 
[10] a) T. Özek, B. Demirci, K. H. C. Baser, J. Essent. Oil Res. 2000, 12, 541-544; b) P. 
Bradesi, F. Tomi, J. Casanova, J. Essent. Oil Res. 1997, 9, 283-288. 
[11] a) Y. Kashman, A. Rotstein, A. Lifshitz, Tetrahedron 1974, 30, 991-997; b) A. 
Rotstein, A. Lifshitz, Y. Kashman, Antimicrob. Agents Ch. 1974, 6, 539-542. 
[12] M. Lounasmaa, H. S. Puri, C. J. Widen, Phytochemistry 1977, 16, 1851-1852. 
[13] C. Puybaret, B. David, M. Charveron, S. Mamatas, Pierre Fabre Dermo-Cosmétique, 
1998, France, FR2783425A1,  
[14] G. Appendino, F. Bianchi, A. Minassi, O. Sterner, M. Ballero, S. Gibbons, J. Nat. 
Prod. 2002, 65, 334-338. 
[15] F. Shaheen, M. Ahmad, S. Nahar Khan, S. Samreen Hussain, S. Anjum, B. 
Tashkhodjaev, K. Turgunov, M. N. Sultankhodzhaev, M. I. Choudhary, R. Atta ur, Eur. 
J. Org. Chem. 2006, 2006, 2371-2377. 
[16] A. R. Carroll, J. Lamb, R. Moni, G. P. Guymer, P. I. Forster, R. J. Quinn, J. Nat. Prod. 
2008, 71, 1564-1568. 
[17] F. Cottiglia, L. Casu, M. Leonti, P. Caboni, C. Floris, B. Busonera, P. Farci, A. Ouhtit, 
G. Sanna, J. Nat. Prod. 2012, 75, 225-229. 
[18] M. I. Choudhary, N. Khan, M. Ahmad, S. Yousuf, H. K. Fun, S. Soomro, M. Asif, M. A. 
Mesaik, F. Shaheen, Org. Lett. 2013, 15, 1862-1865. 
[19] R. Nicoletti, P. Ferranti, S. Caira, G. Misso, M. Castellano, G. Di Lorenzo, M. 
Caraglia, World J. Microb. Biot. 2014, 30, 1047-1052. 
[20] S. J. Bloor, J. Nat. Prod. 1992, 55, 43-47. 
[21] A. Hiranrat, W. Mahabusarakam, Tetrahedron 2008, 64, 11193-11197. 
[22] G. Appendino, L. Maxia, P. Bettoni, M. Locatelli, C. Valdivia, M. Ballero, M. Stavri, S. 
Gibbons, O. Sterner, J. Nat. Prod. 2006, 69, 251-254. 
[23] A. R. Carroll, S. Urban, J. Lamb, R. Moni, G. P. Guymer, P. I. Forster, R. J. Quinn, J. 
Nat. Prod. 2008, 71, 881-883. 
[24] C. Fiorini-Puybaret, J. Luc, Pierre Fabre Dermo-Cosmétique, 2012, FRANCE, 
FR2992862A1 
[25] a) C. Feisst, L. Franke, G. Appendino, O. Werz, J. Pharmacol. Exp. Ther. 2005, 315, 
389-396; b) A. Rossi, R. Di Paola, E. Mazzon, T. Genovese, R. Caminiti, P. Bramanti, 
C. Pergola, A. Koeberle, O. Werz, L. Sautebin, S. Cuzzocrea, J. Pharmacol. Exp. 
Ther. 2009, 329, 76-86. 
[26] a) A. Koeberle, F. Pollastro, H. Northoff, O. Werz, Brit. J. Pharmacol. 2009, 156, 952-
961; b) O. Werz, A. Koeberle, 2006, Germany, DE102006058450A1,  
[27] a) A. M. Dessì, M. Deiana, V. Casu, G. Corona, G. Appendino, F. Bianchi, M. Ballero, 
A. Rosa, Free Radical Res. 2003, 37, 1013-1019; b) A. Rosa, M. P. Melis, M. Deiana, 
References  - 167 - 
A. Atzeri, G. Appendino, G. Corona, A. Incani, D. Loru, M. A. Dessi, Chem. Phys. 
Lipids 2008, 155, 16-23. 
[28] a) I. Tretiakova, D. Blaesius, L. Maxia, S. Wesselborg, K. Schulze-Osthoff, J. Cinatl, 
Jr., M. Michaelis, O. Werz, Apoptosis 2008, 13, 119-131; b) O. Werz, I. Tretiakova, 
2006, GERMANY, DE102006021154A1 
[29] B. Iskender, K. Izgi, J. Jauch, S. Sezen, M. Cakir, A. Turan, H. Aksu, M. Charpentier, 
C. Sakalar, BMC Cancer, submitted, 2015. 
[30] a) L. Burdine, T. Kodadek, Chem. Biol. 2004, 11, 593-597; b) C. Hart, Drug Discov. 
Today 2005, 10, 513-519; c) M. Kawatani, H. Osada, MedChemComm 2014, 5, 277-
287. 
[31] S. Sakamoto, M. Hatakeyama, T. Ito, H. Handa, Bioorg. Med. Chem. 2012, 20, 1990-
2001. 
[32] a) T. Shiyama, M. Furuya, A. Yamazaki, T. Terada, A. Tanaka, Bioorg. Med. Chem. 
2004, 12, 2831-2841; b) T. Tamura, T. Terada, A. Tanaka, Bioconjugate Chem. 2003, 
14, 1222-1230; c) H. Fretz, M. W. Albers, A. Galat, R. F. Standaert, W. S. Lane, S. J. 
Burakoff, B. E. Bierer, S. L. Schreiber, J. Am. Chem. Soc. 1991, 113, 1409-1411; d) 
N. Shimizu, K. Sugimoto, J. Tang, T. Nishi, I. Sato, M. Hiramoto, S. Aizawa, M. 
Hatakeyama, R. Ohba, H. Hatori, T. Yoshikawa, F. Suzuki, A. Oomori, H. Tanaka, H. 
Kawaguchi, H. Watanabe, H. Handa, Nature 2000, 18, 877-881. 
[33] a) Y. Nagumo, H. Kakeya, M. Shoji, Y. Hayashi, N. Dohmae, H. Osada, Biochem. J. 
2005, 387, 835-840; b) T. Usui, H. Watanabe, H. Nakayama, Y. Tada, N. Kanoh, M. 
Kondoh, T. Asao, K. Takio, H. Watanabe, K. Nishikawa, T. Kitahara, H. Osada, 
Chem. Biol. 2004, 11, 799-806; c) S. W. Ki, K. Ishigami, T. Kitahara, K. Kasahara, M. 
Yoshida, S. Horinouchi, J. Biol. Chem. 2000, 275, 39231-39236. 
[34] H. Müller, PhD thesis, Universität des Saarlandes (Saarbrücken, DE), 2012. 
[35] a) H. Muller, M. Paul, D. Hartmann, V. Huch, D. Blaesius, A. Koeberle, O. Werz, J. 
Jauch, Angew. Chem. Int. Ed. Engl. 2010, 49, 2045-2049; b) J. Jauch, 2010, 
GERMANY, WO2010/022953 A2  
[36] J. Jauch, H. Müller, O. Werz, K. Wiechmann, 2014, EP2695874A1 
[37] E. M. O. Yeboah, S. O. Yeboah, G. S. Singh, Tetrahedron 2011, 67, 1725-1762. 
[38] M. Charpentier, Diploma thesis, University of Saarland (Saarbrücken, DE), 2011. 
[39] M. Hans, PhD thesis, Universität des Saarlandes (work in progress) 
[40] M. Hans, M. Charpentier, V. Huch, D. Quandt, T. Bruhn, G. Bringmann, J. Jauch, 
submitted 2015. 
[41] a) N. Harada, Chirality 2008, 20, 691-723; b) H. D. Flack, G. Bernardinelli, Chirality 
2008, 20, 681-690; c) H. D. Flack, Acta. Cryst. 1983, A39, 876-881; d) J. M. Bijvoet, 
A. F. Peerdeman, A. J. van Bommel, Nature 1951, 168, 271-272. 
[42] W. H. Bragg, W. L. Bragg, Proceedings of the Royal Society of London. Series A 
1913, 88, 428-438. 
[43] G. Friedel, Comptes Rendus Acad. Sci. Paris 1913, 157, 1533-1536. 
[44] V. Cechinel-Filho, Z. Vaz, L. Zunino, J. Calixto, R. Yunes, Eur. J. Med. Chem. 1996, 
31, 833-839. 
[45] I. M. Romaine, J. E. Hempel, G. Shanmugam, H. Hori, Y. Igarashi, P. L. Polavarapu, 
G. A. Sulikowski, Org. Lett. 2011, 13, 4538-4541. 
[46] K. Harsanyi, C. Szantay Jr, Heterocycl. Commun. 2002, 8, 255-258. 
[47] a) W.-T. Flowers, D. R. Taylor, A. E. Tipping, C. N. Wright, J. Chem. Soc. 1971, 
1986-1991; b) M. Pal, V. R. Batchu, K. Parasuraman, K. R. Yeleswarapu, J. Org. 
Chem. 2003, 68, 6806-6809; c) C. Winter, T. Knisley, P. K. Karunarathne, 2010,  
[48] S. Cui, S. D. Walker, J. C. S. Woo, C. J. Borths, H. Mukherjee, M. J. Chen, M. M. 
Faul, J. Am. Chem. Soc. 2010, 132, 436-437. 
[49] a) B. L. Feringa, Acc. Chem. Res. 2000, 33, 346-353; b) T. Uchida, T. Katsuki, 
Tetrahedron Letters 2009, 50, 4741-4743; c) N. Krause, A. Hoffmann-Röder, 
Synthesis 2010, 2, 171-196. 
[50] S. B. Bharate, K. K. Bhutani, S. I. Khan, B. L. Tekwani, M. R. Jacob, I. A. Khan, P. S. 
Singh, Bioorg. Med. Chem. 2006, 14, 1750-1760. 
References  - 168 - 
[51] Y. M. A. Yamada, N. Yoshikawa, H. Sasai, M. Shibasaki, Angew. Chem. Int. Ed. Engl. 
1997, 36, 1871-1873. 
[52] H. Sasai, T. Suzuki, N. Itoh, K. Tanaka, T. Date, K. Okamura, M. Shibasaki, J. Am. 
Chem. Soc. 1993, 115, 10372-10373. 
[53] a) H. Sasai, T. Arai, M. Shibasaki, J. Am. Chem. Soc. 1994, 116, 1571-1572; b) T. 
Arai, H. Sasai, K. Aoe, K. Okamura, T. Date, M. Shibasaki, Angew. Chem. Int. Ed. 
Engl. 1996, 35, 104-106; c) Y. S. Kim, S. Matsunaga, J. Das, A. Sekine, T. Ohshima, 
M. Shibasaki, J. Am. Chem. Soc. 2000, 122, 6506-6507; d) Y. Xu, K. Ohori, T. 
Ohshima, M. Shibasaki, Tetrahedron 2002, 58, 2585-2588. 
[54] a) G. Blay, I. Fernandez, J. R. Pedro, C. Vila, Tet. Lett. 2007, 48, 6731-6734; b) G. 
Blay, I. Fernandez, A. Monleon, M. C. Munoz, J. R. Pedro, C. Vila, Adv. Synth. Catal. 
2009, 351, 2433-3440; c) G. Blay, I. Fernandez, M. C. Munoz, J. R. Pedro, C. Vila, 
Chem. Eur. J. 2010, 16, 9117-9122. 
[55] M. Shibasaki, H. Sasai, T. Arai, Angew. Chem. Int. Ed. Engl. 1997, 36, 1236-1256. 
[56] a) R. Noyori, I. Tomino, Y. Tanimoto, J. Am. Chem. Soc. 1979, 101, 3129-3131; b) R. 
Noyori, Pure & Appl. Chem. 1981, 53; 2315-2322; c) R. Noyori, I. Tomino, Y. 
Tanimoto, M. Nishizawa, J. Am. Chem. Soc. 1984, 106, 6709-6716; d) R. Noyori, I. 
Tomino, M. Yamada, M. Nishizawa, J. Am. Chem. Soc. 1984, 106, 6717-6725. 
[57] M. Charpentier, M. Hans, J. Jauch, Eur. J. Org. Chem. 2013, 2013, 4078-4084. 
[58] D. Seebach, A. K. Beck, A. Heckel, Angew. Chem. Int. Ed. Engl. 2001, 40, 92-138. 
[59] a) A. Graven, M. Johannsen, J. K. A., Chem. Commun. 1996, 2373-2374; b) M. 
Nishida, H. Hayashi, A. Nishida, N. Kawahara, Chem. Commun. 1996, 579-580; c) K. 
B. Jensen, M. Roberson, K. A. Jorgensen, J. Org. Chem. 2000, 65, 9080-9084. 
[60] M. G. Vinogradov, L. S. Gorshkova, V. A. Pavlov, O. V. Mikhalev, G. V. Chel'tsova, I. 
V. Razmanov, V. A. Ferapontov, O. R. Malyshev, G. L. Heise, Russ. Chem. Bull. 
2000, 49, 459-464. 
[61] E. Keller, N. Veldman, A. L. Spek, B. L. Feringa, Tetrahedron: Asymmetry 1997, 8, 
3403-3413. 
[62] T. Arai, H. Sasai, K. Yamaguchi, M. Shibasaki, J. Am. Chem. Soc. 1998, 120, 441-
442. 
[63] H. Sasai, T. Arai, Y. Satow, K. N. Houk, M. Shibasaki, J. Am. Chem. Soc. 1995, 117, 
6194-6198. 
[64] a) Y. Xu, G. C. Clarkson, G. Docherty, C. L. North, G. Woodward, M. Wills, J. Org. 
Chem. 2005, 70, 8079-8087; b) P. Le, T. S. Nguyen, J. A. May, Org. Lett. 2012, 14, 
6104-6107. 
[65] W.-Y. Han, Z.-J. Wu, X.-M. Zhang, W.-C. Yuan, Org. Lett. 2012, 14, 976-979. 
[66] Y.-H. Liu, L.-H. Chen, M. Shi, Adv. Synth. Catal. 2006, 348, 973-979. 
[67] R. Zimmer, L. Schefzig, A. Peritz, V. Dekaris, H.-U. Reissig, Synthesis 2004, 2004, 
1439-1445. 
[68] Y. Yuan, X. Wang, X. Li, K. Ding, J. Org. Chem. 2004, 69, 146-149. 
[69] G. Blay, J. Cano, L. Cardona, I. Fernandez, E. Munoz, J. R. Pedro, C. Vila, J. Org. 
Chem. 2012, 77, 10545-10556. 
[70] G. D. Y. Sogah, D. J. Cram, J. Am. Chem. Soc. 1979, 101, 3035-3042. 
[71] K. Huwig, Project thesis, Universität des Saarlandes (Saarbrücken, DE), 2013. 
[72] H. Hocke, Y. Uozumi, Tetrahedron 2003, 59, 619-630. 
[73] a) D. S. Lingenfelter, R. C. Helgeson, D. J. Cram, J. Org. Chem. 1981, 46, 393-406; 
b) K. Pathak, A. P. Bhatt, S. H. R. Abdi, R. I. Kureshy, N.-u. H. Khan, I. Ahmad, R. V. 
Jasra, Tetrahedron: Asymmetry 2006, 17, 1506-1513. 
[74] a) N. Halland, R. G. Hazell, K. A. Jorgensen, J. Org. Chem. 2002, 67, 8331-8338; b) 
N. Halland, P. S. Aburel, K. A. Jorgensen, Angew. Chem. Int. Ed. 2003, 42, 661-665; 
c) W. Chen, W. Du, L. Yue, R. Li, Y. Wu, L.-S. Ding, Y.-C. Chen, Org. Biomol. Chem. 
2007, 5, 816-821; d) J. W. Xie, L. Yue, W. Chen, W. Du, J. Zhu, J.-G. Deng, Y.-C. 
Chen, Org. Lett. 2007, 9. 
[75] A. B. Northrup, D. W. C. MacMillan, J. Am. Chem. Soc. 2002, 124, 2458-2460. 
[76] R. A. H. F. Hui, S. Salamone, T. H. Williams, Pharmacollogy Biochemistry & 
Behaviour 1991, 40, 491-496. 
References  - 169 - 
[77] T. Williams, R. G. Pitcher, P. Bommer, J. Gutzwiller, M. Uskokovic, J. Am. Chem. 
Soc. 1969, 91, 1871-1872. 
[78] a) S. D. Bergman, M. Kol, Inorg. Chem. 2005, 44, 1647-1654; b) E. I. Fedin, V. A. 
Davakanov, Chirality 1995, 7, 326-330; c) S. H. Huang, Z. W. Bai, J. W. Feng, Magn. 
Reson. Chemistry : MRC 2009, 47, 423-427. 
[79] H. Pellissier, Tetrahedron 2007, 63, 9267-9331. 
[80] B. List, Tetrahedron 2002, 58, 5573-5590. 
[81] a) A. G. Doyle, E. N. Jacobsen, Chem. Rev. 2007, 107, 5713-5743; b) A. Erikkilä, I. 
Majander, P. M. Pihko, Chem. Rev. 2007, 107, 5416-5470; c) T. Hashimoto, K. 
Maruoka, Chem. Rev. 2007, 107, 5656-5682; d) S. Mukerjee, J. W. Yang, S. 
Hoffmann, B. List, Chem. Rev. 2007, 107, 5471-5569; e) J. L. Vicario, D. Badia, L. 
Carillo, Synthesis 2007, 14, 2065-2092; f) P. I. Dalko, L. Moisan, Angew. Chem. 
2004, 116, 5248-5286; g) E. A. C. Davie, S. M. Mennen, Y. Xu, S. J. Miller, Chem. 
Rev. 2007, 107, 5759-5812; h) O. V. Maltsev, I. P. Beletkaya, S. G. Zlotin, Russ. 
Chem. Rev. 2011, 80, 1067-1113; i) E. R. Jarvo, S. J. Miller, Tetrahedron 2002, 58, 
2481-2495; j) W. Notz, F. Tanaka, C. F. Barbas, Accounts of chemical research 2004, 
37, 580-591. 
[82] L. A. Al-Momani, ARKIVOC 2012, vi, 101-111. 
[83] a) M. Bararjanian, S. Balalaie, B. Movassagh, A. M. Amani, J. Iran. Chem. Soc. 2009, 
6, 436-442; b) X. H. Liu, J. C. Fan, Y. Liu, Z. C. Shang, J. Zhejiang Univ-Sc. B 2008, 
9, 990-995. 
[84] C. Simon, T. Constantieux, J. Rodriguez, Eur. J. Org. Chem. 2004, 2004, 4957-4980. 
[85] a) S. Tu, C. Miao, Y. Gao, F. Fang, Q. Zhuang, Y. Feng, D. Shi, Synlett 2004, 0255-
0258; b) T.-S. Jin, J.-S. Zhang, J.-C. Xiao, A.-Q. Wang, T.-S. Li, Synlett 2004, 0866-
0870. 
[86] a) Y. Oikawa, H. Hirasawa, O. Yonemitsu, Tet. Lett. 1978, 20, 1759-1762; b) F. 
Cochard, M. Laronze, E. Prost, J.-M. Nuzillard, F. Augé, C. Petermann, P. Sigaut, J. 
Sapi, J.-Y. Laronze, Eur. J. Org. Chem. 2002, 3481-3490; c) N. N. Karade, S. V. 
Gampawar, S. V. Schinde, W. N. Jadhav, Chin. J. Chem. 2007, 25, 1686-1689. 
[87] V. Nair, Synthetic Commun. 1987, 17, 723-727. 
[88] J. Schmitt, Bachelor thesis, Universität des Saarlandes (Saarbrücken, DE), 2012. 
[89] a) S. Paul, W. B. Schweizer, M.-O. Ebert, R. Gilmour, Organometallics 2010, 29, 
4424-4427; b) C. D. Campbell, C. Concellón, A. D. Smith, Tetrahedron: Asymmetry 
2011, 22, 797-811. 
[90] S. Julia, J. Guixer, J. Masana, J. Rocas, S. Colonna, R. Annuziata, H. Molinari, J. 
Chem. Soc., Perkin Trans. 1 1982, 1317-1324. 
[91] a) C.-M. De la Condamine, Memoires de l'Académie Royale des Sciences 1738, 226-
243; b) J. de Jussieu, Mémoire inedit de Joseph de Jussieu 1737; c) L. Taylor, The 
Raintree Tropical Plant Database, http://www.rain-
tree.com/quinine.htm#.VNOfUi7yV_A, 05/02/2014, 18:01 
[92] a) Pelletier, Caventou, Ann. Chim. Phys. 1820, 15, 289-318; b) Pelletier, Caventou, 
Ann. Chim. Phys. 1820, 15, 337-365. 
[93] a) S. M. Weinreb, Nature 2001, 411, 429-431; b) T. S. Kaufmann, E. A. Ruveda, 
Angew. Chem. Int. Ed. 2005, 44, 854-885. 
[94] a) X. Liu, H. Li, L. Deng, Org. Lett. 2005, 7, 167-169; b) H. Li, Y. Wang, L. Tang, L. 
Deng, J. Am. Chem. Soc. 2004, 126, 9906-9907; c) B. Wang, F. Wu, Y. Wang, X. Liu, 
L. Deng, J. Am. Chem. Soc. 2007, 129, 768-769; d) T. Marcelli, J. H. van 
Maarseveen, H. Hiemstra, Angew Chem Int Ed Engl 2006, 45, 7496-7504; e) K. 
Kacprzak, J. Gawronski, Synthesis 2001, 7, 961-998. 
[95] a) W. Chen, W. Du, L. Yue, R. Li, Y. Wu, L. S. Ding, Y. C. Chen, Org. Biomol. Chem. 
2007, 5, 816-821; b) W.-B. Chen, Z.-J. Wu, Q.-L. Pei, L.-F. Cun, X.-M. Zhang, W.-C. 
Yuan, Org. Lett. 2010, 12, 3132-3135; c) Y.-Q. Deng, Z.-W. Zhang, Y.-H. Feng, A. S. 
C. Chan, G. Lu, Tetrahedron: Asymmetry 2012, 23, 1647-1652; d) P. He, X. Liu, J. 
Shi, L. Lin, X. Feng, Org. Lett. 2011, 13, 936-939; e) M. Shi, Z.-Y. Lei, M.-X. Zhao, J.-
W. Shi, Tet. Lett. 2007, 48, 5743-5746. 
References  - 170 - 
[96] J. W. Xie, L. Yue, W. Chen, W. Du, J. Zhu, J.-G. Deng, Y. C. Chen, Org. Lett. 2007, 
9, 413-415. 
[97] H. Hiemstra, H. Wynberg, J. Am. Chem. Soc. 1981, 103, 417-430. 
[98] T. Bürgi, A. Baiker, J. Am. Chem. Soc. 1998, 120, 12920-12926. 
[99] Y. Zhou, Z. Shan, J. Org. Chem. 2006, 71, 9510-9512. 
[100] W. Adam, P. B. Rao, H.-G. Degen, A. Levai, T. Patonay, C. R. Saha-Möller, J. Org. 
Chem. 2002, 67, 259-264. 
[101] E. Diez-Barra, A. De la Hoz, S. Merino, A. Rodriguez, P. Sanchez-Verdu, 
Tetrahedron 1998, 54, 1835-1844. 
[102] S. Colonna, A. Re, H. Wynberg, J. Chem. Soc., Perkin I 1981, 547-552. 
[103] E. V. Dehmlow, S. Wagner, A. Müller, Tetrahedron 1999, 6335-6346. 
[104] J. M. Finefield, D. H. Sherman, M. Kreitman, R. M. Williams, Angew. Chem. Int. Ed. 
Engl. 2012, 51, 4802-4836. 
[105] D. Peters, G. M. Olsen, E. O. Nielsen, T. D. Jorgensen, P. K. Ahring, Neurosearch 
A/S Ballerup (DK), 2003, Danemark, PCT/DK2003/000769, WO 2004/043960 A1 
[106] P. Schlack, W. Koller, Farbe Hoechst Aktiengesellschaft Franfkurt/M (DE), 1963, 
Germany, 1146498,  
[107] a) L. Yang, Y. Dong, X. Hu, A. Liu, Carbohyd. Res. 2012, 347, 40-46; b) D. 
Hartmann, M. Charpentier, J. Jauch, Synthesis of acyl phloroglucinol, Laboratory 
work notes, 2011 
[108] a) D. E. Wolf, J. Valiant, Folkers, J. Am. Chem. Soc. 1951, 73, 4142-4144; b) D. E. 
Wolf, K. Folkers, Merck & Co Inc., 1951, USA, US2538139A,  
[109] R. E. Kent, S. M. McElvain, Org. Synth. 1945, 25, 58-60. 
[110] B. S. Lele, M. G. Kulkarni, 2002, India, US6369249,  
[111] S. P. Chavan, A. B. Pathak, A. N. Dhawane, U. R. Kalkote, Synthetic Commun. 2007, 
37, 1503-1510. 
[112] K. Sukata, Bull. Chem. Soc. Jap. 1985, 58, 838-843. 
[113] Y. Liu, Y. Wang, Y. Wang, J. Lu, V. Pinon, 3rd, M. Weck, J. Am. Chem. Soc. 2011, 
133, 14260-14263. 
[114] N. Cankarova, P. Funk, J. Hlavac, M. Soural, Tet. Lett. 2011, 52, 5782-5788. 
[115] a) L. B. Poole, C. Klomsiri, S. A. Knaggs, C. M. Furdui, K. J. Nelson, M. J. Thomas, J. 
S. Fetrow, L. W. Daniel, B. Kning, Bioconjugate Chem. 2007, 18, 2004-2017; b) I. A. 
Inverarity, R. F. H. Viguier, P. Cohen, A. N. Hulme, Bioconjugate Chem. 2007, 18, 
1593-1603; c) M. Pignatto, N. Realdon, M. Morpurgo, Bioconjugate Chem. 2010, 21, 
1254-1263; d) L. Lu, X. Gu, L. Hong, J. Laird, K. Jaffe, J. Choi, J. Crabb, R. G. 
Salomon, Bioorg Med Chem 2009, 17, 7548-7561. 
[116] H. Zeng, H. Zhang, X. Wu, F. Chao, G. Yu, L. Zhang, H. Jiang, H. Liu, H. Hou, H. 
Zhan, H. Zhang, M. Tian, J. Labelled Compd Rad. 2013, 56, 1-5. 
[117] A. El idrissi, S. EL barkany, H. Amhamdi, A.-K. Maaroufi, J. Appl. Polym. Sci 2013, 
3633-3644. 
[118] S. H. Woo, S. Frechette, E. A. Khalil, G. Bouchain, A. Vaisburg, N. Bernstein, O. 
Moradei, S. Leit, M. Allan, M. Fournel, M.-C. Trachy-Bourget, Z. Li, J. M. Besterman, 
D. Delorme, J. Med. Chem. 2002, 45, 2877-2885. 
[119] a) F. G. Finelli, L. S. Miranda, R. O. de Souza, Chem. Commun. 2015, 51, 3708-
3722; b) T. Jackson, J. H. Clark, D. J. Macquarrie, J. H. Brophy, Green Chem. 2004, 
6, 193; c) C. Zhi, J. Wang, B. Luo, X. Li, X. Cao, Y. Pan, H. Gu, RSC Advances 2014, 
4, 15036. 
[120] N. Kumagai, S. Matsunaga, M. Shibasaki, Org. Lett. 2001, 3, 4251-4254. 
[121] G. Blay, I. Fernandez, J. R. Pedro, C. Vila, Org. Lett. 2007, 9, 2601-2604. 
[122] a) E. F. DiMauro, M. C. Kozlowski, Org. Lett. 2001, 3, 1641-1644; b) E. F. DiMauro, 
M. C. Kozlowski, Organometallics 2002, 21; c) Z. Dong, X. Liu, J. Feng, M. Wang, L. 
Lin, X. Feng, Eur. J. Org. Chem. 2011, 2011, 137-142; d) M. S. Taylor, E. N. 
Jacobsen, J. Am. Chem. Soc., 125, 11204-11205. 
[123] B. Vakula, S. Varga, A. Csampai, T. Soos, Org. Lett. 2005, 7, 1967-1969. 
[124] a) Y. Zhang, Y. L. Shao, H. S. Xu, W. Wang, J. Org. Chem. 2011, 76, 1472-1474; b) 
K. Dudzinski, A. M. Pakulska, P. Kwiatkowski, Org. Lett. 2012, 14, 4222-4225. 
References  - 171 - 
[125] S. H. McCooey, S. J. Connon, Angew. Chem. Int. Ed. Engl. 2005, 44, 6367-6370. 
[126] a) J. Shi, M. Wang, L. He, K. Zheng, X. Liu, L. Lin, X. Feng, Chem. Commun. 2009, 
4711-4713; b) L. Liu, R. Wang, Y.-F. Kang, C. Chen, Z.-Q. Xu, Y.-F. Zhou, M. Ni, H.-
Q. Cai, M.-Z. Gong, J. Org. Chem. 2005, 70, 1084-1086. 
[127] L. Stegbauer, F. Sladojevich, D. J. Dixon, Chem. Sci. 2012, 3, 942-958. 
[128] J. Bitter, J. Leitich, H. Partale, O. E. Polansky, W. Riemer, U. Ritter-Thomas, B. 
Schlamann, B. Stilkerieg, Chem. Ber. 1980, 113, 1020-1032. 
[129] U.-H. Dolling, P. Davis, J. J. Grabowski, J. Am. Chem. Soc. 1984, 106, 446-447. 
[130] B. Liu, F.-Y. Jiang, H.-B. Song, J.-S. Li, Tetrahedron: Asymmetry 2006, 17, 2149-
2153. 
Appendices  - 172 - 
6. Appendices 
6.1. Appendix 1: crystal data for 51 
 
Exp. Data Tab. 7 Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for 51 (sh3343). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
Br(1) 6773(1) 3076(1) 8840(1) 16(1) 
Br(2A) 6810(1) 6618(1) 8442(1) 47(1) 
Br(2B) 6018(12) 6798(5) 8135(6) 96(3) 
O(1) 4436(3) 5937(2) 9128(1) 12(1) 
O(2) 731(4) 7067(2) 9873(1) 35(1) 
O(3) 3306(4) 5432(2) 10743(1) 21(1) 
O(4) 6304(3) 3874(2) 9814(1) 13(1) 
O(5) 5912(4) 4176(2) 8076(1) 20(1) 
O(6) 3871(4) 5663(2) 8053(1) 21(1) 
C(1) 3735(5) 6053(2) 9548(2) 10(1) 
C(2) 2620(5) 6584(2) 9460(2) 11(1) 
C(3) 1727(5) 6696(2) 9907(2) 17(1) 
C(4) 2072(5) 6375(2) 10395(2) 14(1) 
C(5) 3175(5) 5806(2) 10385(2) 13(1) 
C(6) 4058(4) 5728(2) 9967(2) 10(1) 
C(7) 5264(5) 5228(2) 9981(1) 10(1) 
C(8) 5426(5) 4915(2) 9486(2) 9(1) 
C(9) 5943(4) 4239(2) 9412(2) 10(1) 
C(10) 6105(5) 3987(2) 8941(2) 12(1) 
C(11) 5802(5) 4407(2) 8539(2) 12(1) 
C(12) 5321(5) 5083(2) 8608(2) 11(1) 
C(13) 5082(4) 5296(2) 9080(2) 10(1) 
C(14) 1684(6) 6341(2) 9043(2) 19(1) 
C(15) 3291(6) 7289(2) 9322(2) 19(1) 
C(16) 755(6) 6087(3) 10624(2) 29(1) 
C(17) 2666(7) 6969(3) 10715(2) 29(1) 
C(18) 6625(5) 5576(2) 10152(2) 15(1) 
C(19) 7133(5) 6147(3) 9819(2) 20(1) 
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C(20) 6502(6) 5841(2) 10677(2) 20(1) 
C(21) 5042(5) 5560(2) 8181(2) 15(1) 
C(22) 6250(5) 5923(3) 7937(2) 24(1) 
C(23A) 5835(7) 6334(4) 7496(2) 34(2) 
C(24A) 7520(7) 5497(4) 7848(3) 37(2) 
C(23B) 5960(60) 5770(30) 7411(6) 41(5) 
C(24B) 7670(17) 5730(30) 8114(18) 29(4) 
Br(3) -2352(1) 380(1) 8031(1) 39(1) 
Br(4) 1760(1) 3183(1) 7396(1) 34(1) 
O(7) 360(3) 3119(2) 8458(1) 13(1) 
O(8) 947(6) 4847(2) 9642(2) 46(1) 
O(9) 982(5) 2521(2) 10091(1) 36(1) 
O(10) -596(4) 793(2) 8921(1) 21(1) 
O(11) -2273(4) 1735(2) 7404(1) 23(1) 
O(12) -1910(5) 3471(2) 7699(1) 35(1) 
C(25) 662(4) 3277(2) 8928(2) 11(1) 
C(26) 837(5) 4049(2) 8991(2) 14(1) 
C(27) 1031(5) 4251(2) 9524(2) 19(1) 
C(28) 1368(5) 3708(2) 9910(2) 17(1) 
C(29) 1026(5) 2963(2) 9769(2) 18(1) 
C(30) 838(5) 2775(2) 9260(2) 13(1) 
C(31) 891(5) 2016(2) 9123(2) 14(1) 
C(32) -10(5) 1927(2) 8678(2) 12(1) 
C(33) -702(5) 1297(2) 8584(2) 16(1) 
C(34) -1457(5) 1233(2) 8159(2) 20(1) 
C(35) -1540(5) 1778(2) 7823(2) 16(1) 
C(36) -877(5) 2405(2) 7919(2) 14(1) 
C(37) -159(4) 2458(2) 8355(2) 11(1) 
C(38) -394(6) 4452(3) 8786(2) 28(1) 
C(39) 2141(5) 4279(3) 8714(2) 21(1) 
C(40) 2939(6) 3699(4) 9968(3) 44(2) 
C(41) 690(9) 3911(3) 10394(2) 45(2) 
C(42) 2399(5) 1789(2) 9044(2) 16(1) 
C(43) 3142(6) 2214(3) 8658(2) 26(1) 
C(44) 2523(6) 1009(2) 8927(2) 26(1) 
C(45) -1053(5) 3041(2) 7604(2) 15(1) 
C(46) -163(5) 3158(3) 7155(2) 18(1) 
C(47) -425(8) 3851(4) 6922(2) 44(2) 
C(48) -249(8) 2572(4) 6797(2) 43(2) 
C(49) 4848(12) 3971(6) 6980(4) 82(3) 
Cl(1) 5933(3) 4595(2) 6715(1) 76(1) 
Cl(2) 5576(4) 3136(2) 6935(2) 118(1) 
 
Exp. Data Tab. 8 Bond lengths for 51 (sh3343). 
Bond  Length [Å] Bond  Length [Å] 
Br(1)-C(10) 1.886(4) C(24B)-H(24E) 0.9960 
Br(2A)-C(22) 2.007(6) C(24B)-H(24F) 0.9980 
Br(2B)-C(22) 1.782(11) Br(3)-C(34) 1.890(5) 
O(1)-C(1) 1.364(5) Br(4)-C(46) 1.991(5) 
O(1)-C(13) 1.388(5) O(7)-C(25) 1.366(5) 
Appendices  - 174 - 
O(2)-C(3) 1.208(6) O(7)-C(37) 1.395(5) 
O(3)-C(5) 1.226(5) O(8)-C(27) 1.194(6) 
O(4)-C(9) 1.360(5) O(9)-C(29) 1.230(6) 
O(5)-C(11) 1.357(5) O(10)-C(33) 1.346(6) 
O(6)-C(21) 1.212(6) O(11)-C(35) 1.362(5) 
C(1)-C(6) 1.351(6) O(12)-C(45) 1.205(6) 
C(1)-C(2) 1.510(6) C(25)-C(30) 1.342(6) 
C(2)-C(3) 1.524(6) C(25)-C(26) 1.503(6) 
C(2)-C(14) 1.542(6) C(26)-C(27) 1.533(7) 
C(2)-C(15) 1.552(6) C(26)-C(38) 1.536(7) 
C(3)-C(4) 1.520(6) C(26)-C(39) 1.550(7) 
C(4)-C(5) 1.534(6) C(27)-C(28) 1.527(7) 
C(4)-C(16) 1.536(7) C(28)-C(29) 1.519(6) 
C(4)-C(17) 1.556(7) C(28)-C(40) 1.541(8) 
C(5)-C(6) 1.447(6) C(28)-C(41) 1.541(7) 
C(6)-C(7) 1.519(6) C(29)-C(30) 1.463(6) 
C(7)-C(8) 1.501(6) C(30)-C(31) 1.506(6) 
C(7)-C(18) 1.560(6) C(31)-C(32) 1.520(6) 
C(7)-H(7) 1.0000 C(31)-C(42) 1.550(7) 
C(8)-C(13) 1.380(6) C(31)-H(31) 1.0000 
C(8)-C(9) 1.408(6) C(32)-C(37) 1.362(6) 
C(9)-C(10) 1.396(6) C(32)-C(33) 1.410(6) 
C(10)-C(11) 1.403(6) C(33)-C(34) 1.391(7) 
C(11)-C(12) 1.393(6) C(34)-C(35) 1.399(6) 
C(12)-C(13) 1.385(6) C(35)-C(36) 1.391(6) 
C(12)-C(21) 1.518(6) C(36)-C(37) 1.396(6) 
C(14)-H(14A) 0.9800 C(36)-C(45) 1.509(6) 
C(14)-H(14B) 0.9800 C(38)-H(38A) 0.9800 
C(14)-H(14C) 0.9800 C(38)-H(38B) 0.9800 
C(15)-H(15A) 0.9800 C(38)-H(38C) 0.9800 
C(15)-H(15B) 0.9800 C(39)-H(39A) 0.9800 
C(15)-H(15C) 0.9800 C(39)-H(39B) 0.9800 
C(16)-H(16A) 0.9800 C(39)-H(39C) 0.9800 
C(16)-H(16B) 0.9800 C(40)-H(40A) 0.9800 
C(16)-H(16C) 0.9800 C(40)-H(40B) 0.9800 
C(17)-H(17A) 0.9800 C(40)-H(40C) 0.9800 
C(17)-H(17B) 0.9800 C(41)-H(41A) 0.9800 
C(17)-H(17C) 0.9800 C(41)-H(41B) 0.9800 
C(18)-C(19) 1.515(6) C(41)-H(41C) 0.9800 
C(18)-C(20) 1.540(6) C(42)-C(43) 1.525(7) 
C(18)-H(18) 1.0000 C(42)-C(44) 1.536(6) 
C(19)-H(19A) 0.9800 C(42)-H(42) 1.0000 
C(19)-H(19B) 0.9800 C(43)-H(43A) 0.9800 
C(19)-H(19C) 0.9800 C(43)-H(43B) 0.9800 
C(20)-H(20A) 0.9800 C(43)-H(43C) 0.9800 
C(20)-H(20B) 0.9800 C(44)-H(44A) 0.9800 
C(20)-H(20C) 0.9800 C(44)-H(44B) 0.9800 
C(21)-C(22) 1.525(7) C(44)-H(44C) 0.9800 
C(22)-C(24A) 1.504(7) C(45)-C(46) 1.529(6) 
C(22)-C(23A) 1.506(6) C(46)-C(47) 1.499(8) 
C(22)-C(23B) 1.508(10) C(46)-C(48) 1.501(7) 
Appendices  - 175 - 
C(22)-C(24B) 1.513(10) C(47)-H(47A) 0.9800 
C(23A)-H(23A) 0.9800 C(47)-H(47B) 0.9800 
C(23A)-H(23B) 0.9800 C(47)-H(47C) 0.9800 
C(23A)-H(23C) 0.9800 C(48)-H(48A) 0.9800 
C(24A)-H(24A) 0.9800 C(48)-H(48B) 0.9800 
C(24A)-H(24B) 0.9800 C(48)-H(48C) 0.9800 
C(24A)-H(24C) 0.9800 C(49)-Cl(2) 1.758(12) 
C(23B)-H(23D) 0.9800 C(49)-Cl(1) 1.760(12) 
C(23B)-H(23E) 0.9800 C(49)-H(49A) 0.9900 
C(23B)-H(23F) 0.9800 C(49)-H(49B) 0.9900 
C(24B)-H(24D) 0.9999   
 
Exp. Data Tab. 9 Angles for 51 (sh3343). 
Bonds  Angles [°] Bonds  Angles [°] 
C(1)-O(1)-C(13) 116.9(3) H(23E)-C(23B)-H(23F) 109.5 
C(6)-C(1)-O(1) 122.4(4) C(22)-C(24B)-H(24D) 112.3 
C(6)-C(1)-C(2) 128.0(4) C(22)-C(24B)-H(24E) 110.1 
O(1)-C(1)-C(2) 109.6(3) H(24D)-C(24B)-H(24E) 107.3 
C(1)-C(2)-C(3) 112.2(3) C(22)-C(24B)-H(24F) 111.3 
C(1)-C(2)-C(14) 110.0(3) H(24D)-C(24B)-H(24F) 107.7 
C(3)-C(2)-C(14) 107.9(4) H(24E)-C(24B)-H(24F) 107.9 
C(1)-C(2)-C(15) 108.9(4) C(25)-O(7)-C(37) 118.3(3) 
C(3)-C(2)-C(15) 108.5(4) C(30)-C(25)-O(7) 121.1(4) 
C(14)-C(2)-C(15) 109.2(4) C(30)-C(25)-C(26) 128.0(4) 
O(2)-C(3)-C(4) 119.1(4) O(7)-C(25)-C(26) 110.8(4) 
O(2)-C(3)-C(2) 118.7(4) C(25)-C(26)-C(27) 112.0(4) 
C(4)-C(3)-C(2) 122.2(4) C(25)-C(26)-C(38) 111.4(4) 
C(3)-C(4)-C(5) 115.4(4) C(27)-C(26)-C(38) 108.9(4) 
C(3)-C(4)-C(16) 109.0(4) C(25)-C(26)-C(39) 108.4(4) 
C(5)-C(4)-C(16) 109.7(4) C(27)-C(26)-C(39) 107.6(4) 
C(3)-C(4)-C(17) 106.8(4) C(38)-C(26)-C(39) 108.4(4) 
C(5)-C(4)-C(17) 105.7(4) O(8)-C(27)-C(28) 118.7(4) 
C(16)-C(4)-C(17) 110.0(4) O(8)-C(27)-C(26) 119.7(5) 
O(3)-C(5)-C(6) 121.3(4) C(28)-C(27)-C(26) 121.6(4) 
O(3)-C(5)-C(4) 118.4(4) C(29)-C(28)-C(27) 114.6(4) 
C(6)-C(5)-C(4) 120.3(4) C(29)-C(28)-C(40) 103.6(4) 
C(1)-C(6)-C(5) 119.8(4) C(27)-C(28)-C(40) 107.1(4) 
C(1)-C(6)-C(7) 119.5(4) C(29)-C(28)-C(41) 111.5(4) 
C(5)-C(6)-C(7) 120.4(4) C(27)-C(28)-C(41) 109.8(4) 
C(8)-C(7)-C(6) 108.2(3) C(40)-C(28)-C(41) 109.9(5) 
C(8)-C(7)-C(18) 111.0(4) O(9)-C(29)-C(30) 121.3(4) 
C(6)-C(7)-C(18) 113.4(3) O(9)-C(29)-C(28) 118.1(4) 
C(8)-C(7)-H(7) 108.0 C(30)-C(29)-C(28) 120.5(4) 
C(6)-C(7)-H(7) 108.0 C(25)-C(30)-C(29) 119.6(4) 
C(18)-C(7)-H(7) 108.0 C(25)-C(30)-C(31) 121.9(4) 
C(13)-C(8)-C(9) 117.3(4) C(29)-C(30)-C(31) 118.4(4) 
C(13)-C(8)-C(7) 120.0(4) C(30)-C(31)-C(32) 106.9(4) 
C(9)-C(8)-C(7) 122.7(4) C(30)-C(31)-C(42) 109.8(4) 
O(4)-C(9)-C(10) 123.6(4) C(32)-C(31)-C(42) 113.8(4) 
O(4)-C(9)-C(8) 116.6(4) C(30)-C(31)-H(31) 108.7 
Appendices  - 176 - 
C(10)-C(9)-C(8) 119.7(4) C(32)-C(31)-H(31) 108.7 
C(9)-C(10)-C(11) 120.9(4) C(42)-C(31)-H(31) 108.7 
C(9)-C(10)-Br(1) 119.8(3) C(37)-C(32)-C(33) 118.0(4) 
C(11)-C(10)-Br(1) 119.3(3) C(37)-C(32)-C(31) 120.5(4) 
O(5)-C(11)-C(12) 117.4(4) C(33)-C(32)-C(31) 121.5(4) 
O(5)-C(11)-C(10) 122.7(4) O(10)-C(33)-C(34) 124.1(4) 
C(12)-C(11)-C(10) 119.8(4) O(10)-C(33)-C(32) 116.9(4) 
C(13)-C(12)-C(11) 117.5(4) C(34)-C(33)-C(32) 119.0(4) 
C(13)-C(12)-C(21) 121.5(4) C(33)-C(34)-C(35) 121.6(4) 
C(11)-C(12)-C(21) 121.0(4) C(33)-C(34)-Br(3) 118.6(3) 
C(8)-C(13)-C(12) 124.4(4) C(35)-C(34)-Br(3) 119.8(3) 
C(8)-C(13)-O(1) 120.2(4) O(11)-C(35)-C(36) 117.3(4) 
C(12)-C(13)-O(1) 115.3(4) O(11)-C(35)-C(34) 123.2(4) 
C(2)-C(14)-H(14A) 109.5 C(36)-C(35)-C(34) 119.6(4) 
C(2)-C(14)-H(14B) 109.5 C(35)-C(36)-C(37) 117.4(4) 
H(14A)-C(14)-H(14B) 109.5 C(35)-C(36)-C(45) 122.5(4) 
C(2)-C(14)-H(14C) 109.5 C(37)-C(36)-C(45) 119.7(4) 
H(14A)-C(14)-H(14C) 109.5 C(32)-C(37)-O(7) 120.6(4) 
H(14B)-C(14)-H(14C) 109.5 C(32)-C(37)-C(36) 124.3(4) 
C(2)-C(15)-H(15A) 109.5 O(7)-C(37)-C(36) 115.1(4) 
C(2)-C(15)-H(15B) 109.5 C(26)-C(38)-H(38A) 109.5 
H(15A)-C(15)-H(15B) 109.5 C(26)-C(38)-H(38B) 109.5 
C(2)-C(15)-H(15C) 109.5 H(38A)-C(38)-H(38B) 109.5 
H(15A)-C(15)-H(15C) 109.5 C(26)-C(38)-H(38C) 109.5 
H(15B)-C(15)-H(15C) 109.5 H(38A)-C(38)-H(38C) 109.5 
C(4)-C(16)-H(16A) 109.5 H(38B)-C(38)-H(38C) 109.5 
C(4)-C(16)-H(16B) 109.5 C(26)-C(39)-H(39A) 109.5 
H(16A)-C(16)-H(16B) 109.5 C(26)-C(39)-H(39B) 109.5 
C(4)-C(16)-H(16C) 109.5 H(39A)-C(39)-H(39B) 109.5 
H(16A)-C(16)-H(16C) 109.5 C(26)-C(39)-H(39C) 109.5 
H(16B)-C(16)-H(16C) 109.5 H(39A)-C(39)-H(39C) 109.5 
C(4)-C(17)-H(17A) 109.5 H(39B)-C(39)-H(39C) 109.5 
C(4)-C(17)-H(17B) 109.5 C(28)-C(40)-H(40A) 109.5 
H(17A)-C(17)-H(17B) 109.5 C(28)-C(40)-H(40B) 109.5 
C(4)-C(17)-H(17C) 109.5 H(40A)-C(40)-H(40B) 109.5 
H(17A)-C(17)-H(17C) 109.5 C(28)-C(40)-H(40C) 109.5 
H(17B)-C(17)-H(17C) 109.5 H(40A)-C(40)-H(40C) 109.5 
C(19)-C(18)-C(20) 111.0(4) H(40B)-C(40)-H(40C) 109.5 
C(19)-C(18)-C(7) 113.7(4) C(28)-C(41)-H(41A) 109.5 
C(20)-C(18)-C(7) 111.2(4) C(28)-C(41)-H(41B) 109.5 
C(19)-C(18)-H(18) 106.8 H(41A)-C(41)-H(41B) 109.5 
C(20)-C(18)-H(18) 106.8 C(28)-C(41)-H(41C) 109.5 
C(7)-C(18)-H(18) 106.8 H(41A)-C(41)-H(41C) 109.5 
C(18)-C(19)-H(19A) 109.5 H(41B)-C(41)-H(41C) 109.5 
C(18)-C(19)-H(19B) 109.5 C(43)-C(42)-C(44) 109.7(4) 
H(19A)-C(19)-H(19B) 109.5 C(43)-C(42)-C(31) 113.6(4) 
C(18)-C(19)-H(19C) 109.5 C(44)-C(42)-C(31) 112.2(4) 
H(19A)-C(19)-H(19C) 109.5 C(43)-C(42)-H(42) 107.0 
H(19B)-C(19)-H(19C) 109.5 C(44)-C(42)-H(42) 107.0 
C(18)-C(20)-H(20A) 109.5 C(31)-C(42)-H(42) 107.0 
C(18)-C(20)-H(20B) 109.5 C(42)-C(43)-H(43A) 109.5 
Appendices  - 177 - 
H(20A)-C(20)-H(20B) 109.5 C(42)-C(43)-H(43B) 109.5 
C(18)-C(20)-H(20C) 109.5 H(43A)-C(43)-H(43B) 109.5 
H(20A)-C(20)-H(20C) 109.5 C(42)-C(43)-H(43C) 109.5 
H(20B)-C(20)-H(20C) 109.5 H(43A)-C(43)-H(43C) 109.5 
O(6)-C(21)-C(12) 119.5(4) H(43B)-C(43)-H(43C) 109.5 
O(6)-C(21)-C(22) 121.7(4) C(42)-C(44)-H(44A) 109.5 
C(12)-C(21)-C(22) 118.7(4) C(42)-C(44)-H(44B) 109.5 
C(24A)-C(22)-C(23A) 112.0(5) H(44A)-C(44)-H(44B) 109.5 
C(24A)-C(22)-C(23B) 84(3) C(42)-C(44)-H(44C) 109.5 
C(23A)-C(22)-C(23B) 43(2) H(44A)-C(44)-H(44C) 109.5 
C(24A)-C(22)-C(24B) 34(2) H(44B)-C(44)-H(44C) 109.5 
C(23A)-C(22)-C(24B) 129.2(14) O(12)-C(45)-C(36) 120.5(4) 
C(23B)-C(22)-C(24B) 116(3) O(12)-C(45)-C(46) 118.0(4) 
C(24A)-C(22)-C(21) 117.4(4) C(36)-C(45)-C(46) 121.5(4) 
C(23A)-C(22)-C(21) 112.9(5) C(47)-C(46)-C(48) 111.9(5) 
C(23B)-C(22)-C(21) 101(2) C(47)-C(46)-C(45) 112.5(4) 
C(24B)-C(22)-C(21) 117.1(14) C(48)-C(46)-C(45) 113.0(4) 
C(24A)-C(22)-Br(2B) 131.8(6) C(47)-C(46)-Br(4) 106.4(4) 
C(23A)-C(22)-Br(2B) 73.7(7) C(48)-C(46)-Br(4) 106.8(4) 
C(23B)-C(22)-Br(2B) 117(3) C(45)-C(46)-Br(4) 105.6(3) 
C(24B)-C(22)-Br(2B) 104(3) C(46)-C(47)-H(47A) 109.5 
C(21)-C(22)-Br(2B) 101.4(5) C(46)-C(47)-H(47B) 109.5 
C(24A)-C(22)-Br(2A) 104.5(4) H(47A)-C(47)-H(47B) 109.5 
C(23A)-C(22)-Br(2A) 106.6(4) C(46)-C(47)-H(47C) 109.5 
C(23B)-C(22)-Br(2A) 148(2) H(47A)-C(47)-H(47C) 109.5 
C(24B)-C(22)-Br(2A) 72(3) H(47B)-C(47)-H(47C) 109.5 
C(21)-C(22)-Br(2A) 102.0(3) C(46)-C(48)-H(48A) 109.5 
Br(2B)-C(22)-Br(2A) 36.3(5) C(46)-C(48)-H(48B) 109.5 
C(22)-C(23A)-H(23A) 109.5 H(48A)-C(48)-H(48B) 109.5 
C(22)-C(23A)-H(23B) 109.5 C(46)-C(48)-H(48C) 109.5 
C(22)-C(23A)-H(23C) 109.5 H(48A)-C(48)-H(48C) 109.5 
C(22)-C(24A)-H(24A) 109.6 H(48B)-C(48)-H(48C) 109.5 
C(22)-C(24A)-H(24B) 109.4 Cl(2)-C(49)-Cl(1) 110.4(7) 
C(22)-C(24A)-H(24C) 109.4 Cl(2)-C(49)-H(49A) 109.6 
C(22)-C(23B)-H(23D) 109.5 Cl(1)-C(49)-H(49A) 109.6 
C(22)-C(23B)-H(23E) 109.5 Cl(2)-C(49)-H(49B) 109.6 
H(23D)-C(23B)-H(23E) 109.5 Cl(1)-C(49)-H(49B) 109.6 
C(22)-C(23B)-H(23F) 109.5 H(49A)-C(49)-H(49B) 108.1 
H(23D)-C(23B)-H(23F) 109.5   
 
Exp. Data Tab. 10. Anisotropic displacement parameters (Å2x 103) for 51 (sh3343). The anisotropic displacement factor 
exponent takes the form:  -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
Atom U11 U22 U33 U23 U13 U12 
Br(1) 22(1) 11(1) 14(1) -1(1) 5(1) 5(1) 
Br(2A) 65(1) 47(1) 29(1) -1(1) 7(1) -38(1) 
Br(2B) 83(6) 50(4) 155(8) -7(5) 31(6) -18(4) 
O(1) 14(2) 10(1) 13(1) 2(1) 2(1) 4(1) 
O(2) 33(2) 50(3) 22(2) 5(2) 2(2) 28(2) 
O(3) 25(2) 22(2) 15(2) 7(1) 7(1) 11(2) 
Appendices  - 178 - 
O(4) 20(2) 11(2) 10(1) 3(1) -1(1) 4(1) 
O(5) 28(2) 21(2) 10(2) -2(1) 0(1) 9(2) 
O(6) 23(2) 25(2) 15(2) 3(1) -5(1) 6(2) 
C(1) 13(2) 8(2) 10(2) -2(2) 1(2) 1(2) 
C(2) 11(2) 10(2) 13(2) -2(2) 0(2) 1(2) 
C(3) 17(2) 17(2) 17(2) 0(2) -3(2) 8(2) 
C(4) 17(2) 12(2) 14(2) 0(2) 5(2) 6(2) 
C(5) 15(2) 10(2) 14(2) -1(2) -1(2) 0(2) 
C(6) 11(2) 6(2) 14(2) -2(2) -3(2) 2(2) 
C(7) 11(2) 9(2) 9(2) 1(2) -3(2) 5(2) 
C(8) 8(2) 11(2) 8(2) 3(2) 4(2) -2(2) 
C(9) 6(2) 12(2) 12(2) 4(2) 2(2) 2(2) 
C(10) 10(2) 11(2) 14(2) -3(2) 2(2) 5(2) 
C(11) 9(2) 17(2) 11(2) -1(2) 3(2) 1(2) 
C(12) 11(2) 14(2) 8(2) 2(2) -1(2) 0(2) 
C(13) 11(2) 8(2) 12(2) 1(2) 0(2) -3(2) 
C(14) 22(2) 15(2) 20(2) 1(2) -8(2) 6(2) 
C(15) 21(2) 10(2) 25(2) 1(2) -3(2) 1(2) 
C(16) 23(3) 27(3) 37(3) 14(2) 12(2) 10(2) 
C(17) 43(3) 15(2) 28(3) -7(2) -12(2) 11(2) 
C(18) 15(2) 15(2) 15(2) -1(2) -3(2) -1(2) 
C(19) 18(3) 21(2) 22(2) 4(2) -8(2) -11(2) 
C(20) 28(3) 16(2) 15(2) -3(2) -6(2) -2(2) 
C(21) 22(2) 15(2) 8(2) -1(2) 4(2) 6(2) 
C(22) 26(3) 28(3) 18(2) 6(2) 4(2) -1(2) 
C(23A) 37(4) 43(4) 24(3) 20(3) 2(3) -4(3) 
C(24A) 28(3) 36(4) 47(4) 21(3) 30(3) 9(3) 
C(23B) 38(10) 59(10) 27(6) 28(7) 12(7) -7(10) 
C(24B) 21(6) 38(9) 27(10) 35(9) 27(8) -13(8) 
Br(3) 58(1) 24(1) 36(1) 8(1) -27(1) -26(1) 
Br(4) 20(1) 55(1) 27(1) 5(1) 4(1) -5(1) 
O(7) 16(2) 8(1) 14(1) 2(1) -2(1) -2(1) 
O(8) 95(4) 12(2) 31(2) -1(2) -2(2) -1(2) 
O(9) 75(3) 14(2) 19(2) 1(2) -11(2) -3(2) 
O(10) 30(2) 14(2) 19(2) 6(1) -6(2) -10(1) 
O(11) 27(2) 25(2) 18(2) 3(1) -12(1) -10(2) 
O(12) 46(3) 38(2) 20(2) 12(2) 16(2) 27(2) 
C(25) 9(2) 12(2) 12(2) -1(2) -2(2) -2(2) 
C(26) 14(2) 8(2) 20(2) 2(2) -3(2) -1(2) 
C(27) 22(3) 14(2) 21(2) -1(2) 0(2) -6(2) 
C(28) 24(3) 14(2) 13(2) -2(2) -1(2) -2(2) 
C(29) 26(3) 12(2) 15(2) -2(2) -3(2) -5(2) 
C(30) 13(2) 10(2) 16(2) 1(2) -1(2) -4(2) 
C(31) 20(2) 10(2) 11(2) 0(2) -5(2) -2(2) 
C(32) 15(2) 11(2) 12(2) -2(2) -1(2) -3(2) 
C(33) 18(2) 13(2) 16(2) 0(2) 0(2) -3(2) 
C(34) 24(3) 14(2) 21(2) 0(2) -8(2) -8(2) 
C(35) 19(2) 16(2) 15(2) 0(2) -5(2) -1(2) 
C(36) 11(2) 17(2) 14(2) 0(2) 0(2) -1(2) 
C(37) 8(2) 9(2) 15(2) -2(2) 0(2) -2(2) 
C(38) 24(3) 13(2) 45(3) 0(2) -17(2) 3(2) 
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C(39) 22(3) 17(2) 24(2) 2(2) 2(2) -9(2) 
C(40) 31(3) 45(4) 55(4) 21(3) -19(3) -21(3) 
C(41) 83(5) 21(3) 30(3) 0(2) 23(3) -10(3) 
C(42) 17(2) 13(2) 19(2) -2(2) -5(2) 2(2) 
C(43) 21(3) 22(2) 34(3) -1(2) 3(2) 2(2) 
C(44) 32(3) 13(2) 34(3) -6(2) -5(2) 7(2) 
C(45) 19(2) 16(2) 10(2) -1(2) -2(2) 2(2) 
C(46) 16(2) 24(2) 16(2) 2(2) 4(2) 1(2) 
C(47) 45(4) 53(4) 34(3) 29(3) 13(3) 8(3) 
C(48) 46(4) 56(4) 27(3) -21(3) 19(3) -20(3) 
C(49) 78(7) 87(6) 80(7) -8(6) -15(6) -4(5) 
Cl(1) 69(2) 79(2) 81(2) -7(1) -1(1) -5(1) 
Cl(2) 109(2) 68(2) 176(4) -7(2) -6(2) -6(2) 
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6.2. Appendix 2: crystal data for 53 
 
 
 
 
 
 
 
 
 
 
 
 
Exp. Data Tab. 11 Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for 53 (sh3365). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 3102(9) 6440(1) 6678(3) 21(1) 
O(2) 4179(12) 6416(1) 9273(4) 42(2) 
O(3) 5526(12) 7381(1) 7950(3) 38(2) 
O(4) 4409(10) 6268(1) 4154(3) 24(1) 
O(5) 4367(14) 5991(2) 1623(4) 53(2) 
O(6) 4246(11) 7104(1) 2359(3) 34(2) 
O(7) 4324(12) 5823(1) 5783(4) 42(2) 
O(8) 4923(10) 7364(1) 5155(3) 20(1) 
O(9) 1722(10) 7444(1) 4660(3) 30(2) 
O(10) 2644(12) 8073(1) 4283(3) 40(2) 
C(1) 3690(14) 6368(2) 5413(4) 19(2) 
C(2) 3624(13) 6584(2) 6003(5) 18(2) 
C(3) 3902(14) 6915(2) 5936(5) 20(2) 
C(4) 4463(13) 7025(2) 5240(4) 17(2) 
C(5) 4714(14) 6827(2) 4619(5) 22(2) 
C(6) 4290(14) 6501(2) 4730(4) 17(2) 
C(7) 3544(14) 7131(2) 6619(4) 18(2) 
C(8) 4043(14) 6931(2) 7315(5) 21(2) 
C(9) 3781(14) 6606(2) 7303(5) 18(2) 
C(10) 4102(15) 6372(2) 7951(5) 23(2) 
C(11) 4549(15) 6555(2) 8672(5) 28(2) 
C(12) 5540(15) 6890(2) 8683(5) 25(2) 
C(13) 5015(16) 7086(2) 7964(5) 28(2) 
C(14) 5469(14) 6942(2) 3879(4) 22(2) 
C(15) 4810(15) 6700(2) 3272(5) 22(2) 
C(16) 4431(13) 6392(2) 3430(4) 19(2) 
C(17) 3855(16) 6114(2) 2901(5) 26(2) 
C(18) 4260(15) 6210(2) 2097(5) 29(2) 
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C(19) 4465(14) 6565(2) 1855(5) 24(2) 
C(20) 4486(14) 6813(2) 2497(4) 22(2) 
C(21) 3153(15) 6014(2) 5484(5) 22(2) 
C(22) 1029(17) 5914(2) 5211(6) 40(2) 
C(23) -515(17) 6034(2) 5746(6) 40(3) 
C(24) 870(20) 5545(2) 5044(7) 53(3) 
C(25) 1331(14) 7276(2) 6596(4) 21(2) 
C(26) 883(18) 7481(2) 7289(5) 38(3) 
C(27) -374(15) 7020(2) 6502(6) 34(2) 
C(28) 6005(18) 6153(2) 7776(5) 35(2) 
C(29) 2209(18) 6149(2) 8014(5) 37(3) 
C(30) 4790(19) 7083(2) 9371(5) 41(3) 
C(31) 7865(16) 6851(2) 8720(6) 39(2) 
C(32) 7845(15) 6999(2) 3942(5) 24(2) 
C(33) 8988(17) 6690(2) 4198(5) 37(2) 
C(34) 8756(17) 7124(2) 3195(5) 34(2) 
C(35) 5010(20) 5802(2) 3100(6) 51(3) 
C(36) 1498(18) 6049(3) 2929(6) 43(3) 
C(37) 6558(17) 6597(2) 1474(6) 42(3) 
C(38) 2713(18) 6644(2) 1285(6) 40(3) 
C(39) 3378(15) 7557(2) 4841(5) 23(2) 
C(40) 4028(16) 7915(2) 4781(5) 32(2) 
C(41) 6210(20) 7953(2) 4497(6) 42(2) 
F(1) 7731(10) 7865(1) 4985(4) 52(2) 
F(2) 6599(12) 8266(1) 4332(4) 61(2) 
F(3) 6492(11) 7778(1) 3877(3) 55(2) 
C(42) 3794(18) 8072(2) 5556(5) 35(2) 
C(43) 2105(18) 8285(2) 5647(6) 41(3) 
C(44) 1800(30) 8430(3) 6297(7) 73(4) 
C(45) 3140(30) 8355(3) 6914(7) 70(4) 
C(46) 4730(20) 8138(3) 6856(6) 61(3) 
C(47) 5040(20) 8001(2) 6154(6) 45(3) 
C(48) 2400(20) 7961(2) 3508(6) 60(4) 
O(11) -570(10) 8593(1) -395(3) 28(2) 
O(12) 2(13) 7454(1) -271(4) 45(2) 
O(13) 740(13) 8087(1) 1912(4) 48(2) 
O(14) 1189(10) 9693(1) -751(3) 26(1) 
O(15) 920(12) 10811(1) -1350(4) 39(2) 
O(16) 835(14) 10486(2) 1143(4) 53(2) 
O(17A) 1510(20) 9146(4) -1811(8) 30(5) 
O(17B) 1720(20) 8955(4) -1645(8) 51(5) 
O(18) 156(12) 9309(1) 1755(4) 38(2) 
O(19) 3147(13) 9076(2) 2071(4) 50(2) 
O(20) 2494(15) 9151(2) 3512(5) 65(2) 
C(49) 272(15) 9142(2) -552(5) 25(2) 
C(50) -155(15) 8898(2) -63(5) 24(2) 
C(51) -186(14) 8934(2) 709(5) 18(2) 
C(52) 408(14) 9241(2) 976(5) 20(2) 
C(53) 933(14) 9505(2) 517(5) 23(2) 
C(54) 829(15) 9441(2) -247(5) 26(2) 
C(55) -833(14) 8656(2) 1195(5) 22(2) 
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C(56) -287(13) 8339(2) 778(5) 18(2) 
C(57) -294(15) 8322(2) 36(5) 21(2) 
C(58) 67(14) 8027(2) -438(5) 23(2) 
C(59) 232(16) 7718(2) 43(5) 29(2) 
C(60) 848(15) 7724(2) 867(5) 25(2) 
C(61) 435(16) 8059(2) 1242(6) 28(2) 
C(62) 1780(14) 9826(2) 808(5) 23(2) 
C(63) 1243(14) 10086(2) 239(5) 23(2) 
C(64) 1136(15) 10013(2) -499(5) 26(2) 
C(65) 895(16) 10238(2) -1150(5) 29(2) 
C(66) 734(15) 10596(2) -881(5) 29(2) 
C(67) 190(18) 10674(2) -88(5) 35(2) 
C(68) 843(16) 10422(2) 475(5) 28(2) 
C(69) 110(20) 9083(2) -1402(6) 41(3) 
C(70A) -1480(50) 9222(15) -1947(14) 75(5) 
C(71A) -480(90) 9243(13) -2695(19) 80(6) 
C(70B) -2110(30) 9054(4) -1728(10) 74(5) 
C(71B) -2120(40) 8890(4) -2487(9) 82(5) 
C(72) -3440(30) 9330(3) -1724(9) 97(5) 
C(73) -3152(15) 8672(2) 1366(5) 30(2) 
C(74) -3831(19) 8400(2) 1905(6) 45(3) 
C(75) -4563(16) 8670(2) 664(6) 40(2) 
C(76) 2104(16) 8069(2) -867(6) 37(2) 
C(77) -1786(16) 7995(2) -1010(5) 34(2) 
C(78) -431(17) 7470(2) 1260(6) 41(3) 
C(79) 3141(16) 7651(2) 945(5) 32(2) 
C(80) 4142(15) 9795(2) 1015(6) 38(2) 
C(81) 5032(19) 10105(3) 1382(6) 52(3) 
C(82) 5380(17) 9707(3) 339(6) 47(3) 
C(83) -1021(18) 10156(2) -1648(6) 45(3) 
C(84) 2830(20) 10214(3) -1617(7) 53(3) 
C(85) -2276(18) 10675(2) -98(6) 46(3) 
C(86) 950(19) 11013(2) 141(6) 43(3) 
C(87) 1561(19) 9215(2) 2229(6) 36(2) 
C(88) 1054(18) 9316(2) 3041(5) 36(2) 
C(89) -1120(20) 9205(3) 3238(7) 60(3) 
C(90) 1570(16) 9681(2) 3124(5) 27(2) 
C(91) 3351(18) 9767(2) 3535(6) 45(3) 
C(92) 3910(20) 10097(3) 3583(7) 59(3) 
C(93) 2620(20) 10329(3) 3282(7) 60(3) 
C(94) 850(20) 10242(2) 2896(6) 53(3) 
C(95) 310(20) 9921(2) 2819(5) 42(3) 
C(96) 2510(30) 8790(3) 3525(9) 88(5) 
F(4) -1410(18) 9269(2) 3968(4) 115(4) 
F(5) -1572(15) 8905(2) 3095(4) 89(3) 
F(6) -2641(13) 9384(2) 2863(5) 80(2) 
 
Exp. Data Tab. 12 Bond lengths for 53 (sh3365). 
Bond Length [Å]  Bond Length [Å]  
O(1)-C(9)  1.370(10) O(12)-C(59)  1.224(10) 
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O(1)-C(2)  1.395(9) O(13)-C(61)  1.214(11) 
O(2)-C(11)  1.246(10) O(14)-C(64)  1.386(10) 
O(3)-C(13)  1.255(9) O(14)-C(54)  1.394(10) 
O(4)-C(16)  1.391(10) O(15)-C(66)  1.225(10) 
O(4)-C(6)  1.408(9) O(16)-C(68)  1.223(11) 
O(5)-C(18)  1.238(10) O(17A)-C(69)  1.205(15) 
O(6)-C(20)  1.222(9) O(17B)-C(69)  1.252(14) 
O(7)-C(21)  1.204(10) O(18)-C(87)  1.280(13) 
O(8)-C(39)  1.377(10) O(18)-C(52)  1.434(10) 
O(8)-C(4)  1.432(9) O(19)-C(87)  1.212(13) 
O(9)-C(39)  1.200(11) O(20)-C(88)  1.408(13) 
O(10)-C(40)  1.401(12) O(20)-C(96)  1.479(13) 
O(10)-C(48)  1.463(12) C(49)-C(50)  1.360(12) 
C(1)-C(2)  1.379(11) C(49)-C(54)  1.388(11) 
C(1)-C(6)  1.403(11) C(49)-C(69)  1.539(13) 
C(1)-C(21)  1.493(11) C(50)-C(51)  1.391(12) 
C(2)-C(3)  1.372(10) C(51)-C(52)  1.397(11) 
C(3)-C(4)  1.382(11) C(51)-C(55)  1.499(11) 
C(3)-C(7)  1.532(11) C(52)-C(53)  1.405(11) 
C(4)-C(5)  1.387(11) C(53)-C(54)  1.391(12) 
C(5)-C(6)  1.379(10) C(53)-C(62)  1.509(11) 
C(5)-C(14)  1.500(12) C(55)-C(73)  1.536(13) 
C(7)-C(8)  1.518(11) C(55)-C(56)  1.543(11) 
C(7)-C(25)  1.545(12) C(56)-C(57)  1.329(12) 
C(8)-C(9)  1.342(11) C(56)-C(61)  1.482(12) 
C(8)-C(13)  1.448(12) C(57)-C(58)  1.499(11) 
C(9)-C(10)  1.513(11) C(58)-C(59)  1.532(12) 
C(10)-C(11)  1.511(12) C(58)-C(76)  1.550(13) 
C(10)-C(29)  1.531(12) C(58)-C(77)  1.556(13) 
C(10)-C(28)  1.560(13) C(59)-C(60)  1.517(13) 
C(11)-C(12)  1.514(12) C(60)-C(79)  1.511(13) 
C(12)-C(31)  1.507(14) C(60)-C(78)  1.513(12) 
C(12)-C(13)  1.546(12) C(60)-C(61)  1.553(11) 
C(12)-C(30)  1.551(12) C(62)-C(63)  1.506(11) 
C(14)-C(15)  1.522(11) C(62)-C(80)  1.563(13) 
C(14)-C(32)  1.550(13) C(63)-C(64)  1.354(12) 
C(15)-C(16)  1.317(11) C(63)-C(68)  1.467(12) 
C(15)-C(20)  1.471(12) C(64)-C(65)  1.489(12) 
C(16)-C(17)  1.519(11) C(65)-C(84)  1.524(14) 
C(17)-C(35)  1.517(12) C(65)-C(83)  1.540(14) 
C(17)-C(18)  1.521(13) C(65)-C(66)  1.548(12) 
C(17)-C(36)  1.545(15) C(66)-C(67)  1.505(13) 
C(18)-C(19)  1.524(12) C(67)-C(68)  1.494(13) 
C(19)-C(20)  1.534(12) C(67)-C(86)  1.522(12) 
C(19)-C(38)  1.534(13) C(67)-C(85)  1.590(16) 
C(19)-C(37)  1.535(13) C(69)-C(70A)  1.51(2) 
C(21)-C(22)  1.498(14) C(69)-C(70B)  1.53(2) 
C(22)-C(23)  1.485(15) C(70A)-C(72)  1.41(2) 
C(22)-C(24)  1.545(13) C(70A)-C(71A)  1.51(2) 
C(25)-C(27)  1.526(13) C(70B)-C(72)  1.418(18) 
C(25)-C(26)  1.531(12) C(70B)-C(71B)  1.52(2) 
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C(32)-C(33)  1.529(12) C(73)-C(75)  1.529(13) 
C(32)-C(34)  1.561(12) C(73)-C(74)  1.543(12) 
C(39)-C(40)  1.530(12) C(80)-C(82)  1.512(15) 
C(40)-C(41)  1.517(15) C(80)-C(81)  1.532(14) 
C(40)-C(42)  1.540(13) C(87)-C(88)  1.554(14) 
C(41)-F(3)  1.338(11) C(88)-C(89)  1.523(17) 
C(41)-F(2)  1.342(10) C(88)-C(90)  1.540(11) 
C(41)-F(1)  1.343(13) C(89)-F(5)  1.290(12) 
C(42)-C(47)  1.350(15) C(89)-F(4)  1.351(14) 
C(42)-C(43)  1.410(14) C(89)-F(6)  1.382(16) 
C(43)-C(44)  1.324(15) C(90)-C(95)  1.374(13) 
C(44)-C(45)  1.42(2) C(90)-C(91)  1.391(14) 
C(45)-C(46)  1.36(2) C(91)-C(92)  1.400(14) 
C(46)-C(47)  1.394(15) C(92)-C(93)  1.361(18) 
O(11)-C(57)  1.359(9) C(93)-C(94)  1.365(18) 
O(11)-C(50)  1.405(9) C(94)-C(95)  1.366(14) 
 
Exp. Data Tab. 13 Bonds angles for 53 (sh3365). 
Bonds Angle [°]  Bonds Angle [°]  
C(9)-O(1)-C(2) 114.6(6) C(88)-O(20)-C(96) 119.5(10) 
C(16)-O(4)-C(6) 115.9(6) C(50)-C(49)-C(54) 116.8(8) 
C(39)-O(8)-C(4) 116.7(7) C(50)-C(49)-C(69) 120.8(7) 
C(40)-O(10)-C(48) 120.5(8) C(54)-C(49)-C(69) 122.4(7) 
C(2)-C(1)-C(6) 115.5(7) C(49)-C(50)-C(51) 124.8(7) 
C(2)-C(1)-C(21) 123.0(7) C(49)-C(50)-O(11) 114.9(7) 
C(6)-C(1)-C(21) 121.4(7) C(51)-C(50)-O(11) 120.3(7) 
C(3)-C(2)-C(1) 124.1(7) C(50)-C(51)-C(52) 115.0(7) 
C(3)-C(2)-O(1) 122.0(7) C(50)-C(51)-C(55) 120.5(7) 
C(1)-C(2)-O(1) 113.8(6) C(52)-C(51)-C(55) 124.4(7) 
C(2)-C(3)-C(4) 116.0(7) C(51)-C(52)-C(53) 124.2(8) 
C(2)-C(3)-C(7) 118.6(7) C(51)-C(52)-O(18) 117.9(7) 
C(4)-C(3)-C(7) 125.4(7) C(53)-C(52)-O(18) 117.1(7) 
C(3)-C(4)-C(5) 124.8(7) C(54)-C(53)-C(52) 115.1(7) 
C(3)-C(4)-O(8) 118.2(7) C(54)-C(53)-C(62) 120.5(8) 
C(5)-C(4)-O(8) 116.9(7) C(52)-C(53)-C(62) 124.0(8) 
C(6)-C(5)-C(4) 114.9(7) C(49)-C(54)-C(53) 123.9(7) 
C(6)-C(5)-C(14) 120.2(7) C(49)-C(54)-O(14) 116.4(7) 
C(4)-C(5)-C(14) 124.9(7) C(53)-C(54)-O(14) 119.6(7) 
C(5)-C(6)-C(1) 124.3(7) C(51)-C(55)-C(73) 111.8(7) 
C(5)-C(6)-O(4) 122.3(7) C(51)-C(55)-C(56) 106.7(7) 
C(1)-C(6)-O(4) 113.3(6) C(73)-C(55)-C(56) 111.7(7) 
C(8)-C(7)-C(3) 108.0(6) C(57)-C(56)-C(61) 120.8(7) 
C(8)-C(7)-C(25) 113.7(7) C(57)-C(56)-C(55) 122.1(7) 
C(3)-C(7)-C(25) 111.3(7) C(61)-C(56)-C(55) 116.9(7) 
C(9)-C(8)-C(13) 119.9(8) C(56)-C(57)-O(11) 121.4(7) 
C(9)-C(8)-C(7) 119.9(8) C(56)-C(57)-C(58) 127.5(7) 
C(13)-C(8)-C(7) 119.9(7) O(11)-C(57)-C(58) 111.0(7) 
C(8)-C(9)-O(1) 123.0(7) C(57)-C(58)-C(59) 111.1(7) 
C(8)-C(9)-C(10) 126.9(8) C(57)-C(58)-C(76) 109.8(7) 
O(1)-C(9)-C(10) 110.0(6) C(59)-C(58)-C(76) 108.9(8) 
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C(11)-C(10)-C(9) 111.0(7) C(57)-C(58)-C(77) 108.1(7) 
C(11)-C(10)-C(29) 111.3(7) C(59)-C(58)-C(77) 109.8(7) 
C(9)-C(10)-C(29) 110.1(7) C(76)-C(58)-C(77) 109.2(8) 
C(11)-C(10)-C(28) 108.9(8) O(12)-C(59)-C(60) 119.0(7) 
C(9)-C(10)-C(28) 107.6(7) O(12)-C(59)-C(58) 117.8(8) 
C(29)-C(10)-C(28) 107.8(7) C(60)-C(59)-C(58) 123.0(7) 
O(2)-C(11)-C(10) 118.3(8) C(79)-C(60)-C(78) 111.5(7) 
O(2)-C(11)-C(12) 119.6(8) C(79)-C(60)-C(59) 108.2(8) 
C(10)-C(11)-C(12) 122.0(7) C(78)-C(60)-C(59) 108.0(8) 
C(31)-C(12)-C(11) 108.8(7) C(79)-C(60)-C(61) 108.4(7) 
C(31)-C(12)-C(13) 106.6(8) C(78)-C(60)-C(61) 107.8(7) 
C(11)-C(12)-C(13) 112.2(7) C(59)-C(60)-C(61) 113.0(7) 
C(31)-C(12)-C(30) 110.6(8) O(13)-C(61)-C(56) 121.2(7) 
C(11)-C(12)-C(30) 109.3(7) O(13)-C(61)-C(60) 119.0(8) 
C(13)-C(12)-C(30) 109.2(7) C(56)-C(61)-C(60) 119.8(8) 
O(3)-C(13)-C(8) 120.9(8) C(63)-C(62)-C(53) 108.0(7) 
O(3)-C(13)-C(12) 117.8(8) C(63)-C(62)-C(80) 114.9(7) 
C(8)-C(13)-C(12) 121.3(7) C(53)-C(62)-C(80) 110.6(7) 
C(5)-C(14)-C(15) 109.5(7) C(64)-C(63)-C(68) 119.0(7) 
C(5)-C(14)-C(32) 109.2(7) C(64)-C(63)-C(62) 120.4(7) 
C(15)-C(14)-C(32) 113.9(7) C(68)-C(63)-C(62) 120.6(8) 
C(16)-C(15)-C(20) 118.8(7) C(63)-C(64)-O(14) 121.7(7) 
C(16)-C(15)-C(14) 121.4(7) C(63)-C(64)-C(65) 128.8(7) 
C(20)-C(15)-C(14) 119.7(7) O(14)-C(64)-C(65) 109.5(7) 
C(15)-C(16)-O(4) 123.8(7) C(64)-C(65)-C(84) 108.8(9) 
C(15)-C(16)-C(17) 128.9(7) C(64)-C(65)-C(83) 112.4(8) 
O(4)-C(16)-C(17) 107.3(6) C(84)-C(65)-C(83) 108.8(9) 
C(35)-C(17)-C(16) 112.1(8) C(64)-C(65)-C(66) 110.5(7) 
C(35)-C(17)-C(18) 110.0(7) C(84)-C(65)-C(66) 107.1(8) 
C(16)-C(17)-C(18) 110.5(7) C(83)-C(65)-C(66) 109.1(8) 
C(35)-C(17)-C(36) 108.8(9) O(15)-C(66)-C(67) 121.5(8) 
C(16)-C(17)-C(36) 109.4(7) O(15)-C(66)-C(65) 117.4(8) 
C(18)-C(17)-C(36) 105.8(8) C(67)-C(66)-C(65) 120.9(7) 
O(5)-C(18)-C(17) 118.4(8) C(68)-C(67)-C(66) 114.8(8) 
O(5)-C(18)-C(19) 119.3(8) C(68)-C(67)-C(86) 111.4(8) 
C(17)-C(18)-C(19) 122.3(7) C(66)-C(67)-C(86) 111.5(8) 
C(18)-C(19)-C(20) 114.7(7) C(68)-C(67)-C(85) 105.8(8) 
C(18)-C(19)-C(38) 108.7(8) C(66)-C(67)-C(85) 104.5(8) 
C(20)-C(19)-C(38) 110.4(7) C(86)-C(67)-C(85) 108.3(8) 
C(18)-C(19)-C(37) 107.0(7) O(16)-C(68)-C(63) 119.2(8) 
C(20)-C(19)-C(37) 106.6(7) O(16)-C(68)-C(67) 120.2(8) 
C(38)-C(19)-C(37) 109.1(8) C(63)-C(68)-C(67) 120.2(8) 
O(6)-C(20)-C(15) 120.7(7) O(17A)-C(69)-C(70A) 91.9(16) 
O(6)-C(20)-C(19) 119.7(7) O(17B)-C(69)-C(70B) 127.5(11) 
C(15)-C(20)-C(19) 119.6(7) O(17A)-C(69)-C(49) 122.5(12) 
O(7)-C(21)-C(1) 121.7(8) O(17B)-C(69)-C(49) 112.1(11) 
O(7)-C(21)-C(22) 121.4(8) C(70A)-C(69)-C(49) 127.2(15) 
C(1)-C(21)-C(22) 116.7(8) C(70B)-C(69)-C(49) 114.9(11) 
C(23)-C(22)-C(21) 108.9(8) C(72)-C(70A)-C(69) 122.3(16) 
C(23)-C(22)-C(24) 114.1(9) C(72)-C(70A)-C(71A) 130(3) 
C(21)-C(22)-C(24) 112.6(9) C(69)-C(70A)-C(71A) 107(3) 
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C(27)-C(25)-C(26) 108.3(8) C(72)-C(70B)-C(71B) 111.6(14) 
C(27)-C(25)-C(7) 113.6(7) C(72)-C(70B)-C(69) 119.7(13) 
C(26)-C(25)-C(7) 112.7(8) C(71B)-C(70B)-C(69) 110.9(15) 
C(33)-C(32)-C(14) 111.3(7) C(75)-C(73)-C(55) 113.3(8) 
C(33)-C(32)-C(34) 109.8(8) C(75)-C(73)-C(74) 109.7(8) 
C(14)-C(32)-C(34) 112.5(7) C(55)-C(73)-C(74) 112.9(8) 
O(9)-C(39)-O(8) 121.1(7) C(82)-C(80)-C(81) 109.9(9) 
O(9)-C(39)-C(40) 126.5(9) C(82)-C(80)-C(62) 111.3(9) 
O(8)-C(39)-C(40) 112.4(8) C(81)-C(80)-C(62) 112.7(8) 
O(10)-C(40)-C(41) 108.5(8) O(19)-C(87)-O(18) 124.9(10) 
O(10)-C(40)-C(39) 108.5(8) O(19)-C(87)-C(88) 123.0(10) 
C(41)-C(40)-C(39) 112.4(8) O(18)-C(87)-C(88) 112.0(10) 
O(10)-C(40)-C(42) 107.7(7) O(20)-C(88)-C(89) 108.3(9) 
C(41)-C(40)-C(42) 112.0(9) O(20)-C(88)-C(90) 105.7(8) 
C(39)-C(40)-C(42) 107.6(8) C(89)-C(88)-C(90) 117.7(10) 
F(3)-C(41)-F(2) 107.4(8) O(20)-C(88)-C(87) 106.3(9) 
F(3)-C(41)-F(1) 106.2(9) C(89)-C(88)-C(87) 110.9(9) 
F(2)-C(41)-F(1) 105.1(9) C(90)-C(88)-C(87) 107.3(7) 
F(3)-C(41)-C(40) 111.9(9) F(5)-C(89)-F(4) 109.8(10) 
F(2)-C(41)-C(40) 110.8(9) F(5)-C(89)-F(6) 104.7(12) 
F(1)-C(41)-C(40) 114.9(9) F(4)-C(89)-F(6) 104.4(11) 
C(47)-C(42)-C(43) 119.0(9) F(5)-C(89)-C(88) 116.3(11) 
C(47)-C(42)-C(40) 123.5(10) F(4)-C(89)-C(88) 108.8(11) 
C(43)-C(42)-C(40) 117.3(9) F(6)-C(89)-C(88) 112.1(9) 
C(44)-C(43)-C(42) 121.0(12) C(95)-C(90)-C(91) 119.9(9) 
C(43)-C(44)-C(45) 118.9(12) C(95)-C(90)-C(88) 122.1(9) 
C(46)-C(45)-C(44) 121.7(11) C(91)-C(90)-C(88) 117.9(9) 
C(45)-C(46)-C(47) 117.4(12) C(90)-C(91)-C(92) 118.7(10) 
C(42)-C(47)-C(46) 121.9(12) C(93)-C(92)-C(91) 120.0(12) 
C(57)-O(11)-C(50) 117.8(6) C(92)-C(93)-C(94) 120.4(10) 
C(64)-O(14)-C(54) 118.8(7) C(93)-C(94)-C(95) 120.7(11) 
C(87)-O(18)-C(52) 119.1(8) C(94)-C(95)-C(90) 120.1(11) 
 
Exp. Data Tab. 14 Anisotropic displacement parameters (Å2x 103) for 53 (sh3365) The anisotropic displacement factor 
exponent takes the form: -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
Atom U11 U22 U33 U23 U13 U12 
O(1) 27(4) 24(3) 13(3) 3(2) 0(2) -9(2) 
O(2) 68(6) 35(4) 23(4) 4(3) 5(3) -8(3) 
O(3) 58(6) 30(3) 26(4) 4(3) -1(3) -6(3) 
O(4) 33(4) 20(3) 19(3) -1(2) -1(3) 1(2) 
O(5) 89(7) 41(4) 30(4) -12(3) 5(4) -7(4) 
O(6) 59(5) 26(3) 17(3) 0(3) -2(3) 8(3) 
O(7) 39(5) 23(3) 64(5) 9(3) -10(4) -1(3) 
O(8) 23(4) 14(3) 23(3) 0(2) 3(3) -6(2) 
O(9) 25(4) 33(3) 32(4) 6(3) -5(3) 1(3) 
O(10) 72(6) 25(3) 22(4) 6(3) -5(3) 1(3) 
C(1) 21(5) 18(4) 19(4) -2(3) -3(4) -2(3) 
C(2) 12(5) 22(4) 20(4) 1(3) 2(3) -6(3) 
C(3) 15(5) 19(4) 25(4) -1(3) 3(4) 1(3) 
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C(4) 14(5) 19(4) 19(4) 4(3) 0(3) -4(3) 
C(5) 22(6) 14(4) 29(5) -3(3) -6(4) -2(3) 
C(6) 19(5) 15(4) 16(4) -3(3) -6(3) 1(3) 
C(7) 22(5) 19(4) 14(4) 3(3) 2(3) -4(3) 
C(8) 16(5) 24(4) 23(4) 6(3) 1(3) 0(3) 
C(9) 19(5) 18(4) 19(4) 3(3) 3(3) -5(3) 
C(10) 31(6) 18(4) 21(4) 8(3) -9(4) -4(3) 
C(11) 27(6) 35(5) 23(5) 0(4) 3(4) -7(4) 
C(12) 32(6) 27(4) 15(4) -3(3) -4(4) -1(4) 
C(13) 41(7) 26(5) 18(5) 1(3) -3(4) -3(4) 
C(14) 26(5) 25(4) 14(4) -3(3) 1(3) -1(4) 
C(15) 30(6) 19(4) 17(4) -9(3) -6(4) 5(3) 
C(16) 11(5) 30(4) 16(4) -1(3) 2(3) 2(3) 
C(17) 36(6) 19(4) 23(4) -9(3) 3(4) 5(4) 
C(18) 23(6) 41(5) 22(5) -9(4) 1(4) 3(4) 
C(19) 18(5) 28(4) 25(5) -5(3) -5(4) 6(4) 
C(20) 21(6) 30(4) 15(4) 2(3) -1(3) 6(4) 
C(21) 27(6) 19(4) 20(5) -6(3) 2(4) -1(3) 
C(22) 36(7) 30(5) 54(7) 5(5) -5(5) -17(4) 
C(23) 30(7) 46(6) 46(7) 1(5) -4(5) -11(5) 
C(24) 65(10) 27(5) 67(8) -7(5) -7(6) -27(5) 
C(25) 29(6) 25(4) 9(4) 2(3) -2(3) 7(3) 
C(26) 47(8) 37(5) 29(6) -2(4) 10(5) 8(5) 
C(27) 16(6) 46(6) 41(6) -4(4) -3(4) 5(4) 
C(28) 54(7) 32(5) 18(5) -3(4) -9(4) 16(4) 
C(29) 61(7) 34(5) 15(5) 14(4) 6(5) -25(5) 
C(30) 72(9) 32(5) 19(5) 3(4) 9(5) -2(5) 
C(31) 25(6) 41(6) 49(7) 0(5) -11(5) -2(4) 
C(32) 26(5) 25(4) 22(5) -6(4) 5(4) -6(4) 
C(33) 32(7) 48(6) 30(6) -4(4) -7(5) 11(4) 
C(34) 31(7) 49(6) 22(5) -6(4) 1(4) -11(4) 
C(35) 90(10) 26(5) 36(6) -8(4) 1(6) 19(5) 
C(36) 48(7) 54(6) 27(6) -17(5) 2(5) -24(5) 
C(37) 39(7) 47(6) 40(6) -13(5) 20(5) -9(5) 
C(38) 51(7) 38(5) 30(6) -15(4) -13(5) 6(5) 
C(39) 25(6) 19(4) 26(6) -7(3) -4(4) 1(3) 
C(40) 36(6) 27(4) 32(5) -6(4) 5(4) 4(4) 
C(41) 51(7) 20(5) 55(7) -3(4) 13(5) -6(4) 
F(1) 39(4) 42(3) 76(5) -5(3) 4(3) -7(3) 
F(2) 80(6) 24(3) 79(5) 6(3) 38(4) -13(3) 
F(3) 71(5) 39(3) 55(4) -4(3) 31(3) 2(3) 
C(42) 57(8) 23(5) 24(5) -11(4) 4(4) 1(4) 
C(43) 48(8) 33(5) 41(6) -11(4) 14(5) 5(4) 
C(44) 111(13) 51(7) 59(8) -7(6) 39(7) 32(7) 
C(45) 122(14) 46(7) 42(7) -14(6) 28(7) -17(7) 
C(46) 103(11) 48(7) 31(6) 1(5) -7(6) -27(6) 
C(47) 54(8) 36(6) 46(6) -7(5) 2(5) -4(5) 
C(48) 105(12) 37(6) 36(6) 8(5) -10(6) 3(6) 
O(11) 40(5) 14(3) 29(4) -3(2) -3(3) 0(3) 
O(12) 70(6) 15(3) 48(5) -11(3) -21(4) -1(3) 
O(13) 85(7) 25(3) 32(4) 3(3) -19(4) -1(4) 
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O(14) 34(4) 22(3) 21(3) 2(2) 1(3) 5(3) 
O(15) 58(6) 27(3) 33(4) 7(3) -4(3) -8(3) 
O(16) 103(8) 26(4) 30(4) -3(3) -6(4) 6(4) 
O(18) 57(6) 19(3) 38(4) 3(3) -1(3) -5(3) 
O(19) 60(6) 47(4) 42(5) -7(3) -13(4) 12(4) 
O(20) 92(7) 38(4) 66(5) 3(4) -16(5) 4(4) 
C(49) 35(7) 21(4) 21(4) -1(3) 7(4) -1(4) 
C(50) 28(6) 15(4) 27(5) -4(3) -11(4) -1(3) 
C(51) 16(5) 18(4) 20(4) 3(3) 0(3) 2(3) 
C(52) 18(6) 28(4) 16(4) -1(3) 4(3) 5(3) 
C(53) 16(5) 25(4) 29(5) -5(3) -5(4) 1(3) 
C(54) 30(6) 21(4) 26(5) 2(3) 1(4) -3(4) 
C(55) 21(5) 14(4) 29(5) 1(3) 2(4) -6(3) 
C(56) 11(5) 18(4) 27(4) 0(3) 3(3) -4(3) 
C(57) 29(6) 11(4) 23(5) 1(3) -1(4) 3(3) 
C(58) 21(5) 14(4) 34(5) -5(3) -2(4) -4(3) 
C(59) 28(6) 18(4) 41(5) -2(4) -12(4) 2(4) 
C(60) 25(6) 12(4) 37(5) 2(3) 0(4) -4(3) 
C(61) 33(6) 16(4) 36(5) -1(4) 5(4) 2(3) 
C(62) 11(5) 25(4) 32(5) 1(3) -7(4) -3(3) 
C(63) 18(6) 22(4) 29(5) 5(3) -2(4) 3(3) 
C(64) 21(6) 19(4) 39(5) -1(3) 0(4) -1(3) 
C(65) 31(6) 25(4) 32(5) -2(4) -2(4) -4(4) 
C(66) 27(6) 22(4) 37(5) 1(4) -3(4) -7(4) 
C(67) 60(7) 18(4) 25(5) 0(4) -4(5) 2(4) 
C(68) 35(6) 18(4) 32(5) 2(4) 0(4) -6(4) 
C(69) 72(8) 21(5) 30(5) -3(4) -7(5) 1(5) 
C(70A) 115(11) 74(11) 35(8) -15(8) -37(8) 46(9) 
C(71A) 122(14) 80(13) 37(9) -13(10) -36(10) 37(12) 
C(70B) 114(11) 72(10) 32(7) -14(7) -40(7) 53(8) 
C(71B) 122(12) 85(10) 37(8) -18(7) -39(7) 29(9) 
C(72) 90(12) 82(10) 117(14) -28(9) -20(9) 24(8) 
C(73) 21(6) 31(5) 37(6) -7(4) 6(4) -11(4) 
C(74) 53(9) 42(6) 40(6) -5(4) 27(5) -19(5) 
C(75) 23(6) 39(6) 57(6) -12(5) -4(5) 1(4) 
C(76) 30(6) 40(5) 43(6) -8(5) 14(5) -4(4) 
C(77) 38(7) 31(5) 32(6) -6(4) -16(4) -2(4) 
C(78) 32(7) 26(5) 64(7) 6(5) 10(5) -7(4) 
C(79) 29(6) 34(5) 33(6) 1(4) 0(4) 3(4) 
C(80) 14(6) 38(5) 61(7) 16(5) -11(4) -3(4) 
C(81) 47(8) 67(7) 40(7) 18(5) -10(5) -36(6) 
C(82) 17(6) 47(6) 77(8) 7(5) 4(5) 1(5) 
C(83) 53(8) 30(5) 49(7) 9(5) -25(5) -7(5) 
C(84) 52(8) 52(6) 56(8) 5(5) 26(6) 5(5) 
C(85) 45(7) 43(6) 51(7) -10(5) 3(5) -3(5) 
C(86) 65(9) 24(5) 40(6) 11(4) -2(5) -7(5) 
C(87) 41(7) 25(5) 43(5) -4(4) 4(5) -3(4) 
C(88) 65(7) 23(4) 21(5) -2(4) -4(4) -21(4) 
C(89) 68(8) 49(7) 63(8) -4(6) 20(6) -17(6) 
C(90) 34(6) 25(4) 23(5) -1(4) 6(4) -10(4) 
C(91) 42(7) 31(5) 60(8) -17(5) -9(5) 2(4) 
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C(92) 57(9) 51(6) 68(9) -15(6) -7(6) -26(5) 
C(93) 94(11) 28(6) 58(9) -18(5) 7(7) -5(5) 
C(94) 103(11) 37(5) 19(6) 1(5) 1(6) 6(6) 
C(95) 67(9) 34(5) 23(6) 4(4) -13(5) 1(5) 
C(96) 131(16) 40(6) 93(12) 8(7) 15(10) 18(8) 
F(4) 156(10) 132(7) 61(5) -35(5) 66(5) -64(7) 
F(5) 118(8) 63(4) 88(6) -4(4) 25(5) -48(4) 
F(6) 43(5) 102(5) 98(6) -15(4) 28(4) -5(4) 
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6.3. Appendix 3: crystal data for 85 
 
 
Exp. Data Tab. 15 Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for 85 (sh3169). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 1190(3) 3379(2) 2485(5) 26(1) 
O(2) -523(4) 1695(3) -880(6) 50(2) 
O(3) 1990(4) 3562(2) -2533(5) 35(1) 
O(4) 4107(3) 5168(2) 1105(5) 29(1) 
O(5) 3632(3) 4443(2) 6097(5) 31(1) 
C(1) 1121(5) 3133(3) 1046(8) 26(2) 
C(2) 407(5) 2406(3) 986(8) 26(2) 
C(3) 257(6) 2145(3) -600(8) 28(2) 
C(4) 1052(6) 2417(4) -1784(8) 33(2) 
C(5) 1550(5) 3214(4) -1490(8) 29(2) 
C(6) 1598(5) 3525(4) -44(8) 19(2) 
C(7) 2154(5) 4308(3) 193(7) 23(2) 
C(8) 2584(5) 4338(3) 1736(8) 18(2) 
C(9) 3539(5) 4774(3) 2184(7) 20(2) 
C(10) 3892(6) 4805(3) 3637(7) 24(2) 
C(11) 3282(5) 4392(3) 4646(8) 25(2) 
C(12) 2372(5) 3913(4) 4259(7) 21(2) 
C(13) 2073(5) 3910(3) 2826(7) 19(2) 
C(14) 994(6) 1734(4) 1821(9) 44(2) 
C(15) -769(5) 2558(4) 1687(9) 41(2) 
C(16) 2087(6) 1860(3) -1807(9) 52(2) 
C(17) 444(6) 2401(4) -3251(9) 65(3) 
C(18) 1277(5) 4949(3) -219(8) 33(2) 
C(19) 311(6) 5027(4) 890(9) 54(2) 
C(20) 1860(6) 5723(3) -476(9) 52(3) 
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Exp. Data Tab. 16 Bond lengths [Å] for 85 (sh3169). 
Bond Length [Å] Bond Length [Å] 
O(1)-C(1)  1.390(7) C(10)-H(10)  0.9500 
O(1)-C(13)  1.414(6) C(11)-C(12)  1.391(8) 
O(2)-C(3)  1.224(7) C(12)-C(13)  1.361(8) 
O(3)-C(5)  1.242(7) C(12)-H(12)  0.9500 
O(4)-C(9)  1.373(6) C(14)-H(14A)  0.9800 
O(4)-H(4)  0.8400 C(14)-H(14B)  0.9800 
O(5)-C(11)  1.396(8) C(14)-H(14C)  0.9800 
O(5)-H(5)  0.8400 C(15)-H(15A)  0.9800 
C(1)-C(6)  1.330(8) C(15)-H(15B)  0.9800 
C(1)-C(2)  1.508(8) C(15)-H(15C)  0.9800 
C(2)-C(3)  1.534(9) C(16)-H(16A)  0.9800 
C(2)-C(15)  1.535(8) C(16)-H(16B)  0.9800 
C(2)-C(14)  1.553(9) C(16)-H(16C)  0.9800 
C(3)-C(4)  1.503(9) C(17)-H(17A)  0.9800 
C(4)-C(5)  1.519(8) C(17)-H(17B)  0.9800 
C(4)-C(17)  1.522(10) C(17)-H(17C)  0.9800 
C(4)-C(16)  1.544(9) C(18)-C(20)  1.519(8) 
C(5)-C(6)  1.434(9) C(18)-C(19)  1.523(9) 
C(6)-C(7)  1.518(8) C(18)-H(18)  1.0000 
C(7)-C(8)  1.504(8) C(19)-H(19A)  0.9800 
C(7)-C(18)  1.555(8) C(19)-H(19B)  0.9800 
C(7)-H(7)  1.0000 C(19)-H(19C)  0.9800 
C(8)-C(13)  1.379(8) C(20)-H(20A)  0.9800 
C(8)-C(9)  1.405(8) C(20)-H(20B)  0.9800 
C(9)-C(10)  1.397(8) C(20)-H(20C)  0.9800 
C(10)-C(11)  1.368(8)   
 
Exp. Data Tab. 17 Bond angles [°] for 85 (sh3169). 
Bonds Angles [°] Bonds Angles [°] 
C(1)-O(1)-C(13) 116.9(5) C(11)-C(12)-H(12) 121.8 
C(9)-O(4)-H(4) 109.5 C(12)-C(13)-C(8) 126.0(6) 
C(11)-O(5)-H(5) 109.5 C(12)-C(13)-O(1) 113.8(6) 
C(6)-C(1)-O(1) 122.3(6) C(8)-C(13)-O(1) 120.1(6) 
C(6)-C(1)-C(2) 128.9(7) C(2)-C(14)-H(14A) 109.5 
O(1)-C(1)-C(2) 108.8(6) C(2)-C(14)-H(14B) 109.5 
C(1)-C(2)-C(3) 110.0(6) H(14A)-C(14)-H(14B) 109.5 
C(1)-C(2)-C(15) 109.5(5) C(2)-C(14)-H(14C) 109.5 
C(3)-C(2)-C(15) 110.3(6) H(14A)-C(14)-H(14C) 109.5 
C(1)-C(2)-C(14) 111.3(5) H(14B)-C(14)-H(14C) 109.5 
C(3)-C(2)-C(14) 107.3(5) C(2)-C(15)-H(15A) 109.5 
C(15)-C(2)-C(14) 108.2(6) C(2)-C(15)-H(15B) 109.5 
O(2)-C(3)-C(4) 120.2(7) H(15A)-C(15)-H(15B) 109.5 
O(2)-C(3)-C(2) 118.1(6) C(2)-C(15)-H(15C) 109.5 
C(4)-C(3)-C(2) 121.6(6) H(15A)-C(15)-H(15C) 109.5 
C(3)-C(4)-C(5) 113.0(6) H(15B)-C(15)-H(15C) 109.5 
C(3)-C(4)-C(17) 110.4(6) C(4)-C(16)-H(16A) 109.5 
C(5)-C(4)-C(17) 110.6(6) C(4)-C(16)-H(16B) 109.5 
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C(3)-C(4)-C(16) 107.1(5) H(16A)-C(16)-H(16B) 109.5 
C(5)-C(4)-C(16) 105.7(5) C(4)-C(16)-H(16C) 109.5 
C(17)-C(4)-C(16) 109.8(6) H(16A)-C(16)-H(16C) 109.5 
O(3)-C(5)-C(6) 121.1(6) H(16B)-C(16)-H(16C) 109.5 
O(3)-C(5)-C(4) 117.4(6) C(4)-C(17)-H(17A) 109.5 
C(6)-C(5)-C(4) 121.3(6) C(4)-C(17)-H(17B) 109.5 
C(1)-C(6)-C(5) 119.3(6) H(17A)-C(17)-H(17B) 109.5 
C(1)-C(6)-C(7) 121.7(6) C(4)-C(17)-H(17C) 109.5 
C(5)-C(6)-C(7) 118.9(6) H(17A)-C(17)-H(17C) 109.5 
C(8)-C(7)-C(6) 107.9(6) H(17B)-C(17)-H(17C) 109.5 
C(8)-C(7)-C(18) 115.1(6) C(20)-C(18)-C(19) 110.9(6) 
C(6)-C(7)-C(18) 108.8(5) C(20)-C(18)-C(7) 111.9(5) 
C(8)-C(7)-H(7) 108.3 C(19)-C(18)-C(7) 112.6(5) 
C(6)-C(7)-H(7) 108.3 C(20)-C(18)-H(18) 107.0 
C(18)-C(7)-H(7) 108.3 C(19)-C(18)-H(18) 107.0 
C(13)-C(8)-C(9) 114.7(6) C(7)-C(18)-H(18) 107.0 
C(13)-C(8)-C(7) 121.4(6) C(18)-C(19)-H(19A) 109.5 
C(9)-C(8)-C(7) 123.9(6) C(18)-C(19)-H(19B) 109.5 
O(4)-C(9)-C(10) 121.9(5) H(19A)-C(19)-H(19B) 109.5 
O(4)-C(9)-C(8) 115.9(6) C(18)-C(19)-H(19C) 109.5 
C(10)-C(9)-C(8) 122.2(6) H(19A)-C(19)-H(19C) 109.5 
C(11)-C(10)-C(9) 118.3(6) H(19B)-C(19)-H(19C) 109.5 
C(11)-C(10)-H(10) 120.9 C(18)-C(20)-H(20A) 109.5 
C(9)-C(10)-H(10) 120.9 C(18)-C(20)-H(20B) 109.5 
C(10)-C(11)-C(12) 122.2(6) H(20A)-C(20)-H(20B) 109.5 
C(10)-C(11)-O(5) 117.5(6) C(18)-C(20)-H(20C) 109.5 
C(12)-C(11)-O(5) 120.2(6) H(20A)-C(20)-H(20C) 109.5 
C(13)-C(12)-C(11) 116.4(6) H(20B)-C(20)-H(20C) 109.5 
C(13)-C(12)-H(12) 121.8   
 
Exp. Data Tab. 18 Anisotropic displacement parameters  (Å2x 103 for 85 (sh3169). The anisotropic displacement factor 
exponent takes the form: -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
Atom U11 U22 U33 U23 U13 U12 
O(1) 26(3) 29(3) 23(3) 0(2) -2(2) -10(2) 
O(2) 63(3) 49(3) 37(3) -5(3) 2(3) -35(3) 
O(3) 48(3) 38(3) 19(3) -6(3) 2(3) -21(2) 
O(4) 40(3) 25(2) 22(3) -2(3) 3(3) -16(2) 
O(5) 41(3) 33(3) 20(3) 7(3) 0(3) -12(2) 
C(1) 29(4) 24(4) 25(5) -8(4) -12(4) 8(3) 
C(2) 25(4) 25(4) 28(5) -3(4) 4(4) -10(3) 
C(3) 35(4) 20(4) 29(5) 6(4) -3(4) -12(3) 
C(4) 42(5) 32(4) 26(5) 3(4) 3(4) -11(4) 
C(5) 32(4) 30(4) 23(5) -4(4) -7(4) -3(3) 
C(6) 23(4) 16(3) 19(4) 1(3) -1(3) -8(3) 
C(7) 28(4) 22(4) 19(4) -3(3) 1(4) 2(3) 
C(8) 22(3) 16(3) 18(4) -4(3) 4(3) -2(3) 
C(9) 20(3) 11(3) 27(5) 10(3) 4(3) -4(3) 
C(10) 25(4) 22(4) 25(4) 2(4) -3(3) -10(3) 
C(11) 22(4) 25(4) 28(5) -5(4) -4(3) 1(3) 
C(12) 25(4) 21(4) 17(4) 0(3) 4(3) -5(3) 
Appendices  - 193 - 
C(13) 20(4) 8(3) 29(5) 3(3) -6(3) -5(3) 
C(14) 61(5) 22(4) 48(5) 10(4) -15(5) -8(4) 
C(15) 33(4) 47(5) 42(5) -10(4) 6(4) -16(4) 
C(16) 74(6) 23(4) 58(6) -18(4) 26(5) -12(4) 
C(17) 98(7) 68(6) 28(5) 3(5) -12(6) -53(5) 
C(18) 41(4) 18(4) 39(5) 8(4) -7(4) 1(3) 
C(19) 47(5) 52(5) 63(7) 6(5) 4(5) 27(4) 
C(20) 64(5) 19(4) 73(7) 18(4) -18(5) -4(4) 
 
Exp. Data Tab. 19 Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 10 3) for 85 (sh3169). 
Hydrogen atom x y z U(eq) 
H(4) 4659 5414 1469 44 
H(5) 3202 4168 6618 47 
H(7) 2830 4351 -475 28 
H(10) 4539 5104 3917 29 
H(12) 1981 3605 4957 25 
H(14A) 1709 1591 1326 65 
H(14B) 477 1287 1846 65 
H(14C) 1166 1899 2819 65 
H(15A) -667 2666 2727 61 
H(15B) -1257 2101 1569 61 
H(15C) -1132 3003 1215 61 
H(16A) 2496 1891 -875 78 
H(16B) 2609 2005 -2599 78 
H(16C) 1815 1330 -1960 78 
H(17A) 155 1878 -3440 97 
H(17B) 985 2548 -4020 97 
H(17C) -200 2765 -3239 97 
H(18) 916 4792 -1162 39 
H(19A) 629 5198 1824 81 
H(19B) -68 4525 1016 81 
H(19C) -249 5407 543 81 
H(20A) 1301 6091 -870 78 
H(20B) 2491 5656 -1172 78 
H(20C) 2165 5919 447 78 
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6.4. Appendix 4: crystal data for anti-97 
 
Exp. Data Tab. 20 Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for anti-97 
(sh3587a). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 1646(2) 6090(1) 6360(2) 20(1) 
O(2) 1153(2) 4538(1) 3514(2) 37(1) 
O(3) 3714(2) 4303(1) 7384(2) 28(1) 
O(4) 4467(2) 4061(1) 9493(2) 34(1) 
O(5) 3174(2) 5640(1) 10356(2) 21(1) 
O(6) 2000(2) 7675(1) 9511(2) 30(1) 
C(1) 1212(2) 5851(1) 5265(2) 19(1) 
C(2) 301(2) 6217(1) 4621(2) 23(1) 
C(3) -43(2) 6071(1) 3309(2) 25(1) 
C(4) -47(3) 5369(1) 3172(2) 29(1) 
C(5) 932(2) 5045(1) 3823(2) 24(1) 
C(6) 1579(2) 5341(1) 4886(2) 21(1) 
C(7) 2563(2) 5039(1) 5578(2) 21(1) 
C(8) 2714(2) 5187(1) 6854(2) 19(1) 
C(9) 3292(2) 4805(1) 7732(2) 19(1) 
C(10) 3418(2) 4930(1) 8934(2) 20(1) 
C(11) 2978(2) 5486(1) 9188(2) 18(1) 
C(12) 2389(2) 5876(1) 8345(2) 19(1) 
C(13) 2273(2) 5704(1) 7186(2) 18(1) 
C(14) 1825(2) 6417(1) 8675(2) 19(1) 
C(15) 2419(2) 6630(1) 9876(2) 18(1) 
C(16) 2378(2) 7277(1) 10223(2) 22(1) 
C(17) 2832(2) 7428(1) 11501(2) 26(1) 
C(18) 3825(2) 7073(1) 12070(2) 23(1) 
C(19) 3588(2) 6382(1) 11878(2) 21(1) 
C(20) 3020(2) 6240(1) 10644(2) 19(1) 
C(21) 703(3) 6359(2) 2685(2) 32(1) 
C(22) -1131(3) 6324(2) 2784(3) 37(1) 
C(23) 3525(2) 5232(2) 5183(2) 26(1) 
C(24) 3709(3) 5923(2) 5253(3) 33(1) 
C(25) 3465(3) 4995(2) 3953(3) 40(1) 
C(26) 3951(2) 4461(1) 9797(2) 22(1) 
C(27) 3802(2) 4420(1) 11013(2) 25(1) 
Appendices  - 195 - 
C(28) 2664(3) 4283(2) 10905(3) 35(1) 
C(29) 4501(3) 3923(2) 11725(3) 35(1) 
C(30) 686(2) 6242(1) 8579(2) 25(1) 
C(31) 51(3) 6794(2) 8760(4) 51(1) 
C(32) 588(3) 5728(2) 9412(3) 33(1) 
C(33) 4170(3) 7211(2) 13381(2) 32(1) 
C(34) 4688(2) 7265(2) 11529(2) 29(1) 
Cl(1) 1591(2) 2574(1) 4773(2) 173(1) 
Cl(2) 3086(2) 3039(1) 3725(3) 177(1) 
C(35) 2276(6) 3192(3) 4488(7) 143(3) 
 
Exp. Data Tab. 21 Bond lengths [Å] for anti-97 (sh3587a). 
Bond  Length [Å] Bond Length [Å] 
O(1)-C(1)  1.376(3) C(19)-H(19A)  0.9900 
O(1)-C(13)  1.385(3) C(19)-H(19B)  0.9900 
O(2)-C(5)  1.221(4) C(21)-H(21A)  0.9800 
O(3)-C(9)  1.344(3) C(21)-H(21B)  0.9800 
O(3)-H(3)  0.8400 C(21)-H(21C)  0.9800 
O(4)-C(26)  1.225(3) C(22)-H(22A)  0.9800 
O(5)-C(20)  1.375(3) C(22)-H(22B)  0.9800 
O(5)-C(11)  1.384(3) C(22)-H(22C)  0.9800 
O(6)-C(16)  1.217(3) C(23)-C(24)  1.517(5) 
C(1)-C(6)  1.338(4) C(23)-C(25)  1.534(4) 
C(1)-C(2)  1.482(4) C(23)-H(23)  1.0000 
C(2)-C(3)  1.536(4) C(24)-H(24A)  0.9800 
C(2)-H(2A)  0.9900 C(24)-H(24B)  0.9800 
C(2)-H(2B)  0.9900 C(24)-H(24C)  0.9800 
C(3)-C(22)  1.524(4) C(25)-H(25A)  0.9800 
C(3)-C(4)  1.530(4) C(25)-H(25B)  0.9800 
C(3)-C(21)  1.534(4) C(25)-H(25C)  0.9800 
C(4)-C(5)  1.503(4) C(26)-C(27)  1.518(4) 
C(4)-H(4A)  0.9900 C(27)-C(29)  1.524(4) 
C(4)-H(4B)  0.9900 C(27)-C(28)  1.526(4) 
C(5)-C(6)  1.471(4) C(27)-H(27)  1.0000 
C(6)-C(7)  1.503(4) C(28)-H(28A)  0.9800 
C(7)-C(8)  1.512(3) C(28)-H(28B)  0.9800 
C(7)-C(23)  1.549(4) C(28)-H(28C)  0.9800 
C(7)-H(7)  1.0000 C(29)-H(29A)  0.9800 
C(8)-C(13)  1.376(4) C(29)-H(29B)  0.9800 
C(8)-C(9)  1.390(4) C(29)-H(29C)  0.9800 
C(9)-C(10)  1.421(3) C(30)-C(31)  1.518(4) 
C(10)-C(11)  1.412(4) C(30)-C(32)  1.521(4) 
C(10)-C(26)  1.483(4) C(30)-H(30)  1.0000 
C(11)-C(12)  1.381(4) C(31)-H(31A)  0.9800 
C(12)-C(13)  1.396(3) C(31)-H(31B)  0.9800 
C(12)-C(14)  1.506(4) C(31)-H(31C)  0.9800 
C(14)-C(15)  1.506(4) C(32)-H(32A)  0.9800 
C(14)-C(30)  1.549(4) C(32)-H(32B)  0.9800 
C(14)-H(14)  1.0000 C(32)-H(32C)  0.9800 
C(15)-C(20)  1.341(4) C(33)-H(33A)  0.9800 
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C(15)-C(16)  1.468(4) C(33)-H(33B)  0.9800 
C(16)-C(17)  1.512(4) C(33)-H(33C)  0.9800 
C(17)-C(18)  1.526(4) C(34)-H(34A)  0.9800 
C(17)-H(17A)  0.9900 C(34)-H(34B)  0.9800 
C(17)-H(17B)  0.9900 C(34)-H(34C)  0.9800 
C(18)-C(34)  1.530(4) Cl(1)-C(35)  1.712(6) 
C(18)-C(33)  1.532(4) Cl(2)-C(35)  1.631(6) 
C(18)-C(19)  1.536(4) C(35)-H(35A)  0.9900 
C(19)-C(20)  1.490(4) C(35)-H(35B)  0.9900 
 
Exp. Data Tab. 22 Bond angles [°] for anti-97 (sh3587a). 
Bonds Angles [°] Bonds Angles [°] 
C(1)-O(1)-C(13) 117.5(2) C(3)-C(21)-H(21A) 109.5 
C(9)-O(3)-H(3) 109.5 C(3)-C(21)-H(21B) 109.5 
C(20)-O(5)-C(11) 118.6(2) H(21A)-C(21)-H(21B) 109.5 
C(6)-C(1)-O(1) 122.2(2) C(3)-C(21)-H(21C) 109.5 
C(6)-C(1)-C(2) 126.5(2) H(21A)-C(21)-H(21C) 109.5 
O(1)-C(1)-C(2) 111.3(2) H(21B)-C(21)-H(21C) 109.5 
C(1)-C(2)-C(3) 113.0(2) C(3)-C(22)-H(22A) 109.5 
C(1)-C(2)-H(2A) 109.0 C(3)-C(22)-H(22B) 109.5 
C(3)-C(2)-H(2A) 109.0 H(22A)-C(22)-H(22B) 109.5 
C(1)-C(2)-H(2B) 109.0 C(3)-C(22)-H(22C) 109.5 
C(3)-C(2)-H(2B) 109.0 H(22A)-C(22)-H(22C) 109.5 
H(2A)-C(2)-H(2B) 107.8 H(22B)-C(22)-H(22C) 109.5 
C(22)-C(3)-C(4) 109.8(3) C(24)-C(23)-C(25) 110.4(3) 
C(22)-C(3)-C(21) 109.5(3) C(24)-C(23)-C(7) 112.8(3) 
C(4)-C(3)-C(21) 109.6(3) C(25)-C(23)-C(7) 111.7(3) 
C(22)-C(3)-C(2) 109.3(2) C(24)-C(23)-H(23) 107.2 
C(4)-C(3)-C(2) 107.8(2) C(25)-C(23)-H(23) 107.2 
C(21)-C(3)-C(2) 110.8(2) C(7)-C(23)-H(23) 107.2 
C(5)-C(4)-C(3) 115.6(2) C(23)-C(24)-H(24A) 109.5 
C(5)-C(4)-H(4A) 108.4 C(23)-C(24)-H(24B) 109.5 
C(3)-C(4)-H(4A) 108.4 H(24A)-C(24)-H(24B) 109.5 
C(5)-C(4)-H(4B) 108.4 C(23)-C(24)-H(24C) 109.5 
C(3)-C(4)-H(4B) 108.4 H(24A)-C(24)-H(24C) 109.5 
H(4A)-C(4)-H(4B) 107.4 H(24B)-C(24)-H(24C) 109.5 
O(2)-C(5)-C(6) 121.1(3) C(23)-C(25)-H(25A) 109.5 
O(2)-C(5)-C(4) 121.0(3) C(23)-C(25)-H(25B) 109.5 
C(6)-C(5)-C(4) 117.7(3) H(25A)-C(25)-H(25B) 109.5 
C(1)-C(6)-C(5) 117.8(3) C(23)-C(25)-H(25C) 109.5 
C(1)-C(6)-C(7) 121.7(2) H(25A)-C(25)-H(25C) 109.5 
C(5)-C(6)-C(7) 120.3(3) H(25B)-C(25)-H(25C) 109.5 
C(6)-C(7)-C(8) 108.3(2) O(4)-C(26)-C(10) 119.0(3) 
C(6)-C(7)-C(23) 113.3(2) O(4)-C(26)-C(27) 118.3(2) 
C(8)-C(7)-C(23) 110.8(2) C(10)-C(26)-C(27) 122.5(3) 
C(6)-C(7)-H(7) 108.1 C(26)-C(27)-C(29) 110.5(2) 
C(8)-C(7)-H(7) 108.1 C(26)-C(27)-C(28) 108.8(2) 
C(23)-C(7)-H(7) 108.1 C(29)-C(27)-C(28) 111.0(3) 
C(13)-C(8)-C(9) 117.7(2) C(26)-C(27)-H(27) 108.8 
C(13)-C(8)-C(7) 120.8(2) C(29)-C(27)-H(27) 108.8 
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C(9)-C(8)-C(7) 121.5(2) C(28)-C(27)-H(27) 108.8 
O(3)-C(9)-C(8) 116.4(2) C(27)-C(28)-H(28A) 109.5 
O(3)-C(9)-C(10) 121.4(2) C(27)-C(28)-H(28B) 109.5 
C(8)-C(9)-C(10) 122.1(3) H(28A)-C(28)-H(28B) 109.5 
C(11)-C(10)-C(9) 116.0(2) C(27)-C(28)-H(28C) 109.5 
C(11)-C(10)-C(26) 126.0(2) H(28A)-C(28)-H(28C) 109.5 
C(9)-C(10)-C(26) 118.0(2) H(28B)-C(28)-H(28C) 109.5 
C(12)-C(11)-O(5) 119.8(2) C(27)-C(29)-H(29A) 109.5 
C(12)-C(11)-C(10) 123.7(2) C(27)-C(29)-H(29B) 109.5 
O(5)-C(11)-C(10) 116.5(2) H(29A)-C(29)-H(29B) 109.5 
C(11)-C(12)-C(13) 116.3(2) C(27)-C(29)-H(29C) 109.5 
C(11)-C(12)-C(14) 120.9(2) H(29A)-C(29)-H(29C) 109.5 
C(13)-C(12)-C(14) 122.5(2) H(29B)-C(29)-H(29C) 109.5 
C(8)-C(13)-O(1) 121.0(2) C(31)-C(30)-C(32) 109.4(3) 
C(8)-C(13)-C(12) 124.1(2) C(31)-C(30)-C(14) 112.2(3) 
O(1)-C(13)-C(12) 115.0(2) C(32)-C(30)-C(14) 113.0(2) 
C(12)-C(14)-C(15) 108.3(2) C(31)-C(30)-H(30) 107.3 
C(12)-C(14)-C(30) 110.4(2) C(32)-C(30)-H(30) 107.3 
C(15)-C(14)-C(30) 113.6(2) C(14)-C(30)-H(30) 107.3 
C(12)-C(14)-H(14) 108.1 C(30)-C(31)-H(31A) 109.5 
C(15)-C(14)-H(14) 108.1 C(30)-C(31)-H(31B) 109.5 
C(30)-C(14)-H(14) 108.1 H(31A)-C(31)-H(31B) 109.5 
C(20)-C(15)-C(16) 118.3(2) C(30)-C(31)-H(31C) 109.5 
C(20)-C(15)-C(14) 121.1(2) H(31A)-C(31)-H(31C) 109.5 
C(16)-C(15)-C(14) 120.6(2) H(31B)-C(31)-H(31C) 109.5 
O(6)-C(16)-C(15) 121.4(2) C(30)-C(32)-H(32A) 109.5 
O(6)-C(16)-C(17) 121.6(3) C(30)-C(32)-H(32B) 109.5 
C(15)-C(16)-C(17) 117.0(2) H(32A)-C(32)-H(32B) 109.5 
C(16)-C(17)-C(18) 113.5(2) C(30)-C(32)-H(32C) 109.5 
C(16)-C(17)-H(17A) 108.9 H(32A)-C(32)-H(32C) 109.5 
C(18)-C(17)-H(17A) 108.9 H(32B)-C(32)-H(32C) 109.5 
C(16)-C(17)-H(17B) 108.9 C(18)-C(33)-H(33A) 109.5 
C(18)-C(17)-H(17B) 108.9 C(18)-C(33)-H(33B) 109.5 
H(17A)-C(17)-H(17B) 107.7 H(33A)-C(33)-H(33B) 109.5 
C(17)-C(18)-C(34) 110.3(2) C(18)-C(33)-H(33C) 109.5 
C(17)-C(18)-C(33) 109.7(2) H(33A)-C(33)-H(33C) 109.5 
C(34)-C(18)-C(33) 109.0(2) H(33B)-C(33)-H(33C) 109.5 
C(17)-C(18)-C(19) 107.7(2) C(18)-C(34)-H(34A) 109.5 
C(34)-C(18)-C(19) 110.6(2) C(18)-C(34)-H(34B) 109.5 
C(33)-C(18)-C(19) 109.5(2) H(34A)-C(34)-H(34B) 109.5 
C(20)-C(19)-C(18) 112.2(2) C(18)-C(34)-H(34C) 109.5 
C(20)-C(19)-H(19A) 109.2 H(34A)-C(34)-H(34C) 109.5 
C(18)-C(19)-H(19A) 109.2 H(34B)-C(34)-H(34C) 109.5 
C(20)-C(19)-H(19B) 109.2 Cl(2)-C(35)-Cl(1) 115.4(4) 
C(18)-C(19)-H(19B) 109.2 Cl(2)-C(35)-H(35A) 108.4 
H(19A)-C(19)-H(19B) 107.9 Cl(1)-C(35)-H(35A) 108.4 
C(15)-C(20)-O(5) 122.0(2) Cl(2)-C(35)-H(35B) 108.4 
C(15)-C(20)-C(19) 126.2(3) Cl(1)-C(35)-H(35B) 108.4 
O(5)-C(20)-C(19) 111.7(2) H(35A)-C(35)-H(35B) 107.5 
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Exp. Data Tab. 23 Anisotropic displacement parameters (Å2x 103) for anti-97 (sh3587a). The anisotropicdisplacement factor 
exponent takes the form: -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
Atom U11 U22  U33 U23 U13 U12 
O(1) 27(1)  18(1) 13(1)  0(1) 2(1)  2(1) 
O(2) 46(2)  28(1) 32(1)  -13(1) 2(1)  -2(1) 
O(3) 36(1)  23(1) 24(1)  -3(1) 9(1)  9(1) 
O(4) 40(1)  31(1) 30(1)  1(1) 10(1)  16(1) 
O(5) 32(1)  15(1) 15(1)  -1(1) 5(1)  1(1) 
O(6) 38(1)  20(1) 31(1)  1(1) 4(1)  7(1) 
C(1) 20(2)  21(2) 15(1)  1(1) 5(1)  -6(1) 
C(2) 24(2)  24(2) 22(1)  1(1) 8(1)  -3(1) 
C(3) 23(2)  29(2) 20(1)  -1(1) 1(1)  -4(1) 
C(4) 29(2)  30(2) 24(1)  -3(1) 0(1)  -8(2) 
C(5) 28(2)  24(2) 21(1)  -2(1) 8(1)  -8(1) 
C(6) 24(2)  22(2) 17(1)  -1(1) 7(1)  -4(1) 
C(7) 25(2)  20(2) 18(1)  -3(1) 8(1)  -1(1) 
C(8) 18(2)  20(2) 19(1)  -3(1) 6(1)  -3(1) 
C(9) 19(2)  17(1) 23(1)  -3(1) 8(1)  -1(1) 
C(10) 21(2)  17(2) 20(1)  0(1) 4(1)  0(1) 
C(11) 22(2)  16(1) 16(1)  -3(1) 6(1)  -2(1) 
C(12) 22(2)  14(1) 20(1)  -1(1) 6(1)  -1(1) 
C(13) 20(2)  17(1) 17(1)  2(1) 4(1)  -3(1) 
C(14) 24(2)  17(2) 16(1)  -1(1) 4(1)  2(1) 
C(15) 23(2)  17(1) 16(1)  -1(1) 7(1)  0(1) 
C(16) 21(2)  21(2) 25(1)  -2(1) 9(1)  0(1) 
C(17) 33(2)  20(2) 25(1)  -7(1) 10(1)  0(1) 
C(18) 34(2)  19(2) 17(1)  -3(1) 7(1)  -3(1) 
C(19) 27(2)  21(2) 17(1)  -1(1) 7(1)  -2(1) 
C(20) 24(2)  14(1) 21(1)  -3(1) 10(1)  -1(1) 
C(21) 42(2)  36(2) 19(1)  -2(1) 9(1)  -9(2) 
C(22) 32(2)  42(2) 29(2)  -2(2) -4(1)  -1(2) 
C(23) 22(2)  35(2) 22(1)  1(1) 8(1)  3(1) 
C(24) 27(2)  46(2) 28(2)  4(2) 9(1)  -8(2) 
C(25) 41(2)  54(2) 33(2)  -5(2) 21(2)  5(2) 
C(26) 22(2)  17(1) 24(1)  -3(1) 2(1)  0(1) 
C(27) 32(2)  19(2) 22(1)  3(1) 6(1)  3(1) 
C(28) 35(2)  37(2) 34(2)  9(2) 13(2)  2(2) 
C(29) 44(2)  30(2) 28(2)  10(1) 4(2)  11(2) 
C(30) 23(2)  24(2) 27(1)  -7(1) 5(1)  0(1) 
C(31) 25(2)  39(2) 89(3)  -8(2) 16(2)  5(2) 
C(32) 34(2)  38(2) 29(2)  -7(1) 15(1)  -9(2) 
C(33) 47(2)  29(2) 21(1)  -7(1) 7(1)  -7(2) 
C(34) 33(2)  29(2) 26(2)  -3(1) 10(1)  -8(2) 
Cl(1) 274(3)  66(1) 263(3)  -14(1) 216(3)  -21(1) 
Cl(2) 162(2)  134(2) 303(3)  67(2) 179(2)  51(2) 
C(35) 196(8)  58(4) 236(8)  41(5) 162(7)  36(4) 
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6.5. Appendix 5: crystal data for syn-97 
 
 
Exp. Data Tab. 24 Atomic coordinates (x 104) and equivalent  isotropic displacement parameters (Å2x 103) for syn-97 
(sh3590). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 3174(1) 2452(1) 10855(1) 18(1) 
O(2) 6578(1) 3896(1) 14212(1) 27(1) 
O(3) 5022(1) 6644(1) 11742(1) 21(1) 
O(4) 4396(1) 7814(1) 10325(1) 29(1) 
O(5) 2113(1) 4682(1) 8179(1) 21(1) 
O(6) 1592(1) 313(1) 6873(1) 32(1) 
C(1) 4052(1) 2310(1) 11801(1) 16(1) 
C(2) 3985(1) 987(1) 11860(1) 19(1) 
C(3) 4591(1) 877(1) 13022(1) 21(1) 
C(4) 5918(1) 1696(1) 13560(1) 20(1) 
C(5) 5829(1) 3037(1) 13511(1) 18(1) 
C(6) 4829(1) 3276(1) 12568(1) 16(1) 
C(7) 4639(1) 4599(1) 12526(1) 16(1) 
C(8) 4036(1) 4616(1) 11363(1) 15(1) 
C(9) 4181(1) 5685(1) 11013(1) 16(1) 
C(10) 3465(1) 5758(1) 9956(1) 17(1) 
C(11) 2727(1) 4638(1) 9232(1) 17(1) 
C(12) 2642(1) 3534(1) 9517(1) 16(1) 
C(13) 3300(1) 3570(1) 10598(1) 15(1) 
C(14) 1826(1) 2372(1) 8715(1) 16(1) 
C(15) 1686(1) 2472(1) 7598(1) 17(1) 
C(16) 1559(1) 1355(1) 6724(1) 20(1) 
C(17) 1470(1) 1549(1) 5639(1) 24(1) 
C(18) 762(1) 2673(1) 5392(1) 21(1) 
C(19) 1482(1) 3819(1) 6307(1) 23(1) 
C(20) 1761(1) 3587(1) 7389(1) 18(1) 
C(21) 4816(1) -480(1) 12995(1) 32(1) 
C(22) 3670(1) 1295(1) 13655(1) 28(1) 
C(23) 3783(1) 5130(1) 13226(1) 21(1) 
C(24) 2364(1) 4518(1) 12745(1) 28(1) 
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C(25) 3807(1) 6539(1) 13452(1) 31(1) 
C(26) 3510(1) 6983(1) 9709(1) 19(1) 
C(27) 2458(1) 7307(1) 8786(1) 21(1) 
C(28) 1092(1) 7140(1) 8882(1) 31(1) 
C(29) 2757(1) 8639(1) 8752(1) 29(1) 
C(30) 481(1) 2200(1) 8888(1) 21(1) 
C(31) -318(1) 959(1) 8205(1) 38(1) 
C(32) -339(1) 3271(1) 8702(1) 31(1) 
C(33) -680(1) 2459(1) 5300(1) 29(1) 
C(34) 814(1) 2861(1) 4330(1) 34(1) 
 
Exp. Data Tab. 25 Bond lengths [Å] for syn-97 (sh3590). 
Bond Length [Å] Bond Length [Å] 
O(1)-C(1)  1.3753(10) C(18)-C(19)  1.5295(14) 
O(1)-C(13)  1.3829(10) C(19)-C(20)  1.4904(13) 
O(2)-C(5)  1.2240(11) C(19)-H(10)  1.020(15) 
O(3)-C(9)  1.3439(11) C(19)-H(11)  1.006(14) 
O(3)-H(6)  0.906(16) C(21)-H(12)  1.011(16) 
O(4)-C(26)  1.2388(12) C(21)-H(13)  0.980(17) 
O(5)-C(20)  1.3670(11) C(21)-H(14)  0.977(17) 
O(5)-C(11)  1.3827(11) C(22)-H(15)  0.962(14) 
O(6)-C(16)  1.2226(12) C(22)-H(16)  1.015(14) 
C(1)-C(6)  1.3402(12) C(22)-H(17)  0.970(15) 
C(1)-C(2)  1.4916(13) C(23)-C(25)  1.5199(15) 
C(2)-C(3)  1.5387(13) C(23)-C(24)  1.5234(16) 
C(2)-H(1)  0.995(13) C(23)-H(18)  0.992(13) 
C(2)-H(2)  0.981(14) C(24)-H(19)  0.977(14) 
C(3)-C(21)  1.5271(15) C(24)-H(20)  0.985(15) 
C(3)-C(22)  1.5285(16) C(24)-H(21)  0.959(17) 
C(3)-C(4)  1.5325(14) C(25)-H(22)  0.996(14) 
C(4)-C(5)  1.5114(13) C(25)-H(23)  0.975(16) 
C(4)-H(3)  1.001(13) C(25)-H(24)  1.005(16) 
C(4)-H(4)  0.999(14) C(26)-C(27)  1.5183(14) 
C(5)-C(6)  1.4691(13) C(27)-C(29)  1.5212(14) 
C(6)-C(7)  1.5012(13) C(27)-C(28)  1.5327(15) 
C(7)-C(8)  1.5068(12) C(27)-H(25)  1.005(13) 
C(7)-C(23)  1.5630(14) C(28)-H(28)  0.991(16) 
C(7)-H(5)  1.005(13) C(28)-H(26)  0.962(16) 
C(8)-C(13)  1.3797(12) C(28)-H(27)  0.959(15) 
C(8)-C(9)  1.4036(12) C(29)-H(29)  0.961(16) 
C(9)-C(10)  1.4166(12) C(29)-H(30)  1.015(17) 
C(10)-C(11)  1.4169(12) C(29)-H(31)  0.979(15) 
C(10)-C(26)  1.4804(13) C(30)-C(31)  1.5215(15) 
C(11)-C(12)  1.3805(12) C(30)-C(32)  1.5227(16) 
C(12)-C(13)  1.4010(12) C(30)-H(32)  1.002(13) 
C(12)-C(14)  1.5095(12) C(31)-H(33)  1.052(16) 
C(14)-C(15)  1.5091(12) C(31)-H(34)  0.974(15) 
C(14)-C(30)  1.5587(13) C(31)-H(35)  1.003(18) 
C(14)-H(7)  0.976(13) C(32)-H(38)  0.979(17) 
C(15)-C(20)  1.3414(13) C(32)-H(37)  1.007(16) 
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C(15)-C(16)  1.4682(13) C(32)-H(36)  1.004(15) 
C(16)-C(17)  1.5140(14) C(33)-H(41)  1.015(14) 
C(17)-C(18)  1.5298(15) C(33)-H(39)  0.966(15) 
C(17)-H(9)  0.984(15) C(33)-H(40)  0.999(14) 
C(17)-H(8)  1.009(14) C(34)-H(44)  1.010(17) 
C(18)-C(34)  1.5265(14) C(34)-H(43)  1.012(17) 
C(18)-C(33)  1.5280(15) C(34)-H(42)  0.987(15) 
 
Exp. Data Tab. 26 Bond angles [°] for syn-97 (sh3590). 
Bonds Angles [°] Bonds Angles [°] 
C(1)-O(1)-C(13) 117.94(7) C(15)-C(20)-O(5) 122.65(8) 
C(9)-O(3)-H(6) 105.2(10) C(15)-C(20)-C(19) 126.41(9) 
C(20)-O(5)-C(11) 118.46(7) O(5)-C(20)-C(19) 110.94(8) 
C(6)-C(1)-O(1) 122.20(8) C(3)-C(21)-H(12) 110.4(9) 
C(6)-C(1)-C(2) 125.97(8) C(3)-C(21)-H(13) 109.9(10) 
O(1)-C(1)-C(2) 111.80(7) H(12)-C(21)-H(13) 111.9(13) 
C(1)-C(2)-C(3) 111.97(8) C(3)-C(21)-H(14) 111.1(10) 
C(1)-C(2)-H(1) 106.9(8) H(12)-C(21)-H(14) 107.6(13) 
C(3)-C(2)-H(1) 111.2(7) H(13)-C(21)-H(14) 105.8(13) 
C(1)-C(2)-H(2) 109.3(8) C(3)-C(22)-H(15) 111.4(8) 
C(3)-C(2)-H(2) 109.5(8) C(3)-C(22)-H(16) 112.4(8) 
H(1)-C(2)-H(2) 107.9(11) H(15)-C(22)-H(16) 109.1(12) 
C(21)-C(3)-C(22) 109.54(9) C(3)-C(22)-H(17) 109.8(9) 
C(21)-C(3)-C(4) 109.20(9) H(15)-C(22)-H(17) 106.8(12) 
C(22)-C(3)-C(4) 109.95(8) H(16)-C(22)-H(17) 107.1(11) 
C(21)-C(3)-C(2) 108.90(8) C(25)-C(23)-C(24) 109.95(10) 
C(22)-C(3)-C(2) 110.47(9) C(25)-C(23)-C(7) 112.62(8) 
C(4)-C(3)-C(2) 108.74(8) C(24)-C(23)-C(7) 112.79(8) 
C(5)-C(4)-C(3) 113.53(8) C(25)-C(23)-H(18) 107.2(7) 
C(5)-C(4)-H(3) 107.0(7) C(24)-C(23)-H(18) 108.8(7) 
C(3)-C(4)-H(3) 110.5(7) C(7)-C(23)-H(18) 105.2(7) 
C(5)-C(4)-H(4) 108.6(8) C(23)-C(24)-H(19) 110.6(8) 
C(3)-C(4)-H(4) 110.7(8) C(23)-C(24)-H(20) 113.2(9) 
H(3)-C(4)-H(4) 106.3(11) H(19)-C(24)-H(20) 108.2(11) 
O(2)-C(5)-C(6) 120.71(8) C(23)-C(24)-H(21) 109.7(9) 
O(2)-C(5)-C(4) 121.83(8) H(19)-C(24)-H(21) 106.7(13) 
C(6)-C(5)-C(4) 117.44(8) H(20)-C(24)-H(21) 108.2(12) 
C(1)-C(6)-C(5) 119.05(8) C(23)-C(25)-H(22) 111.5(8) 
C(1)-C(6)-C(7) 121.61(8) C(23)-C(25)-H(23) 109.9(9) 
C(5)-C(6)-C(7) 119.19(8) H(22)-C(25)-H(23) 107.9(12) 
C(6)-C(7)-C(8) 108.42(7) C(23)-C(25)-H(24) 109.6(9) 
C(6)-C(7)-C(23) 108.86(7) H(22)-C(25)-H(24) 107.5(12) 
C(8)-C(7)-C(23) 113.51(8) H(23)-C(25)-H(24) 110.4(13) 
C(6)-C(7)-H(5) 108.7(7) O(4)-C(26)-C(10) 118.66(9) 
C(8)-C(7)-H(5) 110.5(7) O(4)-C(26)-C(27) 118.03(8) 
C(23)-C(7)-H(5) 106.7(7) C(10)-C(26)-C(27) 123.11(8) 
C(13)-C(8)-C(9) 117.26(8) C(26)-C(27)-C(29) 110.96(9) 
C(13)-C(8)-C(7) 120.63(8) C(26)-C(27)-C(28) 110.90(8) 
C(9)-C(8)-C(7) 122.11(8) C(29)-C(27)-C(28) 109.60(9) 
O(3)-C(9)-C(8) 116.21(8) C(26)-C(27)-H(25) 107.4(8) 
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O(3)-C(9)-C(10) 121.74(8) C(29)-C(27)-H(25) 109.9(8) 
C(8)-C(9)-C(10) 122.03(8) C(28)-C(27)-H(25) 108.0(7) 
C(9)-C(10)-C(11) 115.96(8) C(27)-C(28)-H(28) 109.6(9) 
C(9)-C(10)-C(26) 118.33(8) C(27)-C(28)-H(26) 111.6(9) 
C(11)-C(10)-C(26) 125.68(8) H(28)-C(28)-H(26) 103.0(13) 
C(12)-C(11)-O(5) 120.08(8) C(27)-C(28)-H(27) 112.9(9) 
C(12)-C(11)-C(10) 123.82(8) H(28)-C(28)-H(27) 110.7(12) 
O(5)-C(11)-C(10) 116.05(8) H(26)-C(28)-H(27) 108.6(12) 
C(11)-C(12)-C(13) 116.36(8) C(27)-C(29)-H(29) 109.5(9) 
C(11)-C(12)-C(14) 121.59(8) C(27)-C(29)-H(30) 110.9(9) 
C(13)-C(12)-C(14) 121.98(8) H(29)-C(29)-H(30) 105.9(13) 
C(8)-C(13)-O(1) 121.32(8) C(27)-C(29)-H(31) 110.3(9) 
C(8)-C(13)-C(12) 124.03(8) H(29)-C(29)-H(31) 110.0(12) 
O(1)-C(13)-C(12) 114.65(7) H(30)-C(29)-H(31) 110.1(12) 
C(15)-C(14)-C(12) 108.28(7) C(31)-C(30)-C(32) 110.32(10) 
C(15)-C(14)-C(30) 113.52(7) C(31)-C(30)-C(14) 112.41(9) 
C(12)-C(14)-C(30) 109.70(8) C(32)-C(30)-C(14) 112.46(8) 
C(15)-C(14)-H(7) 110.1(7) C(31)-C(30)-H(32) 108.1(7) 
C(12)-C(14)-H(7) 107.6(7) C(32)-C(30)-H(32) 108.1(7) 
C(30)-C(14)-H(7) 107.5(7) C(14)-C(30)-H(32) 105.2(7) 
C(20)-C(15)-C(16) 117.72(8) C(30)-C(31)-H(33) 112.0(9) 
C(20)-C(15)-C(14) 121.11(8) C(30)-C(31)-H(34) 109.1(9) 
C(16)-C(15)-C(14) 121.03(8) H(33)-C(31)-H(34) 107.0(12) 
O(6)-C(16)-C(15) 121.62(9) C(30)-C(31)-H(35) 112.9(9) 
O(6)-C(16)-C(17) 120.91(9) H(33)-C(31)-H(35) 108.8(13) 
C(15)-C(16)-C(17) 117.36(8) H(34)-C(31)-H(35) 106.8(13) 
C(16)-C(17)-C(18) 113.52(8) C(30)-C(32)-H(38) 111.7(10) 
C(16)-C(17)-H(9) 104.9(8) C(30)-C(32)-H(37) 111.1(10) 
C(18)-C(17)-H(9) 109.6(8) H(38)-C(32)-H(37) 108.6(13) 
C(16)-C(17)-H(8) 107.9(8) C(30)-C(32)-H(36) 109.4(8) 
C(18)-C(17)-H(8) 111.9(8) H(38)-C(32)-H(36) 109.2(13) 
H(9)-C(17)-H(8) 108.7(12) H(37)-C(32)-H(36) 106.8(12) 
C(34)-C(18)-C(33) 108.81(9) C(18)-C(33)-H(41) 110.6(8) 
C(34)-C(18)-C(19) 109.41(9) C(18)-C(33)-H(39) 109.5(8) 
C(33)-C(18)-C(19) 111.15(9) H(41)-C(33)-H(39) 108.9(12) 
C(34)-C(18)-C(17) 110.02(9) C(18)-C(33)-H(40) 109.1(8) 
C(33)-C(18)-C(17) 109.96(9) H(41)-C(33)-H(40) 109.5(11) 
C(19)-C(18)-C(17) 107.49(8) H(39)-C(33)-H(40) 109.2(12) 
C(20)-C(19)-C(18) 112.40(8) C(18)-C(34)-H(44) 111.6(9) 
C(20)-C(19)-H(10) 107.1(8) C(18)-C(34)-H(43) 110.0(9) 
C(18)-C(19)-H(10) 110.3(8) H(44)-C(34)-H(43) 104.5(13) 
C(20)-C(19)-H(11) 107.0(8) C(18)-C(34)-H(42) 109.6(9) 
C(18)-C(19)-H(11) 111.5(8) H(44)-C(34)-H(42) 112.4(13) 
H(10)-C(19)-H(11) 108.3(11) H(43)-C(34)-H(42) 108.5(12) 
 
Exp. Data Tab. 27 Table 4. Anisotropic displacement parameters (Å2x 103) for syn-97 (sh3590). The anisotropic displacement 
factor exponent takes the form: -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ]. 
Atom U11 U22 U33 U23 U13 U12 
O(1) 21(1) 14(1) 14(1) 6(1) -1(1) -2(1) 
O(2) 26(1) 21(1) 22(1) 5(1) -6(1) -3(1) 
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O(3) 25(1) 15(1) 18(1) 3(1) 2(1) -5(1) 
O(4) 35(1) 17(1) 28(1) 8(1) 2(1) -5(1) 
O(5) 31(1) 15(1) 13(1) 5(1) 0(1) 0(1) 
O(6) 51(1) 18(1) 22(1) 5(1) 7(1) 7(1) 
C(1) 17(1) 16(1) 13(1) 5(1) 1(1) 1(1) 
C(2) 22(1) 14(1) 17(1) 4(1) 2(1) 0(1) 
C(3) 26(1) 15(1) 17(1) 6(1) 2(1) 1(1) 
C(4) 22(1) 18(1) 17(1) 5(1) 1(1) 5(1) 
C(5) 18(1) 18(1) 17(1) 5(1) 2(1) 2(1) 
C(6) 17(1) 15(1) 15(1) 5(1) 2(1) 1(1) 
C(7) 18(1) 13(1) 14(1) 3(1) 1(1) -1(1) 
C(8) 16(1) 14(1) 13(1) 4(1) 2(1) 0(1) 
C(9) 18(1) 13(1) 16(1) 2(1) 4(1) 0(1) 
C(10) 20(1) 14(1) 15(1) 5(1) 4(1) 0(1) 
C(11) 19(1) 16(1) 12(1) 4(1) 2(1) 1(1) 
C(12) 17(1) 15(1) 14(1) 4(1) 2(1) 0(1) 
C(13) 16(1) 13(1) 15(1) 5(1) 3(1) 0(1) 
C(14) 18(1) 13(1) 14(1) 4(1) 2(1) -1(1) 
C(15) 16(1) 17(1) 14(1) 4(1) 2(1) 1(1) 
C(16) 21(1) 20(1) 17(1) 4(1) 3(1) 4(1) 
C(17) 30(1) 26(1) 17(1) 6(1) 8(1) 10(1) 
C(18) 24(1) 23(1) 14(1) 5(1) 3(1) 4(1) 
C(19) 27(1) 23(1) 16(1) 8(1) 3(1) -2(1) 
C(20) 19(1) 17(1) 14(1) 4(1) 2(1) 0(1) 
C(21) 44(1) 17(1) 28(1) 9(1) -1(1) 2(1) 
C(22) 31(1) 29(1) 24(1) 9(1) 10(1) -2(1) 
C(23) 29(1) 18(1) 16(1) 5(1) 7(1) 5(1) 
C(24) 28(1) 25(1) 36(1) 11(1) 16(1) 7(1) 
C(25) 46(1) 20(1) 28(1) 2(1) 17(1) 5(1) 
C(26) 24(1) 15(1) 18(1) 5(1) 8(1) 2(1) 
C(27) 27(1) 18(1) 19(1) 8(1) 8(1) 4(1) 
C(28) 27(1) 33(1) 37(1) 18(1) 11(1) 7(1) 
C(29) 39(1) 21(1) 30(1) 14(1) 12(1) 5(1) 
C(30) 20(1) 24(1) 19(1) 7(1) 4(1) -2(1) 
C(31) 30(1) 34(1) 43(1) 3(1) 10(1) -13(1) 
C(32) 24(1) 39(1) 34(1) 15(1) 13(1) 10(1) 
C(33) 22(1) 32(1) 25(1) 5(1) -1(1) 4(1) 
C(34) 48(1) 38(1) 18(1) 12(1) 11(1) 12(1) 
 
Exp. Data Tab. 28. Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 10 3) for syn-97 (sh3590). 
Hydrogen atom x y z U(eq) 
H(1) 3039(13) 645(12) 11542(10) 27(3) 
H(2) 4451(13) 509(12) 11413(11) 30(3) 
H(3) 6563(13) 1366(12) 13204(10) 26(3) 
H(4) 6314(13) 1682(13) 14330(11) 34(4) 
H(5) 5521(13) 5117(12) 12866(10) 27(3) 
H(6) 5045(15) 7228(15) 11381(13) 47(4) 
H(7) 2297(12) 1661(12) 8864(10) 23(3) 
H(9) 2391(15) 1681(13) 5677(11) 36(4) 
H(8) 1035(14) 751(13) 5073(11) 34(4) 
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H(10) 924(15) 4546(14) 6280(12) 40(4) 
H(11) 2353(14) 4089(13) 6260(11) 34(4) 
H(12) 3954(16) -1038(15) 12626(12) 47(4) 
H(13) 5466(16) -730(15) 12646(13) 48(4) 
H(14) 5190(16) -586(15) 13723(13) 51(4) 
H(15) 2830(14) 791(13) 13332(11) 34(4) 
H(16) 3523(13) 2206(13) 13725(11) 32(3) 
H(17) 4048(14) 1197(13) 14379(12) 40(4) 
H(18) 4207(12) 4936(12) 13927(10) 25(3) 
H(19) 1915(14) 4709(13) 12060(11) 33(3) 
H(20) 2292(14) 3605(14) 12621(11) 39(4) 
H(21) 1889(16) 4848(14) 13216(13) 49(4) 
H(22) 3381(13) 6801(13) 12781(11) 33(3) 
H(23) 4716(16) 6930(14) 13768(12) 44(4) 
H(24) 3306(15) 6843(14) 13953(12) 44(4) 
H(25) 2449(13) 6708(12) 8101(11) 30(3) 
H(28) 1053(15) 7766(15) 9522(13) 47(4) 
H(26) 417(15) 7336(14) 8298(12) 43(4) 
H(27) 858(14) 6313(14) 8909(11) 36(4) 
H(29) 2118(15) 8803(14) 8132(12) 42(4) 
H(30) 2668(16) 9260(15) 9400(13) 50(4) 
H(31) 3644(15) 8767(13) 8726(12) 40(4) 
H(32) 716(12) 2202(12) 9664(10) 26(3) 
H(33) -660(16) 923(15) 7381(13) 50(4) 
H(34) -1092(15) 852(14) 8409(12) 43(4) 
H(35) 182(17) 225(16) 8313(13) 54(5) 
H(38) 131(16) 4073(16) 9178(13) 51(4) 
H(37) -583(16) 3322(15) 7933(13) 50(4) 
H(36) -1188(15) 3122(13) 8831(11) 40(4) 
H(41) -747(14) 2348(13) 6001(12) 38(4) 
H(39) -1123(14) 3169(13) 5137(11) 34(4) 
H(40) -1116(14) 1697(14) 4706(12) 39(4) 
H(44) 350(16) 2117(15) 3706(13) 53(5) 
H(43) 308(15) 3579(15) 4149(12) 46(4) 
H(42) 1738(15) 3059(14) 4395(12) 40(4) 
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6.6. Appendix 6: crystal data for syn-98 
 
 
Exp. Data Tab. 29 Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for syn-98 (sh3583). 
U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 3369(1) 7752(1) 2475(1) 24(1) 
O(2) 5260(2) 10220(2) 3386(1) 32(1) 
O(3) 3444(2) 11319(2) -314(1) 30(1) 
O(4) 2887(2) 11517(2) -2149(1) 31(1) 
O(5) 2478(1) 8085(1) -1042(1) 24(1) 
O(6) 3998(2) 3925(2) 1424(1) 31(1) 
C(1) 3979(2) 8061(2) 3153(2) 22(1) 
C(2) 4421(2) 6997(2) 4178(2) 28(1) 
C(3) 4681(2) 7446(2) 5066(2) 28(1) 
C(4) 5514(2) 8208(2) 4644(2) 29(1) 
C(5) 4968(2) 9295(2) 3621(2) 25(1) 
C(6) 4139(2) 9158(2) 2894(2) 22(1) 
C(7) 3557(2) 10216(2) 1860(2) 23(1) 
C(8) 3378(2) 9605(2) 1079(2) 22(1) 
C(9) 3257(2) 10217(2) -5(2) 22(1) 
C(10) 2895(2) 9756(2) -743(2) 21(1) 
C(11) 2756(2) 8578(2) -316(2) 21(1) 
C(12) 2916(2) 7903(2) 741(2) 20(1) 
C(13) 3225(2) 8459(2) 1408(2) 22(1) 
C(14) 2737(2) 6652(2) 1148(2) 21(1) 
C(15) 2973(2) 6051(2) 283(2) 19(1) 
C(16) 3561(2) 4644(2) 525(2) 23(1) 
C(17) 3713(2) 4099(2) -366(2) 23(1) 
C(18) 2804(2) 5002(2) -1361(2) 25(1) 
C(19) 2889(2) 6314(2) -1650(2) 24(1) 
C(20) 2783(2) 6781(2) -729(2) 21(1) 
C(21) 5418(3) 6276(2) 6014(2) 37(1) 
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C(22) 3392(2) 8290(3) 5391(2) 37(1) 
C(23) 2233(2) 11288(2) 1935(2) 26(1) 
C(24) 1175(2) 10792(2) 2275(2) 37(1) 
C(25) 2362(2) 12009(2) 2659(2) 37(1) 
C(26) 2581(2) 10583(2) -1848(2) 25(1) 
C(27) 1788(2) 10415(2) -2616(2) 30(1) 
C(28A) 1218(3) 11634(3) -3570(2) 35(1) 
C(29A) 266(3) 11590(3) -4303(2) 42(1) 
C(30A) -266(3) 12809(3) -5260(2) 49(1) 
C(28B) 1500(30) 11160(30) -3794(8) 39(2) 
C(29B) 300(30) 12410(20) -3962(19) 42(2) 
C(30B) 332(11) 13290(30) -5056(19) 45(2) 
C(31) -1104(3) 14035(3) -5008(3) 78(1) 
C(32) 1370(2) 6889(2) 1552(2) 26(1) 
C(33) 1224(2) 5628(2) 2073(2) 33(1) 
C(34) 268(2) 7802(2) 691(2) 35(1) 
C(35) 1413(2) 5139(2) -1172(2) 36(1) 
C(36) 3250(3) 4449(2) -2264(2) 35(1) 
 
Exp. Data Tab. 30. Bond lengths [Å] for syn-98 (sh3583). 
Bond Length [Å] Bond Length [Å] 
O(1)-C(1)  1.384(2) C(23)-C(25)  1.530(3) 
O(1)-C(13)  1.396(2) C(23)-H(23)  1.0000 
O(2)-C(5)  1.220(3) C(24)-H(24A)  0.9800 
O(3)-C(9)  1.347(2) C(24)-H(24B)  0.9800 
O(3)-H(3)  0.8400 C(24)-H(24C)  0.9800 
O(4)-C(26)  1.239(3) C(25)-H(25A)  0.9800 
O(5)-C(20)  1.374(2) C(25)-H(25B)  0.9800 
O(5)-C(11)  1.389(2) C(25)-H(25C)  0.9800 
O(6)-C(16)  1.227(2) C(26)-C(27)  1.505(3) 
C(1)-C(6)  1.327(3) C(27)-C(28A)  1.527(3) 
C(1)-C(2)  1.490(3) C(27)-C(28B)  1.529(8) 
C(2)-C(3)  1.534(3) C(27)-H(27A)  0.9900 
C(2)-H(2A)  0.9900 C(27)-H(27B)  0.9900 
C(2)-H(2B)  0.9900 C(27)-H(27C)  0.9900 
C(3)-C(21)  1.522(3) C(27)-H(27D)  0.9900 
C(3)-C(4)  1.529(3) C(28A)-C(29A)  1.517(3) 
C(3)-C(22)  1.535(3) C(28A)-H(28A)  0.9900 
C(4)-C(5)  1.508(3) C(28A)-H(28B)  0.9900 
C(4)-H(4A)  0.9900 C(29A)-C(30A)  1.527(3) 
C(4)-H(4B)  0.9900 C(29A)-H(29A)  0.9900 
C(5)-C(6)  1.470(3) C(29A)-H(29B)  0.9900 
C(6)-C(7)  1.510(3) C(30A)-C(31)  1.522(4) 
C(7)-C(8)  1.514(3) C(30A)-H(30A)  0.9900 
C(7)-C(23)  1.550(3) C(30A)-H(30B)  0.9900 
C(7)-H(7)  1.0000 C(28B)-C(29B)  1.522(8) 
C(8)-C(13)  1.377(3) C(28B)-H(28C)  0.9900 
C(8)-C(9)  1.396(3) C(28B)-H(28D)  0.9900 
C(9)-C(10)  1.418(3) C(29B)-C(30B)  1.524(8) 
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C(10)-C(11)  1.411(3) C(29B)-H(29C)  0.9900 
C(10)-C(26)  1.469(3) C(29B)-H(29D)  0.9900 
C(11)-C(12)  1.376(3) C(30B)-C(31)  1.510(8) 
C(12)-C(13)  1.397(3) C(30B)-H(30C)  0.9900 
C(12)-C(14)  1.511(3) C(30B)-H(30D)  0.9900 
C(14)-C(15)  1.508(3) C(31)-H(31A)  0.9800 
C(14)-C(32)  1.554(3) C(31)-H(31B)  0.9800 
C(14)-H(14)  1.0000 C(31)-H(31C)  0.9800 
C(15)-C(20)  1.338(3) C(31)-H(31D)  0.9800 
C(15)-C(16)  1.464(3) C(31)-H(31E)  0.9800 
C(16)-C(17)  1.505(3) C(31)-H(31F)  0.9800 
C(17)-C(18)  1.530(3) C(32)-C(33)  1.518(3) 
C(17)-H(17A)  0.9900 C(32)-C(34)  1.526(3) 
C(17)-H(17B)  0.9900 C(32)-H(32)  1.0000 
C(18)-C(35)  1.526(3) C(33)-H(33A)  0.9800 
C(18)-C(36)  1.529(3) C(33)-H(33B)  0.9800 
C(18)-C(19)  1.532(3) C(33)-H(33C)  0.9800 
C(19)-C(20)  1.490(3) C(34)-H(34A)  0.9800 
C(19)-H(19A)  0.9900 C(34)-H(34B)  0.9800 
C(19)-H(19B)  0.9900 C(34)-H(34C)  0.9800 
C(21)-H(21A)  0.9800 C(35)-H(35A)  0.9800 
C(21)-H(21B)  0.9800 C(35)-H(35B)  0.9800 
C(21)-H(21C)  0.9800 C(35)-H(35C)  0.9800 
C(22)-H(22A)  0.9800 C(36)-H(36A)  0.9800 
C(22)-H(22B)  0.9800 C(36)-H(36B)  0.9800 
C(22)-H(22C)  0.9800 C(36)-H(36C)  0.9800 
C(23)-C(24)  1.525(3)   
 
Exp. Data Tab. 31. Bond angles [°] for syn-98 (sh3583). 
Bonds Angle [°] Bonds Angle [°] 
C(1)-O(1)-C(13) 117.00(17) C(23)-C(24)-H(24A) 109.5 
C(9)-O(3)-H(3) 109.5 C(23)-C(24)-H(24B) 109.5 
C(20)-O(5)-C(11) 117.60(16) H(24A)-C(24)-H(24B) 109.5 
C(6)-C(1)-O(1) 123.2(2) C(23)-C(24)-H(24C) 109.5 
C(6)-C(1)-C(2) 126.5(2) H(24A)-C(24)-H(24C) 109.5 
O(1)-C(1)-C(2) 110.38(18) H(24B)-C(24)-H(24C) 109.5 
C(1)-C(2)-C(3) 112.45(19) C(23)-C(25)-H(25A) 109.5 
C(1)-C(2)-H(2A) 109.1 C(23)-C(25)-H(25B) 109.5 
C(3)-C(2)-H(2A) 109.1 H(25A)-C(25)-H(25B) 109.5 
C(1)-C(2)-H(2B) 109.1 C(23)-C(25)-H(25C) 109.5 
C(3)-C(2)-H(2B) 109.1 H(25A)-C(25)-H(25C) 109.5 
H(2A)-C(2)-H(2B) 107.8 H(25B)-C(25)-H(25C) 109.5 
C(21)-C(3)-C(4) 109.83(19) O(4)-C(26)-C(10) 119.5(2) 
C(21)-C(3)-C(2) 109.75(19) O(4)-C(26)-C(27) 117.9(2) 
C(4)-C(3)-C(2) 106.87(18) C(10)-C(26)-C(27) 122.3(2) 
C(21)-C(3)-C(22) 109.05(19) C(26)-C(27)-C(28A) 111.2(2) 
C(4)-C(3)-C(22) 111.03(19) C(26)-C(27)-C(28B) 125.8(16) 
C(2)-C(3)-C(22) 110.29(19) C(26)-C(27)-H(27A) 109.4 
C(5)-C(4)-C(3) 115.11(19) C(28A)-C(27)-H(27A) 109.4 
C(5)-C(4)-H(4A) 108.5 C(26)-C(27)-H(27B) 109.4 
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C(3)-C(4)-H(4A) 108.5 C(28A)-C(27)-H(27B) 109.4 
C(5)-C(4)-H(4B) 108.5 H(27A)-C(27)-H(27B) 108.0 
C(3)-C(4)-H(4B) 108.5 C(26)-C(27)-H(27C) 105.9 
H(4A)-C(4)-H(4B) 107.5 C(28B)-C(27)-H(27C) 105.9 
O(2)-C(5)-C(6) 121.4(2) C(26)-C(27)-H(27D) 105.9 
O(2)-C(5)-C(4) 120.9(2) C(28B)-C(27)-H(27D) 105.9 
C(6)-C(5)-C(4) 117.5(2) H(27C)-C(27)-H(27D) 106.2 
C(1)-C(6)-C(5) 118.0(2) C(29A)-C(28A)-C(27) 113.7(2) 
C(1)-C(6)-C(7) 121.84(19) C(29A)-C(28A)-H(28A) 108.8 
C(5)-C(6)-C(7) 120.0(2) C(27)-C(28A)-H(28A) 108.8 
C(6)-C(7)-C(8) 108.09(18) C(29A)-C(28A)-H(28B) 108.8 
C(6)-C(7)-C(23) 113.61(18) C(27)-C(28A)-H(28B) 108.8 
C(8)-C(7)-C(23) 109.29(17) H(28A)-C(28A)-H(28B) 107.7 
C(6)-C(7)-H(7) 108.6 C(28A)-C(29A)-C(30A) 112.6(3) 
C(8)-C(7)-H(7) 108.6 C(28A)-C(29A)-H(29A) 109.1 
C(23)-C(7)-H(7) 108.6 C(30A)-C(29A)-H(29A) 109.1 
C(13)-C(8)-C(9) 116.7(2) C(28A)-C(29A)-H(29B) 109.1 
C(13)-C(8)-C(7) 121.1(2) C(30A)-C(29A)-H(29B) 109.1 
C(9)-C(8)-C(7) 122.0(2) H(29A)-C(29A)-H(29B) 107.8 
O(3)-C(9)-C(8) 115.85(19) C(31)-C(30A)-C(29A) 114.5(3) 
O(3)-C(9)-C(10) 121.4(2) C(31)-C(30A)-H(30A) 108.6 
C(8)-C(9)-C(10) 122.7(2) C(29A)-C(30A)-H(30A) 108.6 
C(11)-C(10)-C(9) 115.59(19) C(31)-C(30A)-H(30B) 108.6 
C(11)-C(10)-C(26) 125.9(2) C(29A)-C(30A)-H(30B) 108.6 
C(9)-C(10)-C(26) 118.3(2) H(30A)-C(30A)-H(30B) 107.6 
C(12)-C(11)-O(5) 120.03(19) C(29B)-C(28B)-C(27) 108.7(15) 
C(12)-C(11)-C(10) 124.24(19) C(29B)-C(28B)-H(28C) 109.9 
O(5)-C(11)-C(10) 115.70(18) C(27)-C(28B)-H(28C) 109.9 
C(11)-C(12)-C(13) 115.9(2) C(29B)-C(28B)-H(28D) 109.9 
C(11)-C(12)-C(14) 121.57(19) C(27)-C(28B)-H(28D) 109.9 
C(13)-C(12)-C(14) 122.51(19) H(28C)-C(28B)-H(28D) 108.3 
C(8)-C(13)-O(1) 121.07(19) C(28B)-C(29B)-C(30B) 105.8(17) 
C(8)-C(13)-C(12) 124.8(2) C(28B)-C(29B)-H(29C) 110.6 
O(1)-C(13)-C(12) 114.18(19) C(30B)-C(29B)-H(29C) 110.6 
C(15)-C(14)-C(12) 108.32(17) C(28B)-C(29B)-H(29D) 110.6 
C(15)-C(14)-C(32) 112.69(17) C(30B)-C(29B)-H(29D) 110.6 
C(12)-C(14)-C(32) 110.81(17) H(29C)-C(29B)-H(29D) 108.7 
C(15)-C(14)-H(14) 108.3 C(31)-C(30B)-C(29B) 85.8(13) 
C(12)-C(14)-H(14) 108.3 C(31)-C(30B)-H(30C) 114.3 
C(32)-C(14)-H(14) 108.3 C(29B)-C(30B)-H(30C) 114.3 
C(20)-C(15)-C(16) 117.80(19) C(31)-C(30B)-H(30D) 114.3 
C(20)-C(15)-C(14) 120.92(19) C(29B)-C(30B)-H(30D) 114.3 
C(16)-C(15)-C(14) 120.89(18) H(30C)-C(30B)-H(30D) 111.5 
O(6)-C(16)-C(15) 120.9(2) C(30A)-C(31)-H(31A) 109.5 
O(6)-C(16)-C(17) 120.4(2) C(30A)-C(31)-H(31B) 109.5 
C(15)-C(16)-C(17) 118.49(19) H(31A)-C(31)-H(31B) 109.5 
C(16)-C(17)-C(18) 115.33(18) C(30A)-C(31)-H(31C) 109.5 
C(16)-C(17)-H(17A) 108.4 H(31A)-C(31)-H(31C) 109.5 
C(18)-C(17)-H(17A) 108.4 H(31B)-C(31)-H(31C) 109.5 
C(16)-C(17)-H(17B) 108.4 C(30B)-C(31)-H(31D) 109.5 
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C(18)-C(17)-H(17B) 108.4 C(30B)-C(31)-H(31E) 109.5 
H(17A)-C(17)-H(17B) 107.5 H(31D)-C(31)-H(31E) 109.5 
C(35)-C(18)-C(36) 109.44(19) C(30B)-C(31)-H(31F) 109.5 
C(35)-C(18)-C(17) 110.04(19) H(31D)-C(31)-H(31F) 109.5 
C(36)-C(18)-C(17) 109.53(18) H(31E)-C(31)-H(31F) 109.5 
C(35)-C(18)-C(19) 110.95(19) C(33)-C(32)-C(34) 110.60(19) 
C(36)-C(18)-C(19) 108.70(19) C(33)-C(32)-C(14) 111.66(18) 
C(17)-C(18)-C(19) 108.15(18) C(34)-C(32)-C(14) 112.62(18) 
C(20)-C(19)-C(18) 112.46(18) C(33)-C(32)-H(32) 107.2 
C(20)-C(19)-H(19A) 109.1 C(34)-C(32)-H(32) 107.2 
C(18)-C(19)-H(19A) 109.1 C(14)-C(32)-H(32) 107.2 
C(20)-C(19)-H(19B) 109.1 C(32)-C(33)-H(33A) 109.5 
C(18)-C(19)-H(19B) 109.1 C(32)-C(33)-H(33B) 109.5 
H(19A)-C(19)-H(19B) 107.8 H(33A)-C(33)-H(33B) 109.5 
C(15)-C(20)-O(5) 122.83(19) C(32)-C(33)-H(33C) 109.5 
C(15)-C(20)-C(19) 125.8(2) H(33A)-C(33)-H(33C) 109.5 
O(5)-C(20)-C(19) 111.33(18) H(33B)-C(33)-H(33C) 109.5 
C(3)-C(21)-H(21A) 109.5 C(32)-C(34)-H(34A) 109.5 
C(3)-C(21)-H(21B) 109.5 C(32)-C(34)-H(34B) 109.5 
H(21A)-C(21)-H(21B) 109.5 H(34A)-C(34)-H(34B) 109.5 
C(3)-C(21)-H(21C) 109.5 C(32)-C(34)-H(34C) 109.5 
H(21A)-C(21)-H(21C) 109.5 H(34A)-C(34)-H(34C) 109.5 
H(21B)-C(21)-H(21C) 109.5 H(34B)-C(34)-H(34C) 109.5 
C(3)-C(22)-H(22A) 109.5 C(18)-C(35)-H(35A) 109.5 
C(3)-C(22)-H(22B) 109.5 C(18)-C(35)-H(35B) 109.5 
H(22A)-C(22)-H(22B) 109.5 H(35A)-C(35)-H(35B) 109.5 
C(3)-C(22)-H(22C) 109.5 C(18)-C(35)-H(35C) 109.5 
H(22A)-C(22)-H(22C) 109.5 H(35A)-C(35)-H(35C) 109.5 
H(22B)-C(22)-H(22C) 109.5 H(35B)-C(35)-H(35C) 109.5 
C(24)-C(23)-C(25) 109.82(19) C(18)-C(36)-H(36A) 109.5 
C(24)-C(23)-C(7) 113.31(18) C(18)-C(36)-H(36B) 109.5 
C(25)-C(23)-C(7) 111.98(18) H(36A)-C(36)-H(36B) 109.5 
C(24)-C(23)-H(23) 107.1 C(18)-C(36)-H(36C) 109.5 
C(25)-C(23)-H(23) 107.1 H(36A)-C(36)-H(36C) 109.5 
C(7)-C(23)-H(23) 107.1 H(36B)-C(36)-H(36C) 109.5 
 
 Exp. Data Tab. 32. Anisotropic displacement parameters  (Å2x 103) for syn-98 (sh3583). The anisotropic displacement factor 
exponent takes the form: -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
Atom U11 U22 U33 U23 U13 U12 
O(1) 35(1) 26(1) 18(1) -8(1) 1(1) -18(1) 
O(2) 37(1) 34(1) 37(1) -18(1) 6(1) -23(1) 
O(3) 44(1) 25(1) 27(1) -6(1) 7(1) -22(1) 
O(4) 41(1) 28(1) 30(1) -9(1) 11(1) -20(1) 
O(5) 32(1) 20(1) 22(1) -7(1) 0(1) -12(1) 
O(6) 41(1) 24(1) 25(1) -4(1) -3(1) -13(1) 
C(1) 25(1) 27(1) 20(1) -11(1) 5(1) -12(1) 
C(2) 35(1) 30(1) 25(1) -13(1) 4(1) -16(1) 
C(3) 36(1) 33(1) 20(1) -13(1) 4(1) -18(1) 
C(4) 31(1) 38(2) 28(1) -14(1) 4(1) -20(1) 
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C(5) 24(1) 30(1) 28(1) -17(1) 9(1) -13(1) 
C(6) 26(1) 24(1) 22(1) -13(1) 8(1) -14(1) 
C(7) 26(1) 24(1) 28(1) -13(1) 7(1) -15(1) 
C(8) 23(1) 22(1) 25(1) -10(1) 4(1) -12(1) 
C(9) 24(1) 19(1) 27(1) -8(1) 8(1) -12(1) 
C(10) 22(1) 22(1) 20(1) -8(1) 7(1) -10(1) 
C(11) 22(1) 22(1) 23(1) -12(1) 3(1) -9(1) 
C(12) 23(1) 19(1) 21(1) -7(1) 4(1) -11(1) 
C(13) 22(1) 24(1) 20(1) -8(1) 4(1) -10(1) 
C(14) 24(1) 23(1) 18(1) -7(1) 2(1) -11(1) 
C(15) 18(1) 20(1) 21(1) -8(1) 2(1) -10(1) 
C(16) 22(1) 25(1) 24(1) -8(1) 4(1) -12(1) 
C(17) 28(1) 20(1) 25(1) -10(1) 3(1) -10(1) 
C(18) 29(1) 24(1) 26(1) -10(1) 0(1) -13(1) 
C(19) 29(1) 25(1) 21(1) -9(1) 3(1) -12(1) 
C(20) 23(1) 21(1) 24(1) -10(1) 2(1) -11(1) 
C(21) 48(2) 42(2) 25(1) -10(1) -1(1) -22(1) 
C(22) 41(2) 53(2) 32(1) -25(1) 14(1) -25(1) 
C(23) 28(1) 22(1) 29(1) -10(1) 6(1) -10(1) 
C(24) 28(1) 37(2) 48(2) -19(1) 10(1) -12(1) 
C(25) 42(2) 28(2) 44(2) -19(1) 10(1) -13(1) 
C(26) 25(1) 22(1) 26(1) -9(1) 10(1) -8(1) 
C(27) 31(1) 33(2) 25(1) -4(1) 0(1) -16(1) 
C(28A) 36(2) 40(2) 27(1) -1(1) -1(1) -21(1) 
C(29A) 46(2) 45(2) 32(1) -6(1) -4(1) -20(1) 
C(30A) 43(2) 63(2) 30(2) -3(1) -4(1) -17(2) 
C(28B) 41(3) 43(3) 29(3) -4(3) -3(3) -20(3) 
C(29B) 42(3) 49(3) 29(3) -5(3) -3(3) -19(3) 
C(30B) 45(3) 52(3) 31(3) -5(3) -4(3) -19(3) 
C(31) 75(2) 81(3) 61(2) -13(2) -21(2) -20(2) 
C(32) 28(1) 31(1) 25(1) -14(1) 9(1) -16(1) 
C(33) 34(1) 38(2) 32(1) -10(1) 9(1) -23(1) 
C(34) 24(1) 36(2) 41(2) -14(1) 8(1) -7(1) 
C(35) 35(1) 39(2) 41(2) -16(1) 0(1) -21(1) 
C(36) 56(2) 27(1) 28(1) -12(1) 3(1) -20(1) 
 
Exp. Data Tab. 33 Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 10 3) for syn-98 (sh3583). 
Hydrogen atom x y z U(eq) 
H(3) 3334 11630 -973 45 
H(2A) 5228 6289 4100 33 
H(2B) 3748 6649 4370 33 
H(4A) 5633 8572 5181 35 
H(4B) 6384 7601 4546 35 
H(7) 4183 10622 1600 28 
H(14) 3408 6052 1750 25 
H(17A) 3564 3296 -116 28 
H(17B) 4623 3860 -552 28 
H(19A) 3729 6241 -1944 29 
H(19B) 2183 6957 -2200 29 
H(21A) 5589 6567 6576 56 
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H(21B) 6245 5735 5812 56 
H(21C) 4894 5773 6264 56 
H(22A) 2893 7771 5685 55 
H(22B) 2888 9017 4775 55 
H(22C) 3572 8621 5922 55 
H(23) 1935 11933 1215 31 
H(24A) 1415 10185 2994 56 
H(24B) 1083 10349 1799 56 
H(24C) 348 11521 2251 56 
H(25A) 1539 12755 2605 55 
H(25B) 3058 12306 2449 55 
H(25C) 2571 11426 3387 55 
H(27A) 1073 10214 -2263 36 
H(27B) 2345 9678 -2852 36 
H(27C) 929 10560 -2336 36 
H(27D) 2203 9488 -2558 36 
H(28A) 769 12387 -3321 42 
H(28B) 1939 11765 -3969 42 
H(29A) -468 11482 -3911 50 
H(29B) 707 10830 -4543 50 
H(30A) 475 12933 -5629 59 
H(30B) -789 12676 -5749 59 
H(28C) 2254 11351 -4070 46 
H(28D) 1351 10632 -4175 46 
H(29C) 321 12813 -3423 50 
H(29D) -500 12251 -3921 50 
H(30C) 867 13785 -5078 54 
H(30D) 536 12865 -5604 54 
H(31A) -1903 13971 -4730 116 
H(31B) -1328 14782 -5649 116 
H(31C) -621 14141 -4482 116 
H(31D) -1333 13748 -4288 116 
H(31E) -1606 13877 -5485 116 
H(31F) -1305 14961 -5219 116 
H(32) 1288 7313 2102 31 
H(33A) 409 5802 2412 49 
H(33B) 1958 5042 2603 49 
H(33C) 1211 5228 1541 49 
H(34A) 351 7441 116 53 
H(34B) 315 8646 424 53 
H(34C) -570 7904 981 53 
H(35A) 1111 5533 -617 54 
H(35B) 1390 4283 -956 54 
H(35C) 844 5689 -1822 54 
H(36A) 2716 5065 -2915 53 
H(36B) 3155 3630 -2105 53 
H(36C) 4165 4298 -2350 53 
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Exp. Data Tab. 34 Atomic coordinates (x 104) and equivalent isotropic displacement parameters (Å2x 103) for syn-110 
(sh3552). U(eq) is defined as one third of the trace of the orthogonalized Uij tensor. 
Atom x y z U(eq) 
O(1) 11949(1) 10118(1) 8918(1) 20(1) 
O(2) 8176(1) 11112(1) 7994(1) 21(1) 
O(3) 8367(1) 8919(1) 9345(1) 20(1) 
O(4) 11972(1) 8983(1) 9718(1) 22(1) 
O(5) 4333(1) 9621(1) 9122(1) 29(1) 
O(6) 11133(1) 12810(1) 7881(1) 33(1) 
C(1) 10162(1) 9470(1) 9114(1) 16(1) 
C(2) 10754(1) 10053(1) 8831(1) 16(1) 
C(3) 10118(1) 10607(1) 8419(1) 17(1) 
C(4) 8884(1) 10572(1) 8343(1) 17(1) 
C(5) 8222(1) 10022(1) 8626(1) 17(1) 
C(6) 8901(1) 9485(1) 9003(1) 16(1) 
C(7) 10893(1) 8893(1) 9502(1) 16(1) 
C(8) 10392(1) 8188(1) 9604(1) 17(1) 
C(9) 11358(1) 7649(1) 9785(1) 20(1) 
C(10) 10832(1) 6941(1) 9850(1) 25(1) 
C(11) 11783(2) 6393(1) 10046(1) 37(1) 
C(12) 11241(3) 5697(1) 10193(2) 59(1) 
C(13) 6859(1) 10051(1) 8552(1) 19(1) 
C(14) 6451(1) 9456(1) 9054(1) 19(1) 
C(15) 7177(1) 8955(1) 9380(1) 19(1) 
C(16) 6561(1) 8413(1) 9825(1) 20(1) 
C(17) 6953(1) 7815(1) 10231(1) 24(1) 
C(18) 6100(1) 7410(1) 10597(1) 28(1) 
C(19) 4908(1) 7600(1) 10541(1) 27(1) 
C(20) 4527(1) 8218(1) 10130(1) 27(1) 
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C(21) 5359(1) 8616(1) 9778(1) 21(1) 
C(22) 5242(1) 9289(1) 9289(1) 21(1) 
C(23) 6199(1) 10080(1) 7590(1) 26(1) 
C(24) 6338(2) 9475(1) 6969(1) 31(1) 
C(25) 7548(2) 9443(1) 6619(2) 52(1) 
C(26) 5341(2) 9508(1) 6184(2) 51(1) 
C(27) 10805(1) 11191(1) 8052(1) 18(1) 
C(28) 9955(1) 11777(1) 7917(1) 19(1) 
C(29) 8763(1) 11697(1) 7866(1) 19(1) 
C(30) 8094(1) 12335(1) 7692(1) 22(1) 
C(31) 6885(1) 12475(1) 7553(1) 27(1) 
C(32) 6555(2) 13160(1) 7398(1) 33(1) 
C(33) 7401(2) 13668(1) 7399(1) 33(1) 
C(34) 8626(2) 13517(1) 7550(1) 28(1) 
C(35) 8953(1) 12846(1) 7679(1) 22(1) 
C(36) 10175(1) 12519(1) 7829(1) 22(1) 
C(37) 11290(1) 10958(1) 7174(1) 21(1) 
C(38) 12163(2) 11432(1) 6772(1) 31(1) 
C(39) 12452(2) 11147(1) 5878(1) 41(1) 
C(40) 13295(2) 11541(2) 7388(2) 64(1) 
 
Exp. Data Tab. 35 Bond lengths [Å] for syn-110 (sh3552). 
Bond Length [Å]  Bond Length [Å]  
O(1)-C(2)  1.3425(15) C(19)-C(20)  1.408(2) 
O(1)-H(1)  0.94(2) C(19)-H(16)  0.87(2) 
O(2)-C(29)  1.3499(16) C(20)-C(21)  1.371(2) 
O(2)-C(4)  1.3960(15) C(20)-H(17)  0.944(19) 
O(3)-C(15)  1.3477(16) C(21)-C(22)  1.5112(19) 
O(3)-C(6)  1.3902(15) C(23)-C(24)  1.530(2) 
O(4)-C(7)  1.2343(16) C(23)-H(18)  1.01(2) 
O(5)-C(22)  1.2157(16) C(23)-H(19)  1.063(19) 
O(6)-C(36)  1.2151(18) C(24)-C(25)  1.513(3) 
C(1)-C(6)  1.4113(17) C(24)-C(26)  1.536(2) 
C(1)-C(2)  1.4143(17) C(24)-H(20)  1.06(2) 
C(1)-C(7)  1.4825(17) C(25)-H(21)  0.98(3) 
C(2)-C(3)  1.4080(17) C(25)-H(22)  1.04(3) 
C(3)-C(4)  1.3823(18) C(25)-H(23)  1.07(3) 
C(3)-C(27)  1.5201(18) C(26)-H(24)  1.01(3) 
C(4)-C(5)  1.4041(18) C(26)-H(25)  1.00(3) 
C(5)-C(6)  1.3864(17) C(26)-H(26)  1.02(3) 
C(5)-C(13)  1.5266(18) C(27)-C(28)  1.4980(18) 
C(7)-C(8)  1.5095(18) C(27)-C(37)  1.5502(19) 
C(8)-C(9)  1.5211(18) C(27)-H(27)  0.965(17) 
C(8)-H(2)  1.012(19) C(28)-C(29)  1.3437(19) 
C(8)-H(3)  0.997(16) C(28)-C(36)  1.4874(18) 
C(9)-C(10)  1.5201(19) C(29)-C(30)  1.4718(18) 
C(9)-H(4)  1.030(19) C(30)-C(31)  1.381(2) 
C(9)-H(5)  1.007(17) C(30)-C(35)  1.396(2) 
C(10)-C(11)  1.525(2) C(31)-C(32)  1.409(2) 
C(10)-H(6)  1.008(18) C(31)-H(28)  0.992(19) 
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C(10)-H(7)  0.99(2) C(32)-C(33)  1.379(3) 
C(11)-C(12)  1.524(3) C(32)-H(29)  0.99(2) 
C(11)-H(8)  1.256(17) C(33)-C(34)  1.403(2) 
C(11)-H(9)  1.02(2) C(33)-H(30)  0.97(2) 
C(12)-H(10)  1.04(4) C(34)-C(35)  1.3769(19) 
C(12)-H(11)  1.02(3) C(34)-H(31)  0.934(19) 
C(12)-H(12)  1.14(4) C(35)-C(36)  1.512(2) 
C(13)-C(14)  1.4904(18) C(37)-C(38)  1.526(2) 
C(13)-C(23)  1.5499(19) C(37)-H(32)  1.021(18) 
C(13)-H(13)  0.964(19) C(37)-H(33)  1.011(18) 
C(14)-C(15)  1.3387(18) C(38)-C(40)  1.504(3) 
C(14)-C(22)  1.4789(19) C(38)-C(39)  1.522(2) 
C(15)-C(16)  1.4701(18) C(38)-H(34)  1.01(2) 
C(16)-C(17)  1.3760(19) C(39)-H(35)  0.98(2) 
C(16)-C(21)  1.4037(19) C(39)-H(36)  0.99(2) 
C(17)-C(18)  1.404(2) C(39)-H(37)  1.03(2) 
C(17)-H(14)  0.971(19) C(40)-H(38)  0.96(3) 
C(18)-C(19)  1.387(2) C(40)-H(39)  0.97(3) 
C(18)-H(15)  1.00(2) C(40)-H(40)  0.98(3) 
 
Exp. Data Tab. 36 Bond angles [°] for syn-110 (sh3552). 
Bonds Angles [°] Bonds Angles [°] 
C(2)-O(1)-H(1) 106.1(14) O(5)-C(22)-C(14) 127.29(13) 
C(29)-O(2)-C(4) 115.68(10) O(5)-C(22)-C(21) 126.66(13) 
C(15)-O(3)-C(6) 116.30(10) C(14)-C(22)-C(21) 106.05(11) 
C(6)-C(1)-C(2) 116.55(11) C(24)-C(23)-C(13) 117.90(12) 
C(6)-C(1)-C(7) 124.75(11) C(24)-C(23)-H(18) 107.0(11) 
C(2)-C(1)-C(7) 118.70(11) C(13)-C(23)-H(18) 111.1(11) 
O(1)-C(2)-C(3) 115.12(11) C(24)-C(23)-H(19) 108.1(10) 
O(1)-C(2)-C(1) 123.14(11) C(13)-C(23)-H(19) 104.6(10) 
C(3)-C(2)-C(1) 121.73(11) H(18)-C(23)-H(19) 107.7(15) 
C(4)-C(3)-C(2) 117.05(11) C(25)-C(24)-C(23) 113.55(15) 
C(4)-C(3)-C(27) 123.65(11) C(25)-C(24)-C(26) 110.23(17) 
C(2)-C(3)-C(27) 119.25(11) C(23)-C(24)-C(26) 108.61(15) 
C(3)-C(4)-O(2) 121.29(11) C(25)-C(24)-H(20) 107.6(11) 
C(3)-C(4)-C(5) 125.08(11) C(23)-C(24)-H(20) 106.5(11) 
O(2)-C(4)-C(5) 113.59(11) C(26)-C(24)-H(20) 110.2(11) 
C(6)-C(5)-C(4) 114.99(11) C(24)-C(25)-H(21) 113.9(19) 
C(6)-C(5)-C(13) 124.22(11) C(24)-C(25)-H(22) 107.8(15) 
C(4)-C(5)-C(13) 120.73(11) H(21)-C(25)-H(22) 99(2) 
C(5)-C(6)-O(3) 121.32(11) C(24)-C(25)-H(23) 115.4(14) 
C(5)-C(6)-C(1) 124.52(12) H(21)-C(25)-H(23) 111(2) 
O(3)-C(6)-C(1) 114.10(10) H(22)-C(25)-H(23) 109(2) 
O(4)-C(7)-C(1) 118.63(11) C(24)-C(26)-H(24) 106.3(15) 
O(4)-C(7)-C(8) 118.24(11) C(24)-C(26)-H(25) 112.6(14) 
C(1)-C(7)-C(8) 123.06(11) H(24)-C(26)-H(25) 104(2) 
C(7)-C(8)-C(9) 113.01(11) C(24)-C(26)-H(26) 108.3(16) 
C(7)-C(8)-H(2) 108.6(10) H(24)-C(26)-H(26) 111(2) 
C(9)-C(8)-H(2) 110.2(10) H(25)-C(26)-H(26) 115(2) 
C(7)-C(8)-H(3) 109.1(9) C(28)-C(27)-C(3) 106.74(11) 
Appendices  - 215 - 
C(9)-C(8)-H(3) 108.9(9) C(28)-C(27)-C(37) 113.03(11) 
H(2)-C(8)-H(3) 106.9(14) C(3)-C(27)-C(37) 108.97(11) 
C(10)-C(9)-C(8) 112.01(12) C(28)-C(27)-H(27) 108.8(10) 
C(10)-C(9)-H(4) 110.4(10) C(3)-C(27)-H(27) 109.2(10) 
C(8)-C(9)-H(4) 107.5(10) C(37)-C(27)-H(27) 109.9(10) 
C(10)-C(9)-H(5) 109.8(10) C(29)-C(28)-C(36) 106.55(12) 
C(8)-C(9)-H(5) 107.9(10) C(29)-C(28)-C(27) 122.35(12) 
H(4)-C(9)-H(5) 109.1(14) C(36)-C(28)-C(27) 131.09(12) 
C(9)-C(10)-C(11) 112.92(13) C(28)-C(29)-O(2) 126.40(12) 
C(9)-C(10)-H(6) 109.5(10) C(28)-C(29)-C(30) 113.42(12) 
C(11)-C(10)-H(6) 107.3(10) O(2)-C(29)-C(30) 120.13(12) 
C(9)-C(10)-H(7) 108.9(11) C(31)-C(30)-C(35) 121.71(13) 
C(11)-C(10)-H(7) 108.9(11) C(31)-C(30)-C(29) 132.32(13) 
H(6)-C(10)-H(7) 109.1(16) C(35)-C(30)-C(29) 105.97(12) 
C(12)-C(11)-C(10) 112.26(17) C(30)-C(31)-C(32) 116.96(15) 
C(12)-C(11)-H(8) 107.9(7) C(30)-C(31)-H(28) 119.6(11) 
C(10)-C(11)-H(8) 115.0(7) C(32)-C(31)-H(28) 123.5(11) 
C(12)-C(11)-H(9) 109.1(12) C(33)-C(32)-C(31) 121.43(15) 
C(10)-C(11)-H(9) 109.9(12) C(33)-C(32)-H(29) 120.2(12) 
H(8)-C(11)-H(9) 102.3(14) C(31)-C(32)-H(29) 118.3(12) 
C(11)-C(12)-H(10) 107.7(19) C(32)-C(33)-C(34) 120.86(14) 
C(11)-C(12)-H(11) 112.7(16) C(32)-C(33)-H(30) 120.0(12) 
H(10)-C(12)-H(11) 103(2) C(34)-C(33)-H(30) 119.2(12) 
C(11)-C(12)-H(12) 112.1(18) C(35)-C(34)-C(33) 117.89(15) 
H(10)-C(12)-H(12) 114(3) C(35)-C(34)-H(31) 117.0(12) 
H(11)-C(12)-H(12) 107(2) C(33)-C(34)-H(31) 125.1(11) 
C(14)-C(13)-C(5) 107.25(10) C(34)-C(35)-C(30) 121.11(14) 
C(14)-C(13)-C(23) 110.92(11) C(34)-C(35)-C(36) 130.78(14) 
C(5)-C(13)-C(23) 116.36(12) C(30)-C(35)-C(36) 108.10(11) 
C(14)-C(13)-H(13) 109.4(11) O(6)-C(36)-C(28) 127.61(13) 
C(5)-C(13)-H(13) 107.4(11) O(6)-C(36)-C(35) 126.53(13) 
C(23)-C(13)-H(13) 105.3(11) C(28)-C(36)-C(35) 105.86(12) 
C(15)-C(14)-C(22) 106.84(12) C(38)-C(37)-C(27) 117.13(12) 
C(15)-C(14)-C(13) 123.58(12) C(38)-C(37)-H(32) 108.9(10) 
C(22)-C(14)-C(13) 129.58(12) C(27)-C(37)-H(32) 108.3(10) 
C(14)-C(15)-O(3) 126.44(12) C(38)-C(37)-H(33) 107.8(11) 
C(14)-C(15)-C(16) 113.57(12) C(27)-C(37)-H(33) 108.0(10) 
O(3)-C(15)-C(16) 119.98(11) H(32)-C(37)-H(33) 106.1(14) 
C(17)-C(16)-C(21) 121.75(13) C(40)-C(38)-C(39) 110.19(17) 
C(17)-C(16)-C(15) 132.55(13) C(40)-C(38)-C(37) 112.55(17) 
C(21)-C(16)-C(15) 105.70(11) C(39)-C(38)-C(37) 109.32(13) 
C(16)-C(17)-C(18) 117.28(13) C(40)-C(38)-H(34) 110.1(12) 
C(16)-C(17)-H(14) 122.9(11) C(39)-C(38)-H(34) 107.0(12) 
C(18)-C(17)-H(14) 119.8(11) C(37)-C(38)-H(34) 107.5(12) 
C(19)-C(18)-C(17) 121.45(14) C(38)-C(39)-H(35) 110.1(13) 
C(19)-C(18)-H(15) 119.2(12) C(38)-C(39)-H(36) 109.8(13) 
C(17)-C(18)-H(15) 119.3(12) H(35)-C(39)-H(36) 107.1(18) 
C(18)-C(19)-C(20) 120.34(14) C(38)-C(39)-H(37) 111.0(14) 
C(18)-C(19)-H(16) 121.3(12) H(35)-C(39)-H(37) 112.6(19) 
C(20)-C(19)-H(16) 118.3(13) H(36)-C(39)-H(37) 106.2(18) 
Appendices  - 216 - 
C(21)-C(20)-C(19) 118.32(14) C(38)-C(40)-H(38) 109.5(16) 
C(21)-C(20)-H(17) 120.3(11) C(38)-C(40)-H(39) 114.3(16) 
C(19)-C(20)-H(17) 121.4(11) H(38)-C(40)-H(39) 108(2) 
C(20)-C(21)-C(16) 120.85(13) C(38)-C(40)-H(40) 108.3(16) 
C(20)-C(21)-C(22) 131.33(13) H(38)-C(40)-H(40) 109(2) 
C(16)-C(21)-C(22) 107.82(12) H(39)-C(40)-H(40) 107(2) 
 
Exp. Data Tab. 37 Anisotropic displacement parameters (Å2x 103) for syn-110 (sh3552). The anisotropic displacement factor 
exponent takes the form: -2π2[ h2 a*2U11 + ...  + 2 h k a* b* U12 ] 
 U11 U22 U33 U23 U13 U12 
O(1) 12(1) 20(1) 29(1) 4(1) 3(1) 0(1) 
O(2) 17(1) 17(1) 28(1) 6(1) 1(1) 2(1) 
O(3) 12(1) 17(1) 31(1) 5(1) 5(1) 1(1) 
O(4) 14(1) 21(1) 31(1) 3(1) 0(1) 2(1) 
O(5) 14(1) 27(1) 44(1) 4(1) 1(1) 3(1) 
O(6) 29(1) 23(1) 49(1) 2(1) 7(1) -4(1) 
C(1) 13(1) 17(1) 18(1) 0(1) 2(1) 2(1) 
C(2) 12(1) 18(1) 18(1) -1(1) 3(1) 1(1) 
C(3) 16(1) 16(1) 18(1) 1(1) 3(1) 1(1) 
C(4) 16(1) 17(1) 19(1) 2(1) 2(1) 3(1) 
C(5) 14(1) 17(1) 20(1) 1(1) 2(1) 1(1) 
C(6) 14(1) 15(1) 20(1) 1(1) 4(1) 0(1) 
C(7) 15(1) 18(1) 16(1) 0(1) 3(1) 3(1) 
C(8) 15(1) 17(1) 20(1) 2(1) 3(1) 1(1) 
C(9) 17(1) 18(1) 23(1) 3(1) 2(1) 4(1) 
C(10) 27(1) 18(1) 29(1) 2(1) 0(1) 2(1) 
C(11) 43(1) 21(1) 46(1) 5(1) -1(1) 10(1) 
C(12) 86(2) 22(1) 66(1) 5(1) -11(1) 4(1) 
C(13) 14(1) 18(1) 25(1) 2(1) 1(1) 2(1) 
C(14) 14(1) 20(1) 23(1) 1(1) 2(1) 1(1) 
C(15) 13(1) 20(1) 24(1) -1(1) 3(1) 0(1) 
C(16) 14(1) 20(1) 25(1) -1(1) 4(1) -1(1) 
C(17) 18(1) 21(1) 32(1) 3(1) 6(1) 2(1) 
C(18) 26(1) 21(1) 38(1) 6(1) 8(1) 1(1) 
C(19) 21(1) 24(1) 37(1) 6(1) 9(1) -4(1) 
C(20) 17(1) 26(1) 39(1) 2(1) 5(1) -1(1) 
C(21) 15(1) 21(1) 28(1) 1(1) 2(1) 0(1) 
C(22) 14(1) 21(1) 27(1) 0(1) 0(1) 0(1) 
C(23) 23(1) 24(1) 28(1) 6(1) -4(1) 2(1) 
C(24) 34(1) 28(1) 29(1) 0(1) -4(1) -2(1) 
C(25) 46(1) 68(2) 42(1) -23(1) 7(1) 1(1) 
C(26) 55(1) 52(1) 40(1) -9(1) -18(1) 2(1) 
C(27) 17(1) 16(1) 20(1) 2(1) 3(1) 0(1) 
C(28) 21(1) 16(1) 20(1) 2(1) 4(1) 1(1) 
C(29) 22(1) 18(1) 19(1) 3(1) 3(1) 1(1) 
C(30) 27(1) 20(1) 18(1) 4(1) 4(1) 5(1) 
C(31) 26(1) 26(1) 28(1) 7(1) 5(1) 6(1) 
C(32) 33(1) 32(1) 33(1) 10(1) 8(1) 14(1) 
C(33) 44(1) 24(1) 31(1) 9(1) 12(1) 14(1) 
C(34) 40(1) 19(1) 25(1) 6(1) 10(1) 3(1) 
Appendices  - 217 - 
C(35) 30(1) 20(1) 19(1) 4(1) 8(1) 3(1) 
C(36) 28(1) 18(1) 21(1) 2(1) 7(1) 0(1) 
C(37) 22(1) 20(1) 23(1) 1(1) 7(1) -1(1) 
C(38) 33(1) 27(1) 35(1) -1(1) 18(1) -4(1) 
C(39) 54(1) 36(1) 38(1) 0(1) 28(1) -3(1) 
C(40) 35(1) 100(2) 59(1) -24(2) 21(1) -30(1) 
 
Exp. Data Tab. 38 Hydrogen coordinates (x 104) and isotropic displacement parameters (Å2x 10 3) for syn-110 (sh3552). 
Hydrogen atom x y z U(eq) 
H(1) 12250(20) 9736(12) 9244(16) 56(6) 
H(2) 9863(16) 8196(9) 10108(13) 31(5) 
H(3) 9872(15) 8066(8) 9046(11) 21(4) 
H(4) 11890(16) 7671(9) 9269(13) 30(5) 
H(5) 11851(15) 7767(8) 10365(12) 24(4) 
H(6) 10354(16) 6819(9) 9263(12) 28(4) 
H(7) 10299(18) 6937(10) 10330(14) 37(5) 
H(8) 12493(14) 6329(8) 9461(11) 18(4) 
H(9) 12343(19) 6522(11) 10601(15) 46(6) 
H(10) 11940(30) 5346(18) 10280(20) 111(11) 
H(11) 10730(30) 5521(14) 9640(20) 82(9) 
H(12) 10650(30) 5701(18) 10770(30) 116(12) 
H(13) 6643(17) 10466(10) 8837(13) 33(5) 
H(14) 7778(17) 7663(9) 10262(12) 31(5) 
H(15) 6359(18) 6978(11) 10909(14) 44(6) 
H(16) 4373(17) 7341(10) 10754(13) 35(5) 
H(17) 3723(17) 8361(9) 10103(12) 30(5) 
H(18) 6431(18) 10502(10) 7263(13) 41(5) 
H(19) 5279(17) 10124(9) 7685(12) 31(5) 
H(20) 6243(18) 9031(10) 7355(14) 42(5) 
H(21) 8220(30) 9437(15) 7090(20) 94(10) 
H(22) 7710(20) 9913(14) 6336(18) 73(8) 
H(23) 7640(20) 9055(13) 6130(18) 72(8) 
H(24) 5470(20) 9943(14) 5857(18) 69(8) 
H(25) 5420(20) 9146(13) 5723(17) 64(7) 
H(26) 4540(30) 9516(14) 6440(19) 82(9) 
H(27) 11461(15) 11317(8) 8490(11) 22(4) 
H(28) 6300(17) 12098(10) 7552(13) 34(5) 
H(29) 5691(19) 13272(10) 7291(14) 41(5) 
H(30) 7153(18) 14135(10) 7297(13) 40(5) 
H(31) 9242(17) 13836(10) 7565(13) 31(5) 
H(32) 10578(16) 10868(9) 6706(12) 28(4) 
H(33) 11701(16) 10504(9) 7292(12) 30(5) 
H(34) 11742(18) 11878(11) 6643(14) 42(5) 
H(35) 13030(20) 11441(11) 5622(15) 50(6) 
H(36) 12830(20) 10693(12) 5970(15) 49(6) 
H(37) 11680(20) 11074(11) 5447(17) 56(7) 
H(38) 13620(20) 11110(14) 7584(18) 64(9) 
H(39) 13910(30) 11796(14) 7120(18) 73(8) 
H(40) 13100(20) 11801(14) 7910(20) 76(8) 
 
